CURRICULUM VITAE

Richard Pestell, AO., MBBS, MD, PhD, MBA, FRACP, FACP, FRCP (Ireland), FRCP (London), MAE., is a clinician scientist, who currently serves as the President of the Pennsylvania Cancer and Regenerative Medicine Center, and Member Wistar Institute Cancer Center (Associate), in Philadelphia, USA.

He was previously **Executive Vice President Thomas Jefferson University**, Philadelphia, USA (30,000 employees, $5.6B USD annual budget). He has founded six biotechnology companies (LightSeed, Shenandoah, ioROC, StromaGenesis, ProstaGene, EcoGenome). He sold ProstaGene with a successful exit in 2018. His companies have been financed primarily through NIH funded research and private investors. He has been the Principal Investigator of >$86 MM USD in grants primarily from the NIH, raised ~$50MM USD from investors for biotechnology company development, published more than 700 works **with ~110,000 citations**, **H index 162** and is ranked by **Google Scholar #1 in the world for his area of science** ("cell cycle"). He holds multiple issued patents in cancer diagnostics and treatment. Of 484 publications published 1996-2023, 161 have been cited in in 677 patents (SciVal). He has authored 1 book, 52 book chapters and delivered 294 invited lectures and 236 meeting presentations.

He previously led cancer not–for-profits, **Director** of two USA Cancer Centers (Lombardi Comprehensive Cancer Center, and the Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University), founded Departments, and Institutes. While Director of the Sidney Kimmel Cancer Center and head of the Jefferson Oncology Service line, the Oncology US News Rankings improved from #64 to #17. He is past President of INCTR (USA), a global not-for-profit working to impact cancer in the developing world and was founding Director of the Delaware Valley Institute for Clinical and Translational Science (University of Delaware, Thomas Jefferson University, Nemours and Christiana).

His preclinical studies of cyclin D1 in breast cancer were **cited in the IND** as the basis for the clinical trials of CDK inhibitors, **now approved by the FDA** and is standard of care world wide for treatment of breast cancer. His preclinical studies of CCR5 inhibitors are cited as the basis for the current clinical trials of CCR5 inhibitors for cancer.

He received M.D. and Ph.D. degrees from Melbourne University, and his MBA from NYU, Stern School of Business. Dr. Pestell completed his M.B., BS at the University of Western Australia, and conducted clinical training in Internal Medicine, Oncology and Endocrinology. He was the Winthrop Fellow at **Harvard Medical School** and was Clinical Fellow at Massachusetts General Hospital.

He has received awards and elected memberships (~20) to academic societies for his research, clinical care and impact on improving health care access. Elected Memberships include **Academia Europaea (MAE**) and American Society for Clinical Investigation. Awards include the RD Wright Medallion, The Eric Susman Prize in Medicine, Doctor of Medical Sciences, *Honoris Causa*, University of Melbourne, Doctor Honoris Causa, University of Western Australia and appointment as an Officer of the **Order of Australia from Queen Elizabeth II (2019**) for "distinguished service to medicine, and to medical education, as a researcher and physician in the fields of endocrinology and oncology". https://en.wikipedia.org/wiki/Richard_Pestell. He previously and or currently served as a member of the Editorial Board of 14 journals, as a Reviewer of 18 funding agencies in 9 countries, and consults for domestic and international research organizations.

Name: Richard George Pestell

Education: Completion date

1981 M.B., B.S. (M.D., University of Western Australia)(diploma 1982)
1989 F.R.A.C.P. (Endocrinology and Oncology training) (diploma 1989)
1991 Ph.D. (University of Melbourne, Howard Florey Institute,diploma 1992)(World Rank 14th)
1991-1993 Research Fellow in Medicine, Harvard Medical School (World ranked #1)
1991-1993 Clinical and Research Fellow in Medicine, Massachusetts General Hospital
1994-1996 Fellowship, Endocrinology, Department of Internal Medicine, Northwestern University.
1997 M.D. (Thesis, University of Melbourne) (diploma 1997)
2008 Doctoris Honoris Causa (University of Western Australia) (diploma 2008)
2009 F.A.C.P. (Fellow American Colale of Physicians) (diploma 2008)
2011 M.B.A. (Executive – MBA, NYU, (diploma 2012)
2016 Doctor of Medical Science, Honoris Causa (University of Melbourne)
`2022 Elected Fellow Royal College of Physicians (London)
2022 Elected Fellow Royal College of Physicians (Ireland)

Current Academic Appointments

2017- present 1. President, Pennsylvania Cancer and Regenerative Medicine Center,Doylestown, PA 18902, USA
2. Blumberg Distinguished Professor, Translational Medical Research, Baruch Blumberg Institute.
3. Wistar Institute Cancer Center, Member (Affiliate), Philadelphia, PA.
2022- present 4. Adjunct Professor, University of Western Australia, Dept Biomedical Science 3/1/2022-May/9//28
2026 - present 5 Research Professor (10% part time) , Semmelweis University, Budapest, Hungary
2026 - present 6 Research Professor (10% part time) , Debrecen University, Debrecen, Hungary

Prior Appointments

Thomas Jefferson University

2015-2016 Special Advisor to the President (for Innovation) Thomas Jefferson University.
2014-2015 Executive Vice President, Thomas Jefferson University (TJU), Philadelphia, PA.
2005-2015 Director, Sidney Kimmel Cancer Center, TJU, Philadelphia, PA.
2005-2015 Chairman, Department of Cancer Biology, TJU, Philadelphia, PA. (11/2005)
2005-2015 Head of Oncology Service line, Vice President for Oncology Services, Philadelphia, PA.
2005-2015 Associate Dean, Cancer Programs, Sidney Kimmel Medical College, Philadelphia, PA.
2008-2010 Director, Delaware Valley Institute for Clinical & Translational Science,
http://www1.udel.edu/udaily/2009/oct/dvicts103108.html
2005-12/2016 Professor with Tenure, Thomas Jefferson University, Philadelphia, PA.

Georgetown University

2005 Associate Vice President, Georgetown University Medical Center,
Washington, DC,
2002-2005 Director, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC
2002-2005 Chairman, Department of Oncology, Georgetown University Medical Center (9/2002)
2002-2005 Francis L. and Charlotte Gragnani Chair, Professor with Tenure, Georgetown University,
Washington, DC

Georgetown Hospital and Hospital System Board Membership

2002-2006 Member, Board of Directors, Georgetown University Hospital
2003-2005 Member, Nominating Board, Development and Ethics Committee,
Georgetown University Hospital Board of Directors
2002-2005 Member, Clinical Advisory Committee, Georgetown University Hospital
2002-2005 Member, Medical Executive Committee, Georgetown University Hospital, MedStar Health
2002-2005 Member, MedStar Research Institute Board of Directors
2002-2005. Member, MedStar Health Board's Quality and Professional Affairs Committee.

Albert Einstein College of Medicine New York

1996-2002 Associate Professor then Professor (2001), Chairman, Division of Hormone-Dependent Tumor Biology, Cancer Center Program co-leader, Albert Einstein College of Medicine New York.

Northwestern University Medical School, Chicago, IL

1993-1995 Assistant Professor, Department of Medicine.

Previous Domestic and International Appointments

2002-2005 President, International Network for Cancer Treatment and Research (INCTR) (USA)
2017-2021 Professor, Geissinger Commonwealth School of Graduate Education, PA. (11/30/17-12/31/21)
2017-2022 Visiting Professor (Honorary), Lee Kong Chian School of Medicine, NTU (NanyangTechnical University, Singapore, ranked 26th QS World Wide)
2018-2025 Vice President of Academic Affairs, and Dean, Xavier University Medical School,
Woodbury, NY, 11797 (June 1-2018-June 30 2025).

Career Synopsis

Physician scientist executive with 30 years of experience, including leadership of complex matrixed University-Hospital systems. As Medical School Dean established new accreditations and research/education/clinical programs. As researcher received >$82M in research funds as Principal Investigator.

1. Director of two distinct NCI-designated cancer centers (LCCC, SKCC) (14 years) and Executive Vice President (EVP rank reports to the President) Thomas Jefferson University (TJU).TJU is a 30,000 employee $5.6B operation.
2. (SKCC was >$350M annual budget with additional matrixed management responsibility for interhospital relationship with 30 hospital system as SKCC Director). $400M annual research budget as Director of DVICTS.
3. I am the recipient of multiple issued patents and founder of six biotechnology companies (raised >$45M in 2018/2019). Advisor in the national and international academic medical space.
4. Received Order of Australia on the Queen's birthday 2019 for "distinguished contribution to Oncology and Medicine".

Scholarship Synopsis

1. Summary: >725 published works, (~111,100 citations), (includes *Cell, Science and Nature Medicine*), includes 48 reviews and book chapters, and the editor of 1 book, 239 published abstracts, and 455 original articles.
2. h-index: 163, i10-index: 463).
3. Of the 484 publications (1996-2023), 161 have been cited in in 677 patents (SciVal).
4. World rankings Cited by Google scholar , #1 Cell-cycle, and ranked for Prostate Cancer, Oncology, Breast Cancer.
5. Invited Lectures, 1996- current > 270 invited lectures including named Keynote and named Plenary speaker.
6. >$82M USD in research grants, additional >$45M raised for Biotechnology research and clinical trials.

Education Synopsis

a) As President of the International Network for Cancer Treatment (INCTR)(USA) responsible for Education and Outreach in developing world (more than 30 countries including African continent, India and South America).
b) As Director of DVICTS created new education programs for Historically black colleges in Delaware and Pennsylvania.
c) Responsible for all education and accreditation education and clinical (2002-2015) at Georgetown University and Thomas Jefferson University in Cancer and cancer research domain.
d) As Thomas Jefferson University Associate Dean and EVP, participated or led accreditation, developed curriculum and courses, developed new school, taught students and directed PhD students (**11 Students Completed PhD, 47 Post-doctoral fellow completed training under my direction).**
e) As Vice President Academic Affairs, Xavier University, developed research curriculum and training programs.
f) **Education Awards**
   g) 1990 Honorary life member Queens College for contribution to medical student teaching.
   h) 1993 Robert Woods Johnson Foundation- award for minority education - Northwestern University Medical School
   i) 1994 Robert Woods Johnson Foundation- award for minority education - Northwestern University Medical School
   j) 2005 Thomas Jefferson University Pathology Department prize (teaching/education)
   k) 2007 Distinguished Speaker award for TJU Departments of Pathology, Anatomy, and Cell Biology

Innovation and Industry synopsis

l) MBA in entrepreneurship and finance (NYU) (2011)
m) Founded and funded six biotechnology companies (LightSeed LLC (2006), ProstaGene LLC (2011- sold 2018), EcoGenome LLC (2021), ioROC (2021), StromaGenesis (2022), Shenandoah Pharmaceuticals (2023).
n) Multiple issued and pending patents.
o) Special Advisor to the President for Innovation Thomas Jefferson University (2015).
p) Member, National Academy of Inventors, Thomas Jefferson University Chapter (2016)
q) Biotechnology Advisory Board member, CytoDyn, VGI Health Technology Limited (was Invictus Biotechnology),

Clinical Synopsis

a) FRACP, FACP, (training in Endocrinology and Oncology), Elected Member Royal Society of Medicine,
b) Elected Member, American Society Clinical Investigators (ASCI) (2000-Present)
c) International Association of Oncologists (IOA)- "Leading Physicians of the World- A Top Oncologist in Philadelphia, PA" (2011)
d) The Eric Susman Prize in Medicine, Awarded by the Royal Australasian College of Physicians (2015).
e) Chairman Department of Oncology (>80 faculty) 2002-2005, (Georgetown University)
f) Head of Oncology Service line and clinical operations (Radiation Oncology, Medical Oncology, 2005-2015) (Thomas Jefferson University and Hospitals), and Sidney Kimmel Cancer Center (>1,000 faculty and staff)
g) Executive Vice President Thomas Jefferson University (2014-2015, (30,000 employees, $5.6B operation)).

Diversity Synopsis

a) I have received awards from the Robert Wood Johnson for minority medical education.
b) I lead the establishment of the first free screening clinic for women in Washington, DC,
c) I received the Susan Komen Award for work with the underinsured (Light of life award 2010),
d) I built new programs in health care disparity at Thomas Jefferson University. This program provided important educational and guidance solutions to increasing diverse representation (both design and participation, in clinical trials).
e) I founded the Center to Eradicate Health Care Disparities. *isley.kcc.tju.edu/disparities/*

Clinical Training, Internship, Residencies, Faculty and Chair Positions
ABIM # 165233
PA Medical License # 429307
FL Medical License # ME 141257 (-2026)

1981-1987	Intern and Registrar Royal Perth Hospital & St. Vincent's Hospital, Melbourne (Internal Medicine, Endocrinology and Oncology training).
1987-1988	Intern and Registrar, St. Vincent's Hospital, (Medicine, Endocrinology).
1985	Tutor in Pathology, Department of Immunology, University of Western Australia
1987-1990	Tutor in Medicine, Queens College, University of Melbourne.
1988-1990	Tutor in Medicine, Department of Medicine, University of Melbourne, Royal Melbourne Hospital
1990-1991	Consultant Endocrinologist, Northwest Hospital (University of Melbourne, Department of Medicine)
1988-1991	NHMRC Scholar, Howard Florey Institute, University of Melbourne, Department of Medicine.
1991-1993	Postdoctoral Clinical and Research Fellow in Medicine – Massachusetts General Hospital. Boston MA, USA Postdoctoral Research Fellow in Medicine – Harvard Medical School. Boston MA, USA
1994-1996	Endocrinology Clinical Fellowship, Northwestern University, Chicago, IL .USA (11/1/1994-8/31/1996).
1993-1996	Licensed medical practitioner in State of Illinois.
1996-2002	Associate Professor, Departments of Medicine and Developmental & Molecular Biology, Albert Einstein College of Medicine, New York.
1996-2002	Licensed medical practitioner in State of New York.
1997-2002	Visiting Attending, Endocrinology and Medicine, Montefiore, Weiler Hospital, and Jacobi Hospitals, New York
2000-2002	Co-leader, Program in Growth Control, Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York
2000-2002	Director, Program in Hormone Responsive Cancers, Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York
2000-2002	Chairman, Division of Endocrine-Dependent Tumor Biology, Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York
2001-2002	Professor, Departments of Medicine and Developmental & Molecular Biology, Albert Einstein College of Medicine, New York
2002	Steering Committee, Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York.
2002-2005	Chairman, Department of Oncology, Georgetown University Medical Center, Washington DC. Director of Lombardi Comprehensive cancer Center.
2002-2005	Licensed medical practitioner in Washington DC.
2005-2017	Licensed Medical practitioner in Philadelphia, PA,
2005-2016	Director of Sidney Kimmel Cancer Center, Head Oncology Service line,
2005-2017	Member Jefferson University Physicians, Hospital Admitting rights, Thomas Jefferson University Hospital. (ABIM number #165233).

Detailed Work History

Clinical Internship and Residencies

1981	Intern in Emergency Medicine
1982	Intern and Resident - Oncology Resident, Palliative Care Resident - Radiation Oncology Resident - Surgical Resident - University Department of Surgery, Royal Perth Hospital
1983	Resident Hematology, Oncology, General Medicine Resident Royal Perth Hospital
1984	Registrar General Medicine including Oncology Care, Nephrology Registrar- (Transplant Unit) Royal Perth Hospital
1985	Registrar General Medicine, including Oncology Care, Cardiology Registrar Royal Perth Hospital
1986	Registrar Hematology, Oncology, (including the Bone Marrow Transplant Unit) Royal Perth Hospital, Endocrinology Fellow, Royal Perth Hospital
1987	Endocrinology Fellow, St Vincent's Hospital, Melbourne.
1988-1991	NHMRC Scholar, University of Melbourne, (Department of Medicine) PhD Oncogene regulation of gene transcription
1991-1993	Postdoctoral Clinical and Research Fellow in Medicine – Massachusetts General Hospital. Postdoctoral Research Fellow in Medicine – Harvard Medical School.
1994-1996	Endocrinology Fellowship training, Northwestern University, Chicago, Il. (Sept/1/1994-Aug/31 1996).
1996-2002	Visiting Attending in Medicine and Endocrinology, Montefiore & Jacobi Medical Centers
1997-2002	Attending physician privileges, Montefiore Hospital

Clinical Duties (1992-present)

1. Visiting Attending in Endocrinology Jacobi and Weiler Hospitals, 1997-2002 (1 month per year)
2. Endocrinology Clinic Attending, Van Etten Clinic Jacobi Hospital 1997-2002 (equivalent 1 month per year)
3. Department of Medicine, Clinical Attending, Jacobi Hospital, (MD/PhD clinic) 1999-2000 (equivalent 1 month per year)
4. Georgetown University Hospital, Visiting Attending, 2002-2005
5. Thomas Jefferson University Hospital, Visiting Attending, 2005-2016
6. Clinical Dean, Xavier University Medical School June 2016-June 30-2025.

Licensure/Boards

1982-1991	Licensed in Australia
1989	Fellow Royal College of Physicians (F.R.A.C.P.) (Australia)
thru 2008	Maintenance of Professional Standards (M.O.P.S.)
thru 2010	Continuing Professional Development (C.P.D.)
1981-current	Education Commission for Medical Graduates (E.C.F.M.G.)
1993-current	Federal Licensing Exam (F.L.E.X.)
1993	Massachusetts Medical License (Limited)
1996-1999	Illinois Medical License
1996-1999	New York Medical License
2003-2005	District of Columbia Medical License
2006- 2022	Pennsylvania Medical License
2019- current	Florida Medical License

CLINICAL and ACADEMIC
Previous Academic and Hospital Appointment

Albert Einstein College of Medicine

2000-2002	Co-leader, Program in Growth Control, Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York
2000-2002	Director, Program in Hormone Responsive Cancers, Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York
2000-2002	Chairman, Division of Endocrine-Dependent Tumor Biology, Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York.

Georgetown University

2002-2005	Director, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC
2002-2005	Professor with Tenure, Departments of Oncology and Medicine (Divisions of Hematology/Oncology, Endocrinology and Metabolic Diseases), Georgetown University School of Medicine, Washington, DC
2002-2005	Francis L. and Charlotte Gragnani Chair, Department of Oncology, Georgetown University Medical Center, Washington, DC
2002-2005	Chairman, Department of Oncology, Georgetown University Medical Center
2002-2005	Member, Space Committee, Georgetown University Medical Center
2002-2005	Member, Basic Science Chairs, Georgetown University Medical Center
2002-2005	Member, Council of Chairs, Georgetown University Medical Center
2002-2005	Member, Executive Committee, Georgetown University Medical Center
2002-2005	Member, Executive Officers, Georgetown University Medical Center
2003-2005	Member, Research Advisory Committee, Georgetown University Medical Center
2004-2005	Member, Advisory Committee, Georgetown University Medical Center (Committee dedicated to financial turnaround and medical center restructuring)
2005-2008	Member, Board of Advisors, Center for Australian and New Zealand Studies (CANZ)
2005	Associate Vice President, Georgetown University Medical Center, Washington, DC

Lombardi Comprehensive Cancer Center

2002-2005	Chair, Executive Committee, Lombardi Comprehensive Cancer Center
2002-2005	Member, Bioinformatics Task Force, Lombardi Comprehensive Cancer Center
2002-2005	Member, Transgenics Task Force, Lombardi Comprehensive Cancer Center
2004-2005	Chair, Lombardi Working Committee
2004-2005	Chair, Lombardi Financial Committee

Georgetown University -Hospital Board and Hospital System Board Membership

2002-2006	Member, Board of Directors, Georgetown University Hospital
2003-2005	Member, Nominating Board, Development and Ethics Committee, Georgetown University Hospital Board of Directors
2002-2005	Member, Clinical Advisory Committee, Georgetown University Hospital
2002-2005	Member, Medical Executive Committee, Georgetown University Hospital MedStar Health
2002-2005	Member, MedStar Research Institute Board of Directors
2002-2005	Member, MedStar Board's Quality and Professional Affairs Committee
2002-2005	Chair, Georgetown University-MedStar Health Oncology Strategic Planning Committee
2002-2005	MedStar Oncology Service Line Taskforce, Leader (Touchstone Consultants).

2025- 2026……HUN REN TKI consultant

CLINICAL and ACADEMIC

Previous Academic and Hospital Appointment

Thomas Jefferson University/Thomas Jefferson University Hospital 2005-2015

- Responsible for Oncology Service line; Radiation Oncology and Medical Oncology Departments reported to me. Annual budget >$350M. Improved Oncology US News from #60 to #17 (2002-2014).
- Provided physician leadership with Thomas Jefferson University Health Affiliates and offsite campus locations, other TJU Health entities to strengthen integration of cancer clinical care and program development that allows for growth and improved patient referral patterns.
- Provided leadership in cancer clinical research management including dissemination of appropriate clinical trials to appropriate network locations.
- Leader of regional M and A for expansion of oncology franchise (PA, New Jersey, Delaware and NY) (2005-2015)
- Responsibilities included leading the cultivation and integration of cancer disease teams into higher functioning teams. Coordinating and leading patient care initiatives.
- Worked with the Hospital President, Deans and Chairs to integrate inpatient unit-based leadership, practice-based leadership and cancer quality committee to sustain a culture of safety and quality across the cancer enterprise.
- Engaged disease teams in establishing objective multimodality patient care measures and worked towards improvement of these measures from baseline. Provide physician leadership to incorporate clinical informatics and diagnostics in care delivery and tracking of treatment outcomes.
- Work with the Department Chairs, Division Chiefs, Executive Directors and other relevant stakeholders to lead the coordination and integration of care across inpatient and outpatient, facilitate the adoption of common care delivery practices as necessary towards readiness to manage complex cancer care cost effectively in a bundled payment environment. Provided strong input and influence on Chairs in the recruitment and selection of cancer-based clinicians throughout TJU Health.

Thomas Jefferson University/Thomas Jefferson University -Clinical Committees 2005-2015

2006-2015	KCC Executive Committee (Renamed SKCC)
2006-2015	KCC Clinical Advisory Committee (Renamed SKCC)
2006-2015	Minority Report Committee
2007-2015	Breast Care Center Executive Committee (Chair)
2006	Department of Medical Oncology Chair Search Committee (committee chair)
2006-2012	Interdisciplinary Collaborative Stimulation Steering Committee (Medical education)
2007-2008	Pathology Chair Search Committee
2006-2015	Executive Council Chair Committee (Department Chairs Committee)
2007-2015	Academic Council (Thomas Jefferson University President's Council)
2007-2013	Ambulatory Care Building Steering Committee
2007-2015	Joint Clinical Management Committee
2007-2009	Lennox Black Committee
2007-2015	TJU Finance Advisory Committee
2007-2011	TJU Medical College Dean's Budget Advisory Committee
2007	TJU School of Nursing Dean Search Committee
2008	Jefferson Medical College Dean Search Committee
2008-2010	Principal Investigator; Clinical and Translational Science Award Grant
2008-2011	Steering Committee and Section Leader, Delaware Valley Institute for Clinical and Translational Science
2008-2011	Member, Health Science Alliance R & D Task Force between Thomas Jefferson University, Christiana Care, Nemours, and University of Delaware.
2012-2013	Jefferson President Search Committee
2013-2015	Jefferson Leadership Group .

International Appointments and Committees

07/2008-2018	Honorary Professor, Department of Medicine, University of Melbourne, Melbourne, Australia
08/2014-2018	Honorary Professorial Fellow,Department of Medicine, St Vincent's Hospital, Melbourne, Australia
01/2015-2017	Scientific Consultant, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia
2014- current	Nominating committee, Global Advance Awards.
2015-2019	Visiting Professor, University of Melbourne, Australia
2017-2019	Visiting Professor with Lee Kong Chian School of Medicine, Nanyang Technological University.
2020-	Member Global Burden of Disease (Institute of Health Metrics collaborator for Dutch Antilles).
2022-2027	Adjunct Professor, University of Western Australia 3/1/2022-2/28/2025
2023-2025	Visiting Scientist Garvan Institute
2023-2025	Member HUN-REN International Advisory Board (IAB),
2024-current	HUN-REN Research Centre for Natural Sciences (HUN-REN RCNS) Advisory Board.
2025-current	Accredited Supervisor, Eötvös Loránd University, Semmelweiss University, Debrecen University

.

CLINICAL and ACADEMIC

NCI Cancer Center Board Member

2001-2005 EAB Roswell Park Cancer Institute, (NCI Designated Cancer Center) Colon Cancer Program
2001-2005 EAB Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics
2003-2007 Howard University Cancer Center, External Scientific Advisory Board
2004-2010 Hollings Cancer Center, (NCI Designated Cancer Center) External
, Charleston, South Carolina
2009-2016 Boston University Cancer Center, (NCI Designated Cancer Center) External Advisory Board, Boston, Massachusetts
2010-2017 Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, Texas (NCI Designated Cancer Center)
2011-2015 University of Hawaii Cancer Center, (NCI Designated Cancer Center) consultant special advisor to and member of External Scientific Advisory Board
2011-2016 Member, External Advisory Board, Breakthrough Breast Cancer Research Unit, Manchester, UK
2012-2017 Member, External Advisory Board, Cancer Institute of New Jersey, (NCI Designated Cancer Center)
2014- 2019 Member, External Advisory Board Shemyakin and Ovchinnikov Institute of Bio-Organic Chemistry, Moscow, Russia.
2020-2025-Chair-Scientific Advisory Board-Chair of The University of Texas MD Anderson Cancer Center SPORE in Breast Cancer.

Other Boards

2000-2003 Vascular Endothelial Growth Factor (VEGF) Educational Resource Network (VERN), Faculty Member
2002 Member, Medical Advisory Council, American Cancer Society, Mid-Atlantic Division
2002- 2004 Member, Breast Health Advisory Council, Susan G. Komen Foundation
2003-2005 Susan G. Komen Breast Cancer Foundation Task Force, Advisory Panel (Chair, Basic & Translational)
2003-2004 The Advisory Board
2003- 2005 Georgetown University, Lombardi Comprehensive Cancer Center, (R. Clarke, PI) – Cooperative Grants for Nutritional Modulation of Genetic Pathways Leading to Cancer.
2003-2005 International Network for Cancer Treatment and Research (INCTR), President
2004-2005 Susan G. Komen Breast Health Advisory Council
2004-2005 D.C. Cancer Consortium, Steering Committee
2004 St. Jude Children's Research Hospital, Dept. of Biochemistry, Review Panel
2004-2008 Honorary Board of Advisors, National Student Leadership Foundation
2004-2009 American Association for Cancer Research- finance committee
2004-2005 American Association for Cancer Research- annual scientific meeting - scientific program committee
2007-2016 Prevent Cancer Foundation (was Cancer Research and Prevention Foundation); Medical Advisory Board
2007-Present LightSeed Inc. (was AAA Phoenix Inc.,). Founder, Chair of Advisory Board
2009-Present American Australian Association, US Advisory Council
2009 Expert Testimony, United States Senate, Committee on Appropriations, Subcommittee on Departments of Labor, Health and Human Services, Education, and Related Agencies (7/6/2009)
2009- 2010 Member, Pennsylvania Division Board of Directors, American Cancer Society
2011 Member, Medical Advisory Board, CORPUS - Journey Through the Human Body
2011-2020 Member, Medical Advisory Board, the Philadelphia Affiliate of Susan G. Komen for the Cure
2011-2013 Internal Advisory Committee, Delaware Valley Institute for Clinical & Translational Science
2012-2016 National Agency for the Evaluation of Universities and Research Institutes (ANVUR)
2014-2019 Basser Board, Basser Research Center, University of Pennsylvania
2018-2019 Member of Board of Directors of CytoDyn Inc.
2023-present Hungarian Government International Advisory board, Hungarian Research Network.
2025- present Endocrine Society of Australia (ESA) Scientific Strengthening Committee

Consulting

2000-2004 National Cancer Institute Health Care Ventures (advisory board novel cancer therapeutics)
2008 Primary Insight, Inc; A subsidiary of The Bear Stearns Companies.
2013 Clarion Healthcare, LLC – Participation in Market Research Studies
2013 Stratas-Partners – Independent Healthcare Consulting Firm. Basel, Switzerland.
2013 Covidien – Lung Solution Clinical Advisory Board. Boston, MA.
2014 MEDACorp. Boston, MA.
2014 Gerson Lehrman Group, Inc. Austin, TX.
2015 Kantar Health
2015 Novartis consulting group
2015- GroupH (independent management consulting company)
2015 Medtronic
2016- SEAK expert witness and other medical legal consulting (patent, hospital system and class actions)
2016- Deloitte- Clinical Challenge Panel (State and National Cancer programs)
2018- Xavier University School of Medicine (Medical School curriculum reform- research, innovation, entrepreneurship).
2023- HUN REN advisory board (International Advisory Board).

CLINICAL and ACADEMIC

Academic Memberships

Current

2025	Elected member Hungarian National Academy of Science (Foreign member)
2024	Elected member Academia Europaea (Foreign member)
2023-	Elected member Order of Australia Association (Lifetime member).
2022	Elected member Royal College of Physicians FRCP (London) Elected Fellow
2022	Elected member Royal College of Physicians FRCP (Ireland), Elected Fellow
2021-	Elected Member, Sigma Xi (Scientific Research Honor Society)
2020-	European Society for Clinical Oncology
2020 –	Elected member Royal Society of Biology, FRSB, (UK) Elected Fellow
2019-	Member Florida Medical Association
2017--	Member American Medical Association
2011-	Elected Fellow, American Association for the Advancement of Science
2009-	Elected Member, American College of Physicians
2007-	Member, American Australian Association
2005-	Elected Member, Royal Society of Medicine (UK) 2005
2004-	Member, Advance – Australian Professionals in America
2003-	Member, American Society of Clinical Oncology
2000-	Elected Member, American Society for Clinical Investigation
1996-	American Association for Cancer Research
1994-	Honorary Lifetime Member, Wyvern Society (For contribution to medical school teaching)
1992-	Member, Endocrine Society of the USA
1990-	Member, Australian Association of Consultant Physicians
1986-	Member, Endocrine Society of Australia

Past

2015-	Member, Knowledge Nation 100
2012-2014	Member, National Medical Association
2009-2011	Member, World Affairs Council of Philadelphia
2009	Member, American Society for Investigative Pathology
2009-2011	Member, New York Academy of Sciences
2009- 2021	Elected Member, College of Physicians of Philadelphia
2007- 2015	Member, American Society Clinical Oncology
2004	Chairman, American Association for Cancer Research, Program Committee, Cell Cycle Section
2002- 2016	Association of American Cancer Institutes
2005-	Member, Royal Australian College of Physicians, Research & Education Foundation
2004-	Member, American Association for Cancer Research, Finance Committee 1998-American Society for Microbiology
1995-	American Society for Biochemistry and Molecular Biology
1999- 2002	International Society for Gene Therapy
1997- 2002	Member, Albert Einstein College of Medicine Cancer Center
1997- 2002	Member, Albert Einstein College of Medicine Diabetes Center
1997- 2002	Member, Albert Einstein College of Medicine Liver Center
1993- 1999	Member, American Federation for Clinical Research
1989- 2000	Member, Australian Society of Medical Research
1987- 1993	Member, International Diabetes Federation
1987- 1991	Member, Medical Association for Prevention of War
1986- 1997	Member, Australian Diabetes Association
1982- 1997	Member, Australian Medical Association

Community Service

2010-Present	Founding Member, National Museum of American Jewish History
2012-2015	Board Member Chamber Orchestra of Philadelphia (Chair Committee 2013)-
2012-	FIDF
2011	American Cancer Society Laureate Society Invitation Committee
2012-2015	Member, Historic St. Peter's Church Preservation Corporation
2012-	Chair – The Chamber Orchestra of Philadelphia Gala
2013	Event Committee Member – Rabin Award Dinner (March 7), Philadelphia-Israel Chamber of Commerce].
2020-	Jewish Federation of Greater Philadelphia
2021	Queens College, Sugden Society
2022	The Florey Society
2022	Albert Einstein College of Medicine, "Legacy Society," and "Medical School Deans Society".

Innovation and Industry Experience

Innovation and Industry synopsis

a) MBA in entrepreneurship and finance (NYU)). (2011)
b) Founded six biotechnology companies (LightSeed LLC, ProstaGene LLC, EcoGenome, Shenandoah, ioROC, StromaGenesis).
c) Multiple issued and pending patents.
d) Special Advisor to the President for Innovation Thomas Jefferson University (2015).
e) Member, National Academy of Inventors, Thomas Jefferson University Chapter (2016)
f) Biotechnology Advisory Board member, CytoDyn (2018-1019), Azure Health Technology Limited (was Invictus Biotechnology) (2018- present).

Education

2011. M.B.A. (Executive – MBA, New York University, Leonard N. Stern School of Business).

Experience

Special Advisor to the President for Innovation Thomas Jefferson University (2015-2016).
Established and developed academic innovation pillar strategy and infrastructure with the President

Biotechnology Companies

1. Founder and CEO. ProstaGene 2011-2018 (molecular diagnostics and therapeutics company) (sold 8/2018).
a. Developed multiple issued patents- domestic and international
b. Conducted all fund raising, clinical trials, and financial management.
c. Acquired by publically traded company (CytoDyn) 2018.

2. CytoDyn Inc. (Director, Board Vice Chairman and CMO- (8/2018- 7/2019).
a.Established and led oncology platform of company (both pre-clinical and clinical)– including fund raising ($50MM), investor meetings and presentations, international and domestic presentations at meetings.
b.Initiated company's first oncology clinical trials.
c. Established clinical trial sites at academic centers,
d. Wrote IND for triple negative breast cancer clinical trial November 2018 (NCT03838367), received fast track designation 5/2019.
e. Wrote and submitted IND for metastatic colon cancer.

3. CytoDyn; Vice Chairman Board of Directors,– (2/2019-7/2019).
4. ***Founder and CEO LightSeed****- 2006- present*. Developed and issued IP., SBIR funded
6. ***Founder and CEO.*** **Shenandoah Pharmaceuticals** (Cancer Therapeutics company). Delaware 1/3/2023-present
7. ***Founder and CEO.*** **EcoGenome** (Cancer Molecular Diagnostics company). Pennsylvania 2/18/2021 raised all funds
8. ***Founder and CEO.*** **StromaGenesis** (Cancer molecular Diagnostics company). 1/24/22- present
9. Founder and CEO. **ioROC** (Cancer molecular Therapeutics and diagnostics company). Delaware 1/13/2023-present

Multiple issued Patents (below).

Consulting

Patent litigation in Biotechnology- Pharma/biotech space (2017-present)

Other Biotech Consulting

2000-2004	National Cancer Institute Health Care Ventures (advisory board novel cancer therapeutics)
2008	Primary Insight, Inc; A subsidiary of The Bear Stearns Companies.
2013	Clarion Healthcare, LLC – Participation in Market Research Studies
2013	Stratas-Partners – Independent Healthcare Consulting Firm. Basel, Switzerland.
2013	Covidien – Lung Solution Clinical Advisory Board. Boston, MA.
2014	MEDACorp. Boston, MA.
2014	Gerson Lehrman Group, Inc. Austin, TX.
2015	Kantar Health
2015	Novartis consulting group
2015-	GroupH (independent management consulting company)
2015	Medtronic
2016-	Deloitte- Clinical Challenge Panel (State and National Cancer programs)

Patents

Granted: AT 2683643, AU 2012225232,CA 2829219, DE 2683643, DK 2683643, EP 2683643, ES 2683643 FFR 2683643, GB 2683643, HK 1194097, IE 2683643, IN 393212, IT 2683643, NL 2683643, US 10952415
CA 2873743, JP 7003083, JP 6518585, US 11633397, US 9453836, DE 2399129, EP 2399129, FR 2399129, GB 2399129, EP2399129,FR 2399129,GE2399129,US WO2004037983, EP 19173075.3,(covers UK, Ireland, France, Italy, Netherlands, Austria, Spain, Denmark, Germany)

Pending AU 2021365816, US 63/555717, AU 2020404930, AU 2022201992, EP 22792654, HK 62024096104. US 18287988

Published EP 21883740.9 JP 2023 -523537, US 18/032743, EP 20902084.1, US 17/785385, US 18/178037
Nationalised US PCT/US2013/040917PCT/US2021/055688, PCT/US2020/065128, BR 112013023050-9, US 17/167578, US PCT/US2012/028546, WO, PCT/US2013/040917, WO PCT/US2010/024606, PCT/US2003/033438

Representative Issued

1. **WO2004037983**, US patent number 8,076,318, issued December 13, 2011, (U.S. Provisional Patent Application Serial No. 10/532,009. PCT Patent Application No. PCT/US2003/033438: *Caged Ligands and Uses Thereof*. International Publication No. A2. May 6, 2004 issued by the International Bureau of the World Intellectual Property Organization. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2004037983).
2. **EP2399129**, EU patent application no. 10744303.8 (issued in France, Germany and the UK under patent number EP2399129). *"A Method of Diagnosis or Prognosis of a Neoplasm Comprising Determining the Level of Expression of a Protein in Stromal Cells Adjacent to the Neoplasm*."
3. US Patent application 14/090,538 (publication number 20,160,139,132, publication date, 5/19/2016 *"A Method of Diagnosis or Prognosis of a Neoplasm Comprising Determining the Level of Expression of a Protein in Stromal Cells Adjacent to the Neoplasm*." Family ID **42634208, Appl #13/202312, filed February 18, 2010, PCT/US2010/024606, 371 date September 14, 2011** https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=10&f=G&l=50&co1=AND&d=PG01&s1=Pestell.IN.&OS=IN/Pestell&RS=IN/Pestell Issued November 2015 (Application number 14/090,538 US Patent Application No. 13/202,312, 8/18/11. International Patent Application PCT/US2010/024606, 2/18/10. European Patent Application No. 10744303.8, 2/18/10.- g ibid, pending related US Patent Application 13/202,318, 8/18/11. International Patent Application PCT/US2010/024685, 2/19/10.
4. **US 2012-00398-05A1** "Therapeutics and Methods for Treating Neoplastic Diseases Comprising Determining the Level of Caveolin-1 and/or Caveolin-2 in a Stromal Cell Sample." 13/202,318 (US 2012-00398-05A1 (2/16/2012)
5. **AU 2012225232** Australian issued Patent No. 2012225232, Title: *Prostate Cancer Cell Lines, Gene Signatures And Uses Thereof*. Ref. 140993.00105 AU. issued August 25, 2016 "Prostate Cancer Cell Lines, Gene Signatures And Uses Thereof: 61/450,767 Patent Methods and Compositions For The Diagnosis, Prognosis And Treatment Of Cancer Related Applications. 03/09/2011 and 09/03/2012, PCT/US2012/028546, agents file ref. 10236-5001WO issued patent.
6. **US 9,453,836** US Patent issued September 27, 2016 as U.S. Patent No. 9,453,836. "*Use of modulators of CCR5 in the treatment of cancer and cancer metastasis"* US Provisional Patent Application Nos. 61/646,593 and 61/646,586 (Reference Nos. 010236-5002-PR & 010236-5002-PR1).
7. **CA 2873743** "Using modulators of CCR5 for treating cancer" filed 14/5/2013, published 21/11/2013, issued 6/12/2022, PCT application # US 2013/040917
8. **CA2829219C** "Prostate cancer cell lines, gene signatures and uses thereof" PCT filed 9/3/2012., PCT Published 13/9/2012., issue date 16/3/2021, priority 9/3/2011 (US 61/450,7670). CCR5 INHIBITORS FOR CANCER
9. **US 10,952,415**
10. **US 16/363,981**
11. **JP 7003083**
12. **EP 2683643**
13. **US 11,633,397**
14. **JP 512749**
15. **CA 28292.**

Published Patent application (Pending).

1. US Patent 13/520,759 US Provisional Application No. 61/292,749 (Georgetown University Ref: 2008-038) – "*Methods and Compositions for the Diagnosis, Prognosis and Treatment of Cancer*." Publication Date: 1/10/2013. U.S. publication Number 20,130,011,411, 2013. International Publication **No. WO/2011/085**,134,2011.
2. US Provisional Patent Application 62/183,08. June 22, 2015 "*Cancers expressing CCR5 and methods of treatment of same*" **WO2016209926.** Serial No.: 15/738,020
3. US Provisional Patent Application 62/035,929 8/11/14 62/037,865 8/15/14 "*Synthesis of Tetracyclic Flavonoids*"
4. *Therapeutics And Methods For Treating Neoplastic Diseases Comprising Determining The Level Of Caveolin-1 And/or Caveolin-2 In A Stromal Cell Sample* Publication Number US 20120039805 Appl no. 13/202,318 Filing Date Feb 20, 2009, PCT 2010-02-19 Publication Date 2012-02-16
5. **Methods, Kits And Compositions For Reducing Cardiotoxicity** Associated With Chemotherapy, filed as U.S. Provisional Application No. 62/948,301 on December 15, 2019; PCT application is **WO 2021/126856**. U.S. Application No. 17/785,385 US. 2023/035491, ; Australian Application No. 2020404930 AU # 2020404930, European Application No. 2,090,084 EP # 4073099
6. Methods And Kits For Diagnosing And Treating Cancers filed as U.S. Provisional Application No 63093772. on 10/19/2020, registration #61347 (DACH1 theragnostic). PCT No. is PCT/US21/55688., Provisional Patent Application METHODS AND KITS FOR DIAGNOSING AND TREATING CANCERS filed as U.S. Provisional Application No 63093772. on 10/19/2020, U.S. Application No.: 18/032,743, Filed: April 19, 2023, registration #61347. Publication Number US 2024/0000977, published on January 04, 2024, This patent refers to the use of determining DACH1 abundance to predict outcome and therapy responses. U.S. Non-Provisional 18/032,743 was filed on April 19, 2023, filed in Europe (**EP21883740.9**), Japan (2023-523537), and Australia (2021365816) from **PCT/US2021/055688** that was filed on October 19, 2021. published as WO 2025/179048
7. **EP3947431A1** Anti-Ccr5 Agents And Methods Of Treatment That Block Cancer Metastasis Or Enhance Cell Death Induced By Dna Damaging Chemotherapy. EP2**0783110.**8 file date 2020-04-01
8. Application No. 62/286,533, filed 1/25/2016 Methods, Kits And Compositions For Reducing Chromosomal Instability In Cancer Cells filed as U.S. Provisional Patent Application Serial No**. 63/178,633** on April 23, 2021 **Expansion of issued** 9,453,836. **US Patent App. 18/287,988,** US20240207248A1
9. **U.S. Application No. 17/167,578**, (expansion to prostate cancer) filed on February 4, 2021, and which is a continuation of U.S. Patent No. 10,952,415. Is being revived.
10. **U.S. Application No. 15/275,050**, filed on September 23, 2016, and which is a continuation of U.S. Patent No. 9,453,836. ("Her2+ breast cancer", "a ccr5 antagonist"). This application has a non-final rejection, mailed on September 28, 2021, and which set a statutory period of 3 months to respond. Thus, this application was effectively abandoned on December 28, 2021, and can still be revived.
11. **U.S. Application No. 16/363,981**, filed on March 25, 2019, (expands to all cancers)., and which is a continuation of U.S. Application No. 15/275,050, which is a continuation of U.S. Patent No. 9,453,836
12. **Application No. US 63/555,717**. Filed February 21, 2023., "ANTIBODIES THAT BIND DACH1 AND METHODS OF USE"**.**
13. **US App 18,178,037** pending, active 2024
14. **EP3597761A1** pending active 2024

RESEARCH

Summary: >700 published works, ~109,600 citations), (includes 455 original artilces, incuding *Cell, Science and Nature Medicine*), 48 book chapters and reviews, and the editor of 1 book, 239 published abstracts. H-index: 162, i10-index: 479. World rankings Cited by Google scholar, (Cell-cycle, Prostate Cancer, Oncology, Breast Cancer).
https://scholar.google.com/citations?hl=en&user=6icYuFsAAAAJ&view_op=list_works&sortby=pubdate
Invited Lectures, 1996- current > 264 invited lectures including named Keynote and named Plenary speaker. Received >$82M USD in research grants as Principal Investigator.

Awards

1. St George's College Prize for first place overall Medical School, University of Western Australia (1976)
2. The Royal Australian College of Physicians Clinical and Written examinations (1986) – Ranked first percentile in Australia
3. University Commonwealth Scholarship, 1975-1981
4. National Health and Medical Research Council of Australia (NHMRC), Postgraduate Scholarship (1988-1991).
5. Higher Education Contribution Scheme (HECS), Postgraduate Scholarship (1988-1991)
6. The Royal Australian College of Physicians, Winthrop Fellowship (1 award given in Australia) (1990).
7. Neil Hamilton Fairley NHMRC, Postdoctoral Fellowship (1991-1994)
8. NIH Shannon Award (1997)
9. Irma T. Hirschl Weil Caulier Career Scientist Award (1998-2002)
10. Elected Member, American Society Clinical Investigators (ASCI) (2000-Present)
11. Diane Belfer Faculty Scholar in Cancer Research, (2002)
12. Francis L. and Charlotte Gragnani Endowed Chair (2002-2005)
13. Australia Endocrine Society, Keith Harrison Memorial Lecture Prize (2005)
14. Elected Member, Interurban Clinical Club
15. Royal Society of Medicine, Elected Member, (2007)
16. Doctor Honoris Causa, University of Western Australia (2008)
17. Elected Honorary Fellow, Queens College, The University of Melbourne (2009)
18. College of Physicians of Philadelphia, FCPP- Elected Fellow (2009)
19. American College of Physicians, FACP- Elected Fellow, (2009)
20. Awarded RD Wright Medallion, University of Melbourne (2010) (award for research excellence).
21. Elected Council Member, Interurban Clinical Club (2010)
22. Honoree, "Light of Life" award, Susan G. Komen for the Cure (2010)
23. Visiting Professorship, Raine Foundation (2010)
24. International Association of Oncologists (IOA)- "Leading Physicians of the World- A Top Oncologist in Philadelphia, PA" (2011)
25. American Association for the Advancement of Science, (FAAAS)- Elected Fellow, (2011)
26. Advance Global Australian Award (Biotechnology) (One National Award given) (2014)
27. The Eric Susman Prize in Medicine, Awarded by the Royal Australasian College of Physicians (2015)
28. Listed amongst Top 10 Australians in the international diaspora (December 2015)
29. Doctor of Medical Sciences, *Honoris Causa*, University of Melbourne Australia (2016)
30. Member, National Academy of Inventors, Thomas Jefferson University Chapter (2016)
31. Jamie Brooke Lieberman Remembrance Award, Susan G. Komen (2016) (for breast cancer metastasis research).
32. AO- Order of Australia (2019). Pestell was appointed an Officer of the Order of Australia in the 2019 Queen's Birthday Honors for "distinguished service to medicine, and to medical education, as a researcher and physician in the fields of endocrinology and oncology.
33. Royal Society of Biology, FRSB, (UK) Elected Fellow (2020)
34. Royal College of Physicians FRCP (London) Elected Fellow (2022)
35. Royal College of Physicians FRCP (Ireland), Elected Fellow (2022)
36. Academia Europaea MAE (Europe), Elected Member (foreign) (2024) (Elected member of the *Academia Europaea*, the European Academy of Humanities, Letters, and Sciences, also known as the Academy of Europe. The Academia is based in London and its members are scholars who live and work in Europe. In cases of "extraordinary achievement," scholars who live outside Europe may be elected as "foreign" members. Pestell was elected in this category)
37. Hungarian Academy of Science, Elected Honorary (life) Member (May 2025)

RESEARCH: Reviewer.

Active Journal Reviewer (28). Science, Cancer Cell, Cell Metabolism, Nature Medicine, EMBO Journal, Proceedings of the National Academy of Science USA, Molecular and Cellular Biology, Molecular and Cellular Endocrinology, Journal of Biological Chemistry, Cancer Research, FASEB Journal, Journal of Cell Physiology, Journal of Clinical Investigation, Cell Growth and Differentiation, Endocrinology, Oncogene, European Journal of Biochemistry, Cancer Detection and Prevention, European Journal of Endocrinology, American Journal of Pathology, American Journal of Physiology – Cell Physiology, Journal of Clinical Endocrinology and Metabolism, Brain Research, Nucleic Acids Research,Expert Review of Anticancer Therapy, BMC Cancer, Cancers, Cell Reports.

Editorial Boards. (previously and or currently member of **editorial board of 14 journals**, including Cancer Research, Senior Editor of IJBCB and active editor of Cancers). **Editorial Boards.** Cancer Research, Senior Editor 2004-2008, Journal of Biological Chemistry, Member, 2002-2007, Trends in, Endocrinology and Metabolism, Member, 2002-2009, International Journal of Oncology, Member, 2001-Present, Frontiers in Bioscience, Member, 1999-Present, Pediatric Pathology and Molecular Medicine, Member, 1999-, Cancer Research, Member Editorial Board, 2003-2004, Current Cancer Therapy Reviews, Member, 2004-2009, The Lancet Oncology, 2005-Present (Journal Advocate), American Journal of Pathology, Review Editor, 2008-2015, International Journal of Biochemistry and Cell Biology, U.S. Editor, 2009-2016, H Journal, 2012-2017, American & Russian Bioscience, 2013, Oncotarget 2014-2015, Cancers 2020-2022

Special Editorial Assignments. Contributing Elected Faculty, Member, Faculty of 1000 Biology (Cell Signaling) (1/60 elected members worldwide), Managing Editor, Frontiers in Bioscience "Cell-cycle dysregulation in disease" (10 chapters), 1999-Present, Cancer Research, Senior Editor, 2004

Grant Reviewer. Study Section. Reviewers of >18 funding agencies in >9 countries. Susan Komen Breast Cancer Foundation:1998-Reviewer, Breast Cancer Research and Education, 1999Chair, Tumor Cell Biology Study Section., 2001-2008, Co-Chair, Tumor Cell Biology Study Section Department of Defense Study Section**:**Ovarian Cancer Research Program, November 1999, Breast cancer study section Cell Biology, 1 (CBY-1), panel, DOD FY2000 (Breast Cancer Program), August 14-15, 2000, State of New York EMPIRE Grants and Fellowships study section, 1998-present, New York State Health Research Science Board and New York State Department of Health Grant Review Board member, 2001, Department of Veterans Affairs, Medical Research Service, Merit Review Grants (United States), Ad hoc reviewer, 1998, 1999, 2000-present, National Science Foundation, Ad Hoc, 1998-current, Raine Medical Research Foundation (Australia), 1999-current, Welcome Trust Reviewer, 1999-current, Juvenile Diabetes Research Foundation International Review Board, Member, 1998-current, Association for International Cancer Research (United Kingdom), 2001-current, Binational Science Foundation (Israel), 2008. Merieux Alliance Grant Review (France), 2009. Health Research Board (Ireland), 2013 Israel Science Foundation, 2013,Czech Science Foundation, 2013, Italian Ministry of Health 2014- present, Florida State Department of Health 2014- present, Medical Research Council UK 2015- present Fondation Contre le Cancer 2015,University of Leuven, Belgium 2022-

NIH.

1.1998- present Subcommittee A NCI Cancer Centers P30 grants (reviewer since)
2. NIH RO1 (TCB study section ad hoc)
3. NIH MONC (12/7/2018), ZRG1-BCMB-C, (40) C, PAR-17-340, Collaborative program for Multidisciplinary Teams (RM1). TCB (Tumor Cell Biology (standing member).

Grant Reviewer: NCI Cancer Center Reviewer – Subcommittee A. Site Visits

NIH Reviewer site visit Reviewer (subset of visits)

Program Project (NCI, Indiana University Cancer Center) - 12/1998
NCI site visit reviewer, NIH-lab of Cellular Oncology - 5/1999, NIH Laboratory of Pathology - 11/17/02
NCI site visit reviewer, University of Pennsylvania Cancer Center, 6/2004
NCI site visit reviewer, University of California San Francisco Cancer Center, CA., 2/2012
NCI site visit reviewer, University of Kansas, February 8, 2017
NCI site visit reviewer, City of Hope, CA., October 3/4, 2017
NCI site visit reviewer, Sloan Kettering Cancer Center, May/10/2018
NCI site visit reviewer, Duncan Cancer Center, Texas., Feb/25/2020
NCI site visit reviewer, O'Neal Cancer Center, Alabama., October/5/2021
NCI site visit reviewer, Roswell Park Cancer Center Site Visit Sep 18-20, 2023
NCI site visit reviewer Memorial Sloan Kettering Comprehensive Cancer Center,

RESEARCH: Representative Key Publications.

Orcid 0000-0003-3244-8777; H-index: 162; i10-index: 488, peer reviewed original articles (464), books, chapters and reviews (55), published abstracts (239) citations ~110,600 (world ranked Google Scholar #1 for cell cycle, and ranked for prostate cancer, oncology, and breast cancer https://scholar.gogle.com/citations?user=RYIsfBQAAAAJ&hl=en

References listing first 24 key papers – then subsequent papers in order of publication.

1. Watanabe, G., Howe, A., Lee, R.J., Albanese, C., Shu, I.W., Karnezis, A.N., Zon, L., Kyriakis, J., Rundell, K., and Pestell, R.G., *Induction of cyclin D1 by simian virus 40 small tumor antigen.* **Proc Natl Acad Sci U S A**. 1996 Nov 12; 93(23): p. 12861-6.
2. Galbiati, F., Volonte, D., Engelman, J.A., Watanabe, G., Burk, R., Pestell, R.G., and Lisanti, M.P., *Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade.* **EMBO J**. 1998 Nov 16; 17(22): p. 6633-48.
3. Beier, F., Lee, R.J., Taylor, A.C., Pestell, R.G., and LuValle, P., *Identification of the cyclin D1 gene as a target of activating transcription factor 2 in chondrocytes.* **Proc Natl Acad Sci U S A**. 1999 Feb 16; 96(4): p. 1433-8.
4. Matsumura, I., Kitamura, T., Wakao, H., Tanaka, H., Hashimoto, K., Albanese, C., Downward, J., Pestell, R.G., and Kanakura, Y., *Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells.* **EMBO J**. 1999 Mar 1; 18(5): p. 1367-77.
5. Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D'Amico, M., Pestell, R.G., and Ben-Ze'ev, A., *The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway.* **Proc Natl Acad Sci U S A**. 1999 May 11; 96(10): p. 5522-7.
6. Fan, S., Wang, J., Yuan, R., Ma, Y., Meng, Q., Erdos, M.R., Pestell, R.G., Yuan, F., Auborn, K.J., Goldberg, I.D., and Rosen, E.M., *BRCA1 inhibition of estrogen receptor signaling in transfected cells.* **Science**. 1999 May 21; 284(5418): p. 1354-6.
7. Bromberg, J.F., Wrzeszczynska, M.H., Devgan, G., Zhao, Y., Pestell, R.G., Albanese, C., and Darnell, J.E., Jr., *Stat3 as an oncogene.* **Cell**. 1999 Aug 6; 98(3): p. 295-303.
8. Lin, S.Y., Xia, W., Wang, J.C., Kwong, K.Y., Spohn, B., Wen, Y., Pestell, R.G., and Hung, M.C., *Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression.* **Proc Natl Acad Sci U S A**. 2000 Apr 11; 97(8): p. 4262-6.
9. Tazebay, U.H., Wapnir, I.L., Levy, O., Dohan, O., Zuckier, L.S., Zhao, Q.H., Deng, H.F., Amenta, P.S., Fineberg, S., Pestell, R.G., and Carrasco, N., *The mammary gland iodide transporter is expressed during lactation and in breast cancer.* **Nat Med**. 2000 Aug; 6(8): p. 871-8.
10. Sampson, E.M., Haque, Z.K., Ku, M.C., Tevosian, S.G., Albanese, C., Pestell, R.G., Paulson, K.E., and Yee, A.S., *Negative regulation of the Wnt-beta-catenin pathway by the transcriptional repressor HBP1.* **EMBO J**. 2001 Aug 15; 20(16): p. 4500-11.
11. Tanaka, H., Matsumura, I., Ezoe, S., Satoh, Y., Sakamaki, T., Albanese, C., Machii, T., Pestell, R.G., and Kanakura, Y., *E2F1 and c-Myc potentiate apoptosis through inhibition of NF-κB activity that facilitates MnSOD-mediated ROS elimination.* **Mol Cell**. 2002 May; 9(5): p. 1017-29.
12. Huang, E., Ishida, S., Pittman, J., Dressman, H., Bild, A., Kloos, M., D'Amico, M., Pestell, R.G., West, M., and Nevins, J.R., *Gene expression phenotypic models that predict the activity of oncogenic pathways.* **Nat Genet**. 2003 Jun; 34(2): p. 226-30.
13. Rowlands, T.M., Pechenkina, I.V., Hatsell, S.J., Pestell, R.G., and Cowin, P., *Dissecting the roles of beta-catenin and cyclin D1 during mammary development and neoplasia.* **Proc Natl Acad Sci U S A**. 2003 Sep 30; 100(20): p. 11400-5.
14. Iyengar, P., Espina, V., Williams, T.W., Lin, Y., Berry, D., Jelicks, L.A., Lee, H., Temple, K., Graves, R., Pollard, J., Chopra, N., Russell, R.G., Sasisekharan, R., Trock, B.J., Lippman, M., Calvert, V.S., Petricoin, E.F., 3rd, Liotta, L., Dadachova, E., Pestell, R.G., Lisanti, M.P., Bonaldo, P., and Scherer, P.E., *Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment.* **J Clin Invest**. 2005 May; 115(5): p. 1163-76.
15. Yang, Y., Stopka, T., Golestaneh, N., Wang, Y., Wu, K., Li, A., Chauhan, B.K., Gao, C.Y., Cveklova, K., Duncan, M.K., Pestell, R.G., Chepelinsky, A.B., Skoultchi, A.I., and Cvekl, A., *Regulation of alphaA-crystallin via Pax6, c-Maf, CREB and a broad domain of lens-specific chromatin.* **EMBO J**. 2006 May 17; 25(10): p. 2107-18.
16. Wang, C., Li, Z., Lu, Y., Du, R., Katiyar, S., Yang, J., Fu, M., Leader, J.E., Quong, A., Novikoff, P.M., and Pestell, R.G., *Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function.* **Proc Natl Acad Sci U S A**. 2006 Aug 1; 103(31): p. 11567-72.
17. Ju, X., Katiyar, S., Wang, C., Liu, M., Jiao, X., Li, S., Zhou, J., Turner, J., Lisanti, M.P., Russell, R.G., Mueller, S.C., Ojeifo, J., Chen, W.S., Hay, N., and Pestell, R.G., *Akt1 governs breast cancer progression in vivo.* **Proc Natl Acad Sci U S A**. 2007 May 1; 104(18): p. 7438-43.

18. Wu, K., Katiyar, S., Li, A., Liu, M., Ju, X., Popov, V.M., Jiao, X., Lisanti, M.P., Casola, A., and Pestell, R.G., *Dachshund inhibits oncogene-induced breast cancer cellular migration and invasion through suppression of interleukin-8.* **Proc Natl Acad Sci U S A**. 2008 May 13; 105(19): p. 6924-9.

19. Genander, M., Halford, M.M., Xu, N.J., Eriksson, M., Yu, Z., Qiu, Z., Martling, A., Greicius, G., Thakar, S., Catchpole, T., Chumley, M.J., Zdunek, S., Wang, C., Holm, T., Goff, S.P., Pettersson, S., Pestell, R.G., Henkemeyer, M., and Frisen, J., *Dissociation of EphB2 signaling pathways mediating progenitor cell proliferation and tumor suppression.* **Cell**. 2009 Nov 13; 139(4): p. 679-92.

20. Zhou, J., Wang, C., Wang, Z., Dampier, W., Wu, K., Casimiro, M.C., Chepelev, I., Popov, V.M., Quong, A., Tozeren, A., Zhao, K., Lisanti, M.P., and Pestell, R.G., *Attenuation of Forkhead signaling by the retinal determination factor DACH1.* **Proc Natl Acad Sci U S A**. 2010 Apr 13; 107(15): p. 6864-9.

21. Yu, Z., Willmarth, N.E., Zhou, J., Katiyar, S., Wang, M., Liu, Y., McCue, P.A., Quong, A.A., Lisanti, M.P., and Pestell, R.G., *microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling.* **Proc Natl Acad Sci U S A**. 2010 May 4;107(18):8231-6. Epub 2010 Apr 20.

22. Casimiro MC, Crosariol M, Loro E, Ertel A, Yu Z, Dampier W, Saria E, Papanikolaou A, Li Z, Wang C, Fortina P, Addya A, Tozeren A, Knudsen ES, Arnold A, Pestell RG. *ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice***. J Clin Invest**. 2012 Mar 1;122(3):833-43. doi: 10.1172/JCI60256. Epub 2012 Feb 6.

23. Yu Z, Wang L, Wang C, Ju X, Wang M, Chen K, Loro E, Wu K, Casimiro MC, Gormley M, Ertel A, Fortina P, Tozeren A, Liu Z, Chen Y, Pestell RG. *Cyclin D1 Induction of Dicer Governs MicroRNA Processing and Expression in Breast Cancer.* **Nat Commun**. 2013 Nov 29;4:2812. doi: 10.1038/ncomms3812.

24. Zhang J, Wang C, Chen X, Takada M, Fan C, Zheng X, Wen H, Liu Y, Pestell RG, Aird KM, Kaelin Jr W, Liu XS, Zhang Q. *EgIN2 Associates, with the NRF1-PGC1 Complex and Controls Mitochondrial Function in Breast Cance*r. **EMBO J** 2015 Oct 22. pii: e201591437

All Peer Reviewed Publications and Reviews

25. Pestell, R.G., Parathyroid adenomas associated with carcinoma of the thyroid. **Med J Aust**. 1982 Jul 24; 2(2): p. 64-5.

26. Pestell, R.G., Peripheral eosinophilia associated with eosinophilic non-Hodgkin's lymphoma. **Med J Aust**. 1982 Aug 7; 2(3): p. 119-20.

27. Pestell, R.G., Barr, A.L., and Brand, G., *Vitamin C and congestive cardiac failure.* **Med J Aust**. 1987 Aug 3; 147(3): p. 153-4.

28. Crock, P.A., Pestell, R.G., Calenti, A.J., Gilford, E.J., Henderson, J.K., Best, J.D., and Alford, F.P., *Multiple pituitary hormone gradients from inferior petrosal sinus sampling in Cushing's disease.* **Acta Endocrinol (Copenh)**. 1988 Sep; 119(1): p. 75-80.

29. Pestell, R.G., Crock, P.A., Ward, G.M., Alford, F.P., and Best, J.D., *Fenfluramine increases insulin action in patients with NIDDM.* **Diabetes Care**. 1989 Apr; 12(4): p. 252-8.

30. Pestell, R.G., Hurley, D.M., and Vandongen, R., *Biochemical and hormonal changes during a 1000 km ultramarathon.* **Clin Exp Pharmacol Physiol**. 1989 May; 16(5): p. 353-61.

31. Pestell, R.G., Alford, F.P., and Best, J.D., *Familial acromegaly.* **Acta Endocrinol (Copenh)**. 1989 Aug; 121(2): p. 286-9.

32. Pestell, R.G. and Taylor, R.R., *Effect of cigarette smoking on the frequency of ventricular premature complexes in normal subjects.* **Clin Exp Pharmacol Physiol**. 1989 Aug; 16(8): p. 647-50.

33. Best, J.D., Alford, F.P., Martin, I.K., Pestell, R.G., and Ward, G.M., *Practical application of methods for in vivo assessment of insulin secretion and action.* **Horm Metab Res Suppl**. 1990; 24: p. 60-6.

34. Chamberlain, K.G., Pestell, R.G., and Best, J.D., *Platelet catecholamine contents are cumulative indexes of sympathoadrenal activity.* **Am J Physiol**. 1990 Aug; 259(2 Pt 1): p. E141-7.

35. Arnott, R.D., Pestell, R.G., McKelvie, P.A., Henderson, J.K., McNeill, P.M., and Alford, F.P., *A critical evaluation of transsphenoidal pituitary surgery in the treatment of Cushing's disease: prediction of outcome.* **Acta Endocrinol (Copenh)**. 1990 Oct; 123(4): p. 423-30.

36. Pestell, R., Alford, F., Ramos, R., Sawyer, S., Best, J., and Ward, G., *Insulin secretion, insulin sensitivity and glucose-mediated glucose disposal in thyrotoxicosis: a minimal model analysis.* **Clin Endocrinol (Oxf)**. 1990 Oct; 33(4): p. 481-93.

37. Pestell, R.G., Best, J.D., and Alford, F.P., *Lymphocytic hypophysitis. The clinical spectrum of the disorder and evidence for an autoimmune pathogenesis.* **Clin Endocrinol (Oxf)**. 1990 Oct; 33(4): p. 457-66.

38. Pestell, R.G., Herington, A., Best, J., Boolell, M., McKelvie, P., Arnott, R., and Alford, F., *Growth hormone excess and galactorrhoea without acromegalic features. Case reports.* **Br J Obstet Gynaecol**. 1991 Jan; 98(1): p. 92-7.

39. Pestell, R.G. and Ball, J.R., *Authoritarianism among medicine and law students.* **Aust N Z J Psychiatry**. 1991 Jun; 25(2): p. 265-9.

40. Pestell, R.G., Kirsner, R.L., and Best, J.D., *Validation and evaluation of test for sympathetic cholinergic function in diabetes mellitus.* **Diabetes**. 1991 Jul; 40(7): p. 867-72.

41. Page, R., Boolell, M., Kalfas, A., Sawyer, S., Pestell, R.G., Ward, G., and Alford, F., *Insulin secretion, insulin sensitivity and glucose-mediated glucose disposal in Cushing's disease: a minimal model analysis.* **Clin Endocrinol (Oxf)**. 1991 Dec; 35(6): p. 509-17.

42. Galvin, P., Ward, G., Walters, J., Pestell, R.G., Koschmann, M., Vaag, A., Martin, I., Best, J.D., and Alford, F., *A simple method for quantitation of insulin sensitivity and insulin release from an intravenous glucose tolerance test.* **Diabet Med**. 1992 Dec; 9(10): p. 921-8.

43. Pestell, R.G., Ward, G.M., Galvin, P., Best, J.D., and Alford, F.P., *Impaired glucose tolerance after endurance exercise is associated with reduced insulin secretion rather than altered insulin sensitivity.* **Metabolism**. 1993 Mar; 42(3): p. 277-82.

44. Pestell, R.G., Hammond, V.E., and Crawford, R.J., *Molecular cloning and characterization of the cyclic AMP-responsive ovine CYP11A1 (cholesterol side-chain cleavage) gene promoter: DNase 1 protection of conserved consensus elements.* **J Mol Endocrinol**. 1993 Jun; 10(3): p. 297-311.

45. Hollenberg, A.N., Pestell, R.G., Albanese, C., Boers, M.E., and Jameson, J.L., *Multiple promoter elements in the human chorionic gonadotropin beta subunit genes distinguish their expression from the luteinizing hormone beta gene.* **Mol Cell Endocrinol**. 1994 Dec; 106(1-2): p. 111-9.

46. Pestell, R.G., Hollenberg, A.N., Albanese, C., and Jameson, J.L., *c-Jun represses transcription of the human chorionic gonadotropin alpha and beta genes through distinct types of CREs.* **J Biol Chem**. 1994 Dec 9; 269(49): p. 31090-6.

47. Pestell, R.G., Albanese, C., Watanabe, G., Johnson, J., Eklund, N., Lastowiecki, P., and Jameson, J.L., *Epidermal growth factor and c-Jun act via a common DNA regulatory element to stimulate transcription of the ovine P-450 cholesterol side chain cleavage (CYP11A1) promoter.* **J Biol Chem**. 1995 Aug 4; 270(31): p. 18301-8.

48. Albanese, C., Johnson, J., Watanabe, G., Eklund, N., Vu, D., Arnold, A., and Pestell, R.G., *Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions.* **J Biol Chem**. 1995 Oct 6; 270(40): p. 23589-97.

49. Albanese, C., Colin, I.M., Crowley, W.F., Ito, M., Pestell, R.G., Weiss, J., and Jameson, J.L., *The gonadotropin genes: evolution of distinct mechanisms for hormonal control.* **Recent Prog Horm Res**. 1996; 51: p. 23-58; discussion 59-61.

50. Sundaresan, S., Colin, I.M., Pestell, R.G., and Jameson, J.L., *Stimulation of mitogen-activated protein kinase by gonadotropin-releasing hormone: evidence for the involvement of protein kinase C.* **Endocrinology**. 1996 Jan; 137(1): p. 304-11.

51. Pestell, R.G., Albanese, C., Watanabe, G., Lee, R.J., Lastowiecki, P., Zon, L., Ostrowski, M., and Jameson, J.L., *Stimulation of the P-450 side chain cleavage enzyme (CYP11A1) promoter through ras- and Ets-2-signaling pathways.* **Mol Endocrinol**. 1996 Sep; 10(9): p. 1084-94.

52. Shambaugh, G.E., 3rd, Lee, R.J., Watanabe, G., Erfurth, F., Karnezis, A.N., Koch, A.E., Haines, G.K., 3rd, Halloran, M., Brody, B.A., and Pestell, R.G., *Reduced cyclin D1 expression in the cerebella of nutritionally deprived rats correlates with developmental delay and decreased cellular DNA synthesis.* **J Neuropathol Exp Neurol**. 1996 Sep; 55(9): p. 1009-20.

53. Watanabe, G., Lee, R.J., Albanese, C., Rainey, W.E., Batlle, D., and Pestell, R.G., *Angiotensin II activation of cyclin D1-dependent kinase activity.* **J Biol Chem**. 1996 Sep 13; 271(37): p. 22570-7.

54. Pestell, R.G., Albanese, C., Lee, R.J., Watanabe, G., Moran, E., Johnson, J., and Jameson, J.L., *A potential role for cell cycle control proteins in regulation of the cyclic adenosine 5'-monophosphate-responsive glycoprotein hormone alpha subunit gene.* **Cell Growth Differ**. 1996 Oct; 7(10): p. 1337-44.

55. Watanabe, G., Howe, A., Lee, R.J., Albanese, C., Shu, I.W., Karnezis, A.N., Zon, L., Kyriakis, J., Rundell, K., and Pestell, R.G., *Induction of cyclin D1 by simian virus 40 small tumor antigen.* **Proc Natl Acad Sci U S A**. 1996 Nov 12; 93(23): p. 12861-6.

56. Thurston, V.C., Pena, P., Pestell, R.G., and Binder, L.I., *Nucleolar localization of the microtubule-associated protein tau in neuroblastomas using sense and anti-sense transfection strategies.* **Cell Motil Cytoskeleton**. 1997; 38(1): p. 100-10.

57. Westwick, J.K., Lambert, Q.T., Clark, G.J., Symons, M., Van Aelst, L., Pestell, R.G., and Der, C.J., *Rac regulation of transformation, gene expression, and actin organization by multiple, PAK-independent pathways.* **Mol Cell Biol**. 1997 Mar; 17(3): p. 1324-35.

58. Li, X., Hales, K.H., Watanabe, G., Lee, R.J., Pestell, R.G., and Hales, D.B., *The effect of tumor necrosis factor-alpha and cAMP on induction of AP-1 activity in MA-10 tumor Leydig cells.* **Endocrine**. 1997 Jun; 6(3): p. 317-24.

59. Xiong, W., Pestell, R.G., Watanabe, G., Li, J., Rosner, M.R., and Hershenson, M.B., *Cyclin D1 is required for S phase traversal in bovine tracheal myocytes.* **Am J Physiol**. 1997 Jun; 272(6 Pt 1): p. L1205-10.

60. Johnson, W., Albanese, C., Handwerger, S., Williams, T., Pestell, R.G., and Jameson, J.L., *Regulation of the human chorionic gonadotropin alpha- and beta-subunit promoters by AP-2.* **J Biol Chem**. 1997 Jun 13; 272(24): p. 15405-12.

61. Watanabe, G., Pena, P., Albanese, C., Wilsbacher, L.D., Young, J.B., and Pestell, R.G., *Adrenocorticotropin induction of stress-activated protein kinase in the adrenal cortex in vivo.* **J Biol Chem**. 1997 Aug 8; 272(32): p. 20063-9.

62. Neuman, E., Ladha, M.H., Lin, N., Upton, T.M., Miller, S.J., DiRenzo, J., Pestell, R.G., Hinds, P.W., Dowdy, S.F., Brown, M., and Ewen, M.E., *Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4.*.

63. Xiong, W., Pestell, R.G., and Rosner, M.R., *Role of cyclins in neuronal differentiation of immortalized hippocampal cells.* **Mol Cell Biol**. 1997 Nov; 17(11): p. 6585-97.

64. Akama, K.T., Albanese, C., Pestell, R.G., and Van Eldik, L.J., *Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NF-κB-dependent mechanism.* **Proc Natl Acad Sci U S A**. 1998 May 12; 95(10): p. 5795-800.

65. Ramakrishnan, M., Musa, N.L., Li, J., Liu, P.T., Pestell, R.G., and Hershenson, M.B., *Catalytic activation of extracellular signal-regulated kinases induces cyclin D1 expression in primary tracheal myocytes.* **Am J Respir Cell Mol Biol**. 1998 Jun; 18(6): p. 736-40.

66. Watanabe, G., Albanese, C., Lee, R.J., Reutens, A., Vairo, G., Henglein, B., and Pestell, R.G., *Inhibition of cyclin D1 kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Sp1.* **Mol Cell Biol**. 1998 Jun; 18(6): p. 3212-22.

67. Watanabe, G., Pena, P., Shambaugh, G.E., 3rd, Haines, G.K., 3rd, and Pestell, R.G., *Regulation of cyclin dependent kinase inhibitor proteins during neonatal cerebella development.* **Brain Res Dev Brain Res**. 1998 Jun 15; 108(1-2): p. 77-87.

68. Westwick, J.K., Lee, R.J., Lambert, Q.T., Symons, M., Pestell, R.G., Der, C.J., and Whitehead, I.P., *Transforming potential of Dbl family proteins correlates with transcription from the cyclin D1 promoter but not with activation of Jun NH2-terminal kinase, p38/Mpk2, serum response factor, or c-Jun.* **J Biol Chem**. 1998 Jul 3; 273(27): p. 16739-47.

69. Engelman, J.A., Lee, R.J., Karnezis, A., Bearss, D.J., Webster, M., Siegel, P., Muller, W.J., Windle, J.J., Pestell, R.G., and Lisanti, M.P., *Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer.* **J Biol Chem**. 1998 Aug 7; 273(32): p. 20448-55.

70. Brown, J.R., Nigh, E., Lee, R.J., Ye, H., Thompson, M.A., Saudou, F., Pestell, R.G., and Greenberg, M.E., *Fos family members induce cell cycle entry by activating cyclin D1.* **Mol Cell Biol**. 1998 Sep; 18(9): p. 5609-19.

71. Galbiati, F., Volonte, D., Engelman, J.A., Watanabe, G., Burk, R., Pestell, R.G., and Lisanti, M.P., *Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade.* **EMBO J**. 1998 Nov 16; 17(22): p. 6633-48.

72. Engelman, J.A., Zhang, X., Galbiati, F., Volonte, D., Sotgia, F., Pestell, R.G., Minetti, C., Scherer, P.E., Okamoto, T., and Lisanti, M.P., *Molecular genetics of the caveolin gene family: implications for human cancers, diabetes, Alzheimer disease, and muscular dystrophy.* **Am J Hum Genet**. 1998 Dec; 63(6): p. 1578-87.

73. Musa, N.L., Ramakrishnan, M., Li, J., Kartha, S., Liu, P., Pestell, R.G., and Hershenson, M.B., *Forskolin inhibits cyclin D1 expression in cultured airway smooth-muscle cells.* **Am J Respir Cell Mol Biol**. 1999 Feb; 20(2): p. 352-8.

74. Beier, F., Lee, R.J., Taylor, A.C., Pestell, R.G., and LuValle, P., *Identification of the cyclin D1 gene as a target of activating transcription factor 2 in chondrocytes.* **Proc Natl Acad Sci U S A**. 1999 Feb 16; 96(4): p. 1433-8.

75. Matsumura, I., Kitamura, T., Wakao, H., Tanaka, H., Hashimoto, K., Albanese, C., Downward, J., Pestell, R.G., and Kanakura, Y., *Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells.* **EMBO J**. 1999 Mar 1; 18(5): p. 1367-77.

76. Lee, R.J., Albanese, C., Stenger, R.J., Watanabe, G., Inghirami, G., Haines, G.K., 3rd, Webster, M., Muller, W.J., Brugge, J.S., Davis, R.J., and Pestell, R.G., *pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells.* **J Biol Chem**. 1999 Mar 12; 274(11): p. 7341-50.

77. Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D'Amico, M., Pestell, R.G., and Ben-Ze'ev, A., *The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway.* **Proc Natl Acad Sci U S A**. 1999 May 11; 96(10): p. 5522-7.

78. Fan, S., Wang, J., Yuan, R., Ma, Y., Meng, Q., Erdos, M.R., Pestell, R.G., Yuan, F., Auborn, K.J., Goldberg, I.D., and Rosen, E.M., *BRCA1 inhibition of estrogen receptor signaling in transfected cells.* **Science**. 1999. May 21;284(5418):1354-6. PMID: 10334989

79. Beier, F., Leask, T.A., Haque, S., Chow, C., Taylor, A.C., Lee, R.J., Pestell, R.G., Ballock, R.T., and LuValle, P., *Cell cycle genes in chondrocyte proliferation and differentiation.* **Matrix Biol**. 1999 1999/06/18; 18(2): p. 109-20.

80. Ashton, A.W., Watanabe, G., Albanese, C., Harrington, E.O., Ware, J.A., and Pestell, R.G., *Protein kinase Cdelta inhibition of S-phase transition in capillary endothelial cells involves the cyclin-dependent kinase inhibitor p27(Kip1).* **J Biol Chem**. 1999 Jul 23; 274(30): p. 20805-11.

81. Page, K., Li, J., Hodge, J.A., Liu, P.T., Vanden Hoek, T.L., Becker, L.B., Pestell, R.G., Rosner, M.R., and Hershenson, M.B., *Characterization of a Rac1 signaling pathway to cyclin D(1) expression in airway smooth muscle cells.* **J Biol Chem**. 1999 Jul 30; 274(31): p. 22065-71.

82. Guttridge, D.C., Albanese, C., Reuther, J.Y., Pestell, R.G., and Baldwin, A.S., Jr., *NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1.* **Mol Cell Biol**. 1999 Aug; 19(8): p. 5785-99.

83. Pena, P., Reutens, A.T., Albanese, C., D'Amico, M., Watanabe, G., Donner, A., Shu, I.W., Williams, T., and Pestell, R.G., *Activator protein-2 mediates transcriptional activation of the CYP11A1 gene by interaction with Sp1 rather than binding to DNA.* **Mol Endocrinol**. 1999 Aug; 13(8): p. 1402-16.

84. Pestell, R.G., Albanese, C., Reutens, A.T., Segall, J.E., Lee, R.J., and Arnold, A., *The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation.* **Endocr Rev**. 1999 Aug; 20(4): p. 501-34.

85. Bromberg, J.F., Wrzeszczynska, M.H., Devgan, G., Zhao, Y., Pestell, R.G., Albanese, C., and Darnell, J.E., Jr., *Stat3 as an oncogene.* **Cell**. 1999 Aug 6; 98(3): p. 295-303.

86. Joyce, D., Bouzahzah, B., Fu, M., Albanese, C., D'Amico, M., Steer, J., Klein, J.U., Lee, R.J., Segall, J.E., Westwick, J.K., Der, C.J., and Pestell, R.G., *Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factor-kappaB-dependent pathway.* **J Biol Chem**. 1999 Sep 3; 274(36): p. 25245-9.

87. Carlson, B., Lahusen, T., Singh, S., Loaiza-Perez, A., Worland, P.J., Pestell, R.G., Albanese, C., Sausville, E.A., and Senderowicz, A.M., *Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol.* **Cancer Res**. 1999 Sep 15; 59(18): p. 4634-41.

88. Engelman, J.A., Zhang, X.L., Razani, B., Pestell, R.G., and Lisanti, M.P., *p42/44 MAP kinase-dependent and -independent signaling pathways regulate caveolin-1 gene expression. Activation of Ras-MAP kinase and protein kinase a signaling cascades transcriptionally down-regulates caveolin-1 promoter activity.* **J Biol Chem**. 1999 Nov 5; 274(45): p. 32333-41.

89. Schlegel, A., Wang, C., Katzenellenbogen, B.S., Pestell, R.G., and Lisanti, M.P., *Caveolin-1 potentiates estrogen receptor alpha (ERalpha) signaling. caveolin-1 drives ligand-independent nuclear translocation and activation of ERalpha.* **J Biol Chem**. 1999 Nov 19; 274(47): p. 33551-6.

90. Albanese, C., D'Amico, M., Reutens, A.T., Fu, M., Watanabe, G., Lee, R.J., Kitsis, R.N., Henglein, B., Avantaggiati, M., Somasundaram, K., Thimmapaya, B., and Pestell, R.G., *Activation of the cyclin D1 gene by the E1A-associated protein p300 through AP-1 inhibits cellular apoptosis.* **J Biol Chem**. 1999 Nov 26; 274(48): p. 34186-95.

91. Lee, R.J., Albanese, C., Fu, M., D'Amico, M., Lin, B., Watanabe, G., Haines, G.K., 3rd, Siegel, P.M., Hung, M.C., Yarden, Y., Horowitz, J.M., Muller, W.J., and Pestell, R.G., *Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway.* **Mol Cell Biol**. 2000 Jan; 20(2): p. 672-83.

92. Bregman, D.B., Pestell, R.G., and Kidd, V.J., *Cell cycle regulation and RNA polymerase II.* **Front Biosci**. 2000 Feb 1; 5: p. D244-57.

93. Shambaugh, G.E., 3rd, Haines, G.K., 3rd, Koch, A., Lee, E.J., Zhou, J., and Pestell, R.G., *Immunohistochemical examination of the INK4 and Cip inhibitors in the rat neonatal cerebellum: cellular localization and the impact of protein calorie malnutrition.* **Brain Res**. 2000 Feb 7; 855(1): p. 11-22.

94. Amanatullah, D.F., Reutens, A.T., Zafonte, B.T., Fu, M., Mani, S., and Pestell, R.G., *Cell-cycle dysregulation and the molecular mechanisms of prostate cancer.* **Front Biosci**. 2000 Apr 1; 5: p. D372-90.

95. Petkova, S.B., Ashton, A., Bouzahzah, B., Huang, H., Pestell, R.G., and Tanowitz, H.B., *Cell cycle molecules and diseases of the cardiovascular system.* **Front Biosci**. 2000 Apr 1; 5: p. D452-60.

96. Lin, S.Y., Xia, W., Wang, J.C., Kwong, K.Y., Spohn, B., Wen, Y., Pestell, R.G., and Hung, M.C., *Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression.* **Proc Natl Acad Sci U S A**. 2000 Apr 11; 97(8): p. 4262-6.

97. Albanese, C., Reutens, A.T., Bouzahzah, B., Fu, M., D'Amico, M., Link, T., Nicholson, R., Depinho, R.A., and Pestell, R.G., *Sustained mammary gland-directed, ponasterone A-inducible expression in transgenic mice.* **FASEB J**. 2000 May; 14(7): p. 877-84.

98. Zahler, M.H., Irani, A., Malhi, H., Reutens, A.T., Albanese, C., Bouzahzah, B., Joyce, D., Gupta, S., and Pestell, R.G., *The application of a lentiviral vector for gene transfer in fetal human hepatocytes.* **J Gene Med**. 2000 May-Jun; 2(3): p. 186-93.

99. Yu, B., Lane, M.E., Pestell, R.G., Albanese, C., and Wadler, S., *Downregulation of cyclin D1 alters cdk 4- and cdk 2-specific phosphorylation of retinoblastoma protein.* **Mol Cell Biol Res Commun**. 2000 Jun; 3(6): p. 352-9.

100. Fu, M., Wang, C., Reutens, A.T., Wang, J., Angeletti, R.H., Siconolfi-Baez, L., Ogryzko, V., Avantaggiati, M.L., and Pestell, R.G., *p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation.* **J Biol Chem**. 2000 Jul 7;. 275 (27), 20853-20860.

101. Zhang, W., Razani, B., Altschuler, Y., Bouzahzah, B., Mostov, K.E., Pestell, R.G., and Lisanti, M.P., *Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1.* **J Biol Chem**. 2000 Jul 7; 275(27): p. 20717-25.

102. Hulit, J., Bash, T., Fu, M., Galbiati, F., Albanese, C., Sage, D.R., Schlegel, A., Zhurinsky, J., Shtutman, M., Ben-Ze'ev, A., Lisanti, M.P., and Pestell, R.G., *The cyclin D1 gene is transcriptionally repressed by caveolin-1.* **J Biol Chem**. 2000 Jul 14; 275(28): p. 21203-9.

103. Galbiati, F., Volonte, D., Brown, A.M., Weinstein, D.E., Ben-Ze'ev, A., Pestell, R.G., and Lisanti, M.P., *Caveolin-1 expression inhibits Wnt/beta-catenin/Lef-1 signaling by recruiting beta-catenin to caveolae membrane domains.* **J Biol Chem**. 2000 Jul 28; 275(30): p. 23368-77.

104. Mani, S., Wang, C., Wu, K., Francis, R., and Pestell, R.G., *Cyclin-dependent kinase inhibitors: novel anticancer agents.* **Expert Opin Investig Drugs**. 2000 Aug; 9(8): p. 1849-70.

105. Shie, J.L., Chen, Z.Y., Fu, M., Pestell, R.G., and Tseng, C.C., *Gut-enriched Kruppel-like factor represses cyclin D1 promoter activity through Sp1 motif.* **Nucleic Acids Res**. 2000 Aug 1; 28(15): p. 2969-76.

106. Tazebay, U.H., Wapnir, I.L., Levy, O., Dohan, O., Zuckier, L.S., Zhao, Q.H., Deng, H.F., Amenta, P.S., Fineberg, S., Pestell, R.G., and Carrasco, N., *The mammary gland iodide transporter is expressed during lactation and in breast cancer.* **Nat Med**. 2000 Aug; 6(8): p. 871-8.

107. Bouzahzah, B., Fu, M., Iavarone, A., Factor, V.M., Thorgeirsson, S.S., and Pestell, R.G., *Transforming growth factor-beta1 recruits histone deacetylase 1 to a p130 repressor complex in transgenic mice in vivo.* **Cancer Res**. 2000 Aug 15; 60(16): p. 4531-7.

108. Galbiati, F., Volonte, D., Chu, J.B., Li, M., Fine, S.W., Fu, M., Bermudez, J., Pedemonte, M., Weidenheim, K.M., Pestell, R.G., Minetti, C., and Lisanti, M.P., *Transgenic overexpression of caveolin-3 in skeletal muscle fibers induces a Duchenne-like muscular dystrophy phenotype.* **Proc Natl Acad Sci U S A**. 2000 Aug 15; 97(17): p. 9689-94.

109. Petkova, S.B., Tanowitz, H.B., Magazine, H.I., Factor, S.M., Chan, J., Pestell, R.G., Bouzahzah, B., Douglas, S.A., Shtutin, V., Morris, S.A., Tsang, E., Weiss, L.M., Christ, G.J., Wittner, M., and Huang, H., *Myocardial expression of endothelin-1 in murine Trypanosoma cruzi infection.* **Cardiovasc Pathol**. 2000 Sep-Oct; 9(5): p. 257-65.

110. Page, K., Li, J., Wang, Y., Kartha, S., Pestell, R.G., and Hershenson, M.B., *Regulation of cyclin D(1) expression and DNA synthesis by phosphatidylinositol 3-kinase in airway smooth muscle cells.* **Am J Respir Cell Mol Biol**. 2000 Oct; 23(4): p. 436-43.

111. Shie, J.L., Chen, Z.Y., O'Brien, M.J., Pestell, R.G., Lee, M.E., and Tseng, C.C., *Role of gut-enriched Kruppel-like factor in colonic cell growth and differentiation.* **Am J Physiol Gastrointest Liver Physiol**. 2000 Oct; 279(4): p. G806-14.

112. D'Amico, M., Hulit, J., Amanatullah, D.F., Zafonte, B.T., Albanese, C., Bouzahzah, B., Fu, M., Augenlicht, L.H., Donehower, L.A., Takemaru, K., Moon, R.T., Davis, R., Lisanti, M.P., Shtutman, M., Zhurinsky, J., Ben-Ze'ev, A., Troussard, A.A., Dedhar, S., and Pestell, R.G., *The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3beta and cAMP-responsive element-binding protein-dependent pathways.* **J Biol Chem**. 2000 Oct 20; 275(42): p. 32649-57.

113. Bailly, M., Wyckoff, J., Bouzahzah, B., Hammerman, R., Sylvestre, V., Cammer, M., Pestell, R.G., and Segall, J.E., *Epidermal growth factor receptor distribution during chemotactic responses.* **Mol Biol Cell**. 2000 Nov; 11(11): p. 3873-83.

114. Henry, D.O., Moskalenko, S.A., Kaur, K.J., Fu, M., Pestell, R.G., Camonis, J.H., and White, M.A., *Ral GTPases contribute to regulation of cyclin D1 through activation of NF-κB.* **Mol Cell Biol**. 2000 Nov; 20(21): p. 8084-92.

115. Huang, H., Petkova, S.B., Pestell, R.G., Bouzahzah, B., Chan, J., Magazine, H., Weiss, L.M., Christ, G.J., Lisanti, M.P., Douglas, S.A., Shtutin, V., Halonen, S.K., Wittner, M., and Tanowitz, H.B., *Trypanosoma cruzi infection (Chagas' disease) of mice causes activation of the mitogen-activated protein kinase cascade and expression of endothelin-1 in the myocardium.* **J Cardiovasc Pharmacol**. 2000 Nov; 36(5 Suppl 1): p. S148-50.

116. Lee, H., Volonte, D., Galbiati, F., Iyengar, P., Lublin, D.M., Bregman, D.B., Wilson, M.T., Campos-Gonzalez, R., Bouzahzah, B., Pestell, R.G., Scherer, P.E., and Lisanti, M.P., *Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette.* **Mol Endocrinol**. 2000 Nov; 14(11): p. 1750-75.

117. Wang, C., Francis, R., Harirchian, S., Batlle, D., Mayhew, B., Bassett, M., Rainey, W.E., and Pestell, R.G., *The application of high density microarray for analysis of mitogenic signaling and cell-cycle in the adrenal.* **Endocr Res**. 2000 Nov; 26(4): p. 807-23.

118. Razani, B., Altschuler, Y., Zhu, L., Pestell, R.G., Mostov, K.E., and Lisanti, M.P., *Caveolin-1 expression is down-regulated in cells transformed by the human papilloma virus in a p53-dependent manner. Replacement of caveolin-1 expression suppresses HPV-mediated cell transformation.* **Biochemistry**. 2000 Nov 14; 39(45): p. 13916-24.

119. Schlegel, A., Pestell, R.G., and Lisanti, M.P., *Caveolins in cholesterol trafficking and signal transduction: implications for human disease.* **Front Biosci**. 2000 Dec 1; 5: p. D929-37.

120. Zafonte, B.T., Hulit, J., Amanatullah, D.F., Albanese, C., Wang, C., Rosen, E., Reutens, A., Sparano, J.A., Lisanti, M.P., and Pestell, R.G., *Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycle.* **Front Biosci**. 2000 Dec 1; 5: p. D938-61.

121. Pruitt, K., Pestell, R.G., and Der, C.J., *Ras inactivation of the retinoblastoma pathway by distinct mechanisms in NIH 3T3 fibroblast and RIE-1 epithelial cells.* **J Biol Chem**. 2000 Dec 29; 275(52): p. 40916-24.

122. Amanatullah, D.F., Zafonte, B.T., Albanese, C., Fu, M., Messiers, C., Hassell, J., and Pestell, R.G., *Ras regulation of cyclin D1 promoter.* **Methods Enzymol**. 2001; 333: p. 116-27.

123. Hulit, J., Di Vizio, D., and Pestell, R.G., *Inducible transgenics. New lessons on events governing the induction and commitment in mammary tumorigenesis.* **Breast Cancer Res**. 2001; 3(4): p. 209-12.

124. Lin, H.M., Lee, Y.J., Li, G., Pestell, R.G., and Kim, H.R., *Bcl-2 induces cyclin D1 promoter activity in human breast epithelial cells independent of cell anchorage.* **Cell Death Differ**. 2001 Jan; 8(1): p. 44-50.

125. Fu, M., Wang, C., Zhang, X., and Pestell, R.G., *Signal transduction inhibitors in cellular function.* **Methods Mol Biol**. 2004; 284: p. 15-36.

126. Wang, C., Li, Z., Fu, M., Bouras, T., and Pestell, R.G., *Signal transduction mediated by cyclin D1: from mitogens to cell proliferation: a molecular target with therapeutic potential.* **Cancer Treat Res**. 2004; 119: p. 217-37.

127. Fan, S., Ma, Y.X., Wang, C., Yuan, R.Q., Meng, Q., Wang, J.A., Erdos, M., Goldberg, I.D., Webb, P., Kushner, P.J., Pestell, R.G., and Rosen, E.M., *Role of direct interaction in BRCA1 inhibition of estrogen receptor activity.* **Oncogene**. 2001 Jan 4; 20(1): p. 77-87.

128. Soriano, S., Kang, D.E., Fu, M., Pestell, R., Chevallier, N., Zheng, H., and Koo, E.H., *Presenilin 1 negatively regulates beta-catenin/T cell factor/lymphoid enhancer factor-1 signaling independently of beta-amyloid precursor protein and notch processing.* **J Cell Biol**. 2001 Feb 19; 152(4): p. 785-94.

129. Joyce, D., Albanese, C., Steer, J., Fu, M., Bouzahzah, B., and Pestell, R.G., *NF-κB and cell-cycle regulation: the cyclin connection.* **Cytokine Growth Factor Rev**. 2001 Mar; 12(1): p. 73-90.

130. Volonte, D., Galbiati, F., Pestell, R.G., and Lisanti, M.P., *Cellular stress induces the tyrosine phosphorylation of caveolin-1 (Tyr(14)) via activation of p38 mitogen-activated protein kinase and c-Src kinase. Evidence for caveolae, the actin cytoskeleton, and focal adhesions as mechanical sensors of osmotic stress.* **J Biol Chem**. 2001 Mar 16; 276(11): p. 8094-103.

131. Park, D.S., Razani, B., Lasorella, A., Schreiber-Agus, N., Pestell, R.G., Iavarone, A., and Lisanti, M.P., *Evidence that Myc isoforms transcriptionally repress caveolin-1 gene expression via an INR-dependent mechanism.* **Biochemistry**. 2001 Mar 20; 40(11): p. 3354-62.

132. Wang, C., Fu, M., Mani, S., Wadler, S., Senderowicz, A.M., and Pestell, R.G., *Histone acetylation and the cell-cycle in cancer.* **Front Biosci**. 2001 Apr 1; 6: p. D610-29.

133. Condeelis, J.S., Wyckoff, J.B., Bailly, M., Pestell, R., Lawrence, D., Backer, J., and Segall, J.E., *Lamellipodia in invasion.* **Semin Cancer Biol**. 2001 2001/04/27; 11(2): p. 119-28.

134. Petkova, S.B., Huang, H., Factor, S.M., Pestell, R.G., Bouzahzah, B., Jelicks, L.A., Weiss, L.M., Douglas, S.A., Wittner, M., and Tanowitz, H.B., *The role of endothelin in the pathogenesis of Chagas' disease.* **Int J Parasitol**. 2001 May 1; 31(5-6): p. 499-511.

135. Reutens, A.T., Fu, M., Wang, C., Albanese, C., McPhaul, M.J., Sun, Z., Balk, S.P., Janne, O.A., Palvimo, J.J., and Pestell, R.G., *Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner.* **Mol Endocrinol**. 2001 May; 15(5): p. 797-811.

136. Wang, C., Fu, M., D'Amico, M., Albanese, C., Zhou, J.N., Brownlee, M., Lisanti, M.P., Chatterjee, V.K., Lazar, M.A., and Pestell, R.G., *Inhibition of cellular proliferation through IκB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1.* **Mol Cell Biol**. 2001 May; 21(9): p. 3057-70.

137. Wang, C., Fu, M., Angeletti, R.H., Siconolfi-Baez, L., Reutens, A.T., Albanese, C., Lisanti, M.P., Katzenellenbogen, B.S., Kato, S., Hopp, T., Fuqua, S.A., Lopez, G.N., Kushner, P.J., and Pestell, R.G., *Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity.* **J Biol Chem**. 2001 May 25; 276(21): p. 18375-83.

138. Allan, A.L., Albanese, C., Pestell, R.G., and LaMarre, J., *Activating transcription factor 3 induces DNA synthesis and expression of cyclin D1 in hepatocytes.* **J Biol Chem**. 2001 Jul 20; 276(29): p. 27272-80.

139. Galbiati, F., Volonte, D., Liu, J., Capozza, F., Frank, P.G., Zhu, L., Pestell, R.G., and Lisanti, M.P., *Caveolin-1 expression negatively regulates cell cycle progression by inducing G(0)/G(1) arrest via a p53/p21(WAF1/Cip1)-dependent mechanism.* **Mol Biol Cell**. 2001 Aug; 12(8): p. 2229-44.

140. Fan, S., Yuan, R., Ma, Y.X., Xiong, J., Meng, Q., Erdos, M., Zhao, J.N., Goldberg, I.D., Pestell, R.G., and Rosen, E.M., *Disruption of BRCA1 LXCXE motif alters BRCA1 functional activity and regulation of RB family but not RB protein binding.* **Oncogene**. 2001 Aug 9; 20(35): p. 4827-41.

141. Lane, M.E., Yu, B., Rice, A., Lipson, K.E., Liang, C., Sun, L., Tang, C., McMahon, G., Pestell, R.G., and Wadler, S., *A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells.* **Cancer Res**. 2001 Aug 15; 61(16): p. 6170-7.

142. Sampson, E.M., Haque, Z.K., Ku, M.C., Tevosian, S.G., Albanese, C., Pestell, R.G., Paulson, K.E., and Yee, A.S., *Negative regulation of the Wnt-beta-catenin pathway by the transcriptional repressor HBP1.* **EMBO J**. 2001 Aug 15; 20(16): p. 4500-11.

143. Schlegel, A., Wang, C., Pestell, R.G., and Lisanti, M.P., *Ligand-independent activation of oestrogen receptor alpha by caveolin-1.* **Biochem J**. 2001 Oct 1; 359(Pt 1): p. 203-10.

144. Razani, B., Engelman, J.A., Wang, X.B., Schubert, W., Zhang, X.L., Marks, C.B., Macaluso, F., Russell, R.G., Li, M., Pestell, R.G., Di Vizio, D., Hou, H., Jr., Kneitz, B., Lagaud, G., Christ, G.J., Edelmann, W., and Lisanti, M.P., *Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities.* **J Biol Chem**. 2001 Oct 12; 276(41): p. 38121-38.

145. Kampfer, S., Windegger, M., Hochholdinger, F., Schwaiger, W., Pestell, R.G., Baier, G., Grunicke, H.H., and Uberall, F., *Protein kinase C isoforms involved in the transcriptional activation of cyclin D1 by transforming Ha-Ras.* **J Biol Chem**. 2001 Nov 16; 276(46): p. 42834-42.

146. Beier, F., Ali, Z., Mok, D., Taylor, A.C., Leask, T., Albanese, C., Pestell, R.G., and LuValle, P., *TGFbeta and PTHrP control chondrocyte proliferation by activating cyclin D1 expression.* **Mol Biol Cell**. 2001 Dec; 12(12): p. 3852-63.

147. Bouzahzah, B., Albanese, C., Ahmed, F., Pixley, F., Lisanti, M.P., Segall, J.D., Condeelis, J., Joyce, D., Minden, A., Der, C.J., Chan, A., Symons, M., and Pestell, R.G., *Rho family GTPases regulate mammary epithelium cell growth and metastasis through distinguishable pathways.* **Mol Med**. 2001 Dec; 7(12): p. 816-30.

148. Zhao, J., Pestell, R., and Guan, J.L., *Transcriptional activation of cyclin D1 promoter by FAK contributes to cell cycle progression.* **Mol Biol Cell**. 2001 Dec; 12(12): p. 4066-77.

149. Park, D.S., Lee, H., Riedel, C., Hulit, J., Scherer, P.E., Pestell, R.G., and Lisanti, M.P., *Prolactin negatively regulates caveolin-1 gene expression in the mammary gland during lactation, via a Ras-dependent mechanism.* **J Biol Chem**. 2001 Dec 21; 276(51): p. 48389-97.

150. Dadachova, E., Bouzahzah, B., Zuckier, L.S., and Pestell, R.G., *Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS).* **Nucl Med Biol**. 2002 Jan; 29(1): p. 13-8.

151. Fan, S., Ma, Y.X., Wang, C., Yuan, R.Q., Meng, Q., Wang, J.A., Erdos, M., Goldberg, I.D., Webb, P., Kushner, P.J., Pestell, R.G., and Rosen, E.M., *p300 Modulates the BRCA1 inhibition of estrogen receptor activity.* **Cancer Res**. 2002 Jan 1; 62(1): p. 141-51.

152. Hawcroft, G., D'Amico, M., Albanese, C., Markham, A.F., Pestell, R.G., and Hull, M.A., *Indomethacin induces differential expression of beta-catenin, gamma-catenin and T-cell factor target genes in human colorectal cancer cells.* **Carcinogenesis**. 2002 Jan; 23(1): p. 107-14.

153. Amanatullah, D.F., Zafonte, B.T., and Pestell, R.G., *The cell cycle in steroid hormone regulated proliferation and differentiation.* **Minerva Endocrinol**. 2002 Mar; 27(1): p. 7-20.

154. Bearss, D.J., Lee, R.J., Troyer, D.A., Pestell, R.G., and Windle, J.J., *Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties.* **Cancer Res**. 2002 Apr 1; 62(7): p. 2077-84.

155. Fu, M., Wang, C., Wang, J., Zhang, X., Sakamaki, T., Yeung, Y.G., Chang, C., Hopp, T., Fuqua, S.A., Jaffray, E., Hay, R.T., Palvimo, J.J., Janne, O.A., and Pestell, R.G., *Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function.* **Mol Cell Biol**. 2002 May; 22(10): p. 3373-88.

156. Tanaka, H., Matsumura, I., Ezoe, S., Satoh, Y., Sakamaki, T., Albanese, C., Machii, T., Pestell, R.G., and Kanakura, Y., *E2F1 and c-Myc potentiate apoptosis through inhibition of NF-κB activity that facilitates MnSOD-mediated ROS elimination.* **Mol Cell**. 2002 May; 9(5): p. 1017-29.

157. Hanai, J., Dhanabal, M., Karumanchi, S.A., Albanese, C., Waterman, M., Chan, B., Ramchandran, R., Pestell, R., and Sukhatme, V.P., *Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1.* **J Biol Chem**. 2002 May 10; 277(19): p. 16464-9.

158. Fu, M., Wang, C., Wang, J., Zafonte, B.T., Lisanti, M.P., and Pestell, R.G., *Acetylation in hormone signaling and the cell cycle.* **Cytokine Growth Factor Rev**. 2002 Jun; 13(3): p. 259-76.

159. Kim, M.O., Si, Q., Zhou, J.N., Pestell, R.G., Brosnan, C.F., Locker, J., and Lee, S.C., *Interferon-beta activates multiple signaling cascades in primary human microglia.* **J Neurochem**. 2002 Jun; 81(6): p. 1361-71.

160. Shivakumar, L., Minna, J., Sakamaki, T., Pestell, R., and White, M.A., *The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation.* **Mol Cell Biol**. 2002 Jun; 22(12): p. 4309-18.

161. Wu, K., Wang, C., D'Amico, M., Lee, R.J., Albanese, C., Pestell, R.G., and Mani, S., *Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.* **Mol Cancer Ther**. 2002 Jul; 1(9): p. 695-706.

162. Liu, M.M., Albanese, C., Anderson, C.M., Hilty, K., Webb, P., Uht, R.M., Price, R.H., Jr., Pestell, R.G., and Kushner, P.J., *Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression.* **J Biol Chem**. 2002 Jul 5; 277(27): p. 24353-60.

163. Suzui, M., Masuda, M., Lim, J.T., Albanese, C., Pestell, R.G., and Weinstein, I.B., *Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1.* **Cancer Res**. 2002 Jul 15; 62(14): p. 3997-4006.

164. Huang, H., Yanagisawa, M., Kisanuki, Y.Y., Jelicks, L.A., Chandra, M., Factor, S.M., Wittner, M., Weiss, L.M., Pestell, R.G., Shtutin, V., Shirani, J., and Tanowitz, H.B., *Role of cardiac myocyte-derived endothelin-1 in chagasic cardiomyopathy: molecular genetic evidence.* **Clin Sci (Lond)**. 2002 Aug; 103 Suppl 48: p. 263S-266S.

165. Page, K., Li, J., Corbit, K.C., Rumilla, K.M., Soh, J.W., Weinstein, I.B., Albanese, C., Pestell, R.G., Rosner, M.R., and Hershenson, M.B., *Regulation of airway smooth muscle cyclin D1 transcription by protein kinase C-delta.* **Am J Respir Cell Mol Biol**. 2002 Aug; 27(2): p. 204-13.

166. Zhang, Z.K., Davies, K.P., Allen, J., Zhu, L., Pestell, R.G., Zagzag, D., and Kalpana, G.V., *Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5.* **Mol Cell Biol**. 2002 Aug; 22(16): p. 5975-88.

167. Guha, U., Gomes, W.A., Kobayashi, T., Pestell, R.G., and Kessler, J.A., *In vivo evidence that BMP signaling is necessary for apoptosis in the mouse limb.* **Dev Biol**. 2002 Sep 1; 249(1): p. 108-20.

168. Hulit, J., Lee, R.J., Russell, R.G., and Pestell, R.G., *ErbB-2-induced mammary tumor growth: the role of cyclin D1 and p27Kip1.* **Biochem Pharmacol**. 2002 Sep; 64(5-6): p. 827-36.

169. Albanese, C., Hulit, J., Sakamaki, T., and Pestell, R.G., *Recent advances in inducible expression in transgenic mice.* **Semin Cell Dev Biol**. 2002 2002/09/21; 13(2): p. 129-41.

170. Lee, H., Park, D.S., Razani, B., Russell, R.G., Pestell, R.G., and Lisanti, M.P., *Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia.* **Am J Pathol**. 2002 Oct; 161(4): p. 1357-69.

171. Park, D.S., Lee, H., Frank, P.G., Razani, B., Nguyen, A.V., Parlow, A.F., Russell, R.G., Hulit, J., Pestell, R.G., and Lisanti, M.P., *Caveolin-1-deficient mice show accelerated mammary gland development during pregnancy, premature lactation, and hyperactivation of the Jak-2/STAT5a signaling cascade.* **Mol Biol Cell**. 2002 Oct; 13(10): p. 3416-30.

172. Coulter, C.L., Pestell, R.G., Ross, J.T., Salkeld, M.D., James, S., Bennett, H.P., and McMillen, I.C., *Effect of N-proopiomelanocortin (1-77) and (1-49) infusions on adrenal expression of cyclin D1 in the fetal sheep.* **Endocr Res**. 2002 Nov; 28(4): p. 625-9.

173. Neumeister, P., Albanese, C., Balent, B., Greally, J., and Pestell, R.G., *Senescence and epigenetic dysregulation in cancer.* **Int J Biochem Cell Biol**. 2002 Nov; 34(11): p. 1475-90.

174. Lin, H.M., Pestell, R.G., Raz, A., and Kim, H.R., *Galectin-3 enhances cyclin D(1) promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells.* **Oncogene**. 2002 Nov 14; 21(52): p. 8001-10.

175. Holnthoner, W., Pillinger, M., Groger, M., Wolff, K., Ashton, A.W., Albanese, C., Neumeister, P., Pestell, R.G., and Petzelbauer, P., *Fibroblast growth factor-2 induces Lef/Tcf-dependent transcription in human endothelial cells.* **J Biol Chem**. 2002 Nov 29; 277(48): p. 45847-53.

176. Lin, W., Albanese, C., Pestell, R.G., and Lawrence, D.S., *Spatially discrete, light-driven protein expression.* **Chem Biol**. 2002 Dec; 9(12): p. 1347-53.

177. Xian Ma, Y., Fan, S., Xiong, J., Yuan, R.Q., Meng, Q., Gao, M., Goldberg, I.D., Fuqua, S.A., Pestell, R.G., and Rosen, E.M., *Role of BRCA1 in heat shock response.* **Oncogene**. 2003 Jan 9; 22(1): p. 10-27.

178. Albanese, C., Wu, K., D'Amico, M., Jarrett, C., Joyce, D., Hughes, J., Hulit, J., Sakamaki, T., Fu, M., Ben-Ze'ev, A., Bromberg, J.F., Lamberti, C., Verma, U., Gaynor, R.B., Byers, S.W., and Pestell, R.G., *IKKalpha regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf.* **Mol Biol Cell**. 2003 Feb; 14(2): p. 585-99.

179. Williams, T.M., Cheung, M.W., Park, D.S., Razani, B., Cohen, A.W., Muller, W.J., Di Vizio, D., Chopra, N.G., Pestell, R.G., and Lisanti, M.P., *Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice.* **Mol Biol Cell**. 2003 Mar; 14(3): p. 1027-42.

180. Huang, H., Petkova, S.B., Cohen, A.W., Bouzahzah, B., Chan, J., Zhou, J.N., Factor, S.M., Weiss, L.M., Krishnamachary, M., Mukherjee, S., Wittner, M., Kitsis, R.N., Pestell, R.G., Lisanti, M.P., Albanese, C., and Tanowitz, H.B., *Activation of transcription factors AP-1 and NF-κ B in murine Chagasic myocarditis.* **Infect Immun**. 2003 May; 71(5): p. 2859-67.

181. Neumeister, P., Pixley, F.J., Xiong, Y., Xie, H., Wu, K., Ashton, A., Cammer, M., Chan, A., Symons, M., Stanley, E.R., and Pestell, R.G., *Cyclin D1 governs adhesion and motility of macrophages.* **Mol Biol Cell**. 2003 May; 14(5): p. 2005-15.

182. Hu, Y.L., Albanese, C., Pestell, R.G., and Jaffe, R.B., *Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells.* **J Natl Cancer Inst**. 2003 May 21; 95(10): p. 733-40.

183. Fu, M., Wang, C., Zhang, X., and Pestell, R., *Nuclear receptor modifications and endocrine cell proliferation.* **J Steroid Biochem Mol Biol**. 2003 Jun; 85(2-5): p. 133-8.

184. Huang, E., Ishida, S., Pittman, J., Dressman, H., Bild, A., Kloos, M., D'Amico, M., Pestell, R.G., West, M., and Nevins, J.R., *Gene expression phenotypic models that predict the activity of oncogenic pathways.* **Nat Genet**. 2003 Jun; 34(2): p. 226-30.

185. D'Amico, M., Wu, K., Di Vizio, D., Reutens, A.T., Stahl, M., Fu, M., Albanese, C., Russell, R.G., Muller, W.J., White, M., Negassa, A., Lee, H.W., DePinho, R.A., and Pestell, R.G., *The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis.* **Cancer Res**. 2003 Jun 15; 63(12): p. 3395-402.

186. Rosen, E.M., Fan, S., Pestell, R.G., and Goldberg, I.D., *BRCA1 gene in breast cancer.* **J Cell Physiol**. 2003 Jul; 196(1): p. 19-41.

187. Song, D.H., Rana, B., Wolfe, J.R., Crimmins, G., Choi, C., Albanese, C., Wang, T.C., Pestell, R.G., and Wolfe, M.M., *Gastrin-induced gastric adenocarcinoma growth is mediated through cyclin D1.* **Am J Physiol Gastrointest Liver Physiol**. 2003 Jul; 285(1): p. G217-22.

188. Nelsen, C.J., Rickheim, D.G., Tucker, M.M., McKenzie, T.J., Hansen, L.K., Pestell, R.G., and Albrecht, J.H., *Amino acids regulate hepatocyte proliferation through modulation of cyclin D1 expression.* **J Biol Chem**. 2003 Jul 11; 278(28): p. 25853-8.

189. Wang, C., Pattabiraman, N., Zhou, J.N., Fu, M., Sakamaki, T., Albanese, C., Li, Z., Wu, K., Hulit, J., Neumeister, P., Novikoff, P.M., Brownlee, M., Scherer, P.E., Jones, J.G., Whitney, K.D., Donehower, L.A., Harris, E.L., Rohan, T., Johns, D.C., and Pestell, R.G., *Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation.* **Mol Cell Biol**. 2003 Sep; 23(17): p. 6159-73.

190. Iyengar, P., Combs, T.P., Shah, S.J., Gouon-Evans, V., Pollard, J.W., Albanese, C., Flanagan, L., Tenniswood, M.P., Guha, C., Lisanti, M.P., Pestell, R.G., and Scherer, P.E., *Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization.* **Oncogene**. 2003 Sep 25; 22(41): p. 6408-23.

191. Rowlands, T.M., Pechenkina, I.V., Hatsell, S.J., Pestell, R.G., and Cowin, P., *Dissecting the roles of beta-catenin and cyclin D1 during mammary development and neoplasia.* **Proc Natl Acad Sci U S A**. 2003 Sep 30; 100(20): p. 11400-5.

192. Rosen, E.M., Fan, S., Pestell, R.G., and Goldberg, I.D., *BRCA1 in hormone-responsive cancers.* **Trends Endocrinol Metab**. 2003 Oct; 14(8): p. 378-85.

193. Cai, D., Iyer, A., Felekkis, K.N., Near, R.I., Luo, Z., Chernoff, J., Albanese, C., Pestell, R.G., and Lerner, A., *AND-34/BCAR3, a GDP exchange factor whose overexpression confers antiestrogen resistance, activates Rac, PAK1, and the cyclin D1 promoter.* **Cancer Res**. 2003 Oct 15; 63(20): p. 6802-8.

194. Shah, S., Hecht, A., Pestell, R., and Byers, S.W., *Trans-repression of beta-catenin activity by nuclear receptors.* **J Biol Chem**. 2003 Nov 28; 278(48): p. 48137-45.

195. Fu, M., Rao, M., Wang, C., Sakamaki, T., Wang, J., Di Vizio, D., Zhang, X., Albanese, C., Balk, S., Chang, C., Fan, S., Rosen, E., Palvimo, J.J., Janne, O.A., Muratoglu, S., Avantaggiati, M.L., and Pestell, R.G., *Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth.* **Mol Cell Biol**. 2003 Dec; 23(23): p. 8563-75.

196. Xiong, J., Fan, S., Meng, Q., Schramm, L., Wang, C., Bouzahza, B., Zhou, J., Zafonte, B., Goldberg, I.D., Haddad, B.R., Pestell, R.G., and Rosen, E.M., *BRCA1 inhibition of telomerase activity in cultured cells.* **Mol Cell Biol**. 2003 Dec; 23(23): p. 8668-90.

197. Wu, K., Yang, Y., Wang, C., Davoli, M.A., D'Amico, M., Li, A., Cveklova, K., Kozmik, Z., Lisanti, M.P., Russell, R.G., Cvekl, A., and Pestell, R.G., *DACH1 inhibits transforming growth factor-beta signaling through binding Smad4.* **J Biol Chem**. 2003 Dec 19; 278(51): p. 51673-84.

198. Balasenthil, S., Sahin, A.A., Barnes, C.J., Wang, R.A., Pestell, R.G., Vadlamudi, R.K., and Kumar, R., *p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells.* **J Biol Chem**. 2004 Jan 9; 279(2): p. 1422-8.

199. Matsuo, T., Matsumura, T., Sakai, M., Senokuchi, T., Yano, M., Kiritoshi, S., Sonoda, K., Kukidome, D., Pestell, R.G., Brownlee, M., Nishikawa, T., and Araki, E., *15d-PGJ2 inhibits oxidized LDL-induced macrophage proliferation by inhibition of GM-CSF production via inactivation of NF-κB.* **Biochem Biophys Res Commun**. 2004 Feb 13; 314(3): p. 817-23.

200. Burbelo, P., Wellstein, A., and Pestell, R.G., *Altered Rho GTPase signaling pathways in breast cancer cells.* **Breast Cancer Res Treat**. 2004 Mar; 84(1): p. 43-8.

201. Bateman, N.W., Tan, D., Pestell, R.G., Black, J.D., and Black, A.R., *Intestinal tumor progression is associated with altered function of KLF5.* **J Biol Chem**. 2004 Mar 26; 279(13): p. 12093-101.

202. Sharma, C., Pradeep, A., Pestell, R.G., and Rana, B., *Peroxisome proliferator-activated receptor gamma activation modulates cyclin D1 transcription via beta-catenin-independent and cAMP-response element-binding protein-dependent pathways in mouse hepatocytes.* **J Biol Chem**. 2004 Apr 23; 279(17): p. 16927-38.

203. Pradeep, A., Sharma, C., Sathyanarayana, P., Albanese, C., Fleming, J.V., Wang, T.C., Wolfe, M.M., Baker, K.M., Pestell, R.G., and Rana, B., *Gastrin-mediated activation of cyclin D1 transcription involves beta-catenin and CREB pathways in gastric cancer cells.* **Oncogene**. 2004 Apr 29; 23(20): p. 3689-99.

204. Williams, T.M., Lee, H., Cheung, M.W., Cohen, A.W., Razani, B., Iyengar, P., Scherer, P.E., Pestell, R.G., and Lisanti, M.P., *Combined loss of INK4a and caveolin-1 synergistically enhances cell proliferation and oncogene-induced tumorigenesis: role of INK4a/CAV-1 in mammary epithelial cell hyperplasia.* **J Biol Chem**. 2004 Jun 4; 279(23): p. 24745-56.

205. D'Amico, M., Wu, K., Fu, M., Rao, M., Albanese, C., Russell, R.G., Lian, H., Bregman, D., White, M.A., and Pestell, R.G., *The inhibitor of cyclin-dependent kinase 4a/alternative reading frame (INK4a/ARF) locus encoded proteins p16INK4a and p19ARF repress cyclin D1 transcription through distinct cis elements.* **Cancer Res**. 2004 Jun 15; 64(12): p. 4122-30.

206. Fu, M., Rao, M., Wu, K., Wang, C., Zhang, X., Hessien, M., Yeung, Y.G., Gioeli, D., Weber, M.J., and Pestell, R.G., *The androgen receptor acetylation site regulates cAMP and AKT but not ERK-induced activity.* **J Biol Chem**. 2004 Jul 9; 279(28): p. 29436-49.

207. Liu, M.C., Marshall, J.L., and Pestell, R.G., *Novel strategies in cancer therapeutics: targeting enzymes involved in cell cycle regulation and cellular proliferation.* **Curr Cancer Drug Targets**. 2004 Aug; 4(5): p. 403-24.

208. Guha, U., Mecklenburg, L., Cowin, P., Kan, L., O'Guin, W.M., D'Vizio, D., Pestell, R.G., Paus, R., and Kessler, J.A., *Bone morphogenetic protein signaling regulates postnatal hair follicle differentiation and cycling.* **Am J Pathol**. 2004 Sep; 165(3): p. 729-40.

209. Hulit, J., Wang, C., Li, Z., Albanese, C., Rao, M., Di Vizio, D., Shah, S., Byers, S.W., Mahmood, R., Augenlicht, L.H., Russell, R., and Pestell, R.G., *Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice.* **Mol Cell Biol**. 2004 Sep; 24(17): p. 7598-611.

210. Mukherjee, S., Huang, H., Petkova, S.B., Albanese, C., Pestell, R.G., Braunstein, V.L., Christ, G.J., Wittner, M., Lisanti, M.P., Berman, J.W., Weiss, L.M., and Tanowitz, H.B., *Trypanosoma cruzi infection activates extracellular signal-regulated kinase in cultured endothelial and smooth muscle cells.* **Infect Immun**. 2004 Sep; 72(9): p. 5274-82.

211. Williams, T.M., Medina, F., Badano, I., Hazan, R.B., Hutchinson, J., Muller, W.J., Chopra, N.G., Scherer, P.E., Pestell, R.G., and Lisanti, M.P., *Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion.* **J Biol Chem**. 2004 Dec 3; 279(49): p. 51630-46.

212. Cui, Y., Zhang, M., Pestell, R., Curran, E.M., Welshons, W.V., and Fuqua, S.A., *Phosphorylation of estrogen receptor alpha blocks its acetylation and regulates estrogen sensitivity.* **Cancer Res**. 2004 Dec 15; 64(24): p. 9199-208.

213. Lewis, J.S., Vijayanathan, V., Thomas, T.J., Pestell, R.G., Albanese, C., Gallo, M.A., and Thomas, T., *Activation of cyclin D1 by estradiol and spermine in MCF-7 breast cancer cells: a mechanism involving the p38 MAP kinase and phosphorylation of ATF-2.* **Oncol Res**. 2005; 15(3): p. 113-28.

214. Katiyar, P., Ma, Y., Fan, S., Pestell, R.G., Furth, P.A., and Rosen, E.M., *Regulation of progesterone receptor signaling by BRCA1 in mammary cancer.* **Nucl Recept Signal**. 2006; 4: p. e006.

215. Lewis, J.S., Thomas, T.J., Pestell, R.G., Albanese, C., Gallo, M.A., and Thomas, T., *Differential effects of 16alpha-hydroxyestrone and 2-methoxyestradiol on cyclin D1 involving the transcription factor ATF-2 in MCF-7 breast cancer cells.* **J Mol Endocrinol**. 2005 Feb; 34(1): p. 91-105.

216. Moadel, R.M., Weldon, R.H., Katz, E.B., Lu, P., Mani, J., Stahl, M., Blaufox, M.D., Pestell, R.G., Charron, M.J., and Dadachova, E., *Positherapy: targeted nuclear therapy of breast cancer with 18F-2-deoxy-2-fluoro-D-glucose.* **Cancer Res**. 2005 Feb 1; 65(3): p. 698-702.

217. Xiao, G.H., Gallagher, R., Shetler, J., Skele, K., Altomare, D.A., Pestell, R.G., Jhanwar, S., and Testa, J.R., *The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression.* **Mol Cell Biol**. 2005 Mar; 25(6): p. 2384-94.

218. Fan, S., Gao, M., Meng, Q., Laterra, J.J., Symons, M.H., Coniglio, S., Pestell, R.G., Goldberg, I.D., and Rosen, E.M., *Role of NF-κB signaling in hepatocyte growth factor/scatter factor-mediated cell protection.* **Oncogene**. 2005 Mar 3; 24(10): p. 1749-66.

219. Bouras, T., Fu, M., Sauve, A.A., Wang, F., Quong, A.A., Perkins, N.D., Hay, R.T., Gu, W., and Pestell, R.G., *SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1.* **J Biol Chem**. 2005 Mar 18; 280(11): p. 10264-76.

220. Bu, X., Avraham, H.K., Li, X., Lim, B., Jiang, S., Fu, Y., Pestell, R.G., and Avraham, S., *Mayven induces c-Jun expression and cyclin D1 activation in breast cancer cells.* **Oncogene**. 2005 Mar 31; 24(14): p. 2398-409.

221. Song, D.H., Kaufman, J.C., Borodyansky, L., Albanese, C., Pestell, R.G., and Wolfe, M.M., *Gastrin stabilises beta-catenin protein in mouse colorectal cancer cells.* **Br J Cancer**. 2005 Apr 25; 92(8): p. 1581-7.

222. Fu, M., Rao, M., Bouras, T., Wang, C., Wu, K., Zhang, X., Li, Z., Yao, T.P., and Pestell, R.G., *Cyclin D1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipogenesis through histone deacetylase recruitment.* **J Biol Chem**. 2005 Apr 29; 280(17): p. 16934-41.

223. Iyengar, P., Espina, V., Williams, T.W., Lin, Y., Berry, D., Jelicks, L.A., Lee, H., Temple, K., Graves, R., Pollard, J., Chopra, N., Russell, R.G., Sasisekharan, R., Trock, B.J., Lippman, M., Calvert, V.S., Petricoin, E.F., 3rd, Liotta, L., Dadachova, E., Pestell, R.G., Lisanti, M.P., Bonaldo, P., and Scherer, P.E., *Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment.* **J Clin Invest**. 2005 May; 115(5): p. 1163-76.

224. Ho, Y.S., Chen, C.H., Wang, Y.J., Pestell, R.G., Albanese, C., Chen, R.J., Chang, M.C., Jeng, J.H., Lin, S.Y., Liang, Y.C., Tseng, H., Lee, W.S., Lin, J.K., Chu, J.S., Chen, L.C., Lee, C.H., Tso, W.L., Lai, Y.C., and Wu, C.H., *Tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) induces cell proliferation in normal human bronchial epithelial cells through NF-κB activation and cyclin D1 up-regulation.* **Toxicol Appl Pharmacol**. 2005 Jun 1; 205(2): p. 133-48.

225. Williams, T.M., Hassan, G.S., Li, J., Cohen, A.W., Medina, F., Frank, P.G., Pestell, R.G., Di Vizio, D., Loda, M., and Lisanti, M.P., *Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice.* **J Biol Chem**. 2005 Jul 1; 280(26): p. 25134-45.

226. Wang, C., Fan, S., Li, Z., Fu, M., Rao, M., Ma, Y., Lisanti, M.P., Albanese, C., Katzenellenbogen, B.S., Kushner, P.J., Weber, B., Rosen, E.M., and Pestell, R.G., *Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity.* **Cancer Res**. 2005 Aug 1; 65(15): p. 6557-67.

227. Wu, K., D'Amico, M., Wang, C., Albanese, C., Pestell, R.G., and Mani, S., *A study of cytotoxic synergy of UCN-01 and flavopiridol in syngeneic pair of cell lines.* **Invest New Drugs**. 2005 Aug; 23(4): p. 299-309.

228. Fu, M., Wang, C., Rao, M., Wu, X., Bouras, T., Zhang, X., Li, Z., Jiao, X., Yang, J., Li, A., Perkins, N.D., Thimmapaya, B., Kung, A.L., Munoz, A., Giordano, A., Lisanti, M.P., and Pestell, R.G., *Cyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanism.* **J Biol Chem**. 2005 Aug 19; 280(33): p. 29728-42.

229. Giampuzzi, M., Oleggini, R., Albanese, C., Pestell, R., and Di Donato, A., *beta-catenin signaling and regulation of cyclin D1 promoter in NRK-49F cells transformed by down-regulation of the tumor suppressor lysyl oxidase.* **Biochim Biophys Acta**. 2005 Sep 30; 1745(3): p. 370-81.

230. Xiao, D., Chinnappan, D., Pestell, R., Albanese, C., and Weber, H.C., *Bombesin regulates cyclin D1 expression through the early growth response protein Egr-1 in prostate cancer cells.* **Cancer Res**. 2005 Nov 1; 65(21): p. 9934-42.

231. Desgranges, Z.P., Ahn, J., Lazebnik, M.B., Ashworth, T., Lee, C., Pestell, R.C., Rosenberg, N., Prives, C., and Roy, A.L., *Inhibition of TFII-I-dependent cell cycle regulation by p53.* **Mol Cell Biol**. 2005 Dec; 25(24): p. 10940-52.

232. Li, J., Hassan, G.S., Williams, T.M., Minetti, C., Pestell, R.G., Tanowitz, H.B., Frank, P.G., Sotgia, F., and Lisanti, M.P., *Loss of caveolin-1 causes the hyper-proliferation of intestinal crypt stem cells, with increased sensitivity to whole body gamma-radiation.* **Cell Cycle**. 2005 Dec; 4(12): p. 1817-25.

233. Sotgia, F., Williams, T.M., Cohen, A.W., Minetti, C., Pestell, R.G., and Lisanti, M.P., *Caveolin-1-deficient mice have an increased mammary stem cell population with upregulation of Wnt/beta-catenin signaling.* **Cell Cycle**. 2005 Dec; 4(12): p. 1808-16.

234. Hassan, G.S., Mukherjee, S., Nagajyothi, F., Weiss, L.M., Petkova, S.B., de Almeida, C.J., Huang, H., Desruisseaux, M.S., Bouzahzah, B., Pestell, R.G., Albanese, C., Christ, G.J., Lisanti, M.P., and Tanowitz, H.B., *Trypanosoma cruzi infection induces proliferation of vascular smooth muscle cells.* **Infect Immun**. 2006 Jan; 74(1): p. 152-9.

235. Sotgia, F., Williams, T.M., Schubert, W., Medina, F., Minetti, C., Pestell, R.G., and Lisanti, M.P., *Caveolin-1 deficiency (-/-) conveys premalignant alterations in mammary epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness.* **Am J Pathol**. 2006 Jan; 168(1): p. 292-309.

236. Yin, Y., Yuan, H., Wang, C., Pattabiraman, N., Rao, M., Pestell, R.G., and Glazer, R.I., *3-phosphoinositide-dependent protein kinase-1 activates the peroxisome proliferator-activated receptor-gamma and promotes adipocyte differentiation.* **Mol Endocrinol**. 2006 Feb; 20(2): p. 268-78.

237. Leslie, K., Lang, C., Devgan, G., Azare, J., Berishaj, M., Gerald, W., Kim, Y.B., Paz, K., Darnell, J.E., Albanese, C., Sakamaki, T., Pestell, R., and Bromberg, J., *Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3.* **Cancer Res**. 2006 Mar 1; 66(5): p. 2544-52.

238. Sotgia, F., Schubert, W., Pestell, R.G., and Lisanti, M.P., *Genetic ablation of caveolin-1 in mammary epithelial cells increases milk production and hyper-activates STAT5a signaling.* **Cancer Biol Ther**. 2006 Mar; 5(3): p. 292-7.

239. Sourisseau, T., Georgiadis, A., Tsapara, A., Ali, R.R., Pestell, R., Matter, K., and Balda, M.S., *Regulation of PCNA and cyclin D1 expression and epithelial morphogenesis by the ZO-1-regulated transcription factor ZONAB/DbpA.* **Mol Cell Biol**. 2006 Mar; 26(6): p. 2387-98.

240. Gong, J., Zhu, J., Goodman, O.B., Jr., Pestell, R.G., Schlegel, P.N., Nanus, D.M., and Shen, R., *Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.* **Oncogene**. 2006 Mar 30; 25(14): p. 2011-21.

241. Pestell, R., *Remembering team science is for the patients.* **Cancer Biol Ther**. 2006 Apr; 5(4): p. 449-52.

242. Seki, Y., Yamamoto, H., Ngan, C.Y., Yasui, M., Tomita, N., Kitani, K., Takemasa, I., Ikeda, M., Sekimoto, M., Matsuura, N., Albanese, C., Kaneda, Y., Pestell, R.G., and Monden, M., *Construction of a novel DNA decoy that inhibits the oncogenic beta-catenin/T-cell factor pathway.* **Mol Cancer Ther**. 2006 Apr; 5(4): p. 985-94.

243. Yang, Y., Stopka, T., Golestaneh, N., Wang, Y., Wu, K., Li, A., Chauhan, B.K., Gao, C.Y., Cveklova, K., Duncan, M.K., Pestell, R.G., Chepelinsky, A.B., Skoultchi, A.I., and Cvekl, A., *Regulation of alphaA-crystallin via Pax6, c-Maf, CREB and a broad domain of lens-specific chromatin.* **EMBO J**. 2006 May 17; 25(10): p. 2107-18.

244. Knights, C.D., Catania, J., Di Giovanni, S., Muratoglu, S., Perez, R., Swartzbeck, A., Quong, A.A., Zhang, X., Beerman, T., Pestell, R.G., and Avantaggiati, M.L., *Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate.* **J Cell Biol**. 2006 May 22; 173(4): p. 533-44.

245. Li, T., Sotgia, F., Vuolo, M.A., Li, M., Yang, W.C., Pestell, R.G., Sparano, J.A., and Lisanti, M.P., *Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status.* **Am J Pathol**. 2006 Jun; 168(6): p. 1998-2013.

246. Li, Z., Wang, C., Jiao, X., Lu, Y., Fu, M., Quong, A.A., Dye, C., Yang, J., Dai, M., Ju, X., Zhang, X., Li, A., Burbelo, P., Stanley, E.R., and Pestell, R.G., *Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling.* **Mol Cell Biol**. 2006 Jun; 26(11): p. 4240-56.

247. Sakamaki, T., Casimiro, M.C., Ju, X., Quong, A.A., Katiyar, S., Liu, M., Jiao, X., Li, A., Zhang, X., Lu, Y., Wang, C., Byers, S., Nicholson, R., Link, T., Shemluck, M., Yang, J., Fricke, S.T., Novikoff, P.M., Papanikolaou, A., Arnold, A., Albanese, C., and Pestell, R.G., *Cyclin D1 determines mitochondrial function in vivo.* **Mol Cell Biol**. 2006 Jul; 26(14): p. 5449-69.

248. Yang, T., Fu, M., Pestell, R., and Sauve, A.A., *SIRT1 and endocrine signaling.* **Trends Endocrinol Metab**. 2006 Jul; 17(5): p. 186-91.

249. Pestell, R.G. and Li, Z., *Antisense to cyclin D1 inhibits VEGF-stimulated growth of vascular endothelial cells: implication of tumor vascularization.* **Clin Cancer Res**. 2006 Aug 1; 12(15): p. 4459-62.

250. Stahl, M., Ge, C., Shi, S., Pestell, R.G., and Stanley, P., *Notch1-induced transformation of RKE-1 cells requires up-regulation of cyclin D1.* **Cancer Res**. 2006 Aug 1; 66(15): p. 7562-70.

251. Wang, C., Li, Z., Lu, Y., Du, R., Katiyar, S., Yang, J., Fu, M., Leader, J.E., Quong, A., Novikoff, P.M., and Pestell, R.G., *Cyclin D1 repression of nuclear respiratory factor 1 integrates nuclear DNA synthesis and mitochondrial function.* **Proc Natl Acad Sci U S A**. 2006 Aug 1; 103(31): p. 11567-72.

252. Cui, Y., Niu, A., Pestell, R., Kumar, R., Curran, E.M., Liu, Y., and Fuqua, S.A., *Metastasis-associated protein 2 is a repressor of estrogen receptor alpha whose overexpression leads to estrogen-independent growth of human breast cancer cells.* **Mol Endocrinol**. 2006 Sep; 20(9): p. 2020-35.

253. Hulit, J., Lee, R.J., Li, Z., Wang, C., Katiyar, S., Yang, J., Quong, A.A., Wu, K., Albanese, C., Russell, R., Di Vizio, D., Koff, A., Thummala, S., Zhang, H., Harrell, J., Sun, H., Muller, W.J., Inghirami, G., Lisanti, M.P., and Pestell, R.G., *p27Kip1 repression of ErbB2-induced mammary tumor growth in transgenic mice involves Skp2 and Wnt/beta-catenin signaling.* **Cancer Res**. 2006 Sep 1; 66(17): p. 8529-41.

254. Sunde, J.S., Donninger, H., Wu, K., Johnson, M.E., Pestell, R.G., Rose, G.S., Mok, S.C., Brady, J., Bonome, T., and Birrer, M.J., *Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer.* **Cancer Res**. 2006 Sep 1; 66(17): p. 8404-12.

255. Bouzahzah, B., Nagajyothi, F., Desruisseaux, M.S., Krishnamachary, M., Factor, S.M., Cohen, A.W., Lisanti, M.P., Petkova, S.B., Pestell, R.G., Wittner, M., Mukherjee, S., Weiss, L.M., Jelicks, L.A., Albanese, C., and Tanowitz, H.B., *Cell cycle regulatory proteins in the liver in murine Trypanosoma cruzi infection.* **Cell Cycle**. 2006 Oct; 5(20): p. 2396-400.

256. Wu, K., Li, A., Rao, M., Liu, M., Dailey, V., Yang, Y., Di Vizio, D., Wang, C., Lisanti, M.P., Sauter, G., Russell, R.G., Cvekl, A., and Pestell, R.G., *DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth.* **Mol Cell Biol**. 2006 Oct; 26(19): p. 7116-29.

257. Li, Z., Jiao, X., Wang, C., Ju, X., Lu, Y., Yuan, L., Lisanti, M.P., Katiyar, S., and Pestell, R.G., *Cyclin D1 induction of cellular migration requires p27(KIP1).* **Cancer Res**. 2006 Oct 15; 66(20): p. 9986-94.

258. Chang, Y.J., Wu, M.S., Lin, J.T., Pestell, R.G., Blaser, M.J., and Chen, C.C., *Mechanisms for Helicobacter pylori CagA-induced cyclin D1 expression that affect cell cycle.* **Cell Microbiol**. 2006 Nov; 8(11): p. 1740-52.

259. Fu, M., Liu, M., Sauve, A.A., Jiao, X., Zhang, X., Wu, X., Powell, M.J., Yang, T., Gu, W., Avantaggiati, M.L., Pattabiraman, N., Pestell, T.G., Wang, F., Quong, A.A., Wang, C., and Pestell, R.G., *Hormonal control of androgen receptor function through SIRT1.* **Mol Cell Biol**. 2006 Nov; 26(21): p. 8122-35.

260. Leader, J.E., Wang, C., Popov, V.M., Fu, M., and Pestell, R.G., *Epigenetics and the estrogen receptor.* **Ann N Y Acad Sci**. 2006 Nov; 1089: p. 73-87.

261. Li, Z., Wang, C., Prendergast, G.C., and Pestell, R.G., *Cyclin D1 functions in cell migration.* **Cell Cycle**. 2006 Nov 1; 5(21): p. 2440-2.

262. Williams, T.M., Sotgia, F., Lee, H., Hassan, G., Di Vizio, D., Bonuccelli, G., Capozza, F., Mercier, I., Rui, H., Pestell, R.G., and Lisanti, M.P., *Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: Caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells.* **Am J Pathol**. 2006 Nov; 169(5): p. 1784-801.

263. Sotgia, F., Rui, H., Bonuccelli, G., Mercier, I., Pestell, R.G., and Lisanti, M.P., *Caveolin-1, mammary stem cells, and estrogen-dependent breast cancers.* **Cancer Res**. 2006 Nov 15; 66(22): p. 10647-51.

264. Leader, J.E., Wang, C., Fu, M., and Pestell, R.G., *Epigenetic regulation of nuclear steroid receptors.* **Biochem Pharmacol**. 2006 Nov 30; 72(11): p. 1589-96.

265. Medina, F.A., de Almeida, C.J., Dew, E., Li, J., Bonuccelli, G., Williams, T.M., Cohen, A.W., Pestell, R.G., Frank, P.G., Tanowitz, H.B., and Lisanti, M.P., *Caveolin-1-deficient mice show defects in innate immunity and inflammatory immune response during Salmonella enterica serovar Typhimurium infection.* **Infect Immun**. 2006 Dec; 74(12): p. 6665-74.

266. Pestell, R.G., *Light-Activated Gene Therapy, New Selective Therapies for Disease*. **J Nucl Med**. 2006 December 1, 2006; 47(12): p. 21N-22.

267. Pavithra, L., Rampalli, S., Sinha, S., Sreenath, K., Pestell, R.G., and Chattopadhyay, S., *Stabilization of SMAR1 mRNA by PGA2 involves a stem loop structure in the 5' UTR.* **Nucleic Acids Res**. 2007; 35(18): p. 6004-16.

268. Katiyar, S., Jiao, X., Wagner, E., Lisanti, M.P., and Pestell, R.G., *Somatic excision demonstrates that c-Jun induces cellular migration and invasion through induction of stem cell factor.* **Mol Cell Biol**. 2007 Feb; 27(4): p. 1356-69.

269. Popov, V.M., Wang, C., Shirley, L.A., Rosenberg, A., Li, S., Nevalainen, M., Fu, M., and Pestell, R.G., *The functional significance of nuclear receptor acetylation.* **Steroids**. 2007 Feb; 72(2): p. 221-30.

270. Wu, K., Liu, M., Li, A., Donninger, H., Rao, M., Jiao, X., Lisanti, M.P., Cvekl, A., Birrer, M., and Pestell, R.G., *Cell fate determination factor DACH1 inhibits c-Jun-induced contact-independent growth.* **Mol Biol Cell**. 2007 Mar; 18(3): p. 755-67.

271. Ozaki, I., Zhang, H., Mizuta, T., Ide, Y., Eguchi, Y., Yasutake, T., Sakamaki, T., Pestell, R.G., and Yamamoto, K., *Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor kappaB activation.* **Clin Cancer Res**. 2007 Apr 1; 13(7): p. 2236-45.

272. Casimiro, M., Rodriguez, O., Pootrakul, L., Aventian, M., Lushina, N., Cromelin, C., Ferzli, G., Johnson, K., Fricke, S., Diba, F., Kallakury, B., Ohanyerenwa, C., Chen, M., Ostrowski, M., Hung, M.C., Rabbani, S.A., Datar, R., Cote, R., Pestell, R., and Albanese, C., *ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo.* **Cancer Res**. 2007 May 1; 67(9): p. 4364-72.

273. Ju, X., Katiyar, S., Wang, C., Liu, M., Jiao, X., Li, S., Zhou, J., Turner, J., Lisanti, M.P., Russell, R.G., Mueller, S.C., Ojeifo, J., Chen, W.S., Hay, N., and Pestell, R.G., *Akt1 governs breast cancer progression in vivo.* **Proc Natl Acad Sci U S A**. 2007 May 1; 104(18): p. 7438-43.

274. Avvisato, C.L., Yang, X., Shah, S., Hoxter, B., Li, W., Gaynor, R., Pestell, R., Tozeren, A., and Byers, S.W., *Mechanical force modulates global gene expression and beta-catenin signaling in colon cancer cells.* **J Cell Sci**. 2007 Aug 1; 120(Pt 15): p. 2672-82.

275. Di Vizio, D., Sotgia, F., Williams, T.M., Hassan, G.S., Capozza, F., Frank, P.G., Pestell, R.G., Loda, M., Freeman, M.R., and Lisanti, M.P., *Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression.* **Cancer Biol Ther**. 2007 Aug; 6(8): p. 1263-8.

276. Fernando, R., Foster, J.S., Bible, A., Strom, A., Pestell, R.G., Rao, M., Saxton, A., Baek, S.J., Yamaguchi, K., Donnell, R., Cekanova, M., and Wimalasena, J., *Breast cancer cell proliferation is inhibited by BAD: regulation of cyclin D1.* **J Biol Chem**. 2007 Sep 28; 282(39): p. 28864-73.

277. Yao, D., Taguchi, T., Matsumura, T., Pestell, R., Edelstein, D., Giardino, I., Suske, G., Rabbani, N., Thornalley, P.J., Sarthy, V.P., Hammes, H.P., and Brownlee, M., *High glucose increases angiopoietin-2 transcription in microvascular endothelial cells through methylglyoxal modification of mSin3A.* **J Biol Chem**. 2007 Oct 19; 282(42): p. 31038-45.

278. Whittle, J.R., Powell, M.J., Popov, V.M., Shirley, L.A., Wang, C., and Pestell, R.G., *Sirtuins, nuclear hormone receptor acetylation and transcriptional regulation.* **Trends Endocrinol Metab**. 2007 Nov; 18(9): p. 356-64.

279. Jiao, X., Katiyar, S., Liu, M., Mueller, S.C., Lisanti, M.P., Li, A., Pestell, T.G., Wu, K., Ju, X., Li, Z., Wagner, E.F., Takeya, T., Wang, C., and Pestell, R.G., *Disruption of c-Jun reduces cellular migration and invasion through inhibition of c-Src and hyperactivation of ROCK II kinase.* **Mol Biol Cell**. 2008 Jan 25; 19(4): p. 1378-90.

280. Bouzahzah, B., Yurchenko, V., Nagajyothi, F., Hulit, J., Sadofsky, M., Braunstein, V.L., Mukherjee, S., Weiss, H., Machado, F.S., Pestell, R.G., Lisanti, M.P., Tanowitz, H.B., and Albanese, C., *Regulation of host cell cyclin D1 by Trypanosoma cruzi in myoblasts.* **Cell Cycle**. 2008 Feb 15; 7(4): p. 500-3.

281. Rao, M., Casimiro, M.C., Lisanti, M.P., D'Amico, M., Wang, C., Shirley, L.A., Leader, J.E., Liu, M., Stallcup, M., Engel, D.A., Murphy, D.J., and Pestell, R.G., *Inhibition of cyclin D1 gene transcription by Brg-1.* **Cell Cycle**. 2008 Mar 1; 7(5): p. 647-55.

282. Wang, C., Powell, M.J., Popov, V.M., and Pestell, R.G., *Acetylation in nuclear receptor signaling and the role of sirtuins.* **Mol Endocrinol**. 2008 Mar; 22(3): p. 539-45.

283. Li, Z., Wang, C., Jiao, X., Katiyar, S., Casimiro, M.C., Prendergast, G.C., Powell, M.J., and Pestell, R.G., *Alternate cyclin D1 mRNA splicing modulates p27KIP1 binding and cell migration.* **J Biol Chem**. 2008 Mar 14; 283(11): p. 7007-15.

284. Sundaram, K., Mani, S.K., Kitatani, K., Wu, K., Pestell, R.G., and Reddy, S.V., *DACH1 negatively regulates the human RANK ligand gene expression in stromal/preosteoblast cells.* **J Cell Biochem**. 2008 Apr 15; 103(6): p. 1747-59.

285. Wu, K., Katiyar, S., Li, A., Liu, M., Ju, X., Popov, V.M., Jiao, X., Lisanti, M.P., Casola, A., and Pestell, R.G., *Dachshund inhibits oncogene-induced breast cancer cellular migration and invasion through suppression of interleukin-8.* **Proc Natl Acad Sci U S A**. 2008 May 13; 105(19): p. 6924-9.

286. Kim, M., Wu, X., Song, I., Fu, M., Chang, S.H., Lisanti, M.P., and Pestell, R., *Selective cytotoxicity of synthesized procyanidin 3-O-galloylepicatechin-4b, 8-3-O-galloylcatechin to human cancer cells.* **Cell Cycle**. 2008 Jun 1; 7(11): p. 1648-57.

287. Marampon, F., Casimiro, M.C., Fu, M., Powell, M.J., Popov, V.M., Lindsay, J., Zani, B.M., Ciccarelli, C., Watanabe, G., Lee, R.J., and Pestell, R.G., *Nerve Growth factor regulation of cyclin D1 in PC12 cells through a p21RAS extracellular signal-regulated kinase pathway requires cooperative interactions between Sp1 and nuclear factor-kappaB.* **Mol Biol Cell**. 2008 Jun; 19(6): p. 2566-78.

288. Mercier, I., Vuolo, M., Jasmin, J.F., Medina, C.M., Williams, M., Mariadason, J.M., Qian, H., Xue, X., Pestell, R.G., Lisanti, M.P., and Kitsis, R.N., *ARC (apoptosis repressor with caspase recruitment domain) is a novel marker of human colon cancer.* **Cell Cycle**. 2008 Jun 1; 7(11): p. 1640-7.

289. Pezo, R.C., Gandhi, S.J., Shirley, L.A., Pestell, R.G., Augenlicht, L.H., and Singer, R.H., *Single-cell transcription site activation predicts chemotherapy response in human colorectal tumors.* **Cancer Res**. 2008 Jul 1; 68(13): p. 4977-82. PMID: 18593893

290. Augustus, A.S., Buchanan, J., Addya, S., Rengo, G., Pestell, R.G., Fortina, P., Koch, W.J., Bensadoun, A., Abel, E.D., and Lisanti, M.P., *Substrate uptake and metabolism are preserved in hypertrophic caveolin-3 knockout hearts.* **Am J Physiol Heart Circ Physiol**. 2008 Aug; 295(2): p. H657-66.

291. Mercier, I., Casimiro, M.C., Wang, C., Rosenberg, A.L., Quong, J., Minkeu, A., Allen, K.G., Danilo, C., Sotgia, F., Bonuccelli, G., Jasmin, J.F., Xu, H., Bosco, E., Aronow, B., Witkiewicz, A., Pestell, R.G., Knudsen, E.S., and Lisanti, M.P., *Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy.* **Cancer Biol Ther**. 2008 Aug; 7(8): p. 1212-25.

292. Yu, Z., Wang, C., Wang, M., Li, Z., Casimiro, M.C., Liu, M., Wu, K., Whittle, J., Ju, X., Hyslop, T., McCue, P., and Pestell, R.G., *A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation.* **J Cell Biol**. 2008 Aug 11; 182(3): p. 509-17.

293. Augustus, A.S., Buchanan, J., Gutman, E., Rengo, G., Pestell, R.G., Fortina, P., Koch, W.J., Bensadoun, A., Abel, E.D., and Lisanti, M.P., *Hearts lacking caveolin-1 develop hypertrophy with normal cardiac substrate metabolism.* **Cell Cycle**. 2008 Aug 15; 7(16): p. 2509-18.

294. Lindsay, J., Jiao, X., Sakamaki, T., Casimiro, M. C., Shirley, L. A., Tran, T. H., Ju, X., Liu, M., Li, Z., Wang, C., Katiyar, S., Rao, M., Allen, K. G., Glazer, R. I., Ge, C., Stanley, P., Lisanti, M. P., Rui, H., and Pestell, R. G. *ErbB2 induces Notch1 activity and function in breast cancer cells*. **Clin Transl Sci**. 2008 Sep; 1(2): p. 107-115.

295. Sotgia, F., Casimiro, M.C., Bonuccelli, G., Liu, M., Whitaker-Menezes, D., Er, O., Daumer, K.M., Mercier, I., Witkiewicz, A.K., Minetti, C., Capozza, F., Gormley, M., Quong, A.A., Rui, H., Frank, P.G., Milliman, J.N., Knudsen, E.S., Zhou, J., Wang, C., Pestell, R.G., and Lisanti, M.P., *Loss of caveolin-3 induces a lactogenic microenvironment that is protective against mammary tumor formation.* **Am J Pathol**. 2009 Feb; 174(2): p. 613-29.

296. Marampon, F., Bossi, G., Ciccarelli, C., Di Rocco, A., Sacchi, A., Pestell, R.G., and Zani, B.M., *MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma.* **Mol Cancer Ther**. 2009 Mar; 8(3): p. 543-51.

297. Sotgia, F., Del Galdo, F., Casimiro, M.C., Bonuccelli, G., Mercier, I., Whitaker-Menezes, D., Daumer, K.M., Zhou, J., Wang, C., Katiyar, S., Xu, H., Bosco, E., Quong, A.A., Aronow, B., Witkiewicz, A.K., Minetti, C., Frank, P.G., Jimenez, S.A., Knudsen, E.S., Pestell, R.G., and Lisanti, M.P., *Caveolin-1-/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts.* **Am J Pathol**. 2009 Mar; 174(3): p. 746-61.

298. Velasco-Velazquez, M.A., Yu, Z., Jiao, X., and Pestell, R.G., *Cancer stem cells and the cell cycle: targeting the drive behind breast cancer.* **Expert Rev Anticancer Ther**. 2009 Mar; 9(3): p. 275-9.

299. Mercier, I., Casimiro, M.C., Zhou, J., Wang, C., Plymire, C., Bryant, K.G., Daumer, K.M., Sotgia, F., Bonuccelli, G., Witkiewicz, A.K., Lin, J., Tran, T.H., Milliman, J., Frank, P.G., Jasmin, J.F., Rui, H., Pestell, R.G., and Lisanti, M.P., *Genetic ablation of caveolin-1 drives estrogen-hypersensitivity and the development of DCIS-like mammary lesions.* **Am J Pathol**. 2009 Apr; 174(4): p. 1172-90.

300. Wu, K., Katiyar, S., Witkiewicz, A., Li, A., McCue, P., Song, L.N., Tian, L., Jin, M., and Pestell, R.G., *The cell fate determination factor dachshund inhibits androgen receptor signaling and prostate cancer cellular growth.* **Cancer Res**. 2009 Apr 15; 69(8): p. 3347-55.

301. Bonuccelli, G., Casimiro, M.C., Sotgia, F., Wang, C., Liu, M., Katiyar, S., Zhou, J., Dew, E., Capozza, F., Daumer, K.M., Minetti, C., Milliman, J.N., Alpy, F., Rio, M.C., Tomasetto, C., Mercier, I., Flomenberg, N., Frank, P.G., Pestell, R.G., and Lisanti, M.P., *Caveolin-1 (P132L), a common breast cancer mutation, confers mammary cell invasiveness and defines a novel stem cell/metastasis-associated gene signature.* **Am J Pathol**. 2009 May; 174(5): p. 1650-62.

302. Liu, M., Ju, X., Willmarth, N.E., Casimiro, M.C., Ojeifo, J., Sakamaki, T., Katiyar, S., Jiao, X., Popov, V.M., Yu, Z., Wu, K., Joyce, D., Wang, C., and Pestell, R.G., *Nuclear factor-kappaB enhances ErbB2-induced mammary tumorigenesis and neoangiogenesis in vivo.* **Am J Pathol**. 2009 May; 174(5): p. 1910-20.

303. Mercier, I., Bryant, K.G., Sotgia, F., Bonuccelli, G., Witkiewicz, A.K., Dasgupta, A., Jasmin, J.F., Pestell, R.G., and Lisanti, M.P., *Using Caveolin-1 epithelial immunostaining patterns to stratify human breast cancer patients and predict the Caveolin-1 (P132L) mutation.* **Cell Cycle**. 2009 May 1; 8(9): p. 1396-401.

304. Mercier, I., Jasmin, J.F., Pavlides, S., Minetti, C., Flomenberg, N., Pestell, R.G., Frank, P.G., Sotgia, F., and Lisanti, M.P., *Clinical and translational implications of the caveolin gene family: lessons from mouse models and human genetic disorders.* **Lab Invest**. 2009 Jun; 89(6): p. 614-23.

305. Witkiewicz, A.K., Casimiro, M.C., Dasgupta, A., Mercier, I., Wang, C., Bonuccelli, G., Jasmin, J.F., Frank, P.G., Pestell, R.G., Kleer, C.G., Sotgia, F., and Lisanti, M.P., *Towards a new "stromal-based" classification system for human breast cancer prognosis and therapy.* **Cell Cycle**. 2009 Jun 1; 8(11): p. 1654-8.

306. Witkiewicz, A.K., Dasgupta, A., Nguyen, K.H., Liu, C., Kovatich, A.J., Schwartz, G.F., Pestell, R.G., Sotgia, F., Rui, H., and Lisanti, M.P., *Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer.* **Cancer Biol Ther**. 2009 Jun; 8(11): p. 1071-9.

307. Witkiewicz, A.K., Dasgupta, A., Sotgia, F., Mercier, I., Pestell, R.G., Sabel, M., Kleer, C.G., Brody, J.R., and Lisanti, M.P., *An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers.* **Am J Pathol**. 2009 Jun; 174(6): p. 2023-34.

308. Zhou, J., Zhang, W., Liang, B., Casimiro, M.C., Whitaker-Menezes, D., Wang, M., Lisanti, M.P., Lanza-Jacoby, S., Pestell, R.G., and Wang, C., *PPARgamma activation induces autophagy in breast cancer cells.* **Int J Biochem Cell Biol**. 2009 Jun 26; 41(11): p. 2334-42.

309. Popov, V.M., Zhou, J., Shirley, L.A., Quong, J., Yeow, W.S., Wright, J.A., Wu, K., Rui, H., Vadlamudi, R.K., Jiang, J., Kumar, R., Wang, C., and Pestell, R.G., *The cell fate determination factor DACH1 is expressed in estrogen receptor-alpha-positive breast cancer and represses estrogen receptor-alpha signaling.* **Cancer Res**. 2009 Jul 15; 69(14): p. 5752-60.

310. Di Vizio, D., Morello, M., Sotgia, F., Pestell, R.G., Freeman, M.R., and Lisanti, M.P., *An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation.* **Cell Cycle**. 2009 Aug; 8(15): p. 2420-4.

311. Nan, F., Lu, Q., Zhou, J., Cheng, L., Popov, V.M., Wei, S., Kong, B., Pestell, R.G., Lisanti, M.P., Jiang, J., and Wang, C., *Altered expression of DACH1 and cyclin D1 in endometrial cancer.* **Cancer Biol Ther**. 2009 Aug; 8(16): p. 1534-9.

312. Liu, M., Casimiro, M.C., Wang, C., Shirley, L.A., Jiao, X., Katiyar, S., Ju, X., Li, Z., Yu, Z., Zhou, J., Johnson, M., Fortina, P., Hyslop, T., Windle, J.J., and Pestell, R.G., *p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo.* **Proc Natl Acad Sci U S A**. 2009 Nov 10; 106(45): p. 19035-9.

313. Genander, M., Halford, M.M., Xu, N.J., Eriksson, M., Yu, Z., Qiu, Z., Martling, A., Greicius, G., Thakar, S., Catchpole, T., Chumley, M.J., Zdunek, S., Wang, C., Holm, T., Goff, S.P., Pettersson, S., Pestell, R.G., Henkemeyer, M., and Frisen, J., *Dissociation of EphB2 signaling pathways mediating progenitor cell proliferation and tumor suppression.* **Cell**. 2009 Nov 13; 139(4): p. 679-92.

314. Pavlides, S., Whitaker-Menezes, D., Castello-Cros, R., Flomenberg, N., Witkiewicz, A.K., Frank, P.G., Casimiro, M.C., Wang, C., Fortina, P., Addya, S., Pestell, R.G., Martinez-Outschoorn, U.E., Sotgia, F., and Lisanti, M.P., *The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma.* **Cell Cycle**. 2009 Dec; 8(23): p. 3984-4001.

315. Tian, L., Zhou, J., Casimiro, M.C., Liang, B., Ojeifo, J.O., Wang, M., Hyslop, T., Wang, C., and Pestell, R.G., *Activating peroxisome proliferator-activated receptor gamma mutant promotes tumor growth in vivo by enhancing angiogenesis.* **Cancer Res**. 2009 Dec 15; 69(24): p. 9236-44.

316. Ma, Y., Fan, S., Hu, C., Meng, Q., Fuqua, S.A., Pestell, R.G., Tomita, Y.A., and Rosen, E.M., *BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha.* **Mol Endocrinol**. 2010 Jan; 24(1): p. 76-90.

317. Popov, V.M., Wu, K., Zhou, J., Powell, M.J., Mardon, G., Wang, C., and Pestell, R.G., *The Dachshund gene in development and hormone-responsive tumorigenesis.* **Trends Endocrinol Metab**. 2010 Jan; 21(1): p. 41-9.

318. Thakur, M.L., Devadhas, D., Zhang, K., Pestell, R.G., Wang, C., McCue, P., and Wickstrom, E., *Imaging spontaneous MMTVneu transgenic murine mammary tumors: targeting metabolic activity versus genetic products.* **J Nucl Med**. 2010 Jan; 51(1): p. 106-11.

319. Yu, Z., Baserga, R., Chen, L., Wang, C., Lisanti, M.P., and Pestell, R.G., *microRNA, cell cycle, and human breast cancer.* **Am J Pathol**. 2010 Mar; 176(3): p. 1058-64.

320. Zhong, Z., Yeow, W.S., Zou, C., Wassell, R., Wang, C., Pestell, R.G., Quong, J.N., and Quong, A.A., *Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells.* **Cancer Res**. 2010 Mar 1; 70(5): p. 2105-14.

321. Jiao, X., Katiyar, S., Willmarth, N.E., Liu, M., Ma, X., Flomenberg, N., Lisanti, M.P., and Pestell, R.G., *c-Jun induces mammary epithelial cellular invasion and breast cancer stem cell expansion.* **J Biol Chem**. 2010 Mar 12; 285(11): p. 8218-26.

322. Gravina, G.L., Marampon, F., Di Staso, M., Bonfili, P., Vitturini, A., Jannini, E.A., Pestell, R.G., Tombolini, V., and Festuccia, C., *5-azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.* **Prostate**. 2010 Aug;70(11):1166-78. [Epub 2010 Mar 23].

323. Zhou, J., Wang, C., Wang, Z., Dampier, W., Wu, K., Casimiro, M.C., Chepelev, I., Popov, V.M., Quong, A., Tozeren, A., Zhao, K., Lisanti, M.P., and Pestell, R.G., *Attenuation of Forkhead signaling by the retinal determination factor DACH1.* **Proc Natl Acad Sci U S A**. 2010 Apr 13; 107(15): p. 6864-9.

324. Yu, Z., Willmarth, N.E., Zhou, J., Katiyar, S., Wang, M., Liu, Y., McCue, P.A., Quong, A.A., Lisanti, M.P., and Pestell, R.G., *microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling.* **Proc Natl Acad Sci U S A**. 2010 May 4;107(18):8231-6. Epub 2010 Apr 20.

325. Pavlides, S., Tsirigos, A., Vera, I., Flomenberg, N., Frank, P.G., Casimiro, M.C., Wang, C., Pestell, R.G., Martinez-Outschoorn, U.E., Howell, A., Sotgia, F., and Lisanti, M.P., *Transcriptional evidence for the "Reverse Warburg Effect" in human breast cancer tumor stroma and metastasis: Similarities with oxidative stress, inflammation, Alzheimer's disease, and "Neuron-Glia Metabolic Coupling".* **Aging (Albany NY)**. 2010 Apr; 2(4): p. 185-99.

326. Vissapragada, S., Ghosh, A., Ringer, L., Salinas, P., Brophy, A., Peaceman, D., Kallakury, B., Banerjee, P.P., Fricke, S.T., Helfrich, W., Lee, Y.C., Pestell, R., Scherer, P., Tanowitz, H.B., Avantaggiati, M.L., Hilakivi-Clarke, L., Lisanti, M.P., Rodriguez, O.C., and Albanese, C., *Dietary n-3 polyunsaturated fatty acids fail to reduce prostate tumorigenesis in the PB-ErbB-2 x Pten(+/-) preclinical mouse model.* **Cell Cycle**. 2010 May 15; 9(9). PMID: 20404514

327. Pavlides, S., Tsirigos, A., Vera, I., Flomenberg, N., Frank, P.G., Casimiro, M.C., Wang, C., Fortina, P., Addya, S., Pestell, R.G., Martinez-Outschoorn, U.E., Sotgia, F., Lisanti, M.P., *Loss of stromal caveolin-1 leads to oxidative stress, mimics hypoxia and drives inflammation in the tumor microenvironment, conferring the "reverse Warburg effect": A transcriptional informatics analysis with validation.* **Cell Cycle**. 2010 Jun 1;9(11):2201-19.

328. Bonuccelli, G., Whitaker-Menezes, D., Castello-Cros, R., Pavlides, S., Pestell, R.G., Fatatis, A., Witkiewicz, A.K., Vander Heiden, M.G., Migneco, G., Chiavarina, B., Frank, P.G., Capozza, F., Flomenberg, N., Martinez-Outschoorn, U.E., Sotgia, F., Lisanti, M.P. *The reverse Warburg effect: Glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts.* **Cell Cycle.** 2010 May 15;9(10):1960-71. Epub 2010 May 15]

329. Migneco, G., Whitaker-Menezes, D., Chiavarina, B., Castello-Cros, R., Pavlides, S., Pestell, R.G., Fatatis, A., Flomenberg, N., Tsirigos, A., Howell, A., Martinez-Outschoorn, U.E., Sotgia, F., Lisanti, M.P. *Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: Evidence for stromal-epithelial metabolic coupling.* **Cell Cycle.** 2010 Jun 15;9(12):2412-22. Epub 2010 Jun 15.

330. Martinez-Outschoorn, U.E., Pavlides, S., Whitaker-Menezes, D., Daumer, K.M., Milliman, J.N., Chiavarina, B., Migneco, G., Witkiewicz, A.K., Martinez-Cantarin, M.P., Flomenberg, N., Howell, A., Pestell, R.G., Lisanti, M.P., Sotgia, F. *Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: Implications for breast cancer and DCIS therapy with autophagy inhibitors.* **Cell Cycle**. 2010 Jun 15;9(12):2423-33. Epub 2010 Jun 15

331. Martinez-Outschoorn, U., Balliet, R., Rivadeneira, D., Chiavarina, B., Pavlides, S., Wang, C., Whitaker-Menezes, D., Daumer, K., Lin, Z., Witkiewicz, A., Flomenberg, N., Howell, A., Pestell, R., Knudsen, E., Sotgia, F., Lisanti M.P. *Oxidative stress in cancer fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells.* **Cell Cycle**. 2010 Aug 15;9(16):3256-76. Epub 2010 Aug 28.

332. Pavlides, S., Tsirigos, A., Migneco, G., Whitaker-Menezes, D., Chiavarina, B., Flomenberg, N., Frank, P.G., Casimiro, M.C., Wang, C., Pestell R.G., Martinez-Outschoorn, U.E., Howell, A., Sotgia, F., Lisanti M.P. *The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism.* **Cell Cycle.** 2010 Sep 1;9(17):3485-505. doi: 10.4161/cc.9.17.12721

333. Bonuccelli, G., Tsirigos, A., Whitaker-Menezes, D., Pavlides, S., Pestell, R.G., Chiavarina, B., Frank, P.G., Flomenberg, N., Howell, A., Martinez-Outschoorn, U.E., Sotgia, F., Lisanti, M.P. *Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism.* **Cell Cycle**. 2010 Sep;9(17):3506-14. Epub 2010 Sep 21.

334. Martinez-Outschoorn U.E., Casey, T., Lin, Z., Whitaker-Menezes, D., Chiavarina, B., Zhou, J., Wang, C., Pavlides, S., Martinez-Cantarin, M.P., Capozza, F., Witkiewicz, A.K., Flomenberg, N., Howell, A., Pestell, R.G., Caro, J., Lisanti, M.P., Sotgia, F. *Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment.* **Cell Cycle**. 2010 Sep;9(17):3515-33. Epub 2010 Sep 9.

335. Chiavarina, B., Whitaker-Menezes , D., Migneco, G., Martinez-Outschoorn, U.E., Pavlides, S., Howell, A., Tanowitz, H.B., Casimiro, M.C., Wang, C., Pestell, R.G., Grieshaber, P., Caro, J., Sotgia, F., Lisanti, M.P. *HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis.* **Cell Cycle**. 2010 Sep;9(17):3534-51. Epub 2010 Sep 4.

336. Baur J.A., Chen D., Chini E.N., Chua K., Cohen H.Y., de Cabo R., Deng C., Dimmeler S., Gius D., Guarente L.P., Helfand S.L., Imai S., Itoh H., Kadowaki T., Koya D., Leeuwenburgh C., McBurney M., Nabeshima Y., Neri C., Oberdoerffer P., Pestell R.G., Rogina B., Sadoshima J., Sartorelli V., Serrano M., Sinclair D.A., Steegborn C., Tatar M., Tissenbaum H.A., Tong Q., Tsubota K., Vaquero A., Verdin E. *Dietary restriction: Standing up for sirtuins*. **Science**. 2010 Aug 27;329(5995):1012-3; PMID: 20798296 author reply 1013-4.

337. Liu, M., Sakamaki, T., Casimiro, M., Willmarth, N., Quong, A., Ju, X., Ojeifo, J., Jiao, X., Yeow, W-S., Wang, C., Katiyar, S., Shirley, L., Albanese, C., Joyce, D., Pestell, R.G. *The canonical NF-κB pathway governs mammary tumorigenesis in transgenic mice via tumor stem cell expansion*. **Cancer Res**. 2010 Dec 15;70(24):10464-10473.

338. Li, Z., Jiao, X., Wang, C., Shirley, L.A., Elsaleh, H., Dahl, O., Wang, M., Soutoglou, E., Knudsen, E.S., Pestell, R.G. *Alternative Cyclin D1 Splice Forms Differentially Regulate the DNA Damage Response*. **Cancer Res.** 2010 Nov 1;70(21):8802-11. Epub 2010 Oct 12.

339. Trimmer, C., Whitaker-Menezes, D., Bonuccelli, G., Milliman, J.N., Daumer, K.M., Aplin, A.E., Pestell, R.G., Sotgia, F., Lisanti, M.P., Capozza, F. *CAV1 Inhibits Metastatic Potential in Melanomas through Suppression of the Integrin/Src/FAK Signaling Pathway.* **Cancer Res**. 2010 Oct 1;70(19):7489-99. Epub 2010 Aug 13.

340. Wu, K., Jiao, X., Li, Z., Katiyar, S., Casimiro, M.C., Yang, W., Zhang, Q., Willmarth, N.E., Chepelev, I., Crosariol, M., Wei, Z., Li, A., Zhao, K., Pestell, R.G. *Cell Fate Determination Factor Dachshund Reprograms Breast Cancer Stem Cell Function*. **J Biol Chem**. 2011 Jan 21;286(3):2132-42. Epub 2010 Oct 11.

341. Zhou, J., Wang, C., Zhang, W., Popov, V.M., Wang, M., Pattabiraman, N., Sune, C., Pestell, R.G. *Transcription elongation regulator 1 is a co-integrator of the cell fate determination factor Dachshund homolog 1.* **J Biol Chem**. 2010 Dec 17;285(51):40342-50. Epub 2010 Oct 18.

342. Gaughan, L., Stockley, J., Wang, N., McCracken, S.R., Treumann, A., Armstrong, K., Shaheen, F., Watt, K., McEwan, I.J., Wang, C., Pestell, R.G., Robson, C.N. *Regulation of the androgen receptor by SET9-mediated methylation.* **Nucleic Acids Res**. 2011 Mar;39(4):1266-79. Epub 2010 Oct 19.

343. Marampon, F., Gravina, G.L., Di Rocco, A., Bonfili, P., Di Staso, M., Fardella, C., Polidoro, L., Ciccarelli, C., Festuccia, C., Popov, V.M., Pestell, R.G., Tombolini, V., Zani, B.M. *MEKs/ERKs inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by down regulating growth and DNA repair signals*. **Mol Cancer Ther**. 2011 Jan;10(1):159-68.

344. Martinez-Outschoorn UE, Whitaker-Menezes D, Pavlides S, Chiavarina B, Bonuccelli G, Trimmer C, Tsirigos A, Migneco G, Witkiewicz AK, Balliet R, Mercier I, Wang C, Flomenberg N, Howell A, Lin Z, Caro J, Pestell RG, Sotgia F, Lisanti MP. *The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox.* **Cell Cycle**. 2010 Nov;9(21):4297-306. Epub 2010 Nov 30.

345. Gravina, G.L., Festuccia, C., Marampon, F., Popov, V.M., Pestell, R.G., Zani, B.M., Tombolini, V. *Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation*. **Mol Cancer**. 2010 Nov 25;9:305. doi: 10.1186/1476-4598-9-305

346. Meng, H., Tian, L., Zhou, J., Li, Z., Jiao, X., Li, W. W., Plomann, M., Xu, Z., Wang, C., and Pestell, R.G. *PACSIN 2 Represses Cellular Migration through Direct Association with Cyclin D1 but not its Alternate Splice Form Cyclin D1b*. **Cell Cycle**. 2011 Jan 1;10(1):73-81. Epub 2011 Jan 1.

347. Powell, M.J., Casimiro, M.C., Cordon-Cardo, C., He, X., Yeow, W.S., Wang, C., McCue, P., McBurney, M.W., Pestell, R.G. *Disruption of a Sirt1 Dependent Autophagy Checkpoint in the Prostate Results in Prostatic Intraepithelial Neoplasia Lesion Formation*. **Cancer Res.** 2011 Feb 1;71(3):964-75. Epub 2010 Dec 28.

348. Wang, C., Tian, L., Popov, V. M., Pestell, R.G. *Acetylation and Nuclear Receptor Action*. **J Steroid Biochem Mol Biol**. 2011 Feb;123(3-5):91-100. Epub 2010 Dec 15.

349. Trimmer C., Sotgia F., Whitaker-Menezes D., Balliet R., Eaton G., Martinez-Outschoorn U.E., Pavlides S., Howell A., Iozzo R.V., Pestell R.G., Scherer P.E., Capozza F., Lisanti M.P. *Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment: A new genetically tractable model for human cancer associated fibroblasts*. **Cancer Biol Ther**. 2011 Feb 15;11(4):383-94. Epub 2011 Feb 15]

350. Bonuccelli G, Whitaker-Menezes D, Castello-Cros R, Pavlides S, Pestell RG, Fatatis A, Witkiewicz AK, Heiden MG, Migneco G, Chiavarina B, Frank PG, Capozza F, Flomenberg N, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. *The reverse Warburg Effect: Glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts.* **Cell Cycle**. 2010 Dec 14;9(10):1960-71. Epub 2010 May 15.

351. Martinez-Outschoorn UE, Pavlides S, Howell A, Pestell RG, Tanowitz HB, Sotgia F, Lisanti MP. *Stromal-Epithelial Metabolic Coupling in Cancer: Integrating Autophagy and Metabolism in the Tumor Microenvironment.* **Int J Biochem Cell Biol**. 2011 Jul;43(7):1045-51. Epub 2011 Feb 15.

352. Janowski E, Jiao X, Katiyar S, Lisanti MP, Liu M, Pestell RG, Morad M. *C-jun is required for TGF-β-Mediated Cellular Migration via nuclear CA^2+ Signaling.* **Int J Biochem Cell Biol**. 2011 Aug;43(8):1104-13. Epub 2011 Apr 5.

353. Li SC, Acevedo J, Schwartz PH, Wang L, Jiang H, Luo J, Pestell RG, Loudon WG, Chang AC. *Mechanisms for Progenitor Cell-mediated Repair for Ischemic Heart Injury* **Curr Stem Cell Res Ther**. 2012 Jan;7(1):2-14.

354. Martinez-Outschoorn UE, Prisco M, Ertel A, Tsirigos A, Lin Z, Pavlides S, Wang C, Flomenberg N, Knudsen ES, Howell A, Pestell RG, Sotgia F, Lisanti MP. *Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis, and poor clinical outcome in breast cancer: Achieving personalized medicine via Metabolo-Genomics*. **Cell Cycle.** 2011 Apr 15;10(8):1271-86. doi: 10.4161/cc.10.8.15330

355. Velasco-Velázquez MA, Popov VM, Lisanti MP, Pestell RG. *The Role of Breast Cancer Stem Cells in Metastasis and Therapeutic Implications*. **Am J Pathol**. 2011 May. Jul;179(1):2-11. Epub 2011 Apr 28.

356. Velasco-Velázquez MA, Li Z, Casimiro MC, Loro E, Homsi N, Pestell RG. *Examining the role of cyclin D1 in breast cancer*. **Future Oncol**. 2011 Jun;7(6):753-65.

357. Martinez-Outschoorn UE, Whitaker-Menezes D, Lin Z, Flomenberg N, Howell A, Pestell RG, Lisanti MP, Sotgia F. *Cytokine production and inflammation drive autophagy in the tumor microenvironment: Role of stromal caveolin-1 as a key regulator*. **Cell Cycle**. 2011 Jun 1;10(11):1784-93. Epub 2011 Jun 1.

358. Whitaker-Menezes D, Martinez-Outschoorn UE, Lin Z, Ertel A, Flomenberg N, Witkiewicz AK, Birbe RC, Howell A, Pavlides S, Gandara R, Pestell RG, Sotgia F, Philp NJ, Lisanti MP. *Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts*. **Cell Cycle**. 2011 Jun 1;10(11):1772-83. Epub 2011 Jun 1.

359. DeAngelis T, Wu K, Pestell RG, Baserga R. *The type 1 insulin-like growth factor receptor and resistance to DACH1*. **Cell Cycle**. 2011 Jun 15;10(12):1956-9. Epub 2011 Jun 15.

360. Castello-Cros R, Bonnuccelli G, Molchansky A, Capozza F, Witkiewicz AK, Birbe RC, Howell A, Pestell RG, Whitaker-Menezes D, Sotgia F, Lisanti MP. *Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis*. **Cell Cycle.** 2011 Jun 15;10(12):2021-34. Epub 2011 Jun 15

361. Lisanti MP, Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, Pestell RG, Howell A, Sotgia F. *Accelerated aging in the tumor microenvironment: Connecting aging, inflammation and cancer metabolism with personalized medicine.* **Cell Cycle.** 2011 Jul 1;10(13):2059-63. Epub 2011 Jul 1

362. Sotgia F, Martinez-Outschoorn UE, Pavlides S, Howell A, Pestell RG, Lisanti MP. *Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment.* **Breast Cancer Res.** 2011 Jul 8;13(4):213. doi: 10.1186/bcr2892

363. Martinez-Outschoorn UE, Lin Z, Trimmer C, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F, Lisanti MP. *Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the reverse Warburg effect: Implications for PET imaging of human tumors*. **Cell Cycle.** 2011 Aug 1;10(15):2504-20. Epub 2011 Aug 1.

364. Martinez-Outschoorn UE, Lin Z, Ko YH, Goldberg AF, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F, Lisanti MP. *Understanding the metabolic basis of drug resistance: Therapeutic induction of the Warburg effect kills cancer cells.* **Cell Cycle.** 2011 Aug 1;10(15):2521-8. Epub 2011 Aug 1.

365. Lisanti MP, Martinez-Outschoorn UE, Lin Z, Pavlides S, Whitaker-Menezes D, Pestell RG, Howell A, Sotgia F. *Hydrogen peroxide fuels aging, inflammation, cancer metabolism and metastasis: The seed and soil also needs "fertilizer"* . **Cell Cycle.** 2011 Aug 1;10(15):2440-9. Epub 2011 Aug 1

366. Gravina GL, Marampon F, Piccolella M, Motta M, Ventura L, Pomante R, Popov VM, Zani BM, Pestell RG, Tombolini V, Jannini E, Festuccia C. *Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models*. **Endocrinology**. 2011 Dec;152(12):4550-61. Epub 2011 Oct 11.

367. Salem AF, Bonuccelli G, Bevilacqua G, Arafat HA, Pestell RG, Sotgia F, Lisanti MP. *Caveolin-1 promotes pancreatic cancer cell differentiation and restores membranous E-cadherin via suppression of the epithelial-mesenchymal transition.* **Cell Cycle**. 2011 Nov 1;10(21):3692-700. Epub 2011 Nov 1.

368. Montie HL, Pestell RG, Merry DE. *SIRT1 Modulates Aggregation and Toxicity through Deacetylation of the Androgen Receptor in Cell Models of SBMA*. **J Neurosci**. (2011). Nov 30;31(48):17425-36

369. Sotgia F, Martinez-Outschoorn UE, Howell A, Pestell RG, Pavlides S, Lisanti MP. *Caveolin-1 and Cancer Metabolism in the Tumor Microenvironment: Markers, Models, and Mechanisms.* **Annu Rev Pathol**. 2012 Feb 28;7:423-67. Epub 2011 Nov 7.

370. Martinez-Outschoorn UE, Goldberg A, Lin Z, Ko YH, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F, Lisanti MP. *Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells.* **Cancer Biol Ther**. 2011 Nov 15;12(10):924-38. Epub 2011 Nov 15.

371. Pavlides S, Vera I, Gandara R, Sneddon S, Pestell RG, Mercier I, Martinez-Outschoorn UE, Whitaker-Menezes D, Howell A, Sotgia F, Lisanti MP. *Warburg Meets Autophagy: Cancer-Associated Fibroblasts Accelerate Tumor Growth and Metastasis via Oxidative Stress, Mitophagy, and Aerobic Glycolysis.* **Antioxid Redox Signal.** 2012 Jun 1;16(11):1264-84. doi: 10.1089/ars.2011.4243. Epub 2011 Nov 17

372. Balliet RM, Capparelli C, Guido C, Pestell TG, Martinez-Outschoorn UE, Lin Z, Whitaker-Menezes D, Chiavarina B, Pestell RG, Howell A, Sotgia F, Lisanti MP. *Mitochondrial oxidative stress in cancer associated fibroblasts drives lactate production, promoting breast cancer tumor growth: Understanding the aging and cancer connection.* **Cell Cycle**. 2011 Dec 1;10(23):4065-73. Epub 2011 Dec 1.

373. Whitaker-Menezes D, Martinez-Outschoorn UE, Flomenberg N, Birbe RC, Witkiewicz AK, Howell A, Pavlides S, Tsirigos A, Ertel A, Pestell RG, Broda P, Minetti C, Lisanti MP, Sotgia F. *Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: Visualizing the therapeutic effects of metformin in tumor tissue.* **Cell Cycle**. 2011 Dec 1;10(23):4047-64. Epub 2011 Dec 1.

374. Martinez-Outschoorn UE, Pestell RG, Howell A, Tykocinski ML, Nagajyothi F, Machado FS, Tanowitz HB, Sotgia F, Lisanti MP. *Energy transfer in "parasitic" cancer metabolism: Mitochondria are the powerhouse and Achilles' heel of tumor cells.* **Cell Cycle**. 2011 Dec 15;10(24):4208-16. Epub 2011 Dec 15.

375. Ko YH, Lin Z, Flomenberg N, Pestell RG, Howell A, Sotgia F, Lisanti MP, Martinez-Outschoorn UE. *Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells: Implications for preventing chemotherapy resistance.* **Cancer Biol Ther**. 2011 Dec 15;12(12):1085-97. doi: 10.4161/cbt.12.12.18671. Epub 2011 Dec 15.

376. Chiavarina B, Whitaker-Menezes D, Martinez-Outschoorn UE, Witkiewicz AK, Birbe RC, Howell A, Pestell RG, Smith J, Daniel R, Sotgia F, Lisanti MP. *Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth.* **Cancer Biol Ther**. 2011 Dec 15;12(12):1101-13. doi: 10.4161/cbt.12.12.18703. Epub 2011 Dec 15

377. Velasco-Velázquez MA, Homsi N, De La Fuente M, Pestell RG. *Breast Cancer Stem Cells*. **Int J Biochem Cell Biol**. 2012 Apr;44(4):573-7. doi: 10.1016/j.biocel.2011.12.020. Epub 2012 Jan 9

378. Ertel A, Tsirigos A, Whitaker-Menezes D, Birbe RC, Pavlides S, Martinez-Outschoorn UE, Pestell RG, Howell A, Sotgia F, Lisanti MP. *Is cancer a metabolic rebellion against host aging? In the quest for immortality, tumor cells try to save themselves by boosting mitochondrial metabolism.* **Cell Cycle**. 2012 Jan 15;11(2). [Epub ahead of print]

379. Casimiro MC, Crosariol M, Loro E, Ertel A, Yu Z, Dampier W, Saria E, Papanikolaou A, Li Z, Wang C, Fortina P, Addya A, Tozeren A, Knudsen ES, Arnold A, Pestell RG. *ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice*. **J Clin Invest**. 2012 Mar 1;122(3):833-43. doi: 10.1172/JCI60256..

380. Katiyar S, Addya S, Covarrubias M, Casimiro MC, Zhou J, Jiao X, Nasim T, Fortina P, Pestell RG. *Mammary gland selective excision of c-jun identifies its role in mRNA splicing.* **Cancer Res**. 2012 Feb 15;72(4):1023-34. Epub 2011 Dec 15.

381. Capozza F, Trimmer C, Castello-Cros R, Katiyar S, Whitaker-Menezes D, Follenzi A, Crosariol M, Llaverias G, Sotgia F, Pestell RG, Lisanti MP. *Genetic ablation of Cav1 differentially affects melanoma tumor growth and metastasis in mice. Role of Cav1 in Shh heterotypic signaling and transendothelial migration.* **Cancer Res**. 2012 May 1;72(9):2262-74. Epub 2012 Mar 6.

382. Yu Z, Pestell RG. *Small Non-coding RNAs Govern Mammary Gland Tumorigenesis*. **J Mammary Gland Biol Neoplasia**. 2012 Mar;17(1):59-64. Epub 2012 Mar 1.

383. Sotgia F, Whitaker-Menezes D, Martinez-Outschoorn UE, Flomenberg N, Birbe RC, Witkiewicz AK, Howell A, Philp NJ, Pestell RG, Lisanti MP. *Mitochondrial metabolism in cancer metastasis: Visualizing tumor cell mitochondria and the "Reverse Warburg Effect" in positive lymph node tissue.* **Cell Cycle**. 2012 Apr 1;11(7):1445-54. Epub 2012 Apr 1.

384. Clark PM, Dawany N, Dampier W, Byers SW, Pestell RG, Tozeren A. *Bioinformatics analysis reveals transcriptome and microRNA signatures and drug repositioning targets for IBD and other autoimmune diseases*. **Inflamm Bowel Dis**. 2012 Dec;18(12):2315-33. Epub 2012 Apr 5

385. Casimiro MC, Pestell RG. *Cyclin D1 Induces Chromosomal Instability*. **Oncotarget**. 2012;3(3):224-5.

386. Velasco-Velázquez M, Jiao X, de la Fuente M, Pestell TG, Ertel A, Lisanti MP, Pestell RG. *CCR5 antagonist blocks metastasis of basal breast cancer cells.* **Cancer Res**. 2012 Aug 1;72(15):3839-50. Epub 2012 May 25.

387. Capparelli C, Whitaker-Menezes D, Guido C, Balliet R, Pestell TG, Howell A, Sneddon S, Pestell RG, Martinez-Outschoorn U, Lisanti MP, Sotgia F. *CTGF drives autophagy, glycolysis, and senescence in cancer associated fibroblasts via HIF1 activation, metabolically promoting tumor growth.* **Cell Cycle**. 2012 Jun 15;11(12):2272-84. Epub 2012 Jun 15.

388. Capparelli C, Guido C, Whitaker-Menezes D, Bonuccelli G, Balliet R, Pestell TG, Goldberg AF, Pestell RG, Howell A, Sneddon S, Birbe R, Tsirigos A, Martinez-Outschoorn U, Sotgia F, Lisanti MP. *Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis, via glycolysis and ketone production.* **Cell Cycle**. 2012 Jun 15;11(12):2285-302. Epub 2012 Jun 15.

389. Carito V, Bonuccelli G, Martinez-Outschoorn UE, Whitaker-Menezes D, Caroleo MC, Cione E, Howell A, Pestell RG, Lisanti MP, Sotgia F. *Metabolic Remodeling of the Tumor Microenvironment: Migration Stimulating Factor (MSF) Reprograms Myofibroblasts Towards Lactate Production, Fueling Anabolic Tumor Growth.* **Cell Cycle**. 2012 Sep 15;11(18):3403-14. Epub 2012 Aug 23.

390. Yu Z, Pestell TG, Lisanti MP, Pestell RG. *Cancer Stem Cells*. **Int J Biochem Cell Biol**. 2012 Nov 6;107(10):1684-91. Epub 2012 Oct 25.

391. Yu Z, Li Y, Fan H, Liu Z, **Pestell RG**. *miRNAs Regulate Stem Cell Self-Renewal and Differentiation.* **Front Genet**. 2012;3:191. doi: 10.3389/fgene.2012.00191. Epub 2012 Sep 25.

392. Myklebust MP, Li Z, Tran TH, Rui H, Knudsen ES, Elsaleh H, Fluge O, Vonen B, Myrvold HE, Leh S, Tveit KM, Pestell RG, Dahl O. *Expression of Cyclin D1a and D1b as Predictive Factors for Treatment Response in Colorectal Cancer.* **Br J Cancer**. 2012 Nov 6;107(10):1684-91. Epub 2012 Oct 25.

393. Schild R, Knuppel T, Konrad M, Bergmann C, Trautmann A, Kemper M, Wu K, Yaklichkin S, Wang J, Pestell RG, Muller-Wiefel DE, Schaefer F, Weber S. *Double homozygous missense mutations in DACH1 and BMP4 in a patient with bilateral cystic renal dysplasia.* **Nephrol. Dial. Transplant**. 2013 Jan;28(1):227-32. Epub 2012 Dec 21.

394. Ju X, Ertel A, Casimiro C, Yu Z, Meng H, McCue P, Walters R, Fortina P, Lisanti M, Pestell RG. *Novel Oncogene Inducted Metastatic Prostate Cancer Cell Lines Define Human Prostate Cancer Progression Signatures*. **Cancer Res**. 2013 Jan 15;73(2):978-89. . Epub 2012 Nov 30. PMID: 23204233

395. Trimmer C, Bonuccelli G, Katiyar S, Sotgia F, Pestell RG, Lisanti M, Capozza F. *Cav1 suppresses tumor growth and metastasis in a murine model of cutaneous SCC through modulation of MAPK/AP-1 activation*. **Am J Pathol**. 2013 Mar;182(3):992-1004. 2012.11.008. Epub 2012 Dec 22.

396. Champ CE, Baserga R, Mishra MV, Jin L, Sotgia F, Lisanti MP, Pestell RG, Dicker AP, Simone NL. *Nutrient Restriction and Radiation Therapy for Cancer Treatment: When Less Is More* **Oncologist.** 2013;18(1):97-103. doi: 10.1634/theoncologist.2012-0164. Epub 2013 Jan 8.

397. Velasco-Velázquez M, Pestell RG. *The CCL5/CCR5 Axis Promotes Metastasis in Basal Breast Cancer*. **OncoImmunology**. 2013 Apr 1;2(4):e23660.

398. Casimiro MC, Crosariol M, Loro E, Li Z, Pestell RG. *Cyclins and cell cycle control in cancer and disease*. **Genes Cancer**. 2012 Nov;3(11-12):649-57. doi: 10.1177/1947601913479022.

399. Chen K, Wu K, Cai S, Zhang W, Zhou J, Wang J, Ertel A, Li Z, Rui H, Quong AA, Lisanti MP, Tozeren A, Tanes C, Addya S, Shirley LA, Wang C, McMahon S, Pestell RG. *Dachshund Binds p53 to Block the Growth of Lung Adenocarcinoma Cells*. **Cancer Res**. 2013 Jun 1;73(11):3262-74. doi: 10.1158/0008-5472.CAN-12-3191. Epub 2013 Mar 14.

400. Shen D, Bai M, Tang R, Xu B, Ju X, Pestell RG, Achilefu S. *Dual fluorescent molecular substrates selectively report the activation, sustainability and reversibility of cellular PKB/Akt activity.* **Sci Rep.** 2013 Apr 22;3:1697. doi: 10.1038/srep01697.

401. Saleh A, Simone B, Palazzo J, Savage J, Sano Y, Dan T, Jin L, Champ C, Zhao, Lim, M, S, Sotgia F, Camphausen K, Pestell RG, Mitchell J, Lisanti M., Simone N, *Caloric Restriction Augments Radiation Efficacy in Breast Cancer.* **Cell Cycle** 12:12, 1–9; June 15, 2013; c 2013 Landes Bioscience

402. Pestell RG. *New Roles of Cyclin D1*. **Am J Pathol**. 2013 Jul;183(1):3-9. doi: 10.1016/j.ajpath.2013.03.001.

403. Wu K, Li Z, Cai S, Tian L, Chen K, Wang J, Hu J, Sun Y, Li S, Ertel A, Pestell RG. *EYA1 Phosphatase Function Is Essential to Drive Breast Cancer Cell Proliferation through Cyclin D1.* **Cancer Res**. 2013 Jul 15;73(14):4488-99. doi: 10.1158/0008-5472.CAN-12-4078. Epub 2013 May 1. PMID: 23636126

404. Chen K, Wu K, Gormley M, Ertel A, Zhang W, Zhou J, Li Z, Rui H, Quong AA, McMahon S, Deng H, Lisanti MP, Wang C, Pestell RG. *Acetylation of the Cell-Fate Factor Dachshund Determines p53 Binding and Signaling Module in Breast Cancer*. **Oncotarget**. 2013 Jun;4(6):923-35.

405. Casimiro MC, Wang C, Li Z, DiSante G, Willmarth NE, Chen L, Liu Y, Lisanti MP, Pestell RG. *Cyclin D1 Determines Estrogen Signaling in the Mammary Gland in vivo.* **Mol Endocrinol**. 2013 Sep;27(9):1415-28. doi: 10.1210/me.2013-1065. Epub 2013 Jul 17.

406. Martinez-Outschoorn UE, Curry JM, Ko YH, Lin Z, Tuluc M, Cognetti D, Birbe RC, Pribitkin E, Bombonati A, Pestell RG, Howell A, Sotgia F, Lisanti MP. *Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment: RAS and NFkB target stromal MCT4.* **Cell Cycle**. 2013 Aug 15;12(16):2580-97. doi: 10.4161/cc.25510. Epub 2013 Jul 8.

407. Martinez-Outschoorn UE, Whitaker-Menezes D, Valsecchi M, Martinez-Cantarin MP, Dulau-Florea A, Gong J, Howell A, Flomenberg N, Pestell RG, Wagner J, Arana-Yi C, Sharma M, Sotgia F, Lisanti MP. *Reverse Warburg effect in a patient with aggressive B-cell lymphoma: is lactic acidosis a paraneoplastic syndrome?* **Semin Oncol**. 2013 Aug;40(4):403-18. doi: 10.1053/j.seminoncol.2013.04.016.

408. Lisanti MP, Sotgia F, Pestell RG, Howell A, Martinez-Outschoorn UE. *Stromal glycolysis and MCT4 are hallmarks of DCIS progression to invasive breast cancer*. **Cell Cycle**. 2013 Sep 15;12(18):2935-6. doi: 10.4161/cc.26280. Epub 2013 Aug 27.

409. Sun X, Jiao X, Pestell TG, Fan C, Qin S, Mirabelli E, Ren H, Pestell RG. *MicroRNAs and cancer stem cells: the sword and the shield*. **Oncogene**. 2013 Nov 18. doi: 10.1038/onc.2013.492. [Epub ahead of print]

410. Ertel A, Casimiro MC, Gomella LG, Ju X, Pestell RG. *Novel Oncogene Driven Gene Signatures as Diagnostic and Prognostic Tools in Human Prostate Cancer*. **UroToday**. 2013. Epub 2013 Dec 13. ISSN 1944-4810.

411. Yu Z, Wang L, Wang C, Ju X, Wang M, Chen K, Loro E, Wu K, Casimiro MC, Gormley M, Ertel A, Fortina P, Tozeren A, Liu Z, Chen Y, Pestell RG. *Cyclin D1 Induction of Dicer Governs MicroRNA Processing and Expression in Breast Cancer.* **Nat Commun**. 2013 Nov 29;4:2812. doi: 10.1038/ncomms3812.

412. Casimiro MC, Velasco-Velázquez M, Aguirre-Alvarado C, Pestell RG. *Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present.* **Expert Opin Investig Drugs.** 2014 Mar;23(3):295-304. doi: 10.1517/13543784.2014.867017. Epub 2014 Jan 3.

413. Wu K, Chen K, Wang C, Jiao X, Wang L, Zhou J, Wang J, Li Z, Addya S, Sorensen PH, Lisanti MP, Quong A, Ertel A, Pestell RG. *Cell Fate Factor DACH1 Represses YB-1-mediated Oncogenic Transcription and Translation.* **Cancer Res**. 2014 Feb 1;74(3):829-39. doi: 10.1158/0008-5472.CAN-13-2466. Epub 2013 Dec 12. PMID: 24335958

414. Ju X, Casimiro MC, Gormley M, Meng H, Jiao X, Crosariol M, Chen K, Wang M, Quong AA, Lisanti MP, Ertel A, Fortina P, Pestell RG. *Identification of a cyclin D1 network in prostate cancer that antagonizes epithelial-mesenchymal restraint.* **Cancer Res**. 2014 Jan 15;74(2):508-19. doi: 10.1158/0008-5472.CAN-13-1313. Epub 2013 Nov 26. PMID: 24282282

415. Pestell RG, Yu Z. *Long and noncoding RNAs (lnc-RNAs) determine androgen receptor dependent gene expression in prostate cancer growth in vivo.* **Asian J Androl**. 2014 Mar-Apr;16(2):268-9. doi: 10.4103/1008-682X.122364.

416. Yu Z, Xu Z, DiSante G, Wright J, Wang M, Li Y, Zhao Q, Ju X, Gutman E, Wang G, Addya S, Li T, Xiang Z, Wang C, Yang X, Yang X, Pestell RG. *miR-17/20 sensitization of breast cancer cells to chemotherapy-induced apoptosis requires Akt1.* **Oncotarget**. 2014 Apr;5(4):1083-90.

417. Mercier I, Gonzales DM, Quann K, Pestell TG, Molchansky A, Sotgia F, Hulit J, Gandara R, Wang C, Pestell RG, Lisanti MP, Jasmin JF. *CAPER, a novel regulator of human breast cancer progression*. **Cell Cycle**. 2014 Apr 15;13(8):1256-64. doi: 10.4161/cc.28156. Epub 2014 Feb 17.

418. Li Z, Chen K, Jiao X, Wang C, Willmarth NE, Casimiro MC, Li W, Ju X, Kim SH, Lisanti MP, Katzenellenbogen JA, Pestell RG. *Cyclin D1 integrates estrogen-mediated DNA damage repair signaling*. **Cancer Res**. 2014 May 15. pii: canres.3137.2013. [Epub ahead of print] PMID: 24830723

419. Ma H, Liang C, Wang G, Jia S, Zhao Q, Xiang Z, Li Y, Cho WC, Pestell RG, Liang L, Yu Z. *MicroRNA-Mediated Cancer Metastasis Regulation via Heterotypic Signals in the Microenvironment.* **Curr Pharm Biotechnol**. Curr Pharm Biotechnol. 2014;15(5):455-8.

420. Yuan Y, Lee K, Park K, Spate LD, Prather RS, Wells KD, Roberts RM, Aoi Y, Sato M, Sutani T, Shirahige K, Kapoor TM, Kawashima SA, Mercier I, Gonzales DM, Quann K, Pestell TG, Molchansky A, Sotgia F, Hulit J, Gandara R, Wang C, Pestell RG, Lisanti MP, Jasmin JF, Li C, Bai J, Hao X, Zhang S, Hu Y, Zhang X, Yuan W, Hu L, Cheng T, Zetterberg A, Lee MH, Zhang J. *Cell cycle synchronization of leukemia inhibitory factor (LIF)-dependent porcine-induced pluripotent stem cells and the generation of cloned embryos*. **Cell Cycle**. 2014 Apr 15;13(8):1265-76. doi: 10.4161/cc.28176. Epub 2014 Feb 17.

421. Jin L, Lim M, Zhao S, Sano Y, Simone BA, Savage JE, Wickstrom E, Camphausen K, Pestell RG, Simone NL. *The metastatic potential of triple-negative breast cancer is decreased via caloric restriction-mediated reduction of the miR-17~92 cluster.* **Breast Cancer Res Treat**. 2014 Jul;146(1):41-50. doi: 10.1007/s10549-014-2978-7. Epub 2014 May 27.

422. Haizhong M, Liang C, Wang G, Jia S, Zhao Q, Xiang Z, Yuan L, Choi WC, Pestell RG, Liang L, Yu Z. *MicroRNA-Mediated Cancer Metastasis Regulation via Heterotypic Signals in the Microenvironment*. **Curr Pharm Biotechnol**. 2014 May 16. [Epub ahead of print]

423. Li Y, Liang C, Ma H, Zhao Q, Lu Y, Xiang Z, Li L, Qin J, Chen Y, Cho WC, Pestell RG, Liang L, Yu Z. *miR-221/222 Promotes S-Phase Entry and Cellular Migration in Control of Basal-Like Breast Cancer*. **Molecules**. 2014 May 30;19(6):7122-37. doi: 10.3390/molecules19067122.

424. Tian L, Wang C, Hagen FK, Gormley M, Addya S, Soccio R, Casimiro MC, Zhou J, Powell MJ, Xu P, Deng H, Sauve AA, Pestell RG. *Acetylation-defective mutant of Pparγ is associated with decreased lipid synthesis in breast cancer cells.* **Oncotarget**. 2014 Sep 15;5(17):7303-15. PMID: 25229978

425. Velasco-Velázquez M, Xolalpa W, Pestell RG. *The potential to target CCL5/CCR5 in breast cancer*. **Expert Opin Ther Targets**. 2014 Sep 26:1-11. [Epub ahead of print]

426. Ringer L, Sirajuddin P, Tricoli L, Waye S, Choudhry MU, Parasido E, Sivakumar A, Heckler M, Abdelgawad I, Liu X, Feldman AS, Lee RJ, Wu C, Yenugonda V, Kallakuri B, Dritschilo A, Lynch J, Schlegel R, Rodriguez O, Pestell RG, Avantaggiati M, Albanese C. *The Induction of the p53 Tumor Suppressor Protein Bridges the Apoptotic and Autophagic Signaling Pathways to Regulate Cell Death in Prostate Cancer Cells*. **Oncotarget**. 2014 Nov 15;5(21):10678-91. PMID: 25296977

427. Pavlides S, Gutierrez-Pajares JL, Katiyar S, Jasmin JF, Mercier I, Walters R, Pavlides C, Pestell RG, Lisanti MP, Frank PG. *Caveolin-1 regulates the anti-atherogenic properties of macrophages.* **Cell Tissue Res**. 2014 Dec;358(3):821-31. doi: 10.1007/s00441-014-2008-4. Epub 2014 Oct 17.

428. Sicoli D, Jiao X, Ju X, Velasco-Velazquez M, Ertel A, Addya S, Li Z, Ando S, Fatatis A, Paudyal B, Cristofanilli M, Thakur ML, Lisanti MP, Pestell RG. *CCR5 receptor antagonists block metastasis to bone of Src-oncogene-transformed metastatic prostate cancer cell lines*. **Cancer Res**. 2014. Cancer Res. 2014 Dec 1;74(23):7103-14

429. Costello JC, Heiser LM, Georgii E, Gönen M, Menden MP, Wang NJ, Bansal M, Ammad-Ud-Din M, Hintsanen P, Khan SA, Mpindi JP, Kallioniemi O, Honkela A, Aittokallio T, Wennerberg K; NCI DREAM Community, Collins JJ, Gallahan D, Singer D, Saez-Rodriguez J, Kaski S, Gray JW, Stolovitzky G; NCI DREAM Community. *A community effort to assess and improve drug sensitivity prediction algorithms*. **Nat Biotechnol**. 2014 Jun 1. doi: 10.1038/nbt.2877. [Epub ahead of print]

430. Di Sante G, Pestell TG, Casimiro MC, Bisetto S, Powell MJ, Lisanti MP, Cordon-Cardo C, Castillo-Martin M, Bonal DM, Debattisti V, Chen K, Wang L, He X, McBurney MW, Pestell RG. *Loss of sirt1 promotes prostatic intraepithelial neoplasia, reduces mitophagy, and delays park2 translocation to mitochondria*. **Am J Pathol**. 2015 Jan;185(1):266-79. doi: 10.1016/j.ajpath.2014.09.014.

431. Cekanova M, Fernando RI, Siriwardhana N, Sukhthankar M, Parra C, Woraratphoka J, Malone C, Ström A, Baek SJ, Wade PA, Saxton AM, Donnell RM, Pestell RG, Dharmawardhane S, Wimalasena J. *BCL-2 family protein, BAD is down-regulated in breast cancer and inhibits cell invasion*. **Exp Cell Res**. 2014 Dec 9. pii: S0014-4827(14)00519-9. doi: 10.1016/j.yexcr.2014.11.016. [Epub ahead of print]

432. Bansal M, Yang J, Karan C, Menden MP, Costello JC, Tang H, Xiao G, Li Y, Allen J, Zhong R, Chen B, Kim M, Wang T, Heiser LM, Realubit R, Mattioli M, Alvarez MJ, Shen Y; NCI-DREAM Community, Pestell, RG, Gallahan D, Singer D, Saez-Rodriguez J, Xie Y, Stolovitzky G, Califano A; NCI-DREAM Community. *A community computational challenge to predict the activity of pairs of compounds*. **Nat Biotechnol**. 2014 Dec;32(12):1213-22. doi: 10.1038/nbt.3052. Epub 2014 Nov 17.

433. Fernando RI; Siriwardhana N, Sukhthankar M, de la Parra C, Woraratphoka J, Malone C, Ström A, Baek AJ; Wade PA, Saxton AM, Donnell RM, Pestell RG; Dharmawardhana S, Wimalasena J, Cekanova M. *BCL-2 family protein, BAD is down-regulated in breast cancer and inhibits cancer cell invasion*. **Experimental Cell Research**. 2014.

434. Di Sante G, Wang L, Wang C, Jiao X, Casimiro MC, Chen K, Horio Y, Powell MJ, McBurney MW, Pestell RG. *Sirt1 determines GnRH neuronal migration via FGF/FGFR1 and hypogonadotropic hypogonadism in mice*. **Mol Endocrinol**. 2014, Dec 29, 20141228.

435. Chen K, Wu K, Wang L, Jiao X, Ju X, Li Z, Ertel A, Addya S, McCue P, Lisanti MP, Wang C, Davis RJ, Mardon G, Pestell RG. *The endogenous Cell-Fate Factor Dachshund restrains prostate epithelial cell migration via repression of cytokine secretion via a CXCL Signaling Module*. **Cancer Research**. 2015 Mar13.15;75(10):1992-2004, PMID: 25769723

436. R. Lamb, H.Harrison, D. L. Smith, P. A. Townsend, T.Jackson, B. Ozsvari, U.E. Martinez-Outschoorn, R.G. Pestell, A. Howell, M. P. Lisanti and F. Sotgia *Targeting tumor-initiating cells: Eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction*. **Oncotarget** 2015 Mar 10;6(7):4585-601.

437. Casimiro MC, Crosariol M, Loro E, Dampier W, Di Sante G, Ertel A, Yu Z, Saria EA, Papanikolaou A, Li Z, Wang C, Addya S, Lisanti MP, Fortina P, Tozeren A, Knudsen ES, Arnold A, Pestell RG. *Kinase-independent Role of Cyclin D1 in Chromosomal Instability and Mammary Tumorigenesis*. **Oncotarget**, 2015. Apr 20;6(11):8525-38.

438. Trerotola M, Ganguly KK, Fazli L, Fedele C, Lu H, Dutta A, Liu Q, De Angelis T, Riddell LW, Riobo NA, Gleave ME, Zoubeidi A, **Pestell RG**, Altieri DC, Languino, LR *Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts* **Oncotarget**, 2015 Jun 10;6(16):14318-28.

439. Pestell RG, Rizvanov AA. Antibiotics for Cancer treatment **Oncotarget.** 2015 Feb 20;6(5):2587-8.

440. Casimiro MC, Di Sante G, Ju X, Chen K, Crosariol M, Yaman I, Gormley M, Meng H, Lisanti MP, Pestell RG *Cyclin D1 promotes androgen-dependent DNA damage repair in prostate cancer cells* **Cancer Res**. 2016 Jan 15;76(2):329-38.

441. Lamb R, Ozsvari B, Bonucelli G, Smith DL, Pestell RG, Martinez-Outschoorn UE, Clarke RB, Sotgia F, Lisanti MP. *Dissecting tumor metabolic heterogeneity: Telomerase and large cell size metabolically define a sub-population of stem-like, mitochondrial-rich, cancer cells.* **Oncotarget**, **2015**, Aug. 27.

442. Zhang J, Wang C, Chen X, Takada M, Fan C, Zheng X, Wen H, Liu Y, Pestell RG, Aird KM, Kaelin Jr W, Liu XS, Zhang Q. *EgIN2 Associates, with the NRF1-PGC1 Complex and Controls Mitochondrial Function in Breast Cancer*. **EMBO J** 2015 Oct 22. pii: e201591437.

443. Raman P, Purwin T, Tozeren A. Pestell, RG FXYD5 *is a marker for poor prognosis and a potential driver for metastasis in ovarian carcinomas.* **Cancer Informatics** 2015 Oct 12;14:113-9.

448. Pestell RG, Fatatis A, Jiao X., *Mitochondrial mass and DNA repair in breast cancer stem cells*: Editorial **Oncotarget**, 2015. Nov 17;6(36):38442-3

449. Marampon F, Gravina GL, Vetuschi A, Sferra R, Pompili S, Ju X, Festuccia C, Colapietro A, Gaudio E,Tombolini V, Pestell RG. *Cyclin D1 silencing suppresse tumorigenicity,impairs DNA double strand break repair and thus radiosensitizes androgen-indepdnent prpstate cancer cells to DNA damage.* **Oncotarget** 2016 Dec 12 doi: 10.18632 Feb 2;7(5):5383-400.

450. Zhao Q, Deng, Shengqiong, Wang D, Liu, C, Meng L, Qiao S, Shen L, Zhang Y, Lv J, Li W, Zhang Y, Wang Pestell RG, Liang C, Yu Z, *A Direct Quantification Method for Measuring Plasma Micro RNAs Identified Potential Biomarkers for Detecting Metastatic Beast Cancer. 2016* **Oncotarget** Apr 19;7(16):21865-74.

451. Ozcan L, Ghorpade D, Cristina de Sozua J, Chen K, Bessler M, Bagloo M, Schrope B, Pestell RG, Tabas *Hepatocyte DACH1 is Increased in Obesity Via Nuclear Exclusion of HDAC4 and Promotes Hepatic Insulin Resistance***. Cell Rep**. 2016 May 26. un 7;15(10):2214-25.

452. Ju X, Jiao X, Ertel A, Lisanti MP, Disante G, Ly Xu DC, Casimiro M, Xu C, Ando S, Pestell RG. *Oncogenic Src oncogene induces Trop2 proteolytic activation via cyclin D1.* **Cancer Research**. 2016 Nov 15;76(22):6723 6734.

453 Meng, L., Liu, C., Lü, J., Zhao, Q., Deng., S., Wang, G., Qiao. J., Zhang, C., Zhen, L., Lu,Y., Li, W., Yuzhen Zhang, Y., **Pestell, RG**, Fan, H., Chen, Y-h., , Liu., Z., and Yu, Z. *Small RNA zippers: lock miRNA molecules and block miRNA function in mammalian cells.* **Nature Communications** 2017 Jan 3;8:13964.

454 Casimiro M, Di Sante, G, Loro E, Pestell TG, Bisetto S, Velasco-Velázquez M, X Jiao, Li Z, Wang C, Ly D, Zheng B, Che-Hung C, Ertel A, **Pestell RG**, *Cyclin D1 Restrains Oncogene-Induced Autophagy via phosphorylation of LKB1*. **Cancer Res**. 2017 Jul 1;77(13):3391-3405.

455. Xu, H., Yu, S., Yuan,X., Xiong, J Kuang, D., Pestell, R.G, and Wu, K. *DACH1 suppresses breast cancer as a negative regulator of CD44*. **Scientific Reports** 2017 Jun 28;7(1):4361.

456. Pestell, TG, Jiao, X., Kumar, M, Peck, AR, Prisco, M, Deng, S., Ertel, A., Casimiro, MC, Ju, X, Di Rocco, A, Di Sante, G. , Katiyar, S, Shupp, A. , Lisanti, MP, Jain, P, Wu, K, Rui, H, Hooper, DC, Yu, Z, Goldman, AR, Speicher, DS, Laury-Kleintop, LL, Pestell, RG, *Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth*. **Oncotarget** 2017; Aug 4;8(47):81754-81775.

457. Gomzikova, M.O. Zhuravleva, M.N..Miftakhova, R.R Arkhipova, S.S. Evtugin, V.G. Khaiboullina, S.F. Kiyasov, A.P. Pestell, R.G. Rizvanov, A.A *Cytochalasin B-induced membrane vesicles convey angiogenic activity of parental cells.* **Oncotarget,** 2017; 8:70496-70507.

458. Jiao, X., Velasco-Velázquez, M., Li, Z., Xu,S., Sicoli , D., Mu,Z., Cristofanilli, M., Rui, H., Den, RB., Fatatis, A., **Pestell, RG**. *CCR5 governs breast cancer stem cell expansion and DNA damage repair.* **Cancer Res**. 2018. 2018 Apr 1;78(7):1657-1671. doi: 10.1158/0008-5472.CAN-17-0915. Epub 2018 Jan 22.PMID:29358169.

459 Yu Z, Gormley M, Chen H, Ju X, Wang M, Li Z, Ertel A, Fortina P, Rigoutsos I, Tozeren A, Pestell RG. *Cyclin D1-Mediated MicroRNA Expression Signature in Breast Cancer Outcome*. **Theranostics,** 2018 Mar 11,8:8, 2251-2263.

460 Romero-Romero, L., Hernandez-Esquivel, MA., Mayra Perez-Tapia, S., Medina-Rivero, E., Pestell, RG., Perez-Torres, A., Reyes-Matute, A., Pavon, L., Mellado-Sanchez. G., Velasco-Velazquez, M.*The dialyzable leukocyte extract Transferon(TM) inhibits tumor growth and brain metastasis in a murine model of prostate cancer.* **Biomedicine and Pharmacotherapy**. 2018 101, 938-944.

461 Liu, Q., Li, A., Yu, S., Qin, S., Han, N., Pestell,RG., Xinwei Han, X., Wu, K. *DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis.* **Journal of Hematology and Oncology**. 2018 April 10:11(1), 53.

462 Xu, H., Bai, X., Yu, S., Liu, Q., Pestell, RG, and Wu, K *MAT1 correlates with molecular subtypes and predicts poor survival in breast cancer.* **Chin J Cancer Res**. 2018 Jun;30(3):351-363. 2018.

463 Giannattasio,S., Megiorni, F., Di Nisio, V., Del Fattore, A., Fontanella, R., Camero, S., Antinozzi, C., Festuccia, C., Gravina, GL., Cecconi, S., Dominici, C., Di Luigi, L., Ciccarelli, C., De Cesaris, P., Riccioli, A Maria Zani, BM Andrea Lenzi, Pestell, RG., Filippini, A, Crescioli, C., Tombolini, V., Marampon, F. *Molecular effects of testosterone mediated activation of androgenic signaling sustains in vitro the transformed and radioresistant phenotype of in vitro rhabdomyosarcoma cell lines*. **J Endocrinol Invest.** 2019 Feb;42(2):183-197. doi: 10.1007/s40618-018-0900-6. Epub 2018 May 22.PMID:29790086.

464 Jiao, X., .Li, Z., Wang, M., Katiyar, S., Di Sante, G., Farshchian, M., South, A.P., Mardon, G., C. Cocola, C.,Colombo, D., Reinbold, R., Zucchi, I., Wu, K., Tabas, I., **Pestell. R.G**. *Dachshund depletion disrupts mammary gland development and diverts the composition of the mammary progenitor pool*. **Stem Cell Reports** 2019 Jan 8;12(1):135-151 PMID:30554919.

465 Zheng, Z., Nayak, L., Wang, W., Yurdagul Jr. A., Wang, X., Cai, B., Ozcan, L., **Pestell, RG.**, K. Jain, MK., Tabas, I. *An ATF6-tPA pathway in hepatocytes contributes to systemic fibrinolysis and is repressed by DACH1* **Blood.** 2019 Feb 14;133(7):743-753]PMID:30504459.

466 Li, Z., Jiao, X., Di Sante, G*, Adam Ertel, A, Casimiro, MC, Min Wang, M, Sanjay Katiyar, S, Xiaoming Ju, X., Klopfenstein, DV, Tozeren, Dampier, W, Chepelev, I, Jeltsch, A, **Pestell, RG** *Cyclin D1 integrates G9a-Mediated Histone Methylation.,* **Oncogene,**. Feb 4. doi: 10.1038/s41388-019-0723-8 PMID:30718920, 2019.

467 Kranjc, M.K., Novak, M., **Pestell, R.G**., Lah, T.T *Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme*. **Radiol. and Oncol**, 2019; 53(4): 397-406.

468 Novak, M., Krajnc, MK, Hrastar, B, Breznik, B, Majc, B., Mlinar, M, Ana Rotter, A., Porčnik, A, Jernej Mlakar, J. Stare, K, **Pestell, RG** and Lah, TT. *CCR5 mediated signaling is involved in invasion of glioblastoma cells in its microenvironment*. **Int J Mol Science**, 2020. Jun 12;21(12):4199. doi: 10.3390/ijms21124199.PMID: 32545571.

469 Lü J, Zhao Q, Ding X, Guo Y, Li Y, Xu Z, Li S, Wang Z, Shen L, Chen H, Yu Z, **Pestell RG**. *Cyclin D1 promotes secretion of pro-oncogenic immuno-miRNAs and piRNAs*. **Clin Sci (Lond**). 2020 Mar 27. pii: CS20191318. doi: 10.1042/CS20191318. [Epub ahead of print]PMID:32219337.

470 Chen K., Jiao, X., Di Rocco A., Xu, S, Ertel, A, Yu, Z., Di Sante, G, Wang, M, Li Z, Pestell T, Casimiro, MC, Skordalakes,

E, Shen, D, Achilefu, A, **Pestell, RG.** *Endogenous cyclin D1 promotes the rate of onset and magnitude of mitogenic signaling via Akt1 Ser473 phosphorylation*. **Cell Reports** 2020 Sep 15;32(11):108151. doi: 10.1016/j.celrep.2020.108151.PMID: 32937140.

471 Chen, K, Jiao X., Ashton, A., Di Rocco, A., Pestell, TG., Sun, Y., Zhao, J, Casimiro, MC, Li, Z., Lisanti, MP, McCue., PA, Shen, D., Achilefu, A. Rui, H, **Pestell, RG**. T*he membrane-associated form of cyclin D1 enhances cellular invasion.* **Oncogenesis**. 2020 Sep 18;9(9):83. doi: 10.1038/s41389-020-00266-y.PMID: 32948740.

472 Sikder, K., Shukla, S.K., Tian, L. Jiao., X., Patel, N., Singh, H., **Pestell, RG.,** Rafiq, K. *High Fat Diet Upregulates Fatty Acid Oxidation and Ketogenesis via Intervention of PPAR-γ.* **Cell Physiol Biochem** 2020;48(3):1317-1331.doi: 10.1159/000492091. Epub 2018 Jul 26.

473 Viviana M. Bimonte Francesco Maranpon, Ambra Antonioni, Simona Fittipaldi Elisabetta Ferretti, Richard G. Pestell, Mariaignazia Curreli, Andrea Lenzi, Giovanni Vitale, Antonio Brunetti, Silvia Migliaccio, Antonio Aversa. *Phosphodiesterase Type-5 Inhibitor, Tadalafil increases Androgen Receptor expression and function and Aromatase expression in prostate cancer cell line*. **Int. J. Mol. Sci. 2021**, 22(2), 754; https://doi.org/10.3390/ijms22020754.

474 Ding X, Zhao, Q, Lü, J, Guo, Y, Lu, Z, Pestell, RG, Liang, C and Yu, Z. piRNA-823 is involved in cancer stem cell regulation through altering DNA methylation in association with luminal breast cancer. **Frontiers Cell and Developmental Biology** 2021 9:21, PMID: 33791297

475 Jiao, X., Wang, M., Zhang, Z., Li, Z.,Ni, D, Ashton, A.W., Tang., H-Y., Speicher, DW, **Pestell, R.G**. *Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapies.* **Breast Cancer Res**. 2021 Jan 23;23(1):11. doi: 10.1186/s13058-021-01391-1.PMID: 33485378.

476 Gakidou, E., …. Pestell, R. et al Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019.GBD 2019 Chewing Tobacco Collaborators. **Lancet Public Health**. 2021 May 27:S2468-2667(21)00065-7. doi: 10.1016/S2468-2667(21)00065-7. Online ahead of print.PMID: 34051920.

477 Doke, T., Huang, S., Qiu, C., Liu, H., Ma, Z., JWu, J., Miao, Z., Sheng,X., Zhou, J., Cao, A., Li,J., Kaufman, L., Hung, A., Pestell, R. and Susztak, K. *Transcriptome-wide association analysis identifies DACH1 as a kidney disease risk gene that contributes to fibrosis.* **Journal of Clinical Investigation,** 2021. May 17;131(10):e141801. doi: 10.1172/JCI141801.PMID: 33998598.

478 Marissa B Reitsma, BS., …Pestell, RG, et al Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019.GBD 2019 Tobacco Collaborators. **Lancet.** 2021 May 27:S0140-6736(21)01169-7. doi: 10.1016/S0140-6736(21)01169-7. Online ahead of print.PMID: 34051883.

479 Jiao, X., Tian, L., Zhang, Z., Wang, C., Ertel, AE., Balcerek J., Kossenkov, A.V, Liu, Q., Tong, W., Casimiro, MC., Liu, Y., Soccio, R., Chen,ER. Ashton, A and **Pestell, RG**. *Pparγ1* Facilitates ErbB2-Mammary Adenocarcinoma in Mice. **Cancers.**, 2021., 13:9; 2171-2182. PMID: 33946495

480 R Sharma, M Abbasi-Kangevari, .. Pestell, RG,. et al Global, regional, and national burden of colorectal cancer and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. GBD 2019 Colorectal Cancer Collaborators. **Lancet Gastroenterol Hepatol.** 2022 Apr 7:S2468-1253(22)00044-9. doi: 10.1016/S2468-1253(22)00044-9. Online ahead of print.PMID: 35397795

481 TYran, KB., .. Pestell RG et al The global burden of cancer attributable to risk factors, 2010–2019: a systematic analysis for the Global Burden of Disease Study 2019, **Lancet.** 2022 Aug 20;400(10352):563-591. doi: 10.1016/S0140-6736(22)01438-6.PMID: 35988567 . (Thyroid cancer) PMID: 35988567

482 Chervoneva, I., Peck, AR., Sun, Y., Sameer S. Udhane, Langenheim, JF., Girondo, MA., Jorns, JM., Chaudhary, LN., Bergom, C., Hooke, JA., Kovatich, AJ., Shriver, CD., Hu, H., Palazzo, JP., Bibbo, M., Hyslop,T., Nevalainen, MT. Pestell, RG., Fuchs, SH., Mitchell, E.P, and Rui, H. PD-L2 protein levels in breast cancer predict unfavorable clinical outcome. **JCO Precision Oncology**. 2023 Jan;7:e2100498. doi: 10.1200/PO.21.00498.PMID: 36652667

483 Li., X., Jiao, X., Di Sante, G., Li., Z., DiRocco, A., Wang, M, Ertel, A, McCue, P., South, AP., Cordon-Cardo, C., Stokes, MP, Languino, L., Marra, M., Jones, SJ, Kossenko, A, Pestell, RG.. The DACH1 gene is frequently deleted in prostate cancer, restrains prostatic intraepithelial neoplasia, augments DNA damage repair and predicts therapy responses. Oncogene 2023 Apr 24. doi: 10.1038/s41388-023-02668-9. Online ahead of print.PMID: 37095257

484 Lü J, Zhao Q, Guo Y, Li D, Xie H, Liu C, Hu X, Liu S, Hou Z, Wei X, Zheng D, **Pestell RG**, Yu Z.J Regulation of ERα-

dependent breast cancer metastasis by a miR-29a signaling. **Exp Clin Cancer Res**. 2023 Apr 20;42(1):93. doi: 10.1186/s13046-023-02665-6.PMID: 37081505.

485 Austin E Schumacher, Pestell, RG., et al. Global fertility in 204 countries and territories, 1950-2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. GBD 2021 Fertility and Forecasting.**Lancet.** 10440, 2057-20992024 Mar 19: 2024 PMID: 38521087

486 Jiao, X., Di Sante G, Casimiro MC, Wang C, Yu Z, Crosariol M, Bjornsti MA, Wright CM, *Lazar, T, Tompa, P* Vadlamudi R, *Skordalakes, E.,* Mann M, Mirabelli E, Pestell RG. A cyclin D1 intrinsically disordered domain accesses modified histone motifs to govern gene transcription. 2024. Jan 8;13(1):4. . **Oncogenesis.**, PMID: 38191593

487 Naghavi.,.. Pestell, RG, et al **.,** Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021.**"** **Lancet** 2024; April., 3., 403 (10440), 2100-2132, 2024., PMID: 38582094

488 Mokdad, A.H .,.. Pestell, RG, et al **.,** The burden of diseases, injuries, and risk factors by state in the USA, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021**.,** GBD 2021 US Burden of Disease Collaborators.**Lancet.** 2024 Dec 7;404(10469):2314-2340. doi: 10.1016/S0140-6736(24)01446-6. PMID: 39645376

489 VL Feigin, … Pestell, RG, et al Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021...**The Lancet Neurology** 2024; 23 (10), 973-1003 PMID: 39304265

490 D Bryazka, … Pestell, RG, et al Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease … **The Lancet Public Health** 2024; 9 (10), e729-e744 PMID: 39366729

491 Cristine Alves da Costa, Eric Duplan, Aurore Bernardin, Thomas Goiran, Nathalie Leroudier, Mathew Casimiro, Richard Pestell, Shinya Tanaka, Céline Malleval, Jérôme Honnorat, Ahmed Idbaih, Lucie Martin, Helene CASTEL, and Frédéric Checle, α-synuclein expression in glioblastoma restores tumor suppressor function and rescues temozolomide drug resistance. **Cell Death & Disease** *2025,* Mar 19;16(1):188. doi: 10.1038/s41419-025-07509-z.PMID: 40108111

492 Tian, L., XJiao, X., Wang, C., Ertel, A., Raymond Soccio, R., Chen, E.R., BGyőrffy, B., Di Sante, G., Zhong, Z., Addya, S., McCue, PA., Kossenkov, AV, Achinger-Kawecka, J.,Clark, S., and **Pestell R.G**., PPARγ acetylation governs mammary adenocarcinoma tumor growth via acetylated residues that determine DNA sequence-specific binding (2025).**Oncogene**7:26, p1-14.

493 Anza-Ramirez, et al., Pestell, R.G. et al Characterising acute and chronic care needs: insights from the Global Burden of Disease Study 2019. GBD 2019 Acute and Chronic Care Collaborators. **Nat Commun**. 2025 May 7;16(1):4235. doi: 10.1038/s41467-025-56910-x.PMID: 40335470

494 Han., HJ., .. Pestell, R.G, et al Burden of Central Nervous System Cancer in the United States, 1990–2021: An analysis of the Global Burden of Disease Study 2021.**"** **JAMA Neurology**. *2025 November 3 2025*doi: 10.1001/jamaneurol.2025.4286

495 Force., L.M., …Pestell., RG., *et al*. National and state-level burden of 32 cancer types in the US, 1990-2021, with forecasts to 2 2050: A systematic analysis for the Global Burden of Disease Study 2021 **Lancet.** *2025* 406 (10512), 1565-1586. PMID: 41015051

496 Lindner, D.J., Drazba, J.A., Parker, Y.A., Guinta, K., Graham, A., Patricia Parsons-Wingerter, P., Pancsa, R., Pestell RG., and Denis R. Burger, D.R. Leronlimab inhibits colon carcinoma metastasis in a humanized mouse xenograft model. Cells., 2025, **BioRx**

497

498

Book Chapters, Textbooks and Reviews

1. Dawkins RL, Uko G, Pestell RG, McCann VJ. The association of MHC Supratypes and Complotypes with Endocrine Disease. (Chapter). In: Farid, N. (ed.). **Immunogenetics of Endocrine Disorders.** Alan R. Liss, Inc. (1988) 433-448.
2. Pestell, RG, Jameson JL. Hormone Action II: Transcriptional Regulation of Endocrine Genes by Second Messenger Signaling Pathways. Chapter. 9 In: **Molecular Endocrinology: Basic concepts and clinical correlations** (ed.) Bruce Weintraub (1995) 774-780.
3. Lowe W. Jr., Pestell RG, Madison L, Jameson JL. Chapter 46: Mechanisms of Hormone Action. In Principles of Molecular Medicine. Editor, Jameson J.L., **Humana Press, Mass** (1998).
4. Mani S, Wang C, Wu K, Francis R, Pestell RG. Cyclin-dependent kinase inhibitors: novel anti-cancer drugs'. Editor J. Heath. Ashley Publications Ltd. **Exp Opin Invest Drugs** (2000) 9(8):1849-1870.
5. Zafonte BT, Amanatullah DF, Sage D, Augenlicht LH, Pestell RG. Ras regulation of cyclin-dependent immunoprecipitation kinase assays. **Methods Enzymol.** (2001); 333:127-38.
6. Amanatullah DF, Zafonte BT, Albanese C, Fu M, Messiers C, Hassell J, Pestell RG. Ras regulation of Cyclin D1 promoter. **Methods Enzymol.** (2001); 333:116-27.

7. Fu, M., Wang, C., Zhang, X., and Pestell, R.G., *Acetylation of nuclear receptors in cellular growth and apoptosis.* **Biochem Pharmacol**. 2004 Sep 15; 68(6): p. 1199-208.

8. Bouras, T., Lisanti, M.P., and Pestell, R.G., *Caveolin-1 in breast cancer.* **Cancer Biol Ther**. 2004 Oct; 3(10): p. 931-41.

9. Fu, M., Wang, C., Li, Z., Sakamaki, T., and Pestell, R.G., *Minireview: Cyclin D1: normal and abnormal functions.* **Endocrinology**. 2004 Dec; 145(12): p. 5439-47.

10. Hilakivi-Clarke, L., Wang, C., Kalil, M., Riggins, R., and Pestell, R.G., *Nutritional modulation of the cell cycle and breast cancer.* **Endocr Relat Cancer**. 2004 Dec; 11(4): p. 603-22.

11. Mani S, Pattabiraman N, and Pestell RG. CDK inhibitors as anticancer agents. **Enzyme Inhibitors** Ed: Eddy Yue and Paul J. Smith, CRC Press, Vol. 2, Chapter 27, (2005).

12. Leader JE, Wang C, Popov VM, Fu M, Pestell R.G. Epigenetics and the estrogen receptor. Estrogens and Human Diseases Ed: H. Leon Bradlow, Giuseppe Carruba, **Ann N Y Acad Sci.** (2006) Nov.; 1089: 73-87.

13. Sridhar J, Pattabiraman N, Rosen E, and Pestell RG. CDK Inhibitors as Anticancer Agents: Perspectives for the Future. **Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents**, CRC Press, Springer Science and Business Media Totowa NJ, 07512 (2007).

14. Knights CD, and Pestell RG. The Cell Cycle: Therapeutic targeting of cell cycle regulatory elements and effector pathways in cancer. Cancer Drug Discovery and Development. **Molecular Targeting in Oncology**, (eds): Kaufman, H. L., Wadler, S., and Antman, K. Humana Press, Totowa, NJ (2007) p. 3-32.

15. Powell MJ, Popov VM, Wang C, Pestell RG. Chapter 3: "Nuclear Receptors and Cyclins in Hormone Signaling". **Hormonal Control of Cell Cycle**. (eds): Melmed, S., Rochefort, H., Chanson, P., Christen, Y. (2007) p. 21-30.

16. Zulig Z, Pestell RG, Nevalainen MT. Transcription Factors Stat5 and Stat3: Key Survival Factors for Prostate Cancer Cells. Chapter in: Prostate Cancer: Signaling Networks, Genetics and New Treatment Strategies, Nevalainen, M.T., Pestell, R.G. (eds), **Humana Press**, (2007) p. 257-290.

17. Nevalainen, M.T., Pestell, R.G. Prostate Cancer: Signaling Networks, Genetics and New Treatment Strategies, (eds), **Humana Press**, (2008).

18. Powell M, Lisanti M, Nevalainen MT**,** Wang C, Pestell RG. "Androgen Receptor Epigenetic Modification and Acetylation Regulate Prostate Cellular Growth." Chapter in: Prostate Cancer: Signaling Networks, Genetics and New Treatment Strategies, Nevalainen, M.T., Pestell, R. (eds), **Humana Press**, (2008) p. 147-162.

19. Wang C, Powell M, Tian L, Pestell RG. "Analysis of Nuclear Receptor Acetylation." Chapter in: **Methods Mol Biol**. (2011) p. 169 - 81.

20. Velasco-Velázquez MA, Jiao X, Pestell RG. "Breast Cancer Stem Cells." Chapter 5 in: Cancer Stem Cells Theories and Practice, Stanley Shostak (Ed.) ISBN: 978-953-307-225-8, **INTECH**. (March 2011) p. 63-78.

21. Yu Z, Pestell RG. "MicroRNA and Cancer Stem Cells." Chapter in: **MicroRNAs in Cancer Translational Research**. **Springer.** (2011) p. 373 - 388.

22. Powell MJ, Popov VM, Wang X, McMahon SB, Mazo A, Pestell RG. Chapter 7 - "The Role of Epigenetic Modifications in Cancer." **Cancer Epigenetics: Biomolecular Therapeutics in Human Cancer**. Giordano A, Macaluso M (eds), **Wiley-Blackwell**, (2011) p. 115-144.

23. Velasco-Velázquez MA, Wu K, Loro E, Pestell RG. "**Inhibition of Breast Tumor Stem Cells Expansion by the Endogenous Cell Fate Determination Factor Dachshund**." Chapter 34 in Volume 6 of: Stem Cells and Cancer Stem Cells: Therapeutic Applications in Disease and Injury. (2012). p385-395. Springer Press

24. Sotgia F, Martinez-Outschoorn UE, Howell A, Pestell RG, Pavlides S, Lisanti MP. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol. 2012;7:423-67. doi: 10.1146/annurev-pathol-011811-120856. Epub 2011 Nov 7.PMID: 22077552

25. Yu Z, Tozeren A, Pestell RG. "Function of miRNAs in Tumor Cell Proliferation." **MicroRNA in Cancer**. Editor: Dr. Suresh Alahari. **Springer Science+Business Media**. p. 13-27. Dordrecht. 2013.

26. Wang C, Pestell TG, Pestell RG. "A New Perspective on Cyclin D1: Beyond Cell Cycle Regulation." Cell and Molecular Biology of Breast Cancer. Editor: Dr. Heide Schatten. **Humana Press** (Springer Science+Business Media LLC), 2013

27 Wang C, Ji JY, Tian LF, Pestell RG. "Transcriptional Regulation of Lipogenesis as a Therapeutic Target for Cancer Treatment." Nuclear Signaling Pathways and Targeting Transcription in Cancer. Editor: Dr. Rakesh Kumar. Springer Press. 2014.

28 Di Sante, G., M C. Casimiro, T. G. Pestell, I Yaman, A. Di Rocco and R. G. Pestell Genetic deletion of Sirt1 results in a Kallmann syndrome phenotype in mice due to defective GnRH neuronal migration Research Trends 2015, **Trends in Developmental Biology,** 8(4): 47-53, 2014.

29 Casimiro, M.C., Di Sante, G., Arnold, A., Pestell, R.G. Cyclin D1 induction of mammary tumors independently of its kinase activity. **Aging** (special Cancer issue) 2015.

30 Jiao, X., Rizvanov, A.A., Cristofanilli, M., Miftakhova, R.R., Pestell, R.G., BREAST CANCER STEM CELL ISOLATION, In Methods in Molecular Biology-Breast Cancer, Ed. Cao, J., Published by Springer, 2015,

31 Wimalasena J,Cekanova M Fernando R, Pestell, R.G., Roles of BCL2 and BAD in Breast Cancer, 2015, **Exp Cell Res**. 2015 Feb 1;331(1):1-10.

32 Wu, K., Yuan, X., Chen, K., Pestell, R.G. *Endogenous Dach1 in Cancer.* **Oncoscience,** 2015 Sep 23;2(10):803-4. eCollection 2015.

33 Di Sante, G., Casimiro, M.C., Pestell, T.G., Pestell, R.G. Time-Lapse Video Microscopy for Assessment of EYFP-Parkin Aggregation As a Marker For Cellular Mitophagy. **Journal of Visualized Experiments** 2016 May 4;(111).

34. Martinez-Outschoorn UE, Peiris-Pages M, Pestell RG, Sotgia F, Lisanti MP Cancer Metabolism: A Therapeutic Perspective. **Nat Rev Clin Oncol**. 2017 Jan;14(1):11-31.

35 Kong D, Liu Y, Liu Q, Han N, Zhang C, Pestell RG, Wu K, Wu G, The retinal determination gene network: from developmental regulator to cancer therapeutic target. **Oncotarget**. 2016 May 17.

36 Peiris-Pagès M, Martinez-Outschoorn UE, Pestell RG, Sotgia F, Lisanti MP. Cancer Stem Cell Metabolism. **Breast Cancer Res**. 2016 May 24;18(1):55.

37 Casimiro, M.C., Di Sante, G., Li, Z, Ertel, A., Tompa, P. and Pestell, R.G. Transcriptional regulation by D type cyclins. In., D-Type Cyclins and Cancer (Eds P. Hinds & N. Brown). **Humana Press**. 2017.

38 Shupp, A., Casimiro, M., Pestell, RG Biological functions of CDK5 and potential CDK5 targeted clinical treatments. 2016. **Oncotarget** 2017 Mar 7;8(10):17373-17382.

39 Xu, H., Yu, S., Liu, Q., Yuan, X., Pestell RG., Wu, K. Advancement of highly selective cdk4/6 inhibitors in breast cancer. **Journal of Hematology and Oncology**. 2017 Apr 24;10(1):97. doi: 10.1186/s13045-017-0467-2. Review.PMID:28438180.

40 Di Sante G, Casimiro MC, Pestell RG. Hormone-Induced DNA Damage Response and Repair Mediated by Cyclin D1 in breast and prostate cancer. Review **Oncotarget** 2017 Jul 20;8(47):81803-81812. doi:.

41 Yu, S., Anping Li, A., Liu, Q., Xun Yuan, X., Hanxiao Xu, H., Jiao, D., Pestell, RG., , Xinwei Han, X., Wu, K., Recent Advances of Bispecific Antibodies in Solid Tumors **Journal of Hematology and Oncology**, 2017, 2017 Sep 20;10(1):155.

42 Di Sante, G, Pagè, J. Cristofanilli, M., Nawab, O., Skordalakes, E., Pestell, RG. *Recent Advances with Cyclin-Dependent Kinase Inhibitors: Therapeutic Agents for Breast Cancer and their Role in Immuno Oncology***. Expert Rev Anticancer Ther.** 2019 Jun 20:1-19. doi: 10.1080/14737140.2019.1615889. [PMID:31219365.

43 Jiao, X., Nawab, O., Patel,T., Jaeger, D., Pestell, RG. *Recent Advances with Therapeutic targeting of CCR5 for Cancer and its Role in Immuno Oncology.* **Cancer Research, 2019,** Jul 10. p4801-4807. pii: canres.1167.2019. doi: 10.1158/0008-5472.CAN-19-1167. PMID: 31292161

44 George, SM, Polepalli, S, Valli Sri Vidya.R, Rodrigues, G, L Ramachandra, L, Raghu Chandrashekar, G., Nayak, D. M, Praveen Rao, P., Nekkar, P, Pestell, RG, Mahadev Rao, M. *The prospective role of uhrf1 in malignancy with a deeper insight into its function as a therapeutic target for molecular docking studies directed towards the sra domain-an overview.* **Int J Biochem Cell Biol**. 2019 Jun 22;114:105558. doi: 10.1016/j.biocel.2019.06.006. [Epub ahead of print] Review.PMID:31238111**.**

45 Upadhyaya, C., Jiao, X., Ashton, A., Patel, K., Kossenkov, A.V., Pestell, RG. *The G protein coupled receptor CCR5 in cancer.* **Adv Cancer Res.** Book Chapter in: GPCR Signaling in Cancer V:145, Elsevier Press. 2020;145:29-47. doi: 10.1016/bs.acr.2019.11.001. Epub 2020 Jan 10.PMID:32089164.

46 Lah, TT, Ashton, AW, Jiao, X, Joyce, D.., Novak, M., Jammula, S., Cicero, G., **Pestell, RG.** "Novel Therapeutic Treatments to Target Glioblastoma Intratumoral Heterogeneity and Plasticity". An Update on Glioblastoma Biology, Genetics and Current Therapies: Novel Inhibitors of the G Protein Coupled Receptor CCR5 **International Journal of Molecular Sciences**. 2021 Apr 24;22(9):4464.doi: 10.3390/ijms22094464. PMID: 33923334

47 Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)[1]DJ Klionsky, AK Abdel-Aziz, ..**Pestell, RG**, ...**Autophagy** 17 (1), 1-382 2021.

48 Patra S, Elahi N, Armorer A, Arunachalam S, Omala J, Hamid I, Ashton AW, Joyce D, Jiao X, **Pestell RG**. Mechanisms Governing Metabolic Heterogeneity in Breast Cancer and Other Tumors. **Front Oncol**. 2021 Sep 23;11:700629. doi: 10.3389/fonc.2021.700629. eCollection 2021.PMID: 34631530.

49 Abdelmalak, M., Singh, R., Ashton, AW., Jiao, X., **Pestell,RG** The Renaissance of CDK Inhibitors in Breast Cancer Therapy. **Cancers**, V14, 21, p5388 2022. **https://doi.org/10.3390/cancers14215388** PMID: 36358806

50 Ashton, A.W., Dhanjal, H.K., Rossner, B., Mahmood, H., Vivek I. Patel, Nadim, M., Lota M, Shahid, F., Li Z., Joyce, D., Pajkos M., Zsuzsa, VI., Dosztányi, A., Jiao, X., **Pestell RG**. Acetylation of nuclear receptors in health and disease; an update. **FEBS J**. 2024, Dec 5. doi: 10.1111/febs.16695. PMID: 36471658

51 Hamid, R, Alaziz, M., Ashton,AW., *Halama, N., Jaeger,* D., Jiao X., and **Pestell RG** The Role and Therapeutic Targeting of CCR5 in *Breast* Cancer. Cells. 2023 Sep 8;12(18):2237. doi: 10.3390/cells12182237. PMID: 37759462

52 Biswal, N., Harish, R., Roshan, M., Samudrala, S., Xuanmao Jiao, **Pestell, RG**., Anthony W. Ashton Role of GPCR signaling in Anthracycline Induced Cardiotoxicity. Cells, 2025, 14, 169, Jan 22;14(3):169. doi: 10.3390/cells14030169.PMID: 39936961

53 Zhang, Z., Elahi, N., Saini, S., Koroleva, A., Umoh, I.N., Ashton, A.W., Jiao, X., **Pestell, R.G,** Targeting WEE1 Kinase for Breast Cancer Therapeutics: An Update. I, 2025 *Int. J. Mol. Sci.* **2025**, *26*(12), 5701; **https://doi.org/10.3390/ijms26125701**

55 Ghafouri, H., Pavel Kadeřávek, Ana M Melo, Maria Cristina Aspromonte, Pau Bernadó, Juan Cortés, Zsuzsanna Dosztányi, Gabor Erdos, Michael Feig, Giacomo Janson, Kresten Lindorff-Larsen, Frans A. A. Mulder, Peter Nagy, **Richard Pestell**, Damiano Piovesan, Marco Schiavina, Benjamin Schuler, Nathalie Sibille, Giulio Tesei, Peter Tompa, Michele Vendruscolo, Jiri Vondrasek, Wim Vranken, Lukas Zidek, Silvio C.E. Tosatto, Alexander Miguel Monzon.Towards a Unified Framework for Determining Conformational Ensembles of Disordered Proteins, **Nature Methods**, 2026, 10.1038/s41592-026-03003-2 in press, https://www.nature.com/articles/s41592-026-03003-2

Manuscripts in review

1. Scharer, CD., Ginwala, R., Kawasawa YI., Madugula, KK., Chigbu, DG., Khan, ZK Pestell, RG., Boss, JM., and Jain, P. *Cell cycle regulator Cyclin D1 is essential for dendritic cell differentiation***.** In Review., 2025**.**
2. Anthony W Ashton, Xuanmao Jiao, Zhiping Li, Joseph C. Wu, Cristobal dos Remedios, Sean Lal, Rick Kitsis, Hector Barajas, Martinez, Jiang F. Zhong, Pestell, RG **CCR5 Antagonism Prevents Doxorubicin-Induced Cardiomyopathy.** 2026 In review.
3. Richard G. Pestell[1], Ritika Haris, Danni Li, M. Cristofanilli, Xuanmao Jiao, Daniel L. Adams, Hallgeir Rui[5], Rita Pancsa[10,13], Milana V. Dolezal[4], Vandana G. Abramson[14,15], Namita Chittoria[16], Sima Ehsani[17], Peter Tompa[10,13], Joe Meidling[7], Hsin-Yao Tang[2], Cleiton Pessoa[19,20], Gabriela M Webb[19,20], Kirby P Gardner[6, 18], A. Cyrus Arman[7], Max Lataillade[7], Ashvathi Raghavakaimal[21], Neil E. Buss[9], Hope S. Rugo[8], Jonah B. Sacha[19,20], Jacob P. Lalezari[7] **Long Term Clinical Outcomes and PD-L1 Immune Checkpoint Inhibitor Responses after Leronlimab Treatment in Patients with Metastatic Triple-Negative Breast Cancer (mTNBC)**
4. Atalel F. Awedew, Pestell.R.G., et al *The global, regional, and national burden of Thyroid Cancer in 204 countries from 2010-2021; a systemic analysis of Global Burden of Disease 2021*
5. Lisa M. Force, … Pestell, R.G, The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023" *Lancet. 2025* In Review
6. Safiri, S., Mohsen Naghav, M., Pestell, RG *et al* Global, regional, and national burden of breast cancer and its attributable risk factors among women in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017. **Lancet Oncology***, 2026 In press*
7. Danni Li, Zhiping Li, Xuanmao Jiao, Anthony W. Ashton, Peter Tompa, Peter Nagy, Li Lan, Janne Purhonen, Arijit Ghosh, Richard G. Pestell[1] **DACH1 gene deletion, sensitizes prostate cancer to WEE1 kinase inhibitors.**
8. And Richard G. Pestell[1] Global, regional, and national burden of stomach cancer from 1990 to 2023 and forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet Gastroenterology and Hepatology.

Manuscripts in preparation

1. Yu Z, Wu K, Crosariol M, Prisco M, Rui H, Casimiro MC, Knudsen E, Lisanti MP, Pestell RG. *Cyclin D1-dependent microRNA signaling pathways regulate STAT activity, breast cancer cellular invasion and stem cell expansion via heterotypic signaling*. (In Preparation).
2. Crosariol M, Casimiro MC, Wang C, Addya S, Pestell RG. *Cyclin D1-Governs Genome Wide Splicing via SC35*. (In Preparation).
3. Patra, S, Elahi, Ni, Armorer, A., Ashton, AW, Jiao, X, Joyce, D. **Pestell, RG**. Metabolic Reprograming of Cellular Proliferation and Growth. Breast Cancer, Tumor Heterogeneity and Epigenetics of the Warburg Effect. Frontiers in Oncology.
4. Epigenetics of Prostate Cancer: An Update on Novel Epigenetic Regulators and therapeutic targeting for DNA damage repair. Sawanjit Saini, Sayani Patra, Navtej S. Athwal, Veera Thind , Anthony W. Ashton, David Joyce, Xuanmao Jiao, Richard G. Pestell **Int J Mol Sci**
5. Stephanie Rawana**,** Tochukwu Okafor, Mona Kawaiah,Anthony W Ashton, Xuanmao Jiao, **Pestell, RG**. DNA Damage review: Breast cancer. **"** Cell cycle control and the DNA damage response in breast cancer" march 31 2021 The role of Cyclin D1 in DNA Damage and Repair..**[Int J Mol Sci**
6. Allexes Koroleva, Harpreet Dhanjal, Anthony W Ashton, Zhiping Li, Xuanmao Jiao, **Pestell, R.G** Autophagy in breast and prostate cancer.: The role of cell-cycle control.. **Cells.**
7. Vivek Patel, Jorim Parmar and David Joyce, Anthony W. Ashton Zhiping Li, Xuanmao Jiao, **Pestell, R.G**., Special Issue; Signaling Pathways between Cancer and Immune Cells; Stromal Cyclin D1 Promotes Heterotypic Immune Signaling and Breast Cancer Growth. Int J Mol Sci
8. Andrew Melek, Alice Bukrinsky, Lakisha Haran, Ahmed Kawam, Aaron Armorer, Ismail Mourad, Xuanmao Jiao, **Pestell, R.G**, Anthony W. Ashton. Getting to the Heart of COVID-19 Or Contribution of SARS-CoV-2 to cardiac complications of COVID-19
9. Sayani Patra, Naveeed Elahi, Aaron Armorer, Swathi Arunachalam, Joshua Omala, Anthony W. Ashton, David Joyce, Xuanmao Jiao, **Richard G. Pestell** An Update on Metabolic Abnormalities in Breast Cancer: The Warburg Effect, Epigenetics, and Cancer Stem Cells; **FIO** Metabolic Reprograming of Cellular Proliferation and Growth: Tumor Heterogeneity and Epigenetics of the Warburg Effect.
10. Epigenetics of Prostate Cancer: An Update on Novel Epigenetic Regulators and therapeutic targeting for DNA damage repair; JTGG
11. Amin Ibrahim, Hardee Mistry, Anthony W Ashton, Zhiping Li, Xuanmao Jiao, **Pestell, R.G**· Cancer Stem Cells and their Regulation by the Non-Coding Genomes. Frontiers Cell and Developmental Biology.
12. .

CURRENT GRANT SUPPORT

Continuously funded from 1994, total Grant support received as Principal Investigator >$85M.

Principal Investigator – Annual Direct Cost/Total Annual Cost /Total Project Costs

Active

1. **W81XWH-22-BCRP**. A Novel mechanisms governing human breast cancer chromosomal instability **($1,186,294;** 3 years (6/30/24-6/30/2027 3 years).
2. RGH_L_2024, Novel approaches for targeting cyclin D1 in CDKi-resistant cancer **($2,590,854 USD, 2,439,750 euro), 1/1/2025-30/12/2029,** EU grant.
3. **StromaGenesis** subcontract (total **$408,037/yr** 11/30/2024-11/29/2026) "Humanised antibody treatment for breast cancer.
4. **StromaGenesis** subcontract (total **$236,588/yr** 2/3/2025-12/30/2026) *Leronlimab effect on immune checkpoint expression and signaling* in homo and heterotypic cancer systems.
5. **StromaGenesis** subcontract (**$42,326) – Glioblastoma subcontract:** *Leronlimab effect on immune checkpoint expression and signaling* in homo and heterotypic cancer systems.

Reviewed by Program

SBIR Phase II LightSeed is a 2R44HL164131-03A1 NHLBI Improving Outcomes in Cancer Treatment-Related Cardiotoxicity**"$ 1,958,223,** Score 21 – Well within SBIR Phase II funding range., 4/1/2025- 3/30/*2027*

SBIR Phase I EcoGenome, An SBIR Phase 1 grant 1R43CA298000-01 (NCI) EcoGenome. Phase I SBIR entitled: "Developing a DACH1 detection assay to predict therapy response in advanced prostate cancer" was submitted 08/20/2025 for $399,106. The score was 35 and is within the range of historical consideration for funding.

Plan 2026

A.Submitted Grants.

1. R01 CA11346244-01A1 "Cyclin D1 Function in Prostate Cancer". (previous scores include14% tile). Submitted 6/5/2025.(4/1/2026-3/31/2031) PI Pestell RG $4,114,774 total
2. **R01CA308516-01** " CCR5 inhibitors to enhance therapeutic response of brain cancer to temozolomide and radiation". (7/1/2023- 6/30/2028; $3,483,815.00)(resubmission date July 5 2025)
3. R01CA292620 "A forkhead-like gene in lethal prostate cancer therapy responses". PI Pestell RG $4,113,882 total (**Submitted** 09/05/2025)
4. 1R43CA298000-01 (NCI) EcoGenome. Phase I SBIR entitled: ""Developing a DACH1 detection assay to predict therapy response in advanced prostate cancer". **Submitted** 08/20/2025.($399,106)

B.Grants resubmission

a. HT942525BCRPBTA12:CCR5 inhibitors to enhance therapeutic response to breast cancer to PARP and immune checkpoint inhibitors:., 02/01/2026-01/31/2029 $2,500,000 (BSBI, $1,834,703; LIMR, $655,297) Preapplication submitted 6/13/2025; submission 6/27/2025
b. HT942525PRCRPIA **Title.** "Novel therapies to enhance therapeutic response of glioblastoma to immune check point inhibitors and current therapy (temozolomide and radiation)".(pre app 6/20/2025) submission. $560,000 total, 2 years
c. Resubmission: R01 HL169795-01 "CCR5 - a target for reducing DNA damaging agent induced cardiotoxicity" $4,103,844 total PI Pestell, RG
d. Resubmission:HT942525PCRPIDAA Forkheadlike Gene in Lethal Prostate Cancer Therapy Responses. (August 8 Preapplication, August 29 final submission).

C.Current Active Coimpany Fund raising

e. **EcoGenome Current A round** $10MM USD, AVPI hired to fund raise (Alpha Venture Private Investments, LLC), Investor meetings active.
f. **StromaGenesis Current A round** $10MM USD A Round Castle Placement., Pre IPO (IPO agreement with EF Hutton)

Previous Grants and Financial Support
Continuously funded from 1994, total Grant support received as Principal Investigator >$82M
https://grantome.com/search?q=@author%20%20Richard%20Pestell.

EcoGenome Subcontract "Precision theragnostics for Prostate Cancer". 8/18/22-2/7/2025 (total $1,860,040 3 years**)**

1R43HL164131-01A1 "Improving Outcomes in Cancer Treatment-Related Cardiotoxicity 1 calendar
1. 8/18/22-8/17/2024 ($225,794 Direct costs/yr (total $649,991, 2 yrs).

Breast Cancer Research, Breakthrough (Pestell PI) 07/01/18 – 06/30/22 0.5 calender #
W81XWH1810605. $390,000/yr (Total $1,170,000).
Novel mechanisms governing human breast cancer chromosomal instability

R21 CA235139-01-A1 (Pestell PI). 09/01/20 – 08/30/2022 1. calendar
NIH $223,290/yr
Improving Outcomes in Cancer Treatment-Related Cardiotoxicity.
CCR5 inhibitors to enhance therapeutic response of breast cancer to DNA damaging agents.

R01 CA 132115-05A1 (Pestell PI) 04/01/14 – 06/30/20 1.2 calendar
NIH $223/yr (IDC $125k) (Total $1,937,500)
DACH1/Eya Cell-fate Determination Factor and Mammary Tumorigenesis

R01 CA 132115-05A1 (Pestell PI)- supplement 07/01/17 – 06/30/20 1. calendar
NIH $55,906/yr (Total $111,812)
DACH1/Eya Cell-fate Determination Factor and Mammary Tumorigenesis

P30 CA 056036-14 (Pestell) **06/22/05-05/31/18** 3 calendar
NIH $2,897,417 **$3,116,058/yr**
Translational Research in Cancer
Cancer Center Support Grant
Specific Aim: This proposal for a Cancer Center Support Grant (CCSG) requests funding to support the cancer research activities of the Kimmel Cancer Center (KCC) in order to increase the survival and quality of life of cancer patients by translating basic research discoveries into new strategies to prevent, diagnose, monitor and cure human cancer.

CytoDyn (Pestell PI) 6/2/2018-11/31/2020 (total $1,170,001)
Humanized monoclonal CCR5 antibody for breast cancer metastasis". $250/yr

CytoDyn (Pestell PI) 3/5/2019-3/4/2021 (total $1,200,250/yr) "Leronlimab for cancer metastasis".

Falk Trust (Pestell PI) 09/01/11 - 5/30/19 -0.2- calendar
$500,000 $500,000/yr (Total $1,500,000)
Targeting CCR5 for cancer treatment (inludes clinical trial)

W81XWH-11-1-0303 (Pestell) 09/30/11 – 09/29/15 N/A
DOD Concept Award $150,000 $232,500 (Total $697,500)
The role of retinal determination gene network (RDGN) in hormone signaling transduction and prostate tumorigenesis

Breast Cancer Research Foundation (Pestell PI) BCRF-16-197
(annual renewable award) 10/01/11 - 09/30/17 N/A
"Molecular Genetic determinants of Breast Cancer Stem Cells" $250,000/yr ($250,000/yr)

R01CA137494-03 (Pestell) 08/01/10 - 01/31/16 -0- calendar
NIH $386,250/yr (Total $1,931,250)
Impact of Cyclin D1 Isoforms in Breast Cancer

3P30 CA 056036-10S3 (Pestell) 09/01/09-08/31/10 -0- calendar
NIH $154,500/yr (Total $154,500)
Translational Research in Cancer
Cancer Center Support Grant

3P30 CA 056036-10S4 (Pestell) 09/01/09-08/31/10 -0- calendar
NIH $50,002/yr (Total $50,002)

Translational Research in Cancer
Cancer Center Support Grant

3P30 CA 056036-10S5 (Pestell) 09/01/09-08/31/10 -0- calendar
NIH $956,943/yr (Total $956,943)
Translational Research in Cancer
Cancer Center Support Grant

SAP#4100047652 – T08 (Pestell) 01/01/09 - 12/31/12 N/A
Commonwealth of PA/Dept. of Health $500,000 $427,800 (Total $427,800)
The Role of MicroRNA Gene Expression in Therapy Resistance of Human Breast Cancer

IRG-08-060-02 (Pestell) 01/01/08-12/31/16
American Cancer Society $210,000 $210,000/yr
Institutional Research Grant

R01 CA 086072-12 (Pestell) 03/01/00 - 08/28/14 1.2 calendar
NIH $250,000 $386,250/yr. (Total $1,931,250)
Androgen Receptor Function in Prostate Cancer
Specific Aim: To determine the role of cyclin D1 and androgen receptor mutations in prostate cancer cellular growth.

R01 CA 120876-01A (PI Lisanti, Co-PI Pestell) 08/03/07-07/31/12 1.2 calendar
NIH $190,615 $294,500/yr (Total $1,472,500)
CAV-1 Epithelial-Stromal Interactions and Breast Cancer
Role: Co-Investigator (50% Pestell, 50% Lisanti)

SAP#4100034615 – T06 (Pestell) 07/26/07-12/31/10 N/A
Commonwealth of PA/Dept. of Health $740,000 $740,000 (Total $740,000)
Identification of a new class of genes that contributes to the development of breast cancer

080-03800-F8 1101 (Pestell Lab) 01/01/08-12/31/10 -0- calendar
Margaret Q. Landenberger Research Foundation
$150,000 $150,000/yr (Total $450,000)
DACH-Six-Eya Pathway in Breast Cancer Proliferation and Metastasis
(Pestell) 01/01/08-12/31/10 N/A

(Pestell) 07/01/07-06/30/09 1.2 calendar
T.J. Martell Foundation N/A ($330,000)/yr (Total $660,000)
DACH1/Eya Cell-fate Determination Factor and Cancer

BC062722 (Pestell) 08/15/07-09/14/09 N/A
DOD Synergistic Idea $250,000 $387,500/yr (Total $775,000)
Cyclin D1 and CAV-1 in Breast Cancer
(50% Pestell, 50% Lisanti)
Specific Aims: 1) Determine the effects of Cav-1 over-expression on cyclin D1-induced mammary tumorigenesis, using Cav-1 transgenic mice and/or Cav-1 mimetic peptides, and 2) Determine the effects of Cav-1 down-regulation on Cyclin D1-induced mammary tumorigenesis, using Cav-1 knockout mice.

SAP#4100043944 (Pestell) 10/01/07- 09/30/2008 N/A
Commonwealth of PA/Dept. of Health $500,000 $500,000
KCC- Patient Programs and Clinical Research

#080-37038-AC07010 (Pestell) 10/01/07-09/30/08 N/A
Commonwealth of PA/Dept of Health $500,000/yr
KCC – Patient Programs and clinical Research

NIH 1 S10 RR 023661-01 (Pestell) 05/15/07-05/14/08 N/A
Equipment Grant $273,969/yr
Automated High throughout DNA Sequencer

(Pestell) 07/01/06-06/30/14 -0- calendar
Falk Trust $500,000 $500,000/yr.
The Role of MicroRNA Gene Expression in Human Breast Cancer

R01 CA 107382-06 (Pestell) 07/02/04 - 04/30/10 0.6 calendar
NIH $194,378 $317,920/yr
Cyclin D1 Regulation of Nuclear Receptor Function in Breast Cancer
Specific Aim: These studies will determine the mechanism by which cyclin D1 inhibits transactivation, determine the mechanism by which cyclin D1 inhibits PPARγ function and expression, and determine the role of PPARγ as a tumor suppressor of ErbB2-induced mammary tumorigenesis.

P30 CA 056036-14 (Pestell) 07/01/03-06/30/08 3 calendar
NIH $1,972,814/yr. $3,061,807/yr. (**Total $15,309,035)**
Translational Research in Cancer
Cancer Center Support Grant
Specific Aim: This proposal for a Cancer Center Support Grant (CCSG) requests funding to support the cancer research activities of the Lombardi Comprehensive Cancer Center (KCC) in order to increase the survival and quality of life of cancer patients by translating basic research discoveries into new strategies to prevent, diagnose, monitor and cure human cancer.

R01 CA 093596-06 (Pestell) 12/11/01-11/30/07 0.6 calendar
NIH $164,840 (Total $1,433,096)
Caveolin1 and Cyclin D1 in Mammary Tumorigenesis (No Cost Extension) (total
Specific Aim: To determine the role of caveolin 1 in mammary tumorigenesis.

R01 CA 086072-06 (Pestell) 06/01/01-07/31/07 0.6 calendar
NIH $104,417
Cyclin D1 Function in Prostate Cancer
Specific Aim: To determine the role of cyclin D1 and androgen receptor mutations in prostate cancer cellular growth.

BCTR00-000465 (**R.G. Pestell, PI)** 10/01/00-09/30/03 (no cost extension) 1%
Susan Komen Breast Cancer Foundation **$100,000 /yr. (direct)**
"Role of p27 in Erb-B2 induced mammary tumorigenesis"
The aims are
i. To determine the role of p27 as a mammary tumor suppressor in vivo.
ii. To determine the effect of p27 on Neu-induced mammary tumors.

Program Grant (R.G. Pestell, PI) 11/01/00-10/31/03 N/A
Breast Cancer Alliance, Inc. **$100,000 /yr. (direct)**
"Inducible gene therapy for breast cancer" (support for Einstein breast cancer program.)
To develop ponasterone regulated tissue specific transgene expression.

Various Foundations (R.G. Pestell, P.I.) 6/01/00-5/31/01
1. Breast Cancer Alliance, Inc. **$30,000 /yr. (direct)**
Inducible gene therapy for breast cancer.
2. Irving Hansen Memorial foundation **$15,000 /yr. (direct)**

R.G. Pestell (PI) 11/01/99-10/31/00 NA
Breast Cancer Alliance, Inc. **$36,500/yr. (direct)**
Inducible gene therapy for breast cancer

R01 CA 075503-13 (Pestell) 06/05/98-07/31/12 0.6 calendar
NIH $247,624 $382,579/yr (Total $1,913,927)
Initiation and Maintenance in Mammary Tumorigenesis
Specific Aim: To apply tissue specific inducible transgenic mice to determine the role of NFκB and β-catenin signaling to the onset and progression of mammary tumorigenesis.

Irma T. Hirschl Award (R.G. Pestell, PI) (1998-2002)
The Irma T. Hirschl Charitable Trust & The Monique Weill-Caulier Charitable Trust **$20,000/yr. (direct)** (Total costs $100,000)

R01 DK53446-01A2
(R.G. Pestell and D. Batlle, Co-Investigators) 12/1/98-11/30/02 5%
"Cell Growth, Na/H Exchange and Cyclins in IDDM Patients **$46,416/yr. (direct)** requested by R.G. Pestell yr. 01) $244,588 (direct costs requested by R.G. Pestell for entire period).

Pfeiffer Foundation (R.G. Pestell, PI) ($94,935 total 7/1/98-7/1/00) 1%
Cyclin D1/p16/p27 in Prostate Cancer Prognosis and Treatment. Specific Aims: To determine the role of Cyclin D1/p16/p27 in human Prostate Cancer Prognosis and Treatment.

R.G. Pestell (PI) $160,000 (direct costs year total project period) 1%
3/01/98-10/01/00 Susan G. Komen Breast Cancer Foundation "Rho Proteins in Breast Tumorigenesis and Metastasis."

R.G. Pestell (PI) 4/01/98-11/30 1%
NIH Pilot project $60,000 total direct costs
Retinal endothelial cell hyperplasia.

R01 CA 75503-01 (R.G. Pestell, PI): 6/01/98-3/30/02 (renewed) 35%
Breast inducible anti-sense cyclin D1 transgenic mice. The aims of this project are to determine the requirement for cyclin D1 in oncogene induced mammary tumorigenesis. (total direct costs 6/5/98-3/31/02 = $856,910) **$233,637/yr. (direct)**

R01 CA77552-01 (**R.G. Pestell, Co-PI)** 5%
$98,726 /yr. (direct) requested by R.G. Pestell; **$23,249/yr. (direct)**. 04/01/98-03/31/02. The goal of (PI L. Augenlicht) this application is to investigate in detail the molecular and cellular events responsible for the mechanism of action of curcumin. "Curcumin-Mechanisms of Chemoprevention."

R.G. Pestell (PI) 6/01/98-5/31/01 5%
Marion Bessin Liver Research Center Core Grant $13,333 /yr. (requested yr. 01) no salary
"Cyclin Kinase Inhibitors in TGFB Transgenic Mice"
The specific aims are: to determine the role of the cyclin dependent kinase inhibitors in TGF-b regulated hepatocyte function using transgenic models that regulate TGF-b expression.

R.G. Pestell (PI) $30,556 (RP yr. 01) 3/01/97-02/28/98 N/A
"p16- murine models of breast tumor genesis."

R.G. Pestell (Co-PI) (1/01/97-6/30 $23,549) (RP yr. 01) 1%
$500,000 total 3yrs Mortimer Harrison Gift for Breast Cancer Research. Development of an interdisciplinary research program focused on the study of breast cancer metastasis and the design of new drugs that inhibit tumor spread.

R55 CA 075503 (R.G. Pestell, PI) 9/30/97-9/29/98 10%
NIH Shannon Award -**$40,000/yr.** (direct cost current yr. 1) ($100,000 total costs)
Breast inducible anti-sense cyclin D1 transgenic mice. The Aims of this Project are to determine the requirement for cyclin D1 in oncogene induced mammary tumorigenesis.

1R29 CA 70897-01 (R.G. Pestell, PI) 5/15/96-2/28/01 30%
$90,286/ current yr. $349,768 (direct costs project period).
Regulation of cyclin D1 expression. The specific aims of this project are to identify DNA elements that regulate cyclin D1 expression.
Administrative supplement to **1R29 CA 70897-01 (R.G. Pestell, PI):** $8,000/yr. $50,000 /yr. 2 (direct costs requested). ($58,000 total direct costs) -this grant is excluded upon the uptake of R01 CA70896-07A1.

P50-HL 56399 (R.G. Pestell, Co-Investigator) 12/01/96-11/30/01 5%
(J. Solway-PI) **(total $1,142,973 /yr.**) ($8,063 /yr.) Cellular and Molecular Mechanisms of Asthma. The specific aims of this project are to examine the effect of growth factors on cyclin D1 kinase activity in tracheal myocytes.

R01 CA 070896-14 (Pestell) 05/15/96-07/31/12 0.6 calendar
NIH $192,695 $307,598/yr
Regulation of Cyclin D1 Expression
Specific Aim: To understand the molecular events regulating the expression of cyclin D1 in cancer.

1995 $4,930 "Regulation of cyclin D1 expression by transforming viruses": (Principal Investigator). Equipment grant. The role of transforming viruses in cyclin D1 expression.

1995-1996 $35,000. (Principal Investigator) (3/1/95-2/28/1996) "E2F1 Mediated Transcriptional Regulation of the Human Chorionic Gonadotropin b subunit genes in Cancer." (American Cancer Society - Illinois Division). The role of the E2F and Rb proteins in understanding the ectopic expression of the gonadotropin gene in Cancer.

1995-1996 $20,000. "Modulation of cyclin D1 expression by anti-sense mRNA in breast and lung cancer cell lines." (Principal Investigator). Northwestern Medical Foundation. The role of cyclin D1 in cell-cycle and mitogen activated cellular proliferation using cyclin D1 anti-sense technology.

K08 CA 62008-03 (R.G. Pestell, PI) 9/30/94-9/29/97 N/A
NIH $69,229 (Total $229,797) (salary award)
Transcriptional regulation of the CG genes in Cancer.

Inter-institutional programmatic grant in prostate cancer (R.G. Pestell, PI)
Department of Defense **(Baylor, Harvard, Memorial Sloan Kettering, UC Davis)**
$150,000/yr. 1- priming grant for yr. 1

R.G. Pestell and E. Rosen, Co-investigators NA
US Army Medical research and materiels command prostate cancer research. (Direct costs: **$213,400**, indirect $83,225- 3 yrs. total **$20,800/yr.** to RGP)
"Cyclin D1 regulation of Brca1"
To determine the mechanisms by which cyclin D1 reverses Brca1 repression of the ERα.

1993-1994 $35,000. (Principal Investigator) December (1/93-11/30/1994) "E2F1 Mediated Transcriptional Regulation of the Human Chorionic Gonadotropin b subunit genes in Cancer." (American Cancer Society - Illinois Division). The role of the E2F and Rb proteins in understanding the ectopic expression of the gonadotropin gene in Cancer.

1991-1993 $98,522 ($49,721/yr.). National Health and Medical Research Council (Australia). "Pituitary Adenoma; Glycoprotein and subunit biosynthesis." (Principal Investigator)**.** The role of several different proto-oncogenes and transforming factors (c-jun and c-fos, adenovirus E1A) in regulating the transcription of the gonadotropin genes was determined.

1991-1993 $169,903/yr. (PHS2, HDRO1 HD23519-06) "Regulation of chorionic gonadotropin gene expression." The role of proto-oncogenes and transforming factors (c-jun and c-fos, adenovirus E1A) in regulating the transcription of the gonadotropin genes was determined. (Co-Investigator).

1991 $10,000. "Pituitary Adenoma; Glycoprotein and subunit biosynthesis." (Principal Investigator). Royal Australian College of Physicians.

1988-1991 $25,000/yr. "Regulation of side chain cleavage gene expression." (Principal Investigator). National Health and Medical Research Council (Australia).

Fellowships and Grants to Lab members mentored by PI

1. Dr. Mark D'Amico, Breast Cancer Research and Education Postdoctoral fellowship and EMPIRE program. EMPIRE GRANT Postdoctoral fellowship- total **$88,000** ($40,000 - direct /yr.), 2 years 3/30/00-3/31/01 Title: Mechanism of CKI in tumor suppression in breast.
2. Dr. Sanjay Katiyar, Breast Cancer Alliance, Inc., Fellow in Breast Cancer Research **($75,000/2 years)**
3. Dr. Peter Neumeister, Erwin Schroedinger fellowship - **$33,000/yr**
4. Dr. Chris Albanese, 1 R03 AG20337-01, 4/1/02-3/31/03 **$50,000/yr.**
   "Mouse Models of ErbB-2 and Cyclin D1 in Prostate Cancer"

Invited Lectures

1996

1. Mar 29 Georgetown University, Washington, DC, "Cyclin D1 regulation during development and in transgenic models of breast tumorigenesis."
2. Apr 9 M.D. Anderson Cancer Center, Houston, TX, "Cyclin D1 regulation during development and in transgenic models of breast tumorigenesis."
3. Apr 29 Albert Einstein College of Medicine, NY, "Cyclins in transgenic models of tumorigenesis."
4. May 22 University of Iowa, IA, "The role of cyclins in Angiotensin II induced cellular proliferation and in transgenic models of tumorigenesis."
5. Jun 21 University of Minnesota, MN "Oncogene regulation of cyclin D1 and transgenic models of breast tumorigenesis."
6. Aug 5 Northwestern University, Chicago, IL, "pp60^{Src} regulation of cyclin D1 in breast tumorigenesis."
7. Nov 8 Northwestern University, Chicago, IL, Department of Nephrology and Hypertension, Grand Rounds, "Cyclin D1 in vascular smooth muscle cell proliferation and spontaneously hypertensive rat model."
8. Nov 12 Albert Einstein College of Medicine, NY, Department of Anatomy, "Cyclins in transgenic models of tumorigenesis."
9. Dec 3 Albert Einstein College of Medicine, NY, Department of Pathology, Seminar Series, "Cyclins in neural differentiation and breast tumorigenesis."
10. Dec 22 Royal Perth Hospital Research Center, WA, Australia, "Cyclin D1 in development and tumorigenesis."

1997

11. Jan 23 Albert Einstein College of Medicine, NY, Internal faculty seminar, "Regulation of cyclin D1"
12. Jan 24 Albert Einstein College of Medicine, NY, Research Seminar Diabetes Center, "The D-type cyclins - lynchpins in hormonal regulation of cellular proliferation and differentiation."
13. Feb 11 Albert Einstein College of Medicine, NY, Department of Medicine, Research Seminar Series, "The D-type cyclins-lynchpins in hormonal regulation of cellular proliferation and differentiation."
14. Dec 23 Queen Elizabeth II Medical Center, Perth, Australia, "Cyclin D1 in transgenic models of breast tumorigenesis."

1998

15. Jan 5 Walter and Eliza Hall Institute, Melbourne, Australia, "Inducible transgenics to study breast tumorigenesis."
16. Jan 6 St Vincent's Hospital, Medical Research Center, Melbourne Australia, "Regulation of cyclin D1 by breast oncogenes."
17. May 18 Montefiore Medical Center, NY, Department of Oncology Grand Rounds, "Cyclin D1 and breast cancer - new gene therapy approaches."
18. Sep19 University of Chicago, IL, "Cyclin D1 in mammary tumorigenesis. The use of Tissue specific inducible transgenics."
19. Oct 18 Susan G. Komen Breast Cancer Foundation National Grant Conference, San Antonio, TX, "Cyclin D1 and breast cancer - The role of Rho proteins and cyclin D1 in breast tumorigenesis and metastasis."
20. Oct 18 University of Texas Southwestern Medical Center, Dallas, TX, Biochemistry Department Seminar Series, "The molecular mechanisms of Erb-2 and pp60Src regulation of cyclin D1 and its kinase activity in mammary cells."
21. Oct 28 National Cancer Institute, Rockville, MD, "Oncogene regulation of the *cyclin D1* gene."
22. Nov 17 Mount Sinai Medical Center, NY, Pathology Department and Cancer Center Seminar Series. "The molecular mechanisms of Erb-2 and pp60^{Src} regulation of cyclin D1 and its kinase activity in mammary cells."
23. Nov 10 University of Texas Southwestern Medical Center, Dallas, TX, Endocrine Department Seminar Series, "Regulation of the p450 side chain cleavage gene - new transcriptional interactions in trans."

1999

24. Feb 11 Albert Einstein College of Medicine, NY, Department of Medicine Research Seminar Series, "The use of knockout mice to study human breast cancer."
25. Feb 17 University of Connecticut Health Science Center, Molecular Medicine Seminar, "Oncogene regulation of the cyclin D1 (PRAD1) gene in mammary epithelial cells."
26. Feb 25 Georgetown UCHC Lombardi Comprehensive Cancer Center, DC, "Oncogene regulation of the *cyclin D1* gene in mammary epithelial cells."
27. May 7 Albert Einstein College of Medicine, NY, Department of Medicine, Diabetes Research Seminar Series, "Regulation of the p450 side chain cleavage gene; new transcriptional interactions in trans."
28. Jun 9 University of Washington, Fred Hutchinson Cancer Center, Seattle, WA, "Novel functions of the G1 cyclins."
29. Jul 23 Massachusetts General Hospital, MA, "Cyclin D1 in bone and breast-novel properties of cyclin D1 in cellular differentiation."
30. Jul 30 Picower Institute, NY, "New insights into breast cancer from transgenic analysis of cell-cycle proteins."
31. Aug 20 Albert Einstein College of Medicine, NY, A practical course in the construction of transgenic and knockout mice. "Tissue specific inducible transgenics, NCI funded Mouse Developmental Genetics Course."
32. Sep 28 Tulane University, New Orleans, LA, "New insights into breast cancer from transgenic analysis of cell-cycle proteins."
33. Sep 25 University of Calgary, Canada, "Oncogene regulation of the *cyclin D1* gene" (Alberta Heritage Foundation Visiting lecturer)

34. Sep 28 Regeneron, Tarrytown, NY, “New Tissue specific Inducible transgenics.” (invited lecture)
35. Oct 27 The State University of New York, Buffalo, University Research Seminar Series, “Novel functions of the D1 cyclin.”
36. Nov 5 Interurban Clinical Club, NY, “Cyclin D1, Cell-cycle dysregulation and cancer.”
37. Nov 4 McMaster University, Ontario, Canada, “Cyclins and cyclin inhibitors in mammary tumorigenesis - new insights from knockout mice.”
38. Nov 24 The Weizmann Institute of Science, Dead Sea, Israel, Advancement of Science in Israel, Bat-Sheva Seminar Meeting: The Dialogue between Cell Adhesion, Protein Degradation and Transcriptional Regulation in Cancer. "Cyclin D1 regulation by oncogenic and integrin linked signaling pathways.”

2000

39. Mar 7 Vanderbilt University, Nashville, TN, “New insights into breast cancer from transgenic analysis of cell-cycle proteins.”
40. Mar 8 Emory University, Atlanta, GA, “Cyclin D1 in bone and breast-Novel properties of cyclin D1 in cellular differentiation.”
41. Mar 9 The State University of New York, Roswell Park Cancer Center, “Cyclins and cyclin inhibitors in cancer”
42. Apr 7 New York University School of Medicine, NY, “Cyclins and cyclin inhibitors in mammary tumorigenesis - new insights from knockout mice.”
43. May 30 Columbia University, NY, “Cyclins and cyclin inhibitors in Hormonal responsive tumors: new mechanism.”
44. Aug 31 University of Texas at San Antonio, TX, Department of Surgery seminar series, “Cyclins and cyclin inhibitors in Hormonal responsive tumors: new mechanisms.”
45. Jun 12 International Conference on New Targets of the NF-κB Pathway for Novel Therapies in Cancer and Inflammation, Madrid, Spain, “NF-κB and the cell-cycle.” (Invited speaker)
46. Jun 18 Adrenal 2000, IXth International Conference on the Adrenal Cortex, Toronto, Canada, “Cyclins, CDKs and adrenal cellular proliferation,” (Invited speaker)
47. Aug Albert Einstein College of Medicine, NY, NCI funded Mouse Developmental Genetics Course, “Tissue specific inducible transgenics: A practical course in the construction of transgenic and knockout mice.”
48. Oct 13 Albert Einstein College of Medicine, NY, Diabetes Conference, "New mechanisms governing hormone regulation of nuclear receptor signaling.”
49. Oct 30 Molecular and Genetic Basis of Breast Cancer Symposium, Long Island, NY, “The role of cyclin D1 in the genesis of breast cancer.” (Prepared syllabus for CME)
50. Oct 31 5th International Symposium on Biotechnology in Preventive Oncology, Impact of biotechnology on cancer diagnostic and prognostic indicators, Geneva, “The application of knockout and transgenic mice in breast cancer therapeutics.”
51. Nov 3 11th International Congress of Endocrinology, Adelaide, Australia, “The application of microarray analysis in the identification of Angiotensin II regulation of the Cell-cycle.”
52. Nov 8 Queen Elizabeth II Medical Center, Perth, Australia, “Cyclins and Cyclin inhibitors in hormonal responsive tumors: new mechanisms.”
53. Nov 9 11th International Congress of Endocrinology, Perth, Australia, Hormones and Cancer Symposium, “Nuclear receptor mutations in breast and prostate cancers. “
54. Nov 21 New York University, Department of Cell Biology Seminar series, “Cyclins and CDKs in breast cancer - new mouse models.”

2001

55. Feb 18 University of Naples, Italy, Department of Bio-Morphology and Functional Sciences, “Cyclins and cyclin inhibitors in mammary tumorigenesis - new insights from knockout mice.”
56. Mar 1 Albert Einstein College of Medicine, NY, Internal Faculty Seminar, “Cyclins and cyclin inhibitors in mammary tumorigenesis - new insights from knockout mice.”
57. Apr 18 Wayne State University, Detroit, MI, “Cyclins and cyclin inhibitors in Hormonal responsive tumors: new mechanisms.”
58. Apr 23 Queen Elizabeth II Medical Center, WAIMR, Perth, Australia, “Histone acetylation and the cell-cycle in hormone signaling and cancer.”
59. Apr 24 11th International Congress of Second Messengers and Phosphoproteins, Melbourne, Australia, “Acetylation and Nuclear receptor function.”
60. May 16 University of Illinois, Chicago, IL, “Cyclins and cyclin inhibitors in Hormonal responsive tumors: new mechanisms.”
61. Aug 27 The Jackson Laboratory, Bar Harbor, ME, Novel Mechanisms for Regulating Gene Expression in vivo conference, “Ponasterone regulated transgenics to study breast cancer in the mouse."
62. Aug 31 Albert Einstein College of Medicine, NY, NCI-funded Mouse Developmental Genetics Course, (A practical course in the construction of transgenic and knockout mice), “Tissue specific inducible transgenics.”
63. Oct 18 6th World Congress on Advances in Oncology and the 4th International Symposium on Molecular Medicine, Crete, Greece, “The role of p27Kip1 as a mammary gland tumor suppressor using knockout and transgenic mice.”
64. Dec 4 North Shore-LIJ Health System, Manhasset, NY, Combined Research Seminar Series, “What are the real breast cancer tumor suppressors and oncogenes knockout and transgenic mice provide new in vivo insights.”
65. Dec 11 Rutgers University, NJ, “Cyclins and cyclin inhibitors in Hormonal-responsive tumors: new mechanisms.”

2002

66. Feb 2 Centre Universitaire de Luxembourg, Luxembourg, Cell Signaling, Transcription and Translation as Therapeutic Targets Conference, “Mechanisms of p27 haplo insufficient breast tumor suppression in transgenic mice.”
67. Mar 27 Queen Elizabeth II Medical Center, Perth, Australia, Lockett Lecture “A key role for the breast oncogene cyclin D1 in fat differentiation and cellular migration."
68. Jul 21 US Endocrine Society, San Francisco, CA, “Nuclear receptor modifications and endocrine cell proliferation.”
69. Sep 20 3rd Geneva Aging Workshop 2002, Geneva, Switzerland, “Acetylation and Nuclear receptor function.”
70. May 5 Albert Einstein College of Medicine, NY, Diabetes Center meeting, “PPARγ –mechanism of action in adipocyte differentiation.”
71. May 13 Georgetown University, Washington DC, “Cyclins and cyclin inhibitors in Hormonal-responsive tumors: new mechanisms.”
72. Aug 28 NCI Workshop, Post-translational Modification: Implication for the Pathogenesis and Prevention of Cancer, Washington DC, “Signaling pathways regulating cancer development” relevance of post-translational modifications.”
73. Sep 25 Georgetown University, Washington DC, Distinguished Lecture Series, “Cyclins and cyclin inhibitors in Hormonal-responsive tumors: new mechanisms.”
74. Oct 11 7th World Congress on Advances in Oncology and 5th International Symposium on Molecular Medicine, Crete, Greece, “Cyclins and cyclin inhibitors in hormonal-responsive tumors: novel mechanisms.”
75. Oct 12 7th World Congress on Advances in Oncology and the 4th International Symposium on Molecular Medicine, Crete, Greece, “Cyclins and cyclin inhibitors in Hormonal-responsive tumors: new mechanisms.”
76. Oct 21 The International Congress on Hormonal Steroids and Hormones and Cancer, Fukuoka City, Japan, “Nuclear receptor modifications and endocrine cell proliferation.”
77. Oct 23 University of Tokyo, Tokyo, Japan, Invited Lecture Series, Japan, “Cyclins and cyclin inhibitors in hormonal responsive tumors: new mechanisms.”

2003

78. Jan 19 Breast Cancer Symposium “Think Tank 13”, Aruba, “Novel Properties of Cyclin D1 in Cancer”.
79. Jan 29 Apoptosis 2003: From signaling pathways to therapeutic tools, Luxemburg, “Cyclin D1 and nuclear receptors in apoptosis-novel pathways.”
80. Mar 14 NIH Inter-Institute Endocrine Grand Rounds, Bethesda, MD, “Cyclins and cyclin inhibitors in Hormonal-responsive tumors: new mechanisms.”
81. Mar 28 Lawrence Livermore Laboratories, Livermore, CA, “Signal transduction-based mouse models of Cancer.”
82. Apr 2 Georgetown University, Washington, DC, Timing of Dietary Exposure and Breast Cancer Risk U54 Program Mini-Symposium: Prevention of Breast Cancer, “Cyclin D1 and Mammary tumorigenesis.”
83. Apr 6-8 Frontiers of Estrogen Action Program, Hot Springs, VA, “Nuclear Receptors and Cyclins in Hormone Signaling.”
84. Apr 17 Georgetown University, Washington, DC, Georgetown University School of Medicine, Department of Internal Medicine Medical Grand Rounds. “Cyclins and cyclin inhibitors: novel targets for cancer therapy.”
85. Apr 23-24 Georgetown University, Washington DC, Georgetown University Center for Drug Development Science Workshop, “Clinical Development of Oncologic Agents: Challenging the Tradition.” (Session Chair)
86. May 20 Howard University, Howard University Cancer Center, Washington, DC, “Nuclear Receptors and Cyclins in Hormone Signaling.”
87. Jul 1-6 N. Blokhin Cancer Center, Moscow, Russia, Institute of Carcinogenesis. “Nuclear Receptors and Cyclins in Hormone Signaling.”
88. Aug 27 Jackson Laboratory, Bar Harbor, ME, Experimental Genetics of the Laboratory Mouse in Cancer Research, Faculty Lecturer, “Approaches to 2-hit modeling in mice.”
89. Sep 16 George Washington University, Washington, DC, Department of Biochemistry, “Novel Properties of Cyclin D1 in Cancer.”
90. Oct 3 Georgetown University, Washington, DC, Insights into Gastrointestinal Physiology and Cancer, “Cyclin D1 in Gastrointestinal Cancers.”
91. Oct 10 Gaslini Institute, Genoa, Italy, “Revisiting retinoblastoma: Novel functions of cyclin D1 in tumorigenesis and fat cell differentiation.”
92. Oct 21 Georgetown University, Washington, DC, International Life Science Summit, “Comprehensive Cancer Centers: Private-Public Partnerships.”
93. Nov 2 Jewish Community Center, Rockville, MD, Jewish Women and Breast Cancer Conference: Breaking the Silence, “Breast Cancer Research Diagnoses and Treatment: Old Fears, New Hopes.”
94. Nov 20 Harvard University, Cambridge, MA, SPORE in Breast Cancer, “Enabling technologies: integration of tissue specific transgenics and microarray technologies.”
95. Dec 3-6 San Antonio Breast Cancer Symposium, San Antonio, TX, Plenary Speaker, “Control of Cell Cycle Progression in Breast Cancer.”
96. Dec 8 Walter Reed Army Medical Center, Washington, DC, “Novel properties of cyclin D1 in cancer.”

2004

97. Jan 29 Chromatin 2004 Meeting, Luxembourg, "Acetylation of Non-Histone Substrates in Growth and Apoptosis".

98. Feb17 National Cancer Institute, Bethesda, MD, Center for Cancer Research (CCR) Grand Rounds, “Nuclear Receptors and Cyclins in Hormone Signaling.”
99. Apr 5 Australian Embassy, Washington, DC, Young Australian Professionals Association Meeting, “New Technologies and Care Parity: Building Allies in the Battle with Cancer.”
100. Apr 9 Columbia University, New York, NY, "Nuclear Receptors and Cyclins in Hormone Signaling."
101. Apr 13 Georgetown University Medical Center, Washington, DC, Department of Pharmacology, "Nuclear Receptor and Cyclins in Hormone Signaling."
102. Apr 16 Case Western Reserve, Cleveland, OH, “Cyclin and Cyclin inhibitors in Hormonal Responsive Cancers.”
103. May 13 Washington Hospital Center, Washington, DC, Washington Cancer Institute Surgical Oncology Division Meeting, “Molecular Diagnostics and Cancer Care.”
104. Jun 10 Master foods Inc, Mars, McLean, VA, Epigenetics: Fetal Origins of Health Multidisciplinary Research Unit Symposium, “Epigenetics and cancer.”
105. Aug 5 Union Memorial Hospital, Baltimore, MD, Grand Rounds, “Cyclins and Cyclin Inhibitors in Hormonal Responsive Cancers.”
106. Aug 18-21 kConFab and Australian Ovarian Cancer Study (AOCS) and Family Cancer Clinics of Australia and New Zealand, Couran Cove Island Australia, Familial Cancer 2004: Research and Practice, “The BRCA1 Tumor Suppressor in Signal Transduction and Oncogenesis.”
107. Sep 21 Inova Fairfax Hospital, Fairfax, VA, Department of Medicine Grand Rounds, “Molecular Signatures of Cancer: Prognostication and Therapeutic Stratification.”
108. Oct 1-2 Geneva University Hospital, Geneva, Switzerland, 4th Geneva Aging Workshop: Aging and Cancer at the Crossroads. “Cell Cycle Control of Epigenetic Signals Regulating Aging and Cancer”.
109. Oct 7-8 Vermont Cancer Center, Burlington, VT, The Course of Cancer. “Cyclins and Cyclin Inhibitors in Hormonal Responsive Cancer”.
110. Nov 30 University of Pennsylvania, Philadelphia, PA, Hematology-Oncology Grand Rounds “Novel properties of cyclin D1 in cancer”,

2005

111. Apr 3-6Virginia Tech – National Capital Region, Riva San Vitale, Switzerland, Looking to the Future: Computational Methods in Drug Design. “Modeling of Microarray Data for Generating Transgenic Mice that Identify Molecular Genetic Pathways of Cancer”.
112. Apr 15 New York University, New York, NY, School of Medicine, Lynne Cohen Foundation Symposium on the Emerging Role of Screening and Prevention in Women’s Cancer, “Hormone and Cell Cycle Control: New Paradigms”,
113. May 12 Boston University, Boston, MA, Evans Seminar Series, “Cyclins and Cyclin Inhibitors in Hormonal Responsive Cancer.”
114. May 14 Georgetown University, Washington, DC, The Atlantic Region Society for Developmental Biology, Keynote Speaker, “Approaches to 2-Hit Modeling in Mice.”
115. May 16 Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, Cancer Biology Program Seminar, “Novel Properties of Cyclin D1 in Cancer.”
116. May 26 Wayne State University, Detroit, MI, Karmanos Cancer Center, Grand Rounds, “Hormone and Cell Cycle Control: New Paradigms.”
117. Sep 5 Endocrine Society of Australia, Perth Australia, Harrison Plenary Lecture.
118. Oct 28 George Mason University, Manassas, VA, Research Seminar, “Nuclear Receptors and Cyclins in Hormone Signaling.”
119. Nov 13 Spanish National Cancer Centre, Madrid, Spain, “New Opportunities for Cancer Therapy.”
120. Dec 10 6th INCTR Annual Meeting, Chennai, India, “New Approaches to the Treatment of Breast Cancer.”

2006

121. Jan 16 Breast Cancer Symposium “Think Tank 16” Meeting, Grand Cayman, Cayman Island, “Novel Functions of Cyclin D1: Regulation of Mitochondrial Metabolism.”
122. Jan 27 Signaling World 2006 Meeting, Luxembourg, Signal Transduction Pathways as Therapeutic Targets. “Cyclins and cdk’s: Targets for Cancer Therapy
123. Feb 24 National Institutes of Health, Bethesda, MD, Inter-Institute Endocrine Grand Rounds, “Nuclear Receptors & Cyclins in Hormone Signaling.”
124. Mar 3 St. Jude Children’s Research Hospital, Memphis, TN, Danny Thomas Lecture Series, 2006 Visiting Professor, “Nuclear Receptors and Cyclins in Hormone Signaling.”
125. Mar 26 Centenary Institute of Cancer Medicine and Cell Biology, Sydney, Australia, “Nuclear Apr1 Receptors & Cyclins in Hormone Signaling”. March 26-April 01.
126. Apr 21 Riddle Memorial Hospital, Media, PA, 12th Annual Anthony J. and Ruth H. Moretti Cancer Conference, “Understanding Basic Model of Cell-Cycle Control and Understanding the Basic Model of Androgen Regulated Gene Expression”.
127. May 9 7th Annual Philadelphia-Japan Health Sciences Dialogue, Philadelphia, PA, “Distinctions and Similarities: Three Perspectives.”
128. May 16 Ettore Majorana Foundation and Center for Scientific Culture, Erice (Sicily), Italy, Estrogens and Human Disease Course, “Estrogens and Epigenetic Signals.”

129. Jul 28 Society of Nuclear Medicine, Key Biscayne, FL, Molecular Imaging: Shaping the Future, "Light Activated Gene Therapy, New Selective Therapies for Disease."
130. Nov 1-4 University of Western Australia Dental School, Perth, Australia, Anniversary Research Symposium, "The Hormonal Control of Nuclear Receptors and Cyclins in Hormone Signaling."
131. Dec 4 Ipsen Foundation, Paris, France, "The Hormonal Control of Nuclear Receptors and Cyclins in Hormone Signaling."

2007

132. Mar 1-4 7th INCTR Annual Meeting, Sao Paulo, Brazil, Meet the Expert Session: "Use of Breast Cancer Treatment Guidelines in Developing Countries"
133. Jan 17 Australian American Association, New York, NY, "Australians: Global Citizenship in Science."
134. Apr 25 University of Delaware, Newark, DE, Seminar "Acetylation of transcription factors regulates cellular growth."
135. May 2 Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, Seminar "Cell Fate Determination Factors and the Cell Cycle in Breast Cancer."
136. May 30 Thomas Jefferson University, Philadelphia, PA, Frontiers in Vascular Biology Seminar Series, "Cell-cycle control in angiogenesis: the cell cycle goes inside-out."
137. Jun 2-5 The Endocrine Society's 89th Annual Meeting, Toronto, Canada, "Acetylation of Nuclear Receptors."
138. Jun 2-7 FASEB, Snowmass Village, CO, Summer Research Conferences, Histone Deacetylases (HDACs) in Health & Diseases, Seminar "Acetylation and Deacetylation of Nuclear Receptors."
139. Jun 18 Kimmel Cancer Center, Philadelphia, PA, Department of Biochemistry & Molecular Biology Microbiology & Immunology/Cancer Biology: Joint Faculty Seminar Series. "New signaling mechanisms governing invasion and metastasis in vivo."
140. Jul 18 Colby-Sawyer College, New London, NH, The Gordon Research Conference on Hormone Action in Development and Cancer, "Functional Significance of Nuclear Receptor Acetylation and Deacetylation – the Role of SIRTUINs."
141. Oct 4-5 GTCbio, Philadelphia, PA, 4th Tumor Progression & Therapeutic Resistance Conference: "New Signaling Mechanisms Governing invasion and metastasis *in vivo*".
142. Sep 5 Thomas Jefferson University, Philadelphia, PA, GI Grand Rounds, "Colon Cancer-Onset and Progression – New Molecular Targets."
143. Nov 8 Drexel University College of Medicine, Philadelphia, PA, Molecular and Cell Biology and Genetic Seminar Series, "New Signaling Mechanisms Governing Invasion and Metastasis In Vivo."
144. Jul 29 FASEB, Tucson, AZ, Summer Conference on Mechanisms of Steroid Hormone Action. "Functional Significance of Acetylation of Androgen Nuclear Receptor."

2008

145. Feb 22 Medical University of South Carolina, Hollings Cancer Center Grand Rounds, "New Signaling Mechanisms Governing Invasion and Metastasis in vivo."
146. Mar 20 Karmanos Cancer Institute, Detroit, MI, Grand Rounds, "New Signaling Mechanisms Governing Invasion and Metastasis in Vivo."
147. Apr 20 Australia 2020 Summit, Canberra, Australia, Plenary Panel Session "How does the world view us?"
148. Apr 21 The University of Western Australia, "New Signaling Mechanisms Governing Invasion and Metastasis in vivo."
149. Apr 27 Tianjin Medical University Cancer Institute & Hospital, Tianjin, China, "New Signaling Mechanisms Governing Invasion and Metastasis in vivo."
150. Apr 30 National Center of Biomedical Analysis, Beijing, China, "New Signaling Mechanisms Governing Invasion and Metastasis in vivo."
151. May 9 The University of Rochester, Rochester, NY, "New Signaling Mechanisms Governing Invasion and Metastasis in vivo."
152. May 15 Thomas Jefferson University, Philadelphia, PA, Prostate Cancer Symposium "New Gene Targets for Prostate Cancer Therapy and Aging."
153. Jun 11 Thomas Jefferson University, Philadelphia, PA, 1st Annual Jefferson Stem Cell Symposium, "Stem Cells in Cancer Biology."
154. Jun 29 Queens College New York Reunion, New York NY, "Building an Intellectual Nation."
155. Jul 21 City of Hope Comprehensive Cancer Center, Los Angeles, CA, "New Signaling Mechanisms Governing Invasion and Metastasis in vivo."
156. Sep 19 Dana-Farber Cancer Institute, Boston, MA, "New Signaling Mechanisms Governing Invasion and Metastasis in vivo."
157. Sep 19 Children's Hospital Boston, Boston, MA, "Cyclin D1 Regulates Micro RNA to Control Breast Cancer Cell Proliferation."
158. Sep 26 Sydney University Graduates in North America, Philadelphia, PA, "Death to the cultural cringe-Australians on the global stage."
159. Sep 30 13th International Congress on Hormonal Steroids & Hormones and Cancer, Quebec, Canada, "Epigenetic mechanisms involved in NR action."

160. Nov 10 Lennox Black Symposium, Philadelphia, PA "Acetylation of hormone-regulated nuclear receptors controls cellular growth."

2009

161. Feb 4 University of Illinois at Chicago, Chicago, IL, "New Signaling Mechanisms Governing Invasion and Metastasis in vivo."
162. Feb 6 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, Basic Research Grand Rounds, "Acetylation of hormone-regulated nuclear receptors controls cellular growth."
163. Feb 11 Thomas Jefferson University Prostate Cancer Seminar, Philadelphia, PA., "Androgen receptor acetylation in hormone signaling."
164. Mar 24 International Network for Cancer Research and Treatment, 8th Annual Meeting, Antalya, Turkey, "Breast Cancer Control" workshop Chair.
165. Apr 16 National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) Bethesda, MD, Chemical Approaches to Nuclear Receptors and Metabolism Symposium, "Functional Significance of Nuclear Receptor Acetylation."
166. May 6 2009 Delaware Health Sciences Alliance Research Conference, University of Delaware, Newark, Delaware; "From Bench to Bedside and Beyond: Lessons Learned in the CTSA Network" Panel Moderator.
167. Jun 15 Delaware Health Sciences Alliance meeting at Christiana Care Health Services, Newark, DE.
168. Jul 9 University of Melbourne, Special Dean's Lecture, Melbourne, Victoria, Australia; "Personalized Medicine and Cancer Care: What does the future hold?"
169. Oct 18 Hollings Cancer Center External Science Advisory Board, Charleston, SC, "How Do Cancer Centers Foster Translational Research?"
170. Oct 23 II Workshop Internatcional de Telemedicina & Biotecnologia, Fortaleza, Brazil, "Light-Activated Gene Expression. Tissue Specific Inducible Gene Expression. Spatially-Discrete Gene Activation in a Multicellular Environment"
171. Nov 6 Nevada Cancer Institute, Las Vegas, NV. "New Signaling Mechanisms governing invasion and metastasis in vivo."
172. Nov 10 MD Anderson Cancer Center, Division of Cancer Medicine Grand Rounds, Houston, TX. "New Signaling Mechanisms governing invasion and metastasis in vivo."
173. Nov 17 Istituto Europeo di Oncologia (IEO), Milan, Italy. "Breast Cancer Invasion and Metastasis-New Mechanisms."
174. Nov 19 Institut National dei Tumori, Milan, Italy. "Invasion and Metastasis in Breast Cancer-New Mechanisms"
175. Nov 23 Institut National dei Tumori, Aviano, Italy. "Invasion and Metastasis in Breast Cancer"
176. Nov 24 University of Ferrara, Venice, Italy. "Invasion and Metastasis in Breast Cancer"
177. Nov 25-27 Catholic University, Rome, Italy. "Invasion and Metastasis in Breast Cancer-New Mechanism and Role of miRNA"
178. Nov 30 Sapienza University of Rome, Rome, Italy. "Invasion and Metastasis in Breast Cancer-New Mechanism and Role of miRNA"
179. Dec 1 University of Calabria, Cosenza, Italy. "Invasion and Metastasis in Breast Cancer"
180. Dec 2 Italian Society of Pathology Meeting, Naples, Italy. "Breast Cancer Stem Cells"
181. Dec 4 Università degli Studi di Napoli Federico II, Naples, Italy "Breast Cancer Stem Cells"
182. Dec 7 Genome Institute of Singapore, Singapore. "New Signaling Mechanisms governing invasion and metastasis in vivo."
183. Dec 8 Eli Lilly Company, Singapore. "Tissue Specific Transgenes to Identify Signaling Pathway in Vivo"
184. Dec 11 Queen Elizabeth II Medical Center, Perth, Australia. "Invasion and metastasis – new mechanisms and role of miRNA"

2010

185. Feb 10 University of Melbourne, RD Wright Lecture. "Recent advances in cancer treatment: the dependence on research."
186. Apr 30 OU Health Sciences Center, Oklahoma City, OK. Hematology Oncology Grand Rounds Distinguished Speaker Series. "New Targets for Cancer Therapy."
187. Apr 30 OU Cancer Institute, Oklahoma City, OK. Distinguished Seminar Series, "New Signaling Mechanisms Governing Invasion and Metastasis in vivo."
188. Jun 2 Center for Cancer Research at Massachusetts General Hospital, Boston, MA. "Invasion and metastasis – new mechanisms and role of miRNA"
189. Jul 1 University of Texas Southwestern, Dallas, TX. "Cyclin D1 in Metabolism & Metastasis, New Findings."
190. Dec 9 Lankenau Institute for Medical Research (LIMR), "Invasion and metastasis – new mechanisms and role of miRNA"
191. Dec 15 University of Western Australia, Raine Foundation Lecture. "Novel Functions of cyclin D1: epigenetic regulation and small RNA."
192. University of Western Australia. Research Seminar. "Signaling Pathways Linked to Metastasis."
193. Dec 16 University of Western Australia, Research Seminar. "Cellular energy metabolism in inflammation and cancer."

194. University of Western Australia, Raine Foundation Lecture. “Invasion and metastasis – new mechanisms and role of miRNA”
195. Dec 17 Royal Perth Hospital, Perth, Western Australia. “Breast cancer onset and progression- new regulators of cancer stem cells defined by gene knockout.”
196. Royal Perth Hospital, Perth, Western Australia. “Careers and opportunities in research.”
197. Dec 21 University of Western Australia, Research Seminar. “Signaling Pathways Linked to Metastasis.”

2011

198. Jan 11 Thomas Jefferson University, Philadelphia, PA. Grand Rounds. “Cancer Invasion and Metastasis and a new role for junk DNA.”
199. Feb 18 Sylvester Comprehensive Cancer Center, Distinguished lecturer, University of Miami, Miami, Florida. “Cancer Invasion and Metastasis and a New Role for Junk DNA.”
200. Mar 11 University of Manchester, School of Cancer & Enabling Sciences, Manchester, England. “Cancer Invasion and Metastasis and a New Role for Junk DNA.”
201. May 6 ACS-Kimmel Cancer Center Research Symposium, Philadelphia, PA. “Cancer Invasion and Metastasis and a New Role for Junk DNA.”
202. Aug 15 University of Hawaii Cancer Center. “Cancer Invasion and Metastasis and a New Role for Junk DNA.”
203. Sep 15 Prostate Cancer Foundation. “Sirt-1-dependent autophagy checkpoint that results in PIN lesions.”
204. Sep 30 Drexel University. “Novel functions for a DNA bound form of cyclin D1 - chromosomal instability and non coding mRNA.”
205. Oct 31 Thomas Jefferson University, Philadelphia, PA. Joint Seminar Series. “Novel functions for a DNA bound form of cyclin D1 - chromosomal instability and non coding mRNA.”
206. Dec 8 National Cancer Institute at Frederick, Maryland. “Novel roles for cyclin D1 in chromosomal instability and metastasis.”

2012

207. May 21 Wistar Institute, Philadelphia, PA. Distinguished Lecturer Seminar. “Non-Canonical Functions of Cyclins.”
208. June 14 Thomas Jefferson University, Philadelphia, PA. Mitochondria & Metabolism Symposium 2012. “Cyclin D1 regulation of Cellular Metabolism.”
209. June 21 Drexel University, Philadelphia, PA. International Symposium on Molecular Medicine and Infectious Disease. “The HIV CCR5 Receptor Signaling and Function In Breast and Prostate Cancer Metastases.”
210. June 22 Paterson Institute, Manchester, England. “Non-Canonical Functions of Cyclin D and the Non-Coding Genome.”
211. Oct 17-18 Targeting the Tumor Microenvironment Conference. Boston, MA. “CCR5 is a tractable intervention target in cancer metastasis.”
212. Nov 12-14 2nd World Congress on Cell Science & Stem Cell Research, Hilton San Antonio. “Genetic Determinants of Breast Cancer Stem Cell Defined in Mice.”

2013

213. Feb 7 2013 Stem Cell Online Symposium and 2nd World Molecular & Cell Biology Online Conference. “Molecular genetic control of breast tumor stem cells defined in mouse models of cancer.”
214. Feb 25-26 4th CA Targets & Therapeutics. Las Vegas, NV. “CCR5 Antagonists Block Basal Breast Cancer and Prostate Cancer Metastasis In Vivo”
215. Apr 6-10 2013 AACR Annual Meeting. Washington, D.C. “CCR5 Antagonists Block Basal Breast Cancer and Prostate Cancer Metastasis In Vivo”
216. Jun 3-6 Drug Discovery & Therapy World Congress 2013. Boston, MA. “CCR5 Antagonists Block Basal Breast Cancer and Prostate Cancer Metastasis In Vivo”
217. Jun 4 Molecular Biology and Genetics Seminar Series, Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, Pa. “Non-Canonical Functions of Cyclin D and the Non-Coding Genome.”
218. Aug 18-23 2013 Faseb-HDAC/Sirtuin Meeting. Barga, Italy. “Sirt1 Regulates Androgen Signaling in Vito.”
219. Aug 19-24 Wilhelm Bernhard Workshop. Debrecen, Hungary. “Cell Cycle Control of Genomic Signaling.”
220. Oct 17-19 Shanghai International Symposium on Stem Cells & Cancer. Shanghai, China. “Genetic Determinants of Mammary Stem Cell Expansion in vivo.”
221. Dec 4 BIT’s 2nd Lung Cancer Summit. Rome, Italy. “The Cell Fate Determination Factor – Non-Small Cell Lung Cancer Growth.”
222. Dec 5 Institute of Bio-Organic Chemistry. Moscow, Russia. “Regulation of Nuclear Receptor Signaling by Acetylation.”
223. Dec 6 Medical Genetics Center. Moscow, Russia. “Cell Cycle Control of Genomic Signaling.”
224. Dec 9 Blokhin Cancer Center. Moscow, Russia. “CCR5 Antagonists Block Basal Breast Cancer and Prostate Cancer Metastasis In Vivo.”

2014

225. Feb 10 11th International Symposium on GnRH. Salzburg, Austria. “SIRT1 Deficiency Governs A Kallmans Syndrome Phenotype in Mice.”
226. Feb 12 Special Seminar. University of Gratz. Gratz, Austria. "Cell Cycle and Control of Genomic Signaling."
227. March 12 Special Seminar. Garvan Institute. Sydney, Australia. “Non-Canonical Functions of Cyclin D and the Non-Coding Genome.”
228. March 17 Special Seminar. Imperial College. London, England. “SIRT1 Deficiency Governs A Kallmans Syndrome Phenotype in Mice.”
229. March 29 TEDx Speaker. Occidental College. Los Angeles, California. “Reimagining the American Dream. is Good Health a Choice?”
230. May 21-24 Weizmann Institute, Israel “Non-Canonical Functions of Cyclin D1 and the Non-Coding Genome”
231. Aug 11-12 MD Anderson, Houston Texas “Cell Cycle Control in Cancer”
232. Aug 27-31 Institute of Enzymology “Cell Cycle Control in Cancer.” Budapest Hungary
233. Sept 11-19 Institute of Bio-Organic Chemistry, Moscow. “Cell Cycle Control in Cancer.”
234. Sept 22-26 FIOCRUZ, University, Rio de Janiero, Brazil “Sidney Kimmel Cancer Center * Health is All We Do”
235. Oct 26-30 University of Debrecen, Budapest Hungary “Cell Cycle Control in Cancer.”
236. Nov 03-05 OMICS Translational Medicine 2014, Las Vegas Nevada “HIV Receptor Antagonists Block Basal Breast Cancer and Prostate Cancer Metastasis in Vivo.
237. Nov 25 Kazan Federal University, Kazan, Russia. Meeting Plenary Lecture “Cell Cycle Control in Cancer.”
238. Nov 26 Kazan Federal University, Kazan, Russia. “CCR5 Antagonists Block Basal Breast Cancer and Prostate Cancer Metastasis In Vivo.”
239. Nov 27 Kazan Federal University, Kazan, Russia. “Acetylation of factors in growth control and cancer.”

2015

240. March 6 Clinical Epigenetics International Meeting CLEPSO 2015 Dusseldorf Germany. Session chair and presentation. “Cyclin D1 integrates G9a-mediated histone methylation and nuclear lamina association with Lamina-associated domains”.
241. March 22 Kazan Federal University, Kazan, Russia “Cancer Invasion and Metastasis and a New Role for Junk DNA.”
242. March 24 Kazan Federal University, Kazan, Russia "Cellular metabolism and the Warburg effect- control by the cell cycle”
243. May 29 German Cancer Research Center, Heidelberg, Germany. Distinguished Lecturer Seminar Series, “Cell Cycle Control in Cancer.”
244. July 17 Department of Medicine, Minsk First Hospital. Minsk Belarus: Plenary Lecture “non coding RNA in endocrine disease and thyroid cancer”.
245. July 23 Breast cancer stem cell function. Rome Italy: Plenary Lecture “Molecular genetic determinants and the cell fate determination pathway”. 4th International Conference on Tissue Science and Regenerative Medicine
246. Nov 3 Cancer and Metabolism meeting, Cell Press meeting. University of Pennsylvania, Philadelphia PA “Cell cycle control of metabolism”.

2016

247. March 11 Distinguished Lecturer Seminar Series, Herbert Irving Comprehensive Cancer Center (HICCC), Columbia University, New York, USA “Cell fate determination factor Dachshund in cancer and other diseases”.
248. May 15 Eric Susman Award Lecture, Royal Australasian College of Medicine Annual Meeting, “Precision Medicine in Cancer treatment. Precise landing for a cancer moonshot”. Adelaide, Australia.
249. May 20 Walter and Elisa Hall Institute, Melbourne Australia, “Cell fate determination factor Dachshund in cancer and other diseases”.
250. June 14 Cedars-Sinai, Los Angeles CA, USA, “CCR5 Governs Cancer Metastasis and the DNA damage response of radiation and chemotherapy”.
251. June 18 2nd Annual World Pathology Conference, Prague, Czech Republic, “Novel mechanism of cell cycle control identify new therapeutic targets”.
252. June 23 Wistar Institute, Philadelphia, “Cell fate determination factor Dachshund in cancer and other diseases”.
253. July 21 Lenkenau Institute for Medical Research PA. “CCR5 is a tractable intervention target in cancer metastasis.”
254. July 27- University Southern California, Grand Rounds, “ Novel functions of cyclins: beyond cell-cycle control”.
255. September 14 Berlin, Germany, 5th International Tissue Engineering and Regenerative Medicine. Plenary. CCR5 Governs Stem cell characteristics, therapy resistance and metastasis of breast and prostate cancer
256. September 21 MD Anderson Cancer Center Seminar Series, Houston, Tx, “Novel functions of cyclin D1”
257. October 3 Princeton University, “Novel functions of cyclins: beyond cell-cycle control.”
258. October 5 V Russian Congress on Biochemistry, Dagomys, Russia. “Novel functions of cyclins: beyond cell-cycle control.”
259. October 10 University of Miami Sylvester Cancer center. “Novel functions of cyclins: beyond cell-cycle control.”

2017

260. January 17 Distinguished Lecturer, Seminar Series, Medical School, Nanyang Technological University, Singapore “Novel functions of cyclins: beyond cell-cycle control.”
261. May 14 2017, World Nucleome Meeting Krakov, Poland, “Cyclin D1 integrates G9a-mediated histone methylation”.

262. September 25 2017, Key Note speaker, Annual World Stem cell and regenerative medicine conference. Berlin, Germany, “CCR5 governs stem cell characteristics therapy resistance and metastasis of breast and prostate cancer”.
263. September 27 2017, Stuttgart University, Germany, “Novel functions of cyclins-Cyclin D1 integrates G9a-mediated histone methylation” Distinguished Lecturer, Seminar Series.
264. October 20 2017, Key Note speaker, MD Anderson, “Novel functions of cyclins: beyond cell-cycle control.”
265. November 9 2017, Singapore, “Novel Precision Approaches to Cancer Therapy”, Future Health, 2017, Innovations Transforming Healthcare Conference, Nanyang Technological University.

2018

266. April 17 , University of British Columbia, Canada, “Novel Precision Approaches to Cancer Therapy”.
267. May 4, Mt Sinai Medical School, New York, New York., “Regenerative Medicine: Novel approaches to Therapy Precision”.
268. September 25, Xavier University, Deans Annual Lecture, “The opioid crises” causes and management.
269. October 15, Helsinki, Sweden, Plenary Session Lecture, 11th Annual Stem Cell and Regenerative Medicine Meeting., “Cancer Stem cells (CSC). Genetic drivers and therapeutic targeting via CCR5”.
270. October 15, Helsinki, Sweden, University of Helsinki, Plenary Lecture, “CCR5 - a novel precise target for cancer therapy. Mechanism of action in cancer stem cells and a clinical update.(role of Leronlimab)”.
271. October 25, Robert H. Lurie Comprehensive Cancer Center, Chicago Illinois, USA., “Cancer Stem cells (CSC). Genetic drivers and therapeutic targeting via CCR5”.
272. December 20, Queen Elizabeth II Medical Center, Perth Australia, “The discovery of a novel cancer target and clinical development of targeted therapy with Leronlimab “

2019

273. March 17., “Portraits of prostate cancer”., ***PacRim Meeting*** Adelaide South Australia, March 17-20, 2019.
274. March 13 Distinguished Lecturer, Seminar Series, Medical School, Nanyang Technological University, Singapore “immuno miRs -novel control mechanisms in cancer”
275. November 16 2019 Susan Komen Foundation Annual Meeting, Philadelphia PA **Keynote Address** “*Promising Research and What it Means for You as a Survivor or Individual with MBC”*
276. December 10-14, San Antonio Breast Cancer meeting, “Leronlimab, a humanized monoclonal antibody to CCR5, restrains breast cancer metastasis and enhances cell death induced by DNA damaging chemotherapies”. Selected for “In the spot light oral presentation”.

2020

277. **March 28,** “A novel cytoplasmic membrane Estrogen mediated biogenic signaling pathway”. US Endocrine Society Meeting, San Francisco, USA. (virtual presentation)
278. April 1., Cancer biology and Immunotherapy, Annual Meeting, United Scientific Group, Savannah, GA, (Plenary).” Genetic drivers and therapeutic targeting via a new receptor”. COVID cancelled”.
279. April 16 th “8h International Meet on Cancer”, Miami Florida, USA, “Cancer Stem Cells. Genetic Drivers and therapeutic targeting” (Plenary). COVID cancelled
July 8, 45th FEBS conference, Plenary Lecture, “CCR5 - a novel precise target for cancer therapy. Mechanism of action in cancer stem cells and a clinical update”. (Plenary). COVID rescheduled”.
280 Targeting the tumor micoenvironment to combat cancer June 15, 2020 Israel, “Cyclin dependent kinase inhibitors and the tumor microenvironment” .
280. CCR5 governs stem cell characteristics, therapy resistance and metastasis of breast cancer**.** Cellular therapies, Cancer stem cells and Biomedical Engineering, Annual Meeting, Plenary Lecture., July 17 2020 Vienne, Austrla.

2021

281. Plenary. COVID rescheduled July 8, 45th FEBS conference, Lubjana, Plenary Lecture, “Precision cancer therapy: The journey of CCR5 from bubonic plague to current clinical treatments.
282. October 26 2021- Plenary lecture - 6th International Conference on Cancer Research and Drug Development (Cancer R&D 2021) to be held in Baltimore, USA October 25-27,2021 “Cancer Stem cells: Therapeutic targeting for the clinic"(Plenary).

2022

283 7th Global Insight Conference on Breast Cancer, Cyclin D1 Restrains Oncogene-Induced Autophagy by Regulating the AMPK–LKB1 Signaling Axis September 20-21, 2022, Barcelona, Spain.
284 "Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy"; 8th World Congress on BREAST CANCER October 21, 2022 London, UK.
285 CCR5 Inhibitors Reduce Chemotherapy-Induced Cardiotoxicity While Enhancing Breast Cancer Cell Killing. 8th World Congress on BREAST CANCER October 21, 2022 London, UK.

.

2023

286. May 19 2023, Advance Global Australian Network, Research Commercialisation (utube video) https://www.youtube.com/watch?v=QLcEQz8H9H4
287. 13th world congress breast cancer research and therapies, June 12, 2023 Melbourne Australia, "Immune Oncology Therapy for Breast Cancer: CCR5 Inhibitors Enhance Breast Cancer Cell Killing and Reduce Doxorubicin-Induced Cardiotoxicity". Plenary R G. Pestell Xuanmao Jiao, Hsin Yao Tang, Sean Lal, Anthony W. Ashton.
288 July 20, 2023 8th World Congress on CANCER RESEARCH AND THERAPY, Frankfurt, Germany "The humanized monoclonal anti-CCR5 antibody blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy" Plenary. R G. Pestell
289 September 22, 2023, Budapest, Hungary, HUN REN , "Research Commercialization In Academic EcoSystems" R G. Pestell (HUN Ren is the National Research Network of Hungary).

2024

290 March 21, 2024, Budapest, Hungary, HUN REN , "Research Commercialization In Academic EcoSystems" R G. Pestell.
291. "Dachshund. A new tumor suppressor governing PARP inhibitor resistance: from bench to bedside" National Institute of Oncology, Budapest, March 19 2024
292. Prague, Czech Republic, June 22 The DACH1 gene is frequently co-deleted with BRCA2 in prostate cancer and governs PARP inhibitor resistance 10th World Congress on CANCER RESEARCH AND THERAPY (WCCRT-2024), 2024
293. Prague, Czech Republic, June 22. A cyclin D1 intrinsically ed domain accesses modified histone motifs to govern gene transcription**.** 10th World Congress on CANCER RESEARCH AND THERAPY (WCCRT-2024), 2024
294 August 8, 2024, Perth, Australia, Perkins Institute , "DACH1- pleiotropic player in cancer, kidney disease and insulin resistance: from bench to bedside".
295 October 3, 2024 Perth, Australia, School of Biomedical Sciences, The University of Western Australia. "Targets for co-extinction in therapeutic resistance cancers. A cyclin D1 intrinsically disordered domain governs gene transcription and an oncogenic secretome".

2025

296 May 31, 2025, Budapest, Hungary, Institute of Molecular Sciences, 75th Anniversary Invited Lecture., Plemary; HUN REN, "Immune Oncology Therapy for Cancer: CCR5 Inhibitors,Bench to Bedside." R G. Pestell
297 June 26 2025 Budapest, Hungary Institute of Molecular Sciences "Targets for co-extinction in therapeutic resistance cancers. A cyclin D1 intrinsically disordered domain governs gene transcription and an oncogenic secretome". R G. Pestell
298 July 8 2025, Cancer Congress 2025, Vienna, July 8th, Speaker: "Immune Oncology Therapy for Cancer: CCR5 Inhibitors for triple negative breast cancer ,Bench to Bedside."
299 August 1 2025, Houston, Texas, USA., Breast Cancer Clinical and Translational Research Conference (BCCTR) MD Anderson Cancer Center, Speaker: "Immune Oncology Therapy for Cancer: CCR5 Inhibitors for triple negative breast cancer ,Bench to Bedside."
300 September 4, Temple University Medical School, Invited Speaker, "Immune Oncology Therapy for Cancer: CCR5 Inhibitors,Bench to Bedside"."
301 September 27 2025., Montreal Canada. Richard G. Pestell, CCR5 inhibition with leronlimab is associated with enhanced PD-L1 expression, ICI response, and long-term survival in metastatic TNBC. **AACR** Mechanisms of Cancer Immunity and Cancer-related Autoimmunity.
302 October 7th 2025 Wake Forest University School of Medicine, USA "*Research Commercialization In Academic EcoSystems,* Wake Forest University School of Medicine, USA.
303 November 12, 2025, Debrecen, Debrecen, University, "CCR5 Inhibitor therapy for metastatic cancer: priming the tumor microenvironment"."keynote speaker. Oncology meeting.
304. November 13, 2025, Budapest, Hungary Research Centre for Natural Sciences "The Future of Drug Research: Science and Innovation" "Immune Oncology Therapy for Cancer: CCR5 Inhibitors,Bench to Bedside"."keynote speaker.
305. November 20, 2025, Philadelphia, PA., USA , "CCR5 Inhibitors for metastatic cancer: priming the tumor microenvironment. Bench to Bedside;" Grand Rounds.

2026

306. April 28, 2026., Inaugural lecture: Member Inductee presentation to the National Academy of Science, Budapest, Hungary, "Cancer vulnerabilities: The surprising 7,000 year journey of CCR5 to the bedside".
."

Abstracts:

1. **Pestell, R.G.**, Van Dongen, R., Tunney, A. Hormonal mediators in a 1000km footrace. Royal Australian College of Physicians Scientific Meeting, 1987.
2. McCann, V.J., **Pestell, R.G.**, Williamson, J., Christiansen, F., Dawkins, R. The Increased Frequency of HLA DQ3 (TA 10 negative) in Diabetic Patients is Secondary to an Association with B62 DR4 Supratype. British Diabetes Association Meeting, March 1987.
3. Ward, G.M., **Pestell, R.G.**, Alford, F.P. Reduced Carbohydrate Tolerance in Thyrotoxicosis: Impaired Insulin Sensitivity, Not Reduced Secretion. Australian Diabetes Society, 1987.
4. **Pestell, R.G.,** Kirsner, R.L.G., Best, J.D. The Skin Potential Response: A New and Sensitive Marker for Sympathetic Nervous System Dysfunction in Diabetes Mellitus. Australian Diabetes Society, 1987.
5. **Pestell, R.G.**, Hurley, D.M., Van Dongen, R. Hormonal Changes During a 1000 kilometer Foot Race. Endocrine Society of Australia, 1987.
6. Arnott, R., **Pestell, R.G.**, McKelvie, P., Henderson, J.K., McNeil, P., Alford, F.P. Pituitary Surgery in Acromegaly: An Australian Experience. Endocrine Society of Australia, 1987.
7. **Pestell, R.G.,** Kirsner, R.L.G., Best, J.D. The Skin Potential Response. World Diabetes Complications Conference, (Rome) 1987.
8. **Pestell, R.G.**, Best, J.D., Ward, G.M. Fenfluramine Increases Insulin Action in Non Insulin Dependent Diabetes Mellitus (NIDDM). International Diabetes Federation Meeting (Sydney), 1988.
9. **Pestell, R.G.,** Kirsner, R.L., Best, J.D. The skin potential response as a measure of autonomic dysfunction in Diabetes Mellitus - Validation Studies. International Diabetes Federation Meeting (Sydney), 1988.
10. **Pestell, R.G.**, Hammond, V., Crawford, R. Characterization of the ovine side chain cleavage gene. Royal Australian College of Physicians - Scientific Meeting (Melbourne), 1988.
11. **Pestell, R.G.**, Ward, G.M., Galvin, P., Best, J.D., Alford, F.P. Insulin secretion but not insulin sensitivity is changed after severe exercise in highly trained athletes. US Endocrine Society Meeting, 1989.
12. Chamberlain, K., **Pestell, R.G.**, Best, J.D. Platelet catecholamine levels are cumulative indices of sympathoadrenal activity. US Endocrine Society Meeting, 1989.
13. Chamberlain, K., **Pestell, R.G.**, Best, J.D. Platelet catecholamine's are cumulative indices of chronic sympathoadrenal activation. Australian Endocrine Society Meeting, 1989.
14. Arnott, R., **Pestell, R.G.**, McKelvie, P., Henderson, J.K., McNeil, P., Alford, F.P. Cushing's Disease: Prediction of relapse following transphenoidal surgery. Australian Endocrine Society Meeting, 1989.
15. **Pestell, R.G.,** Herington, A., Best, J.D., Arnott, R., McKelvie, P., Alford, F.P. Growth hormone excess without Acromegaly. Australian Endocrine Society Meeting, 1989.
16. **Pestell, RG.**, Ward, G., Galvin, P., Alford, F.P., Best, J.D. Reduced insulin secretion causes impaired glucose tolerance after severe exercise in highly trained athletes. Australian Endocrine Society Meeting, 1989.
17. **Pestell, R.G.**, Arnott, R., Best, J.D., Alford, F.P. Familial Acromegaly. Australian Endocrine Society Meeting, 1989.
18. **Pestell, R.G.**, Hammond, V., Coghlan, J.P., Crawford, R. Location of c'AMP responsive sequences in the ovine P-450 SCCgene. Australian Endocrine Society Meeting, 1989.
19. Kluger, R., Best, J.D., **Pestell, R.G.**, Jenkins, A., Sawyer, S. Hormonal and metabolic changes during lower limb vascular surgery in NIDDM and non-diabetic patients under spinal and general anaesthesia. Australian Diabetes Association Meeting, 1989.
20. Kluger, R., Best, J.D., **Pestell, R.G.**, Jenkins, A., Sawyer, S. Hormonal and metabolic changes during vascular surgery in non-diabetic and diabetic subjects under general and spinal anaesthesia. Royal Australian College of Surgeons Meeting, 1989.
21. Galvin, P., Ward, G., Kalfas, A., Walters, J., **Pestell, R.G.**, Martin, I., Best, J.D., Alford, F.P. A simplified method for the simultaneous quantitation of insulin sensitivity and insulin release. Australian Diabetes Association Meeting, 1990.
22. **Pestell, R.G.,** Hammond, V., Crawford, R. Regulatory sequences in the 5' flanking region of the ovine cytochrome P-450 cholesterol side-chain cleavage (P-450 SCC) gene promoter Australian Endocrine Society Meeting, 1990.
23. **Pestell, R.G.**, Hammond, V., Crawford, R. Molecular cloning and characterisation of the cAMP-responsive ovine CYP11A1 (P450 SCC) gene promoter: DNase 1 protection of conserved consensus elements. Australian Genomic Conference, 1991.
24. **Pestell, R.G.,** Crawford, R. The cAMP responsive ovine *CYP11A1* promoter is transactivated by c-jun. Australian Society for Medical Research, 1991.
25. Crawford, R., Hammond, V., **Pestell, R.** Regulation of steroid hydroxylase gene expression by the ACTH in the ovine adrenal cortex, 4th Conference on the Adrenal Cortex, Atlanta, Georgia, USA, 1991.
26. **Pestell, R.G.**, Crawford, R. Location of a region within the cAMP responsive P-450(CYP11A1) promoter transactivated by c-jun. US Endocrine Society Meeting, 1992.
27. Hollenberg, A., **Pestell R.G.,** Albanese, C., Jameson, J.L., The CGb Gene Cluster: Analysis of functional promoter sequences. Serono Symposium: Pathways for Maternal Embryonic Communication, 1992.
28. **Pestell, R.G.**, Troccoli, N., Albanese, C., Hollenberg, A., Jameson, J.L. The chorionic gonadotropin b5 gene is stimulated by cAMP and E1A through distinct regions. Keystone Symposia: Transcription: Factors, Regulation and Differentiation. 1993. (J. Cell. Biochem. p302) Wiley Press, Inc. New York. Keystone Symposia: Transcription: Factors, Regulation and Differentiation. 1993.
29. Hollenberg, A., **Pestell, R.G.**, Albanese, C., Jameson, L.J. Placental Specific expression of the beta subunit of chorionic gonadotropin requires multiple promoter elements. American Federation for Clinical Research, 1993.
30. **Pestell, R.G.**, Albanese, C., Hollenberg, A., Jameson, J.L. c-jun mediates trans-repression of the Human Chorionic Gonadotropin Glycoprotein Subunits through distinct mechanisms. US Endocrine Society Meeting, 1993.

31. **Pestell, R.G.,** Albanese, C., J. Larry Jameson. Distinguishable Activation Surfaces of E1a Target Distinct Cis Elements Of The Human Chorionic Gonadotropin b-Subunit Gene. US Endocrine Society Meeting, 1994.
32. **Pestell, R.G.,** Albanese, C., Jameson, J.L. Repression of The Gonadotropin a-Subunit Gene Transcription By E1a12s Is Mediated Via Its Cyclic Amp Response Element. US Endocrine Society Meeting, 1994.
33. Eklund, N., Johnson, J., Chris Albanese, C., Arnold, A., **Pestell, R.G.** Distinguishable Proliferative Pathways Collaborate By Activating Transcription of the Human Cyclin D1 Through Distinct Promoter Regions. Schweppe Colloquium- Tumor Metastases, Chicago. 1994.
34. Johnson, J., Eklund, N., Albanese, C., Arnold, A., **Pestell, R.G.** Epidermal Growth Factor and c-Jun Stimulate Transcription of the *CYP11A1* Promoter Through the Same Regulatory Element. Reproductive Biology Meeting. Center for Reproductive Science Evanston, 1994.
35. Albanese, C., Johnson, J., Eklund, N., Arnold, A., **Pestell, R.G.** Distinguishable Proliferative Pathways Collaborate By Activating Transcription Of The Human Cyclin D1 Through Distinct Promoter Regions. (J. Cell. Biochem.) Wiley Press, Inc. New York. Keystone Symposia: Transcription: Factors, Regulation and Differentiation, 1993.
36. Albanese, C., Watanabe, G., Johnson, J., Lastowiecki, P., **Pestell, R.G.** p21^{ras} and c-Ets-2 activate the Ovine *CYP11A1* (P_{450} Side Chain Cleavage) Promoter in Steroidogenic Cells through Distinguishable Regions. US Endocrine Society Meeting, 1995.
37. Watanabe, G., Lastowiecki, P., Albanese, C., Angus MacNicol, A., Rainey, W.E., **Pestell, R.G.** Angiotensin II activates human cyclin D1 transcription through both SAPK and MAPK dependent pathways. AFCR Clinical Research Meeting, San Diego, CA 1995.
38. Shu, I-W., Howe, A., Rundell, K., Watanabe, G., **Pestell, R.G.** SV40 small t antigen activates the Cyclin D1 promoter through collaborative interactions between multiple enhancer sequences. Northwestern University Undergraduate Program, 1995.
39. Li, C.X., Hales, K.H., Watanabe, G., **Pestell, R.G.,** Hales, D.B. Tumor necrosis factor a mediated inhibition of 17a hydroxylase/C17-20 lyase gene (*Cyp 17*) expression. Possible role of c-jun/c-fos and protein kinase C. Reproductive Biology Meeting, Center for Reproductive Science Evanston, 1995.
40. Lee R. J., Erfurth, F., Watanabe, G., **Pestell, R.G.** Localization of a Novel Nerve Growth Factor Responsive Element in the Cyclin D1 Promoter. Coleman Foundation Symposium: The Regulation of Cell Growth, 1995.
41. Erfurth, F., Lee, R.J., Watanabe, G., Shambaugh III, G.E., Young, J.B., **Pestell, R.G.** Characterization of the *ras*/MEK/ERK dependent regulation of the cyclin D1 promoter in PC12 cells. Coleman Foundation Symposium: The Regulation of Cell Growth, 1995.
42. Lee, R.J., Watanabe, G., Albanese, C., Karnezis, A.N., Penya, P., Webster, M., Siegel, P.M., Muller, W.J., **Pestell, R.G.** Transforming Neu and pp60$^{v\text{-}Src}$ mutants: induction of cyclin D1 kinase activity and transcription in breast cancer cells. US Endocrine Society Meeting, 1996.
43. Shambaugh III, G.E., Lee, R.J., Karnezis, A.N., Watanabe, G., Haines III, G.K., **Pestell, R.G.** Reduced Cyclin D1 expression in the cerebellar of nutritionally deprived neonatal rats correlates with developmental delay and decreased cellular DNA synthesis. US Endocrine Society Meeting, 1996.
44. Watanabe, G., Howe, A., Lee, R.J., Albanese, C., Shu, I-W., Johnson, J., Karnezis, A.N., Rundell, K., **Pestell, R.G.** Induction of the EGF Responsive Cyclin D1 Promoter by SV40 Small T Antigen. US Endocrine Society Meeting, 1996.
45. Pena, P., Shu, I.W., Lee, R.J., Watanabe, G., Albanese, C., Williams, T., **Pestell, R.G.** AP-2a Dependent Regulation of the Ovine P-450 Side Chain Cleavage (Cyp11A1) Promoter through a Conserved Footprinted Region is Steroidogenic Cell-Type Specific. US Endocrine Society Meeting, 1996.
46. Porras, A., Howe, A., Watanabe G., **Pestell, R.G.,** Henglein, B., Rundell, K. The Simian Virus 40 Small-T Antigen Activates Transcription Of Cyclins A and D1. Cold Spring Harbor Symposium, Control of the Cell-Cycle, 1996.
47. Johnson, W., Albanese, C., **Pestell, R.G.**, Williams, T., Handwerger, S., Jameson, J.L. Transcription factor AP-2a increases during placental trophoblast differentiation and stimulates the human chorionic gonadotropin b gene promoter. FASEB Meeting, Snowmass, Co., 1996.
48. Thurston, V.C., **Pestell, R.G.,** Binder, L.I. Tau localization in nucleoli and NORs of neuronal and nonneuronal cells: regulation by anti-sense mRNA. American Society of Human Genetics, San Francisco, CA, 1996.
49. Pena, P., Shu, I.W., Lee, R.J., Watanabe, G., Albanese, C., Williams, T., **Pestell, R.G.** AP-2a Dependent Regulation of the Ovine P-450 Side Chain Cleavage (*CYP11A1*) Promoter Reproductive Biology Meeting. Center for Reproductive Science, Evanston, IL. 1996.
50. Watanabe, G., Pena, P., Young, J., **Pestell, R.G.** ACTH activates the p54 Stress Activated Protein Kinases and inhibits the p42/p44 Extracellular regulated kinase in the adrenal cortex in vivo. Reproductive Biology Meeting. Center for Reproductive Science, Evanston, IL. 1996.
51. Musa, N., Xiong, W., Ramakrishnan, M., Li, J., Liu, P., **Pestell, R.G.**, Hershenson, M.B. Cyclic Amp Inhibits Airway Smooth Muscle Growth By Suppressing Cyclin D1 Transcriptional Activation. American Lung Association/American Thoracic Society Meeting, (1997).
52. Lee, R.J., Watanabe, G., Albanese, C. Karnezis, A.N., Pena, P., Webster, M., Siegel, P.M., Muller, W.J., **Pestell, R.G.** Cyclin D1-Dependent Kinase In Neu and pp60$^{c\text{-}src}$ Transgenic Models Of Breast Tumorigenesis: Cyclin D1 Activation Requires Mek/ERK/ATF-2 (AFMR Meeting, Washington, DC, (1997).
53. Song, R., La Pointe, M.S., **Pestell, R.G.**, Batlle, D. Hypertonic stress activation of the Na^+/H^+ antiporter in cultured fibroblasts from homozygous cAbl knockout mice. AFMR Meeting, Washington, DC, (1997).
54. Watanabe, G., Albanese, C., Pena, P., Lee, R.J., Reutens, A.T., Karnezis, T., Kitsis, R.N., **Pestell, R.G.** Cyclin D1 regulation by the Adenovirus E1A-associated protein p300. Albert Einstein College of Medicine Poster session, New York, (1997).

55. Pena, P., Albanese, C., Lee, R.J., Watanabe, G., Reutens, A.T., Shu, I-W.X., Williams, T., **Pestell, R.G.** AP-2a regulation of the cAMP responsive Ovine P-450 side Chain Cleavage Enzyme (*CYP11A1*) Promoter. Albert Einstein College of Medicine Poster session, New York, (1997).
56. Lee R.J., Watanabe, G., Albanese, C., Webster, M., Siegel, P., Muller, W.J., **Pestell, R.G.** Cyclin D1-dependent kinase in Neu and pp60$^{c\text{-}src}$ transgenic models of breast tumorigenesis: Cyclin D1 activation Requires Mek/Erk/Atf-2. Albert Einstein College of Medicine Poster session, New York, (1997).
57. Watanabe, G., Pena, P., Albanese, C., Crying, J.B., **Pestell, R.G.** Adrenocorticotropin Induction of Stress Activated Protein Kinase in the Adrenal Cortex in vivo. Albert Einstein College of Medicine Poster session, New York, (1997).
58. Musa, N., Ramakrishnan, M., Li, J., **Pestell, R.G.**, Hershenson, M. Localization of The Cyclin D1 Promoter PDGF Response Element In Airway Smooth Muscle. ALA/ATS International Conference, (1997). Published: Am. J. Critical Care Med.
59. Ramakrishnan, M., Musa, N., Li, J., **Pestell, R.G.**, Hershenson, M. Catalytic Activation Of Extracellular Signal-Regulated Kinases Induces Cyclin D1 Expression In Primary Tracheal Myocytes. ALA/ATS International Conference, (1997). Published: Am. J. Critical Care Med.
60. Watanabe, G., Albanese, C., Lee, R.J., Reutens, A., Vairo, G., Henglein, B., and **Pestell, R.G.** E2F-1 inhibits cyclin D-kinase activity and cyclin D1 promoter activity through E2F and Sp1. American Association for Cancer Research, Annual Meeting, New Orleans, (1998).
61. Lee, R.J., Watanabe, G., Albanese, C., Reutens, A.T., Haines, G.K. III, Siegel, P.M., Muller, W.J., **Pestell, R.G**. Regulation of cyclin D1 by the Neu, c-*erb*B2, proto-oncogene. American Association for Cancer Research, Annual Meeting, New Orleans, (1998).
62. Watanabe, G., Pena, P., Shambaugh, G.E. III, Haines, G.K. III, **Pestell, R.G**. Regulation of Cyclin Dependent Kinase Inhibitor Proteins During Neonatal Cerebellar Development. US Endocrine Society Meeting, New Orleans, (1998).
63. Beier, F., Lee, R., **Pestell, R.G.,** Lu Valle, P. Identification Of The Cyclin D1 Gene As A Target Of The Transcription Factor ATF-2 In Chondrocytes 6th Int. Limb Development and regeneration Conference, Sun Valley, Id. (1998).
64. Watanabe, G., **Pestell, R.G**. Vascular Endothelial Growth Factor Regulation of the Cyclin D1 Promoter In Retinal Endothelial Cells. US Endocrine Society Meeting, New Orleans, (1998).
65. Reutens, A., Watanabe, G., Albanese, C., McPhaul, M.J., Balk, SP, **Pestell, R.G**. Cyclin D1 Binds Activating Mutants of the Androgen Receptor. US Endocrine Society Meeting, New Orleans, Louisiana. (1998). Abstract number P1-528, page 228. Endocrine Society Press, Bethesda, MD.
66. Beier, F., Lee, R., **Pestell, R.G.,** Lu Valle, P. Identification of the Cyclin D1 Gene as A Target of the Transcription Factor ATF-2 Signaling in normal and cancer cells, Banff, AB, Canada, (1998).
67. Albanese, C., Lee, R.J. Smith, J., Watanabe, G., Reutens, A., Windle, J.J., Bearss, D.J., **Pestell, R.G.** Cyclin D1 regulation by Ras. US Endocrine Society Meeting, New Orleans, (1998).
68. Watanabe, G., **Pestell, R.G.** Vascular Endothelial Growth Factor Regulation of the Cyclin D1 Promoter in Retinal Endothelial Cells. Albert Einstein College of Medicine Poster session, New York, (1998).
69. Reutens, A., Watanabe, G., Albanese, C., McPhaul, M.J., Balk, S.P., **Pestell, R.G.** Cyclin D1 Binds Activating Mutants of the Androgen Receptor. Albert Einstein College of Medicine Poster Session, New York, (1998).
70. Albanese, C., Lee, R.J., Karnezis, A., Smith, J., Watanabe, G., Reutens, A., Windle, J.J., Bearss, D.J., **Pestell, R.G.** Cyclin D1 regulation by Ras. Albert Einstein College of Medicine Poster session, New York, (1998).
71. Watanabe, G., Pena, P., Shambaugh III, G.E., Haines III, G.K., **Pestell, R.G.** Regulation of Cyclin Dependent Kinase Inhibitor Proteins During Neonatal Cerebellar Development Albert Einstein College of Medicine Poster session, New York (1998).
72. **Pestell, R.G.,** Susan G. Komen Breast Cancer Foundation National Grant Conference, San Antonio, TX (18/10. "Cyclin D1 and breast cancer -The role of Rho proteins and cyclin D1 in breast tumorigenesis and metastasis."
73. Bearss, D.J., Lee, R.L., Troyer, D.A., **Pestell R.G.**, Windle, J.J. p21WAF1/CIP1 Deficiency has differential cell cycle effects in tumors arising from MMTV-Ras and MMTV-Myc Transgenic Mice. Cold Spring Harbor Suppressor Genes Symposium, New York, NY.
74. Zhou, Q., Melhoumian, Z.K., Lee, R.J., **Pestell, R.G**., Strobl, J.S. Quinidine activates p21WAF-1 expression and phosphorylation of pRb prior to onset of apoptosis in MCF-7 human breast cancer cells. American Association for Cancer Research, Annual Meeting, Philadelphia, (1999).
75. Lane, M.E., Yu, B., Albanese, C., **Pestell, R.G.**, Wadler, S. Characterization of growth and cell cycle control of RKO cells stably transfected with an inducible cyclin D1 gene. American Association for Cancer Research, Annual Meeting, Philadelphia, (1999).
76. Yu, B., Lane, M., Albanese, C., **Pestell, R.G.**, Wadler, S**.** Overexpression of cyclin D1 in stable human cell lines with ecdysone-inducible system. American Association for Cancer Research, Annual Meeting, Philadelphia, (1999).
77. Ding, W., Zhou, D.C., Reutens, A., **R.G. Pestell**, Gallagher, R.E. Variable Functional Relationship Of Naturally-Occurring Missense Mutations In The Pml-RARa Fusion Gene To Loss Of Retinoic Acid Sensitivity In Acute Promyelocytic Leukemia Cells From Relapse Patients. American Association for Cancer Research, Steroid Receptor Co-activator Meeting (1999).
78. Reutens, A.T., Fu, M., Albanese, C., D'Amico, M.D., McPhaul, M.J., Ben-Ze'ev, A., **Pestell, R.G.** New Roles for Cyclin D1. Cyclin D1 is directly induced by b-Catenin and inhibits androgen receptor nuclear function through a novel mechanism in prostate cells. (New York, N.Y.). Cancer Center Meeting, New York. Jan. 25.
79. D'Amico, M.D., Lee, R., Albanese, C., Reutens, A., **Pestell, R.G.** Neu-regulation of cyclin D1-the role of p16Ink4a. Proceedings. Cancer Biology and the Mutant Mouse: New Methods, New Models, New Insights. American Association for Cancer Research, Keystone, Colorado. (1999) A. C.19
80. Bouzahzah, B., Joyce, D., Fu, M., D'Amico, M., Albanese, C., Steer, J., Klein, J.U., Segall, R.E., Westwick, J.K., Der, C.J., **Pestell, R.G.** Integration of Rac-Dependent regulation of Cyclin D1transcription through an NK-kB-dependent pathway. The Endocrine Society's 81st Annual Meeting, San Diego, California, USA, 1999

81. Sampson, E.M., Haque, Z., **Pestell, R.G.**, Yee, A.S. βCatenin Activation of the Cyclin D1 Promoter is inhibited by HBP1, an HMG box Transcriptional Repressor and Cell Cycle Regulator GCRC meeting (1999).
82. Ashton, A.W., Watanabe, G., Albanese, C., Harrington, E.O., Ware, J.A., **Pestell, R.G.** Protein Kinase Cδ Inhibition of S-Phase Transition In Capillary Endothelial Cells Involves the Cyclin Dependant Kinase Inhibitor $p27^{Kip1}$. American Heart Assoc Meeting, Atlanta Georgia, (1999).
83. Beier, F., Taylor, A.C., Mock, D., **Pestell, R.G.**, Lu Valle, P. TGFb and PTHrP cooperatively stimulate cyclin D1 gene expression in chondrocytes through a CRE, Gordon Conference.
84. Wadler, S., Yu, B., Lane, M., Lee, R., Albanese, C., **Pestell, R.G.** Temporal Effects Of Cyclin D1 Antisense Induction In An Ecdysone-Inducible Human Colon Cancer Cell Line. AACR Meeting, Genetic and Functional Consequences of Cancer, San Diego, Oct 1999.
85. Reutens, A.T., Fu, M., Wang, C., Zahler, M., McPhaul, M.J., Sun, Z., Nakatani, Y., **Pestell, R.G**. Cyclin D1 inhibits androgen receptor function through a novel mechanism in prostate cells. Endocrine Society's 81st Annual Meeting, San Diego, California, USA, (1999).
86. Bailly, M., Wycoff, J., Bouzahzah, B., Hammerman, R., Sylvestre, V., Cammer, M., **Pestell, R.G.,** Segall, J.E: Polarized endocytosis rather receptor distribution reflects cell polarity during chemotaxis towards EGF. ASCB meeting, Washington DC, USA, 1110, (December, 11-15, 1999).
87. Wang, C., Fu, M., Angeletti, R.H., Siconolfi-Baez, L., Katzenellenbogen, B., Ogryzko, V., **Pestell, R.G**. Acetylation regulates Estrogen Receptor α transactivation. AACR Meeting, 2000.
88. Fassett, J., Albrecht, J., **Pestell, R.G.,** Hansen, L.K. Extracellular matrix regulates EGF induction of cyclin D1 transcription in primary rat hepatocytes via p42/44 and p38 Map kinase pathways. Keystone Symposium 12/22 "Joint regulation of signaling pathways by integrins and growth factors."
89. Dhanabal, M., Ananth, S., Jha, V., Bouzahzah, B., **Pestell, R.G.**, Sukhatme, V.P. Endostatin causes G1 cell cycle arrest by inhibiting Cyclin D1 transcription. AACR meeting, 2000.
90. Lane, M.E., Yu, B., **Pestell, R.G.**, Berk, A., McMahon, G., Makower, D., Wadler, S. Combined adenovirus dl1520 and su9516 therapy produces a synergistic response in human colon carcinoma cells. AACR meeting, 2000.
91. **Pestell, R.G.**, "Cyclin D1 regulation by oncogenic and integrin linked signaling pathways." The Bat Sheva Seminar: The dialogue between cell adhesion, protein degradation and transcriptional regulation in cancer. November 21-25, 1999.
92. Shtutman, M., Zhurinsky, J., Simcha, I., **Pestell, R.G.,** Ben-Ze'ev, A. The cyclin D1 gene is a target of the β-Catenin/LEF-1 pathway. The Bat Sheva Seminar: The dialogue between cell adhesion, protein degradation and transcriptional regulation in cancer. November 21-25, 1999.
93. Wang, C., Fu, M., Angeletti, R.H., Siconolfi-Baez, L., Katzenellenbogen, B., Ogryzko, V., **Pestell, R.G.** Acetylation regulates Estrogen Receptor α transactivation. US Endocrine Society Meeting, 2000.
94. Hulit, J., Tal Bash, T., Fu, M., Galbiati, F., Albanese, C., Sage, D.R., Schlegel, A., Zhurinsky, J., Shtutman, M., Ben-Ze'ev, A., Lisanti, M.P., **Pestell, R.G.** The *cyclin D1* gene is transcriptionally repressed by caveolin-1. US Endocrine Society Meeting, 2000.
95. Albanese, C., Reutens, A.T., Bouzahzah, B., Fu, M., D'Amico, M., Link, T., Nicholson, R., DePinho, R.A., **Pestell, R.G.** Sustained Mammary gland directed Ponasterone A-inducible expression in transgenic mice. US Endocrine Society Meeting, 2000.
96. D'Amico, M., Hulit, J., Amanatullah, D.F., Zafonte, B.T., Albanese, C., Bouzahzah, B., Fu, M., Augenlicht, L.H., Donehower, L.A., Takemaru, K-I., Moon, R.T, Davis, R., Lisanti, M., Shtutman, M., Zhurinsky, J., Ben-Ze'ev, A., Troussard, A.A., Dedhar, S., **Pestell, R.G**. The integrin-linked kinase regulates the *cyclin D1* gene through glycogen synthase kinase 3b and CREB-dependent pathways. US Endocrine Society Meeting, 2000.
97. Bouzahzah, B., D'Amico, M., Pixley, F., Wyckoff, J., Ahmed, F., Segal, J., Minden, A., **Pestell, R.G**. The Rho GTPases regulate distinct functions *in vitro* and *in vivo*. US Endocrine Society Meeting, 2000.
98. Yu, R.M.E., Lane, B., **Pestell, R.G.**, Albanese, C., Wadler, S. Downregulation of cyclin D1 alters both cdk4 and cdk2-specific phosphorylation of retinoblastoma protein. AACR Annual Meeting, San Francisco, CA, 2000.
99. Wang, C., Fu, M., Angeletti, R.H., Siconolfi-Baez, L., Katzenellenbogen, B., Ogryzko, V., **Pestell, R.G.** Acetylation regulates Estrogen Receptor α transactivation. AACR Annual Meeting, San Francisco, CA, 2000.
100. Fan, S., Wang, J., Yuan, R., Ma, Y., Meng, Q., Erdos, M., Goldberg, I., Webb, P., Kusner, P., **Pestell, R.G.,** Rosen, E.M. Inhibition of estrogen receptor-α signaling and transcriptional activity by BRCA1. AACR Annual Meeting, San Francisco, CA, 2000.
101. Wang, C., Fu, M., Angeletti, R.H., Siconolfi-Baez, L., Katzenellenbogen, B., Ogryzko, V., **Pestell, R.G.** Estrogen Receptor α Acetylation regulates transactivation. AECOM DOM Annual Meeting, 2000.
102. Hulit, J., Fu, M., Galbiati, F., Albanese, C., Sage, D.R., Schlegel, A., Ben-Ze'ev, A., Lisanti, M.P., **Pestell, R.G.** Transcriptional repression of the cyclin D1 gene by caveolin-1. AECOM DOM Annual Meeting, 2000.
103. Albanese, C., Reutens, A.T., Bouzahzah, B., Fu, M., D'Amico, M., Link, T., **Pestell, R.G.** Tissue specific inducible transgenics - a modular system. AECOM DOM Annual Meeting, 2000.
104. D'Amico, M., Hulit, J., Amanatullah, D.F., Zafonte, B.T., Albanese, C., Bouzahzah, B., Fu, M., Augenlicht, L.H., Lisanti, M., Ben-Ze'ev, A., Dedhar, S., **Pestell, R.G**. Regulation of the *cyclin D1* gene by Wnt in mammary tumors. AECOM DOM Annual Meeting, 2000.
105. Bouzahzah, B., D'Amico, M., Pixley, F., Wyckoff, J., Ahmed, F., Segal, J., Minden, A., **Pestell, R.G.** Functional analysis of the Rho GTPases in tumor metastasis *in vivo*. AECOM DOM Annual Meeting, 2000.
106. Lu, Y., Mani, S., Albanese, C., **Pestell, R.G.**, States, J.C., Agrawal, S., Bregman, D.B., Targeting nucleotide excision repair or transcription coupled repair gene products with anti-sense oligonucleotide sensitizes cancer cells to cisplatin or oxiplatin. AACR, 2000.

107. Hulit, J., Lee, R.J., Zhaou, J-N., Bouzahzah, B., Russell, R., **Pestell, R.G.** $p27^{Kip1}$ is haplo-insufficient for suppression of Neu-induced mammary tumor growth in transgenic mice. Impact of biotechnology on cancer diagnostic and prognostic indicators," Geneva, 2000 Oct. 28-31, (published, Cancer Detection and Prevention, Vol. 245 (5).
108. Ahmed, F., Wyckoff, J., Condeelis, J.S., Lin, E., Pollard, J.W., **Pestell, R.G**., Segall, J.E. Development of MMTV-GFP mice for analysis of metastasis. AACR, 2001.
109. Lim, J.T.E., **Pestell, R.G.**, Weinstein, I.B. The Characterization of Cyclin D1 promoter sequence that is induced in the presence of Androgen Receptor Signaling Pathway. AACR, 2001.
110. Lewis, J.S., Thomas, T.J., Albanese, C., **Pestell, R.G.**, Thomas, T. 16α-Hydroxyestrone (16α-OHE1) enhances cyclin D1 promoter ACTIVITY and stimulates the recruitment of co activator proteins. AACR, 2001.
111. Hopp, T., Allred, D.C., Hilsenbeck, S., Mohsin, S., Nawaz, Z., O'Connell, P., Wang, C., **Pestell, R.G.**, Fuqua, A.W. A hypersensitive estrogen receptor a protein in breast cancer. AACR, 2001.
112. Sterio, J., Wang, C., Francis, R., Murray, S.B., Batlle, D., Mayhew, B., Bassett, M., Rainey, W.E., **Pestell, R.G.** A functional analysis of Angiotensin II targets through genome wide surveys. American Hypertension Society meeting 2001 (received ASH travel award).
113. Matsumura, T., Sakamoto, K., Edelstein, D., **Pestell, R.G.**, Brownlee, M. Hyperglycemia-Induced Mitochondrial Superoxide Overproduction Inhibits $PPAR\gamma_2$ Activation By Increasing ERK-Mediated Phosphorylation Of Serine 112. US Diabetes Society Meeting.
114. Kinoshita, Y., Wang, C., **Pestell, R.G.**, Chen, S. Up regulation of aromatase expression in SK-BR-3 breast cancer cell line by estrogen. AACR, 2001.
115. Rana, B., Choi, G., Wang, T., **Pestell, R.G.**, Albanese, C., Wolfe, M.M. Cyclin D1 mediates the trophic properties of gastrin in gastric adenocarcinoma. Amer. Gastro. Assoc. Meeting, 2001.
116. Albanese, C., Hughes, J., Hulit, J., D'Amico, M., Fu, M., Bromberg, J., **Pestell, R.G.** Activation of Phosphotidyl inositol 3-kinase induces cell-cycle progression and *cyclin D1* gene expression through NF-κB signaling pathways. US Endocrine Society Meeting, 2001.
117. Fu, M., Wang, J., Wang, C., **Pestell, R.G.** Androgen Receptor Acetylation site governs co activator regulation and cAMP-dependent function. US Endocrine Society Meeting, 2001.
118. Fu, M., Wang, C., Wang, J., Zhang, X., **Pestell R.G.,** The androgen receptor acetylation sites govern cAMP-dependent Regulation of the liganded Receptor. 9th Annual Poster Session, The Department of Medicine, Albert Einstein College of Medicine. June 13, 2001. Max & Sadie Friedman Lounge, Main & Upper Levels, Forchheimer Building. Poster No. 13.
119. D'Amico, M., Reutens, A., Albanese, C., Fu, M., Davies, K.P., Ganjam, K., Engel, D.A., Murphy, D.J., **Pestell, R.G.** Transcriptional regulation of the glucocorticoid receptor and the *cyclin D1* gene by Human SWI-SNF components BRG1 and hBRM1 involves intrinsic ATPase activity. US Endocrine Society Meeting, 2001.
120. Wang, C., Fu, M., D'Amico, M., Albanese, C., Brownlee, M., Lisanti, M.P., Chatterjee, V.K., Lazar, M.A., **Pestell, R.G.** Inhibition of cellular proliferation through IκB Kinase-independent and PPARγ-receptor dependent repression of cyclin D1.
121. Wang, C., Fu, M., D'Amico, M., Albanese, C., Brownlee, M., Lisanti, M.P., Krishna V., Chatterjee, K., Lazar, M. A., **Pestell, R.G.** US Endocrine Society Meeting, 2001. (Received ESA travel Award).
122. Hawcroft, G., D'Amico, M., Albanese, C., **Pestell, R.G.,** Hull, M.A. Indomethacin treatment is associated with differential expression of beta-catenin/TCF target genes in human sporadic colorectal cancer cells.
123. Wu, K., Wang, C., Lee, R.J., **Pestell, R.G.**, Mani, S. Digestive Disease Week DDW (AGA) Atlanta, Georgia, May 20-23, 2001. Flavopiridol Synergizes with c-erbB-2 Inactivation to inhibit multiple signal transduction pathways involved in breast cancer cellular proliferation. Abstract # 86 p16, 2001.
124. Wang, C., Fu, M., Katzenellenbogen, B.S., Hopp, T., Fuqua, S.A., Kushner, P.J., **Pestell, R.G.** Direct acetylation of the estrogen receptor a govern hormone sensitivity. Proceedings of the Endocrine Society's 83rd Annual Meeting 2001 Jun. 20-23, Denver, Colorado. page 571, poster no. 574.
125. Lewis, J.S., Thomas, T.J., **Pestell, R.G.**, Albanese, C., Gallo, M.A., Thomas, T. Differential effects of 16a-hydroxyestrone and 2-methoxyestradiol on cyclin D1 involving the transcription factor ATF-2. AACR, 2002.
126. Lewis, J.S., Thomas, T.J., **Pestell, R.G.**, Albanese, C., Gallo, M.A., Thomas, T. Phosphorylation of ATF-2 by estradiol and spermine: A possible mechanism for cyclin D1 activation in breast cancer cells. AACR Annual Meeting, San Francisco, CA, 2002.
127. Wu, K., D'Amico, M., Wang, C., **Pestell, R.G.**, Mani, S. Flavopiridol modulates UCN-01 cytotoxicity in surviving overexpressing Hela cells." AACR Annual Meeting, San Francisco, CA 2002.
128. Hu, Y-L., Albanese, C., **Pestell, R.G.**, Jaffe, R.B. Lysophosphatidic Acid (Lpa) Induces Cyclin D1 Transcription in Human Ovarian Cancer Cells. US Endocrine Society Meeting, 2002.
129. Fu, M., Wang, C., Wang, J., Zhang, X., Sakamaki, T., Yeung, Y.G., Chang, C., Hopp, T., Fuqua, S.A., Jaffray, E., Hay, R.T., Palvimo, J.J., Jänne, O.A., **Pestell, R.G.** Androgen receptor acetylation governs trans-activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function, (p3-159). The Endocrine Society's 84th Annual Meeting. 2002, San Francisco, CA.
130. Fu, M., Wang, C., Wang, J., Sakamaki, T., Di Vizio, D., Zhang, X., Albanese, C., Balk, S., Chang, C., Fan, S., Rosen, E., Palvimo, J., Jänne, O.A., Muratoglu, S., Avantaggiati, M.L., **Pestell, R.G**. Transcription Factor Acetylation determines cellular growth in vivo. Submitted to The Endocrine Society's 85th annual meeting. Pennsylvania, 2003 Jun. 18-22. Poster Board Number P3-200.
131. Lewis, J.S., Vijayanathan, V., Gallo, M.A., Albanese, C., **Pestell, R.G.**, Thomas, T.J., Thomas, T. Spermine enhances estrogen receptor-mediated signaling in MCF-7 breast cancer cells by phosphorylation of p38 mitogen activated protein kinase (MAPK).

132. Fu, M., Rao, M., Wang, C., Sakamaki, T., Wang, J., Di Vizio, D., Zhang, X., Albanese, C., Balk, S., Chang, C., Fan, S., Rosen, E., Palvimo, J.J., Jänne, O.A., Muratoglu, S., Avantaggiati, M.L., **Pestell, R.G.**, Acetylation of Androgen Receptor Enhances Co activator Binding and Promotes Prostate Cancer Cell Growth. AACR/NCI/EORTC conference: Molecular Targets in Cancer. Boston, MA, Nov. 19.
133. Wang, C., Fu, M., Sakamaki, T., Wu, K., and **Pestell, R.G.** Cyclin D1 repression of peroxisome proliferator-activated receptor gamma (PPARγ) expression and transactivation. US Endocrine Society Meeting, 2003, Travel Grant Award.
134. Wang, C., Fu, M., Sakamaki, T., Albanese, C., Li, Z., Wu, K., **Pestell, R.G.** Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mini Symposium, AACR Meeting, 2004.
135. D'Amico, M., Zhou, J., Reutens, A., Albanese, C., Fu, M., Davies, K., Kalpana, G., Goff, S., Engel, D., Murphy, D., **Pestell, R.G.** Human SWI-SNF components BRG-1 and hBRM1 regulate transcription of the cyclin D1 gene.
136. D'Amico, M., Reutens, A., Lee, R.J., Fu, M., Albanese, C., Lee, H-W., Muller, W.J., DePinho, R., **Pestell, R.G.** Neu-regulation of cyclin D1-the role of P16Ink4a.
137. Bouras, T., Fu, M., Perkins, N.D., Hay, R.T., **Pestell, R.G.** SIRT1 regulation of the p300 co activator. Lombardi Comprehensive Cancer Center Research Fair, 2003.
138. Fu, M., Wang, C., Wang, J., Sakamaki, T., Di Vizio, D., Zhang, X., Albanese, C., Balk, S., Chang, C., Fan, S., Rosen, E., Palvimo, J.J., Jänne, O.A., Muratoglu, S., Avantaggiati, M.L., and **Pestell, R.G.** Acetylation of Androgen Receptor enhances co activator binding and promotes prostate cancer cell growth. AACR/NCI/EORTC conference: Molecular Targets in Cancer. Boston, MA, 2003 Nov. 19.
139. Weber, H.C., Albanese, C., **Pestell, R.G,** Xiao, D. Bombesin Regulates Cyclin D1 Expression through EGR-1 Dependent Mechanisms. 15th International Symposium on Regulatory Peptides, 2004.
140. Xiao, D., Albanese, C., **Pestell, R.G.,** Weber, H.C. Bombesin Regulates Cyclin D1 Expression through Activation of the Early Growth Response Protein EGR-1. Hormones/Receptors: Gene Expression and Regulation. Digestive Disease Week, 2004.
141. **Pestell, R.G.,** 4th Geneva Aging Workshop: Aging and Cancer at the Crossroads. Geneva University Hospital, Geneva, Switzerland, 2004 Oct. 1-2.
142. **Pestell, R.G.** The Course of Cancer. "Cyclins and Cyclin Inhibitors in Hormonal Responsive Cancer". Vermont Cancer Center, Burlington, VT, 2004 Oct. 7-8.
143. **Pestell, R.G.** Lynne Cohen Foundation Symposium on Emerging Role of Screening and Prevention in Women's Cancer. New York University, New York, NY "Hormone and Cell Cycle Control: New Paradigms" 2005 Apr. 15.
144. Wu, K., Li. A., Rao, M., Dettin, L.E., Wang, C., Liu, M., Yang, Y., Cveklova, K., Cvekl, A., Russell, R., **Pestell, R.G.**: DACH1 Inhibits breast cancer cell growth and invasion through down-regulating cyclin D1 kinase activity. The 96th Annual Meeting of AACR, California, 2005 Apr. 16.
145. **Pestell, R.G.** Atlantic Region of Society for Developmental Biology, Georgetown University, Washington, DC. "Approaches to 2-Hit Modeling in Mice". 2005 May 14.
146. **Pestell, R.G.** INCTR Annual Meeting, Chennai, India "New Approaches to the Treatment of Breast Cancer", 2005 Dec. 10-13.
147. Wang, C., Yuan, L., Li, Z., Fu, M., Quong, A., **Pestell, R.G.** PPARγ Signaling Collaborates in ErbB2-induced Tumorigenesis and Cellular Migration. 13th Spore Investigators' Workshop, Washington DC, 2005.
148. **Pestell, R.G.** Cell Signaling World Meeting, Luxemburg "Cyclins and HDAC/HAT's", 2006 Jan. 25-28.
149. Gong, J., Zhu, J., Zheng, R., **Pestell, R.G.**, Nanus, D.M., Schlegel, P.N., Shen, R. The growth-promoting neuropeptides, but not the growth-inhibitory neuropeptide, can activate androgen receptor through p300-mediated acetylation in prostate cancer cells. American Urology Association, 2006.
150. **Pestell, R.G**. Cell Signaling World Meeting, Luxemburg "Cell signaling pathways leading to regulating chromatin modifications". 2006 Jan. 25-28.
151. **Pestell, R.G**. Danny Thomas Lecture Series, St. Jude Children's Research Hospital, "Nuclear Receptors and Cyclins in Hormone Signaling, 2006 Mar. 2-3.
152. Wu, K., Liu, M., Li, A., Donninger, H., Birrer, M., Cvekl, A., **Pestell, R.G.**: The cell fate determination factor DACH1 inhibits c-Jun induced contact-independent growth. The 97th Annual Meeting of AACR, Washington DC, 2006 Apr. 1-5.
153. **Pestell, R.G.** Ettore Majorana Foundation and Centre for Scientific Culture, Estrogens and Human Diseases, "Estrogens and Epigenetic Signals", Erice, Sicily, 2006 May 15-21.
154. **Pestell, R.G.** Society of Nuclear Medicine, Molecular Imaging: Shaping the Future, "Light Activated Gene Therapy, New Selective Therapies for Disease, Key Biscayne, FL, 2006 Jul. 27-28.
155. **Pestell, R.G.** FASEB Summer Research Conference, Mechanisms of Action of Steroid Hormones: Integration of Membrane- and Nucleus-Initiated Effects, " Functional Significance of Acetylation of Androgen Nuclear Receptor", Tucson, AZ , 2006 Jul. 29-Aug. 3.
156. **Pestell, R.G.** University of Delaware, Newark, Delaware, Seminar "Acetylation of transcription factors regulates cellular growth" 2007 Apr. 25.
157. **Pestell, R.G.** Frontiers in Vascular Biology, Seminar Series, Dept. of Molecular Physiology and Biophysics, Jefferson Medical College. "Cell-cycle control in angiogenesis: the cell cycle goes inside-out", Philadelphia, PA, 2007 May 30.
158. **Pestell, R.G.** Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Seminar "Cell Fate Determination Factors and the Cell Cycle in Breast Cancer" Chicago, IL. 2007 May 2.
159. **Pestell, R.G.** The Endocrine Society's 89th Annual Meeting, Seminar "Acetylation of Nuclear Receptors" Toronto, Canada, 2007 June 2-5.
160. **Pestell, R.G.** FASEB Summer Research Conferences, Histone Deacetylases (HDACs) in Health & Diseases, Seminar "Acetylation and Deacetylation of Nuclear Receptors" Snowmass Village, Colorado, 2007 Jun. 2-7.
161. **Pestell, R.G.** Joint Faculty Seminar Series, Jefferson Medical College, Thomas Jefferson University, "New Signaling Mechanisms Governing Invasion and Metastasis *in vivo*", Philadelphia, PA, 2007 Jun. 18.

162. Yu, Z., Wu, K., Wan, C., **Pestell, R.G.** 2nd Annual Jefferson Postdoctoral Research Symposium, Thomas Jefferson University. "microRNA 17/20 inhibits breast tumor cell proliferation by regulating cyclin D1", Philadelphia, PA, 2007 Jun. 19.
163. **Pestell, R.G.** The Gordon Research Conference on Hormone Action in Development and Cancer, Seminar "Functional Significance of Nuclear Receptor Acetylation and Deacetylation – the Role of SIRTUINs" Colby-Sawyer College in New London, NH, Jul. 15- 20, 2007.
164. **Pestell, R.G.** GTCbio 4th Tumor Progression & Therapeutic Resistance Conference: "New Signaling Mechanisms Governing invasion and metastasis *in vivo*". Philadelphia, PA, Oct. 4-5, 2007.
165. Wang, C., Hulit, J., Li, Z., and **Pestell, R.G.** Cyclin D1 regulates colonic epithelial cell differentiation. Keystone Meeting. Beijing, 2007.
166. Shirley, L.A., Zhou, J., Popov, V., Wu, K., Tran, T.H., Rui, H., Sauter, G., Wang, C., **Pestell, R.G**. "The cell fate determination factor DACH1 is a nucleolar protein whose expression correlates with estrogen receptor-alpha expression in breast cancer" AACR Centennial Conference, Singapore, 2007.
167. Wang, C., Ju, X., **Pestell, R.G**. Akt1 governs ErbB2-induced breast tumorigenesis in vivo. CBIS meeting, Beijing, China, 2007.
168. Wang, C., Casimiro, M., Tian, L., Sakamaki, T., Quong, A., **Pestell, R.G**. Cyclin D1 Regulation of Mitochondrial Function in Breast Cancer. AACR Annual Meeting. 2007 Apr. 14.
169. Zhou, J., Popov, V., Zafonte, B.T., Quong, J.N., **Pestell, R.G.**, Wang, C. Cyclin D1 Stabilization of Estrogen Receptor a Co-activator Complex. AACR Annual Meeting. 2007 Apr. 14.
170. Wu, K., Li, A., Liu, M., Jiao, X., Cvekli, A., **Pestell, R.G.** "The cell fate determination factor Dachshund reduces breast cancer cellular migration and invasion". Los Angeles, CA. AACR Annual Meeting. 2007 Apr. 14.
171. Wang, C., Hulit, J., Li, Z., **Pestell, R.G.** Cyclin D1 regulates Colonic Cell Differentiation. Frontiers in Gastrointestinal Cancer Conference. Beijing, China. 2007 Oct. 17.
172. Shirley, L.A., Popov, V., Zhou, J., Wu, K., Tran, T.H., Rui, H., Vadlamudi, R.K., Kumar, R., Wang, C., **Pestell, R.G.** "The cell fate determination factor DACH1 represses estrogen receptor-alpha activity by binding to the transcription regulator PELP1". Academic Surgical Congress, Huntington Beach, CA, 2007.
173. Popov, V., Zhou, J., Shirley, L.A., Wu, K., Rui, H., Vadlamudi, R.K., Wang, C., **Pestell, R.G.** DACH1 regulation of estrogen receptor alpha through PELP1 in breast cancer. Abcam Meeting. 2008 Jan. 15.
174. Zhou, J., Popov, V., Shirley, L.A., Wu, K., Rui, H., Valdamudi, R.K., **Pestell, R,G.,** Wang, C. DACH1 regulation of estrogen receptor alpha through PELP1 in breast cancer. AACR Annual Meeting. 2008 Apr. 13.
175. Popov, V., Zhou, J., Shirley, LA., Wu, K., Rui, H., Valdamudi, R.K., Wang, C., **Pestell, R.G**. DACH1 regulation of estrogen receptor alpha in breast cancer. Thomas Jefferson University Sigma Xi Conference. 2008 Apr. 2.
176. Willmarth, N., Wang, C., Zhou, J., Casimiro, M., Fortina, M., Rosen, E., **Pestell, R.G**., Cyclin D1 regulates estrogen-mediated gene expression via selective promoter recruitment. Abstract #2472, Poster Session - Cell Cycle 2; AACR Annual Meeting , April 18 – 22, 2009, Denver, CO.
177. Zhou, J., Zhang, W., Dampier, W., Wang, M., Yu, Z., Wu, K., Popov, V., Willmarth, N., Casimiro, M., Lisanti, M., Tozeren, A., **Pestell, R.G**., Wang, C., DACH1 is a Cell-fate Determination Factor that Governs Forkhead Protein Function in Tumorigenesis. Abstract #3456, Poster Session – Nuclear Oncoproteins and Tumor Suppressors 2; AACR Annual Meeting, April 18 – 22, 2009, Denver, CO.
178. Popov, V.M., Zhou, J., Shirley, L.A., Wu, K., Vadlamudi, R.K., Kumar, R., Jiang, J., Quong, J., Rui, H., Yeow, W-S., Wang, C., **Pestell, R.G**. The cell fate determination factor DACH1 is expressed in estrogen receptor α positive breast cancer and represses ERα signaling. Abstract #613, Poster Session 9 – Tumor Suppressors 1, AACR Annual Meeting, April 18 – 22, 2009, Denver, CO.
179. Wu, K., Jiao, X., Katiyar, S., Willmarth, N., Casimiro, M., Zhang, W., Ju, X., **Pestell, R.G.** DACH1 inhibits cancer stem cells self-renewal and propagation. Abstract #3060, Poster Session 5 – Breast Cancer Stem Cells, AACR Annual Meeting , April 18 – 22, 2009, Denver, CO.
180. Powell, M., Yu, Z., Casimiro, M., Marapom, F., Yeow, W., Parlow, A., Cardiff, R., Katiyar, S., He, X., McCue, P., McBurney, M., **Pestell, R.G.** Sirt1 is required for normal prostate gland development and androgen signaling in vivo. Abstract #4126, Poster Session – Hormones and Cancer, AACR Annual Meeting, April 18 - 22, 2009, Denver, CO.
181. Yu Z, Wang C, Wang M, Li Z, Casimiro MC, Liu M, Wu K, Whittle J, Ju X, Hyslop T, McCue P, Pestell RG. A cyclin D1/miRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. Keystone Symposia on Molecular and Cellular Biology, June 10-15, 2009, Keystone, CO.
182. Zhou J, Tian L, Casimiro MC, **Pestell RG**, Wang C. Activating peroxisome proliferator-activated receptor γ mutant promotes tumor growth in vivo by enhancing angiogenesis. AACR 101st Annual Meeting, April 17-21, 2010, Washington, DC.
183. Yu Z, Willmarth NE, Zhou J, Katiyar S, Wang M, Liu Y, McCue PA, Quong AA, Lisanti MP, **Pestell RG**. microRNA 17/20 mediates cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Seventh Annual microRNA in Human Disease and Development Conference, March 28-30, 2011, Cambridge, MA.
184. Li Z, Hu J, Sun Y, Li S, **Pestell RG**, Wu K. EYA promotes proliferation through up-regulation of cyclin D1. AACR 102nd Annual Meeting, April 2-6, 2011, Orlando, FL.
185. Wang C, Zhou J, Wu K, Tozeren A, Zhao K, **Pestell RG**. DACH1 (Dachshund homolog 1) attenuates forkhead signaling through recruiting transcription elongation regulator 1 (TCERG1) AACR 102nd Annual Meeting, April 2-6, 2011, Orlando, FL.
186. Katiyar S, Casimiro M, Dettin L, Ju X, Wagner E, Tanaka H, **Pestell RG**. Endogenous c-jun inhibits mammary epithelial cellular apoptosis in vivo. AACR 102nd Annual Meeting, April 2-6, 2011, Orlando, FL.
187. Trimmer C, Katiyar S, **Pestell RG**, Lisanti MP, Capozza F. Caveolin-1 in cutaneous squamous cell carcinoma development. AACR 102nd Annual Meeting, April 2-6, 2011, Orlando, FL.

188. Chen K, Wu K, Zhang W, Zhou J, Stanek TS, Li Z, Wang C, Shirley LA, Rui H, McMahon S, **Pestell RG**. A p53-dependent G_2/M checkpoint governed by the cell-fate factor Dachshund in non-small cell lung cancer. AACR 103rd Annual Meeting, March 31 – April 4, 2012, Chicago, IL.
189. Li Z, Hu J, Chen K, Wu J, **Pestell RG**. DACH1 inhibited prostate cancer cellular proliferation and Interleukon-6 signaling. AACR 103rd Annual Meeting, March 31 – April 4, 2012, Chicago, IL.
190. Wang C, Tian L, Hagen FK, Casimiro M, Sauve AA, Pestell RG. PPARgamma acetylation governs differentiation function. Metabolism, Diet and Disease. May 29-31, 2012, Washington, DC.
191. Fu M, Pattabiraman N, Wang C, Ju X, Sauve A, **Pestell RG**. Screening of Sirt1 activating compounds and their cytotoxicity in prostate cancer cell lines. 2012 ASCO Annual Meeting, June 1-5, 2012, Chicago, IL.
192. Ju X, Ertel A, Yu Z, Fortina P, **Pestell RG**. New Metastatic Murine Prostate Cancer Cell Lines with the Genetic Characteristics of Human Cancer. Endo 2012, June 23-26, 2012, Houston, TX.
193. **Pestell RG**. The canonical nf-kb pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Molecular Medicine Conference 2012, December 19-22, 2012, Bangkok, Thailand.
194. Ju X, **Pestell RG**. New Metastatic Murine Prostate Cancer Cell Lines and Preclinical Model of Human Prostate Cancer. AACR Annual Meeting, April 6-10, 2013, Washington, DC.
195. Tian L, Wang C, Hagen FK, Casimiro M, Sauve AA, **Pestell RG**. PPARγ acetylation governs differentiation function. AACR Annual Meeting, April 6-10, 2013, Washington, DC.
196. Wang J, Cai S, Chen K, Sun Y, Li S, Pestell RG, Wu K. Regulation of AR transcriptional activity and prostate cancer cellular proliferation by DACH1/Eya1/Six1 pathway. AACR Annual Meeting, April 6-10, 2013, Washington, DC.
197. **Pestell RG**, Tian L, Wang C, Soccio R, Hagen F, Chen, E, Gormley M., Zhong, Zhijiu Z, Ertel A, Addya S, Zhou J, Powell M, Xu P, Casimiro M, Lisanti M., Portina F, Deng, H, Sauve A. Pparγ Deacetylation by SIRT1 Determines Breast Tumor Lipid Synthesis and Growth. San Antonio Breast Cancer Symposium, December 10-14, 2013. San Antonio, Texas.
198. **Pestell RG,** Jiao X, Velasco M, Sicoli D, Ju X, Pestell T, Ertel A, Ando S**.** Ccr5 Antagonists Block Basal Breast Cancer And Prostate Cancer Metastasis In Vivo. San Antonio Breast Cancer Symposium, December 10-14, 2013, San Antonio, Texas
199. **Pestell RG**, Yu Z, Wang L, Wang C, Ju X, Wang M, Chen K, Loro E, Wu K, Casimiro M, Gormley M, Ertel A, Fortina P, Chen Y, Tozren A, Liu Z. Cyclin D1 induction of Dicer governs microRNA processing and expression in breast cancer. San Antonio Breast Cancer Symposium, December 10-14, 2013, San Antonio, Texas
200. **Pestell RG**, Wu K, Chen K, Wang C, Jiao X, Wang J, Cai S, Addya S, Sorensen P, Lisanti M, Quong A, Ertel A. The Cell Fate Factor DACH1 Represses YB-1-mediated Oncogenic Transcription and Translation. San Antonio Breast Cancer Symposium, December 10-14, 2013. San Antonio, Texas.
201. **Pestell RG**, Chen K, Wu K, Gormley M, Ertel A, Zhang W, Zhou J, DiSante G, Li Z, Rui H, Quong A, McMahon S, Deng H, Lisanti M, Wang C, Post-translational Modification of the Cell-Fate Factor Dachshund Determines p53 Binding and Signaling Modules in Breast Cancer, San Antonio Breast Cancer Symposium, December 10-14, 2013, San Antonio, Texas.
202. **Pestell, RG**, Wu K, Li Z, Tian L, Chen K, Wang J, Hu J, Sun Y, Li X, Ertel A. The Phosphatase Function of the Eyes Absent (EYA) Homolog Is Required For the Induction of Breast Cancer Cellular Proliferation via Cyclin D1. San Antonio Breast Cancer Symposium, December 10-14, 2013. San Antonio, Texas.
203. **Pestell RG**, Casimiro, M, Di Sante G, Crosariol M, Loro E, Dampier W, Ertel A, Yu Z, Saria E, Papanikolaou A, Li Z,, Wang C, Addya S, Lisanti M, Fortina P, Tozeren A, Knudsen E, Arnold A. Kinase-Independent Role of Cyclin D1 in Chromosomal Instability and Mammary Tumorigenesis. San Antonio Breast Cancer Symposium, December 10-14, 2013. San Antonio, Texas
204. Jiao X, Velasco M, Xu S, Li Z, Cristofanilli M, Rui H, **Pestell RG** CCR5 contributes to breast cancer stem cell expansion and DNA damage repair. Fourth AACR International Conference on Frontiers in Basic Cancer Research. Oct 23-26, 2015 Philadelphia, PA
205. Di Sante G, Casimiro M, Wang C, Yu Z, Crosariol M, Vadlamudi R, Mann M, Tompa P, Tantos A, **Pestell RG.** Cyclin D1 functions as an epigenetic reader in promoting chromosomal instability. Fourth AACR International Conference on Frontiers in Basic Cancer Research. Oct 23-26, 2015 Philadelphia, PA
206. Ju X, Jiao X, Ertel A, Lisanti MP, Disante G, Ly Xu DC, Casimiro M, Xu C, Ando S, **Pestell RG.** Oncogenic Src induces Trop2 proteolytic activation via cyclin D1 in prostate cancer. Fourth AACR International Conference on Frontiers in Basic Cancer Research**.** Oct 23-26, 2015 Philadelphia, PA
207. Li, Z, Jiao X, . Casimiro MC , Katiyar S, Loro E, Chen K, Ju X, Ertel A, Klopfenstein D, Tozeren A, **Pestell RG** Cyclin D1 integrates G9a-mediated histone methylation and nuclear lamina association with lamina-associated domains. Fourth AACR International Conference on Frontiers in Basic Cancer Research. Oct 23 - 26, 2015 Philadelphia, PA
208. Jiao X, Chen, K., Xu, S., Ju, X., Ertel A, **Pestell RG**. The membrane associated cyclin D1 promotes contact-independent growth via phosphorylation of Akt1 Ser 473. AACR Precision Medicine Series: Cancer Cell Cycle: Tumor Progression and Therapeutic Response. Feb 28-March2 , 2016 Orlando, FL
209 Farshchian,M. Hamilton, JM**, Pestell, RG** Lee,JB, Joseph M Curry, Sahu,J, Andrew P South, AP A role for DACH1 in squamous cell carcinoma? International Investigative Dermatology meeting, Orlando Florida, March 16, 2018.
210 Jiao X, Andrew P. South, Ileana Zucchi, **Pestell RG**. The Gordon Research Conference, Mammary Gland Development, Baga Italy. May 2018. *Dachshund* depletion disrupts mammary gland development and diverts the composition of the mammary progenitor pool.
211 , Aimee Abbott,Domenica Carrier, Carlos Barbery, **Richard Pestell** and Khadija Rafiq**.** Inflammatory Serine Protease Inhibition Attenuates Myocyte Apoptosis and Cardiac Dysfunction via Intervention of Peroxisome Proliferator-activated Receptor Gamma-induced Lipotoxicity and Inflammation in High Fat Diet-induced Diabetic Cardiomyopathy 29 Mar 2018 Circulation. 2016;134:A17161

212 Pestell, R., "Portraits of prostate cancer"., ***PacRim Meeting*** Adelaide South Australia, March 17-20, 2019 *Endocrine-Related Cancer*, *Oncology Abstracts* (2019) **1** P041 | DOI: 10.1530/oncolabs.1.P041

213 Jiao, X, Wang, M, Richard G. **Pestell RG**. Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular invasion and enhances cell death induced by DNA damaging chemotherapies, AACR Annual Conference, Altanta GA, April 1, 1-5 pm Exhibit Hall B, #4023, 1-5 pm, 2019

213 Di Sante, G., Agnes Tantos, A, Mathew C. Casimiro, MC, Tompa, P., **Pestell, RG.** The Cyclin D1 carboxyl terminus encodes an epigenetic reader domain. AACR Annual Conference, Altanta GA, 1-5 pm Exhibit Hall B April 1 #5012, 2019

214 Jiao, X., Gabriele Di Sante, G., Zhiping Li, Z, Agnese DiRocco, A., Wang, M., Ertel, A, McCue, PA South, AP, Cordon-Cardo, C., Stokes, MP, Languino, L, Marra, M, Jones, SJ, Kossenkov, A, **Pestell, RG** · *DACH1* gene deletion extends portraits of human prostate cancer. AACR Annual Conference, Altanta GA, #4558, 8-12am Exhibit Hall B April 1, 2019

215 Q. Zhang: L. Gerratana: A.N. Shah: A.A. Davis: L. FlaumY. Zhang: **R.G. Pestell**: F. Wehbe: A. Behdad: L. PlataniasW. Gradishar: M. Cristofanilli: Expression of CCR5 associated with HER2 in circulating tumor cells (CTCs) is a novel biomarker for patients with metastatic breast cancer (MBC). AACR Annual Conference, Altanta GA, #408/10, 8-12am Exhibit Hall B March 31, 2019.

216 **Pestell RG**. Cristofanilli, M., Rui, H., Jiao, X,. Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer metastasis and enhances cell death induced by DNA damaging chemotherapies, San Antonio Breast Cancer Annual Conference, San Antonio, December, 12., 2019 .

217. Xuanmao Jiao, Ke Chen, Jun Zhao, Agnese Di Rocco Timothy G. Pestell Mathew C. Casimiro Michael P. Lisanti Peter A. McCue **Richard G. Pestell**. A novel cytoplasmic membrane Estrogen mediated biogenic signaling pathway. **US Endocrine Society Meeting, San Francisco, USA 2020 March 28, 2020**

218 Tomohito Doke, Shizheng Huang, Chengxiang Qiu, Xin Sheng, Hongbo Liu, Aili Cao, Jianhua Li, Lewis Kaufman, **Richard Pestell** and Katalin Susztak Kidney transcriptome wide association study (TWAS) analysis identifies Dach1 as a kidney disease risk gene. **American Society of Nephrology Denver , October 20 2020.**

219. Pestell RG CCR5 governs stem cell characteristics, therapy resistance and metastasis of breast cancer**.** Cellular therapies, Cancer stem cells and Biomedical Engineering, Annual Meeting, Plenary Lecture., July 17 2020 Vienna, Austrla.

220. Pestell, R.G. Prostate Cancer Foudation 27th Annual Scientific retreat. October 22 2020. **DACH1 deletion promotes prostatic intraepithelial neoplasia, DNA damage and targeted therapeutic vulnerabilities**.

221. **Pestell, R.G**., Jiao, X., Kossenkov, AV., Ertel, A., Tong, W. Zhang, Z. and McCue, P. **Pparg1 induces an EGF-EphA2 receptor tyrosine kinase module to promote ErbB2- mammary adenocarcinoma in mice**. San Antonio Breast Cancer Symposium, December 10-14, 2020. San Antonio, Texas.

222. Ashton, A, Zhang, L., Liang, Y, Divakar, P, Cordon-Cardo, C, Pestell, RG. **SARS-CoV-2 infection of the human heart governs intracardiac innate immune response.** AACR Annual Conference, 2021

223. Jiao, X., Xu, C, Tian, L, Zhang, Z, Ashton, A, Li, Z., Pestell, RG. **Cyclin D1 mediated exosomes are enriched for pro-oncogenic miRNAs and promote cancer stem cell expansion**. AACR Annual Conference, 2021 April 10th

224. Li, Z, Jiao, X, Ashton, AW, Kossenkov, A., Hao, C, Lan, L, **Pestell, RG.**The Forkhead-like protein Dach1 governs sensitivity to WEE1 kinase and PARP inhibitors. AACR Annual Conference, 2021 April 10th

225. Ashton, AW, Jiao, X, Li, Z, Wu, JC, dos Remedios, C, Lal, S., , Kitsis, R., Pestell, RG.**CCR5 inhibitors enhance Doxorubicin-induced breast cancer cell killing while reducing cardiotoxicity**. AACR Annual Conference, 2021

226. Transcriptome-wide association analysis identifies DACH1 as a kidney disease risk gene that contributes to fibrosis. Doke, T., Huang, S., Qiu, C., Liu, H., Guan, Y., Hu, H., Ma, Z., Wu, J., Miao, Z., Xin Sheng, X., Zhou, J., ao, A., Li, J., Kaufman, L., Hung[3]A., Brown, CD., Pestell R., Susztak, K.. **American Society for Nephrology 2021**.

228. Jiao, X., Xu, C, Tian, L, Zhang, Z, Ashton, A, Li, Z., Pestell, RG. Cyclin D1 mediated exosomes are enriched for pro-oncogenic miRNAs and promote cancer stem cell expansion. AACR meeting 2022, Cancer Research 82 (4_Supplement), P3-10-03-P3-10-03.

229. Chaudhary L et al (**Pestell, R**). High PD-L2 protein expression in cancer cells is an independent marker of unfavorable prognosis in luminal breast tumors. San Antonio breast Cancer meeting 2022.

230. Li, Z., Jiao, A. X., Robertson, G., Di Sante, G., Ashton, AW., Agnese DiRocco, A., Wang, M., Zhao, J., Addya, S., Wang, C., McCue, PA. South, AP., Cordon-Cardo, C., Liu, R., Patel, K., Hamid, R., Parmar, J., DuHadaway, JB., Schultz, N., Kossenkov, A., Phoon, LY., Chen, H., Lan, L., Sun, Y., Iczkowski, KA, Rui,H. **Pestell, RG** The *DACH1* gene is frequently deleted in prostate cancer, restrains prostatic intraepithelial neoplasia, augments DNA damage repair and predicts therapy responses, AACR Annual Meeting, 2023.

231 **Pestell, R**. "The humanized monoclonal anti-CCR5 antibody blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy" July 20, 2023 8th World Congress on cancer research and therapy., Frankfurt, Germany

232 **R G. Pestell** Xuanmao Jiao, Hsin Yao Tang Sean Lal, Anthony W. Ashton, CCR5 Inhibitors Enhance Breast Cancer Cell Killing and Reduce Doxorubicin-Induced Cardiotoxicity 13th world congress breast cancer research and therapies, June 12, 2023 Melbourne, Australia Immune Oncology Therapy for Breast Cancer.

233 Li, Z., Jiao, X., Khan, T., Li, D., Zha, S., Phoon, L.Y., Lan, L., Robertson, A.G., Ashton, A.W., Iczkowski, K.A., Borowsky, A.D., Ashworth, A., **Pestell R,G**, The DACH1 gene, frequently co-deleted with BRCA2 in prostate cancer, governs PARP inhibitor resistance AACR Annual Meeting, 2024

234 Jiao, X., Ashton, A., Li, Z., Harish, R., Li, D., Robertson, G., Shen, D., Ju, X., Chen, K., Zhang, W., Achilefu, WS., , KA., Rui, H., Knudsen, B., Timpson, Nobis, M., **Pestell RG**., Cyclin D1 induces Akt1 activity in RB deficient prostate cancer. AACR Annual Meeting, 2024.A1634 *Cancer Res* (2024) 84 (6_Supplement): 1634.

235 Tian, L., XJiao, X., Wang, C., Ertel, A., Raymond Soccio, R., Chen, E.R., BGyőrffy, B., Di Sante, G., Zhong, Z., Addya, S., McCue, PA., Kossenkov, AV, Achinger-Kawecka, J.,Clark, S., and **Pestell R.G**., PPARγ acetylation governs mammary adenocarcinoma tumor growth via acetylated residues that determine DNA sequence-specific binding. AACR Annual Meeting, 2024

236 Li, Z., Jiao, X., Khan, T., Li, D., Zha, S., Phoon, L.Y., Lan, L., Robertson, A.G., Ashton, A.W., Iczkowski, K.A., Borowsky, A.D., Ashworth, A., **Pestell R,G**, The DACH1 gene is frequently co-deleted with BRCA2 in prostate cancer and governs PARP inhibitor resistance 10th World Congress on CANCER RESEARCH AND THERAPY (WCCRT-2024), 2024

237. **Richard G. Pestell**, M. Cristofanilli, Milana Dolezal Hallgeir Rui, Daniel L. Adams, A. Cyrus Arman, Joe Meidling, Bernie Cunningham, Jacob Lalezari, Hope S. Rugo., "Observed survival following treatment with Leronlimab in patients with metastatic Triple-Negative Breast Cancer (mTNBC).369P **ESMO Breast** Munich, Germany. May 15 2025

238. Milana Dolezal, Vandana G. Abramson, Namita Chittoria, Sima Ehsani[4], **Richard G. Pestell** Hope S. Rugo, Hallgeir Rui[8], Daniel L. Adams, Joe Meidling, Max Lataillade, Jacob P. Lalezari Prolonged survival following PD-L1/PD-1 immune checkpoint inhibitor therapy after leronlimab induced PD-L1 upregulation on cancer-associated macrophage-like cells and circulating tumor cells in patients with metastatic or locally advanced triple-negative breast cancer **SanAntonio Breast Cancer Meeting**, Dec 9-12 2025. PS5-02-30

239 **Richard G. Pestell**, Zhiping Li, Ritika Harish, Xuanmao Jiao, Hallgeir Rui, M. Cristofanilli, Daniel L. Adams, Max Lataillade, Neil E. Buss, Denis R. Burger, A. Cyrus Arman, Jacob P. Lalezari CCR5 inhibition with leronlimab is associated with enhanced PD-L1 expression, ICI response, and long-term survival in metastatic TNBC. **AACR** Mechanisms of Cancer Immunity and Cancer-related Autoimmunity. September 24-27 2025., Montreal Canada.

240 Richard G. Pestell, Zhiping Li, Ritika Harish, Xuanmao Jiao, Hallgeir Rui, M. Cristofanilli, Daniel L. Adams, Max Lataillade, Neil E. Buss, A. Cyrus Arman, Jonah B. Sacha, Jacob P. Lalezari. Leronlimab is associated with long-term survival in metastatic TNBC: enhancing PD-L1 expression, ICI response, and the role of T cell exhaustion. Los Angeles, 2/19/26. **AACR Special Conference in Cancer Research Immune Oncology February 18-21, 2026**

241 Danni Li[1]., Ritika Harish, Zhiping Li, Xuanmao Jiao, Neil E. Buss, Luciano Garafano, Jinan Behnan, Jacob P. Lalezari, Richard G. Pestell. CCR5 inhibition with the human monoclonal antibody leronlimab enhances temozolomide- and radiation-induced killing of glioblastoma multiforme cells. **March 23, Philadelphia 2026, AACR Special Conference in Cancer research: Brain cancer Meeting**

242 Xuanmao Jiao, Danni Li, Rita Pancsa, Ritika Harish, Gideon Tolufashe, Hallgeir Rui, Beatrice Knudsen, Yanming Du, Hsin-Yao Tang, Peter Tompa, Richard G. Pestell Stromal cyclin D1 promotes prostate cancer stemness via the transcriptional regulatory E domain. **April 17, San Diego 2026, AACR Annual Meeting**

243 Danni Li, Arijit Ghosh, Zhiping Li*, Kenneth Iczkowski, Hidetoshi Mori, Samiha Nasser, Csaba Kerepesi, Andras Benczur, Hallgeir Rui, Ritika Harish, Li Lan, Xuanmao Jiao, Fred Saad, Janne Purhonen, Anthony W Ashton, Richard G. Pestell, Deletion of the DACH1 gene tumor suppressor increases replication fork stress, epithelial mesenchymal transition and sensitivity to WEE1 kinase inhibitors in prostate cancer **April 20, San Diego 2026, 4/20/ #**1751 Poster Session Abstract # 2408 **AACR Annual Meeting**

244 Richard G. Pestell, Ritika Harish, Zhiping Li, Danni Li, Xuanmao Jiao, Hallgeir Rui, M. Cristofanilli, Daniel L. Adams, Neil E. Buss Jonah B. Sacha, Jacob P. Lalezari. Leronlimab induces PD-L1 expression and is associated with long-term survival with an ICI in PD-L1 low metastatic TNBC. Abstract # 3605, **April 19, Poster Number:** 1033 **San Diego 2026, AACR Annual Meeting**

245 Kenneth Iczkowski, Zhiping Li, Hidetoshi Mori, Danni Li, Sameha Nas, Csaba Kerepesi, Andras Benczur, Hallgeir Rui, Ritika Harish, Xuanmao Jiao, Hallgeir Rui, Fred Saad, Richard G. Pestell, DACH1 conveys isoform specific tumor suppressor functions. **April 17, San Diego 2026,** #606 4/19 **AACR Annual Meeting**

246 Debu Tripathy, Milana V. Dolezal, Vandana G. Abramson, Namita Chittoria, Sima Ehsani, Richard G. Pestell, Hope S. Rugo, Hallgeir Rui, Daniel L. Adams, Joseph Meidling, Max Lataillade, Jacob P. Lalezari Safety and 5-year survival following treatment with leronlimab plus physicians choice chemotherapy/immunotherapy in patients with metastatic triple-negative breast cancer **ASCO Annual Meeting, 2026 Chicago Illinois, May 29 to June 2**

247 Pashtoon M. Kasi, Ari D. Baron, Arvind Chaudhry, Laura Tenner, Namrata Vijayvergi, Michael F. Driscoll, Daniel L. Adams, Alexis B. Duffy Hallgeir Rui, Richard G. Pestell, Patrick Vittner Joseph Meidling, and Jacob P. Lalezari CCR5 targeting leronlimab in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab for patients with refractory metastatic colorectal cancer (mCRC): The phase 2 CLOVER study. **ASCO Annual Meeting, 2026 Chicago Illinois, May 29 to June**

TEACHING and EDUCATION overview

Northwestern University Medical School, Chicago, IL

1. Faculty Search Committees, Northwestern University Medical School, Chicago, IL
   i. Molecular Pharmacology and Biological Chemistry
   ii. Pathology
   iii. Department of Urology, and Department of ENT Surgery
2. Clinical Administrative Committee, Northwestern Medical Faculty Foundation, NMFF. Chicago, IL
3. Organizer of Endocrinology and Molecular Medicine Journal Club and Data sessions, Northwestern University Medical School, Chicago, IL
4. Tumor Cell Biology Journal Club, Northwestern University Medical School, Chicago, IL
5. Northwestern University Lurie Cancer Center Development Research Committee, Northwestern University Medical School. Chicago, IL

Albert Einstein College of Medicine

6. Albert Einstein College of Medicine, Medical Student Research Committee of the DOE. 1998-2002
7. Einstein Quarterly Journal Editorial Board, Co-Chairman, 1998-2002
8. Sue Golding Graduate School Committee, Department of Developmental and Molecular Biology, Representative, 1998-2000
9. Disclosure, Albert Einstein College of Medicine, Ombudsman and Reviewer, 1997
10. Ad Hoc Committee, to the Committee on Appointments and Promotions at the Albert Einstein College of Medicine, Chairman, 1997
11. Faculty recruitment committee Department of Developmental and Molecular Biology, at the AECOM. 1998-2001, Department of Neuroscience, 1999-2001
12. Medical Student Research Committee, Sue Golding Graduate School, 1998-2000
13. Julius Marmur Award Committee, Co-Chairman, 1999
14. Julius Marmur Award Committee, Chair, 2000
15. Developmental & Molecular Biology- Departmental Retreat Organizer 1999
16. Cancer Center Pilot Project Grant reviewer 1998, 1999-2002
17. Faculty Search Committee Member- Neuroscience, Developmental & Molecular Biology (1997-2002)
18. Cancer Center Recruiting Committee- Fall 1997-Spring 1998
19. MD-PhD Retreat, Attendee, Oct. 1998, Feb. 1999, Oct. 2000, Oct. 2001,
20. Sue Golding Qualifying Exam Committee, 1999
21. Sue Golding Graduate School Selection Committee for the new SGGD Director, Member, 2001
22. Seminar Presentation, M.D., PhD Program retreat, AECOM, Co-Chair, 1998
23. British Schools and Universities Foundation, Queens College US Representative 2001-
24. Albert Einstein Cell Cycle group - Founder/Organizer-1998-2000
25. “Signal transduction” Journal Club Organizer, Albert Einstein College of Medicine, New York, 1997-1998
26. “Signaling and Cancer” DMB Journal Club Organizer, 2000-2002
27. Executive Advisory Board - Training grant #5T32GM0852-10. 1999-2002
28. Internal Advisory Board- Program in Colon Cancer (Augenlicht PI) 2002-2002
29. Director of Albert Einstein Cancer Center Program in Growth Control 2000-2002
30. Head and Subsequent Program PI – leading to current PPG (transgenic models of breast cancer initiation and progression) obtained funding for program, including philanthropic donor sources, for all members 1998-2002
1. Space Allocation Committee, Endocrinology (AECOM), 1997-1999
2. Course Director, Oncology Grand Rounds Series, Georgetown University Hospital, 2002-2005

Thomas Jefferson University

3. Medical Oncology Chair Search Committee, Thomas Jefferson University Hospital, 2006
4. Jefferson Kimmel Cancer Center Network, Jefferson Oncology Group Annual Investigators Meeting, Speaker, 2008
5. American Society for Clinical Investigation (ASCI) Representative, Jefferson Medical College at Thomas Jefferson University, 2010-2015.

Xavier University.

6. As Vice President of Academic Affairs (reports to President) developed strategic plan, instituted curriculum reform for Medical School including development of research modules, creation of dual degree (Masters in Medical Research and Innovation), creation of new research elective programs, creation of postdoctoral training program including facultiies and financing, introduced professional training programs for faculty. Estabished new hospital clinical training sites for students. Coordinated accrediaions of the Medical School.
7. As Dean, Ensured successful external accreditations of Medical School (2019), administered three graduations (2018,2019,2020).

TEACHING and EDUCATION (awards)

- Active involvement in student education since 1982

Teaching Awards

1990 Honorary life member Queens College for contribution to medical student teaching.
1993 Robert Woods Johnson- award for minority education - Northwestern University Medical School
1994 Robert Woods Johnson- award for minority education - Northwestern University Medical School
2005 Thomas Jefferson University Pathology Department prize
2007 Distinguished Speaker award for TJU Departments of Pathology, Anatomy, and Cell Biology

Education, accreditation, innovation and development: responsibilities

- ACGME reaccreditation of Hematology Oncology Fellowship, TJUH/TJU (2005-2015)
- ACGME reaccreditation of Radiation Oncology training program, TJUH (2005-2015)
- Participation of ACGME site visit for Medical Schools, Georgetown University Medical Center (2003, successful renewal), Thomas Jefferson University (2007)
- Monthly medical student and fellow clinical teaching in the hospital 2005-2016
- Active involvement in undergraduate and graduate education (1992-present) and minority medical education (1993-present)
- Established Office and subsequently Center for Minority Affairs (2006- present) Thomas Jefferson Univeristy, Kimmel Cancer Center
- Established three new Departments (Cancer Biology, Medical Oncology, Stem Cell Biology and Regenerative Medicine).
- Established new education training program funded by American Cancer Society (2006-present)

1985 Tutor in Pathology, Department of Immunology, University of Western Australia.
1984-1987 Mentor/Teacher to medical students General Internal Medicine (Royal Perth Hospital).
1988-1990 Tutor in Medicine, Department of Medicine, University of Melbourne, Royal Melbourne Hospital.
1987-1990 Tutor in Medicine, Queens College, University of Melbourne.
1987-1988 Subspecialty Mentor/Teacher to medical students and Registrars in Internal Medicine and Endocrinology (St. Vincent's Hospital).
1988-1990 Tutor in Medicine, Department of Medicine, University of Melbourne, Royal Melbourne Hospital.
1993-1996 Northwestern University Medical School, Chicago IL (below).
1996-2002 Albert Einstein College of Medicine, New York (below).

Teaching (1993-1996) Northwestern University Medical School, Chicago IL.

1993-1996 Integrated Graduate Program (IGP) Faculty Research Advisor, (Northwestern University Medical School, Chicago, IL.)
1994-1995 Teacher - Problem based learning group leader (second year medical students) and Scientific Basis of Medicine (second year medical students)
1993-1996 Preceptor - Endocrinology and Diabetes clinics (NMFF), teaching medical students and residents, and Laboratory Preceptor (details over)
1994-1996 Lecturer - Developmental Biology Course
1995-1996 Lecturer - Eukaryotic molecular biology course (Northwestern University Integrated graduate program (IGP)
1995-1996 Journal Club host, Lecture in Life Sciences Journal Club

Teaching (1996-2002) Albert Einstein College of Medicine, New York.

1997-2002 Preceptor, Medical Students Endocrine System Course (8hrs)
1997-2002 Teacher, Molecular and Cellular Foundations of Medicine (cell-cycle syllabus, exam questions and lecturer)
1997-2000 Teacher, Clinical and Pathological Case conferences
1998-2002 Lecturer, "Signal Transduction" Course at AECOM (3rd yr PhD students)
1999-2000 Lecturer, "Cancer – A Basic Science Approach" Albert Einstein College of Medicine (Ph.D., M.D./Ph.D. students) Organized and wrote exam questions

Teaching (2002-2005) Georgetown University, Washington, DC

2003 Lecturer, "Cancer: Old Fears, New Hopes", Department of Pharmacology, Georgetown University
2004 Lecturer, "Nuclear Receptors and Cyclins in Hormone Signaling", Georgetown University
2002 Department of Pharmacology, Local Scientist Seminars, Georgetown University

Teaching (2005-2016) Thomas Jefferson University, Philadelphia, PA, Xavier University School of Medicine, NY

2005-2006 Lecturer, Department of Pathology, Anatomy and Cell Biology Seminar Series, Thomas Jefferson University
2006 Teach GE652 Class for Cancer Biology Graduate Students, Thomas Jefferson University
2007 Meet the Expert Session: 30-min presentation to medical students "Overview of Cancer Biology."
2008-2017 TJU Student lectures- "Advanced topics in Protein function and Dysfunction" 2 lectures and exam preparation.
2018-present Xavier University, School of Medicine.,
Lectures (3 per week on Molecular biology techniques and methods (inclides statistics)

Didactic lecturs (~every 6 weeks) include: "Lung Cancer screening Diagnosis and Treatments" ,"The opioid crises- Practical issues for the Practicing physician", "Lymphoma **Genetics, Diagnostic and clinical care', "**Breast cancer **Genetics, Diagnostic and clinical care',**
Annual Dean's lecture "The opioid crises – Practical issues for the Practicing physician"

10/2/19 " The opioid crises – Practical issues for the Practicing physician"

Student Teaching (conducted PhD thesis under my guidance)

PhD Chris Albanese, Rick Lee, Anne Reutens, Derek Amanatullah, Udayan Guha, Tony Karnezis, James Hulit, Mark Stahl, Jennifer Leader, Michael Powell, Vladimir Popov,

PhD Advisory Committees

Stephanos Pavlides, Michael Powell, Vladimir M. Popov, Hui Meng
Sonia Pilar Zamora-Leon, Ilia Ichetovkin, Hyangkyu Lee, Punneeth Iyengar, Ilir Topalli, William Gomes, Roger Greenberg, Amanda Chan, Tony Karnezis, Li Wei, Peiyee Lee, Bo Chen, Derek Amanatullah, Jian Wang, Dolores Di Vizio, Udayan Guha, Mark Stahl, James Hulit (all graduated).

Student Teaching (conducted Master thesis under my guidance), Ritika Harish IIIser Kolkata)

11 Students Completed PhD, 49 Post doctoral fellow completed training in Dr. Pestell's Laboratory

Qualifying Exam Committees - USA

Thesis committee and examiner – AECOM: Wei Tong, Igor Matushansky, K, Singh, Jianyu Lan, Rick Lee, Barbak Razini, Pei Lee, 1999-2002 Ilia Ichetovkin, 1999-2002 Joel Friedman. 1999-2002 Hyangkyu Lee, 1999-2002 William Gomes, 2001 Brian Zafonte, Derek Amanatullah.
External examiner - Columbia University: 1999 - Soh, JT, Jian Qu, 2001
External examiner – Yeshiva University: 2007 – Pezo, R.

Qualifying Exam Committees (3)- International

Organizer of International Symposiums

1. Co-Chair, International Immunogenetics meeting, 1983, Perth, Australia
2. Co-Chair session, Annual ASCI meeting, Biomedicine 1997, "Cell Cycle and Cancer." Washington D.C.
3. Session leader, and speaker, Gordon Research Conference, Chemotherapy, "Transcription Factors as Targets for Therapy and Prevention" New Hampshire, July 17, 2001
4. Chair, Cell Signaling Transcription and Translation as Therapeutic Targets - Session Chair, "Cell-cycle control," Feb. 1, 2002.
5. Chair, Apoptosis 2003, "Signaling Pathways to Therapeutic Tools" – Session Chair, "Apoptosis and Chromatin Structure," Jan. 31, 2003
6. Co-Organizer, Breast Cancer Symposium "Think Tank 14", January 18-24, 2004, St. Kitts.
7. Chair, Prostate Cancer Symposia, "Prostate Cancer: Mechanism to Therapy," 2004 Meetings of the Endocrine Society, New Orleans LA, June 16-19 2004.
8. Co-Organizer, Breast Cancer Symposium "Think Tank 15", January 16-22, 2005, Curacao
9. Chair, Cell-Cycle Symposia," 2005 AACR Meeting, Anaheim LA, 2005.
10. Co-Organizer, Breast Cancer Symposium "Think Tank 16", January 15-21, 2006, Grand Cayman.
11. Co-Chair, Molecular Medicine Conference 2012, December 19-22, 2012, Bangkok, Thailand.

Organizer of National Symposiums

2006 Scientific and Clinical Update on Pancreatic Cancer. Kimmel Cancer Center, Philadelphia, PA. February 24.
2006 10th Anniversary Dinner Symposium- Genitourinary Cancer Program. Kimmel Cancer Center. April 6.
2007 Scientific and Clinical Update on Breast Cancer. Kimmel Cancer Center. February 23.
2007 Hepatoma Dinner Symposium. Kimmel Cancer Center. November 27.
2008 Speaker and organizer, Nuclear Receptors: Co-activators and Co-repressors meeting. Abcam, Inc. "Acetylation of Nuclear Receptors" Constitution Center, Philadelphia, PA, January 15.
2008 PET/CT Oncology Symposium. Kimmel Cancer Center. Philadelphia, PA. February 9.
2008 Scientific and Clinical Update on Colorectal Cancer. Kimmel Cancer Center. Philadelphia, PA. February 29.
2008 PanCAN Symposium for Pancreatic Cancer. Thomas Jefferson University. Philadelphia, PA. April 5.
2008 Spirit of Courage, Prostate Cancer Symposium. Kimmel Cancer Center. Philadelphia, PA. May 15.
2008 Lennox Black Symposium, Transformational Discoveries in Cancer. Thomas Jefferson University. Philadelphia, PA. November 10-11.

Addendum 1. **Position/responsibilities and institution/organization.**

1 Georgetown University and Hospital (2002-2005, 4.5 years) Georgetown University is a comprehensive private research university in the Georgetown neighborhood of Washington, D.C., and comprises nine undergraduate and graduate schools, among which are the School of Foreign Service, School of Business, Medical Center, and Law School. Ranked #21 top colleges, #14 in research institutes (financial grade A-). With approximately 18,459 students, 7,562 undergraduate students, 2,500 faculty and 11,600 new students accepted annually, 6,400 degrees granted annually, and research expenditures of approximately $183M annually. My positions were: Lombardi Comprehensive Cancer Center Director, (reports to the President), Associate Vice President, Georgetown University Medical Center and Member of the Board, Georgetown University Hospital.

2 Thomas Jefferson University and Jefferson Health, Philadelphia (2005-2016, 11 years), is a comprehensive private research university in Pennsylvania, USA. With an annual budget of $5.6B, eleven hospitals and 30,000 employees in the Philadelphia region, with more than 160 undergraduate and graduate programs, Thomas Jefferson University is a private university in Center City, Philadelphia, Pennsylvania, United States and includes Philadelphia University (College of Architecture and the Built Environment, Kanbar College of Design, Engineering and Commerce College of Science, Health and the Liberal Arts School of Continuing and Professional Studies): together with TJU's six constituent colleges and schools: Sidney Kimmel Medical College, Jefferson College of Biomedical Sciences, Jefferson College of Health Professions, Jefferson College of Nursing, Jefferson College of Pharmacy, and Jefferson College of Population Health. TJU has 7,800 students, more than 4,000 faculty. Thomas Jefferson University is also the primary academic affiliate of the Jefferson Health System. Jefferson Health System was founded in 1995 when Thomas Jefferson University Hospital and the Main Line Health System signed an agreement establishing a new, nonprofit, corporate entity known as the Jefferson Health System. The agreement brought together the Thomas Jefferson University Hospitals, Inc. and Main Line Health under one corporate parent. Since then, other established networks have joined Jefferson Health System as founding members, which at one point included the Albert Einstein Healthcare Network Frankford Health Care System (now Aria Health Main Line Health and Magee Rehabilitation Hospital). Thomas Jefferson University Hospital. My positions were: Sidney Kimmel Cancer Center Director, (Sits at the Level of the Dean and reports to the President), and subsequently Executive Vice President, Thomas Jefferson University. The Executive Vice President reports to the President. On behalf of Thomas Jefferson University, I crafted bi-national research and education agreements with countries including Russia (University of Kazan), Hungary (University of Debrecen), Italy (University Federico Secundo, University of Rome), and Australia (Melbourne University).

Current

1. **Blumberg Institute** http://blumberginstitute.org/. **Distinguished Blumberg Professor (2017-current)**. The Blumberg is the administrative center for my funded research laboratories.
2. **PCARM, President (2017-6/2022).** The Pennsylvania Cancer and Regenerative Medicine Research Center (PCARMRC) is part of an international hub-and-spoke model for regenerative medical inquiry, spearheading research and collaborating with similar centers around the world. https://www.pcarmrc.org/
3. **CEO and Founder of ProstaGene, LightSeed, EcoGenome** and **StromaGenesis**. I founded and sold **ProstaGene** after completing fund raising (7 X return to investors). LightSeed currently funded by SBIR grant., completed **EcoGenome** seed round (>$2MM), currently conducting **StromaGenesis** A round. PABC outperformed the majority of its 148 peer US biotechnology ecosystems institutions, in areas that indicate success and ranked first or second among peers in most areas in the USA, including a combined peak valuation of **$1.75 billion** for graduate companies. In 2018, PABC was named one of the most successful biotechnology incubators in the country, according to an independent study by the International Business Innovation Association. Other companies at PABC include Antengene (raised $120M). There are eight individuals working at PABC who have discovered drugs which are now FDA-approved, including Mike Sofia, PhD, inventor of Sorafenib, who won the 2016 Lasker Prize for leading the discovery of a cure for hepatitis C; and Kunwar Shailubhai, PhD, whose drug TRULANCE was approved for treatment of chronic constipation in 2017.
4. **Xavier University Medical School (2018-present). Dean of the Medical School and Vice President of Academic Affairs**. My efforts have been to ensure accreditation of the medical school, creation of research programs, develop clinical training sites and new programs in medical entrepreneurship.

Teaching addendum

Teaching

- Active involvement in student education since 1982

Teaching Awards

1990	Honorary life member Queens College for contribution to medical student teaching.
1993	Robert Woods Johnson- award for minority education - Northwestern University Medical School
1994	Robert Woods Johnson- award for minority education - Northwestern University Medical School
2005	Thomas Jefferson University Pathology Department prize
2007	Distinguished Speaker award for TJU Departments of Pathology, Anatomy, and Cell Biology

Current responsibilities

- ACGME reaccreditation of Hematology Oncology Fellowship, TJUH/TJU
- ACGME reaccreditation of Radiation Oncology training program, TJUH
- Participation of ACGME site visit for Medical Schools, Georgetown University Medical Center (2003, successful renewal), Thomas Jefferson University (2007)
- Monthly medical student and fellow clinical teaching in the hospital 2005-current
- Active involvement in undergraduate and graduate education (1992-present) and minority medical education (1993-present)
- Established Office and subsequently Center for Minority Affairs (2006- present) Thomas Jefferson Univeristy, Kimmel Cancer Center
- Established tthree new Deprtaments (Cancer Biology, Medical Oncology, Stem Cell Biology and Regenerative Medicine).
- Established new education training program funded by American Cancer Society (2006-present)

1985	Tutor in Pathology, Department of Immunology, University of Western Australia.
1984-1987	Mentor/Teacher to medical students General Internal Medicine (Royal Perth Hospital).
1988-1990	Tutor in Medicine, Department of Medicine, University of Melbourne, Royal Melbourne Hospital.
1987-1990	Tutor in Medicine, Queens College, University of Melbourne.
1987-1988	Subspecialty Mentor/Teacher to medical students and Registrars in Internal Medicine and Endocrinology (St. Vincent's Hospital).
1988-1990	Tutor in Medicine, Department of Medicine, University of Melbourne, Royal Melbourne Hospital.
1993-1996	Northwestern University Medical School, Chicago IL (below).
1996-2002	Albert Einstein College of Medicine, New York (below).

Teaching (1993-1996) Northwestern University Medical School, Chicago IL.

1993-1996	Integrated Graduate Program (IGP) Faculty Research Advisor, (Northwestern University Medical School, Chicago, IL.)
1994-1995	Teacher - Problem based learning group leader (second year medical students) and Scientific Basis of Medicine (second year medical students)
1993-1996	Preceptor - Endocrinology and Diabetes clinics (NMFF), teaching medical students and residents, and Laboratory Preceptor (details over)
1994-1996	Lecturer - Developmental Biology Course
1995-1996	Lecturer - Eukaryotic molecular biology course (Northwestern University Integrated graduate program (IGP)
1995-1996	Journal Club host, Lecture in Life Sciences Journal Club

Teaching (1996-2002) Albert Einstein College of Medicine, New York.

1997-2002	Preceptor, Medical Students Endocrine System Course (8hrs)
1997-2002	Teacher, Molecular and Cellular Foundations of Medicine (cell-cycle syllabus, exam questions and lecturer)
1997-2000	Teacher, Clinical and Pathological Case conferences
1998-2002	Lecturer, "Signal Transduction" Course at AECOM (3rd yr PhD students)
1999-2000	Lecturer, "Cancer – A Basic Science Approach" Albert Einstein College of Medicine (Ph.D., M.D./Ph.D. students) Organized and wrote exam questions

Teaching (2002-2005) Georgetown University, Washington, DC

2003	Lecturer, "Cancer: Old Fears, New Hopes", Department of Pharmacology, Georgetown University
2004	Lecturer, "Nuclear Receptors and Cyclins in Hormone Signaling", Georgetown University
2002	Department of Pharmacology, Local Scientist Seminars, Georgetown University

Teaching (2005-present) Thomas Jefferson University, Philadelphia, PA

2005-2006	Lecturer, Department of Pathology, Anatomy and Cell Biology Seminar Series, Thomas Jefferson University
2006	Teach GE652 Class for Cancer Biology Graduate Students, Thomas Jefferson University
2007	Meet the Expert Session: 30-min presentation to medical students "Overview of Cancer Biology."

Student Teaching (conducted PhD thesis under my guidance)

PhD Chris Albanese, Rick Lee, Anne Reutens, Derek Amanatullah, Udayan Guha, Tony Karnezis, James Hulit, Mark Stahl, Jennifer Leader, Michael Powell, Vladimir Popov

PhD Advisory Committees

Stephanos Pavlides, Michael Powell, Vladimir M. Popov, Hui Meng
Sonia Pilar Zamora-Leon, Ilia Ichetovkin, Hyangkyu Lee, Punneeth Iyengar, Ilir Topalli, William Gomes, Roger Greenberg, Amanda Chan, Tony Karnezis, Li Wei, Peiyee Lee, Bo Chen, Derek Amanatullah, Jian Wang, Dolores Di Vizio, Udayan Guha, Mark Stahl, James Hulit (all graduated).

Students Completed PhD in Dr. Pestell's Laboratory

1999 R.J. Lee
2000 A. Reutens
2000 C. Albanese
2002 D. DiVizió
2003 U. Guha
2004 J. Hulit
2006 J. Leeder
2007 M. Stahl
2010 V. Popov
2011 M. Powell

Qualifying Exam Committees - USA

Thesis committee and examiner – AECOM: Wei Tong, Igor Matushansky, K, Singh, Jianyu Lan, Rick Lee, Barbak Razini, Pei Lee, 1999-2002 Ilia Ichetovkin, 1999-2002 Joel Friedman. 1999-2002 Hyangkyu Lee, 1999-2002 William Gomes, 2001 Brian Zafonte, Derek Amanatullah.
External examiner - Columbia University: 1999 - Soh, JT, Jian Qu,
2001 External examiner – Yeshiva University: 2007 – Pezo, R.

Qualifying Exam Committees - International

Thesis committee and examiner – University of Western Australia: Melissa Greeve Thesis committee and examiner – University of Western Australia: Tina Carter Thesis committee and examiner – University of Western Australia: Wee Ting Tay

Other Undergraduate Teaching

1. Case leader - Clinicopathological case conferences 1997-2000
2. International exchange program laboratory mentor:
   Bath University - Julian Hughes, 1999, Richard Francis 2000
   University of Naples - Dolores Di Vizio 2000- Present University of
   Egypt - Adel Nour 200- Present

Member - AECOM member, exchange program between AECOM and University of Naples

3. Chair Julius Marmur awards committee - (award given annually to best AECOM students in program).1998-2000
4. MSTP retreat - annual attendant 1997-2001
5. Lecturer - signal transduction course (cell-cycle). 1997- Present
6. Interviewer for applicant to graduate school (both PhD and MD, PhD program). 1997-Present
7. Participant in AECOM annual summer college program -laboratory mentor to Josh Klein -1998- Nicole Appelle, - 1999 Robert Stenger - 1999, Marissa Zahler, 1999, Tal Bash, 1999, Sanaz Harirchian, S., 2000
8. Mentor to high school students- Westinghouse program - John-Paul Gonzalez, Manhattan Center High School for Science and Mathematics
9. Examiner- qualifying exam member- 1997-Present (chair of qualifying exam 2001-)
10. Endocrinology – Instructor in Endocrinology case conferences – minimum 8 hrs teaching /yr 2001-2002
11. US Representative for BSUF (Queens College) (British Schools and Universities Foundation Inc) – an international inter-university educational foundation
12. Medical Student clinical Teaching:
    i. clinical attending (1 month/yr) (1996-Present)
    ii. in Endocrinology clinics (15/yr) (1996-Present)
    iii. M.D., PhD clinic – clinical preceptor (1999-2001) teacher

Previous Trainees 1994-Present (attached grid)

Past Students	Degree	Year	Support	Present Position
I-W. Shu	Predoc	1995	David Shemin Fellowship Student	Resident, Massachusetts General Hospital
R. Lee	Predoc (AB, AM)	1995-2000	NIH training grant 5T32GM0852-10	Oncology Fellow, Dana-Farber Cancer Institute, Boston, MA
T. Karnezis	Predoc (BA)	1995-1998	NIH Grant # CA09560	Research Fellow, U.C.S.F., California
A. Reutens	Student	1997-1999	NIH Grant # CA09560	Senior Lecturer, Monash University, Medicine
C. Albanese	Student	1997-2000		Assistant Professor, Lombardi Cancer Center, Georgetown Univ. Medical Center, Washington, DC
D. Amanatullah	Student	1997-2000		
V. Popov	Student	2007-2010		
M. Powell	Student	2006-2011		Executive Office Program Administrator, American Association for Cancer Research
E. Mirabelli	Student	2013		
D. Sicoli	Student	2011-2012		

Past Postdoctoral Fellows

Students	Degree	Year	Support	Present Position
G. Watanabe		1994-1997		Head Clinical services affiliated Hospital, Nagoya University, Japan
P. Lastowiecki	MD	1994-1995	NIH Postdoc Fellowship Fulbright	MD, PhD, Bonaventure Medical Group, Elk Grove Physicians, Elk Grove Village, IL
P. Pena	PhD	1995-1998	Fellowship	Researcher, CNIO, Madrid
S. Shanmugam	MD, MS	1995-1996	VA Merit award	Postdoctoral Research Fellow, Northwestern University
B. Bouzahzah	MD	1997-2002		Associate Faculty, Albert Einstein College of Medicine
F. Ahmed	MD	1997-2002		Postdoctoral Research Fellow, Albert Einstein College of Medicine
M. D'Amico	PhD	1997-2004	NIH Grant	Postdoctoral Fellow
M. Fu	PhD	1997-2001	NIH Grant	Associate Professor of Clinical Medicine, LSU Health New Orleans
C. Wang	PhD	1998-2002	NIH Grant	Assistant Professor, Kimmel Cancer Center at Thomas Jefferson University
J. Zhou	PhD	1999-2002	NIH Grant	
E. Kulig	PhD	2000-2002	NIH Grant	
L. Peng	PhD	2004-2005	NIH Grant	
T. Sakamaki	MD	2000-2005	NIH Grant	Assistant Professor, Niigata University, Niigata, Japan
K. Wu	MD	2000-2005	NIH Grant	Assistant Professor Kimmel Cancer Center at Jefferson
Z. Li	PhD	2002-Present	NIH Grant	Assistant Professor Kimmel Cancer Center at Jefferson
S. Katiyar	PhD	2002-2010	NIH Grant	Assistant Professor Kimmel Cancer Center at Jefferson
M. Rao	PhD	2003	NIH Grant	
X. Ju	PhD	2003-Present	NIH Grant	Research Instructor Kimmel Cancer Center at Jefferson
M. Liu	PhD	2003-2008	NIH Grant	Research Instructor Kimmel Cancer Center at Jefferson
L. Yuan	PhD	2004-2006	NIH Grant	Assistant Professor, Children's National Medical Center, Washington, D.C.
X. Jiao	PhD	2004-Present	NIH Grant	Research Instructor Kimmel Cancer Center at Jefferson

R. Du	PhD	2005-2005	NIH Grant	Post Doc, Case Western Reserve University
M. Casimiro	PhD	2005-Present	NIH Grant	Assistant Professor Kimmel Cancer Center at Jefferson
X. Wu	PhD	2005	NIH Grant	Instructor, Children's National Medical Center, Washington, D.C.
N. Willmarth	PhD	2007-2009	NRSA-Training Grant	
Z. Yu	PhD	2006-Present	Falk Foundation Grant	Research Center for Translational Medicine, East Hospital, Tongji University School of Medicine
M. Velasco-Velazquez	PhD	2010-2012		Associate Professor, Department of Pharmacology, School of Medicine, National Autonomous University of Mexico